HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

CEAs

If you want to keep on top of the latest CEAs, below are our quick monthly searches of journals.  Please note this isn't meant to be comprehensive....if you want that, or any other searches, please contact us!

December 2019

1. Abecassis IJ, Sen R, Kelly CM, Levy S, Barber J, Ghodke B, et al. Clinical outcomes and cost-effectiveness analysis for the treatment of basilar tip aneurysms. J Neurointerv Surg. 2019;11(12):1210-5.
2. Aguiar PN, Jr., Adashek JJ, Roitberg F, Noia Barreto CM, Del Giglio A, Lopes GL, Jr. In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments. Value Health Reg Issues. 2019;20:47-50.
3. Amirsadri M, Mousavi S, Karimipour A. The cost-effectiveness and cost-utility analysis of the use of enoxaparin compared with heparin for venous thromboembolism prophylaxis in medical inpatients in Iran. Daru. 2019;27(2):627-34.
4. Anyiwe K, Richardson M, Brophy J, Sander B. Assessing adolescent immunization options for pertussis in Canada: A cost-utility analysis. Vaccine. 2019.
5. Avancena ALV, Tejano KPS, Hutton DW. Cost-effectiveness analysis of a physician deployment program to improve access to healthcare in rural and underserved areas in the Philippines. BMJ Open. 2019;9(12):e033455.
6. Azari S, Rezapour A, Omidi N, Alipour V, Behzadifar M, Safari H, et al. Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review. Heart Fail Rev. 2019.
7. Bai L, Zhang P, Zhou K, Liao W, Li Q. Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer. Cancer Manag Res. 2019;11:10419-26.
8. Barnett CL, Davenport MS, Montgomery JS, Kunju LP, Denton BT, Piert M. (18)F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis. J Nucl Med. 2019;60(12):1705-12.
9. Barnett J, Belsey J, Tavare AN, Saini A, Patel A, Hayward M, et al. Pre-surgical lung biopsy in management of solitary pulmonary nodules: a cost effectiveness analysis. J Med Econ. 2019;22(12):1307-11.
10. Benard A, Duroux T, Robert G. Cost-utility analysis of focal high-intensity focussed ultrasound vs active surveillance for low- to intermediate-risk prostate cancer using a Markov multi-state model. BJU Int. 2019;124(6):962-71.
11. Brito NC, Machado de Assis TS, Rabello A, Cota G. Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis. PLoS Negl Trop Dis. 2019;13(12):e0007856.
12. Cai H, Zhang L, Li N, Zheng B, Liu M. Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma. Leuk Lymphoma. 2019;60(12):2951-9.
13. Carsley S, Fu R, Borkhoff CM, Reid N, Baginska E, Birken CS, et al. Iron deficiency screening for children at 18 months: a cost-utility analysis. CMAJ Open. 2019;7(4):E689-e98.
14. Castaneda-Orjuela C, Garcia-Molina M, De la Hoz-Restrepo F. Is There Something Else Beyond Cost-Effectiveness Analysis for Public Health Decision Making? Value Health Reg Issues. 2019;23:1-5.
15. Cheng HH, Kung PT, Wang BR, Chiu LT, Tsai WC. Cost-benefit analysis, cost-effectiveness analysis, and impact of antiepileptic drugs on the risk of fracture in patients with epilepsy: A nationwide cohort study. Epilepsy Behav. 2019:106851.
16. Chiang TT, Shtein RM, McCoy K, Hurlbert S, Grossman GH. Cost-Benefit and Cost-Utility Analysis of Amphotericin B Supplementation of Corneal Storage Media With Endothelial Keratoplasty-Prepared Tissue. Cornea. 2019.
17. Choi SE, Sima C, Pandya A. Impact of Treating Oral Disease on Preventing Vascular Diseases: A Model-Based Cost-effectiveness Analysis of Periodontal Treatment Among Patients With Type 2 Diabetes. Diabetes Care. 2019.
18. Du X, He X, Jia Y, Wu J, Long D, Yu R, et al. A Long-Term Cost-Effectiveness Analysis Comparing Radiofrequency Catheter Ablation with Antiarrhythmic Drugs in Treatment of Chinese Patients with Atrial Fibrillation. Am J Cardiovasc Drugs. 2019;19(6):569-77.
19. Dunlap LJ, Orme S, Zarkin GA, Arias SA, Miller IW, Camargo CA, Jr., et al. Screening and Intervention for Suicide Prevention: A Cost-Effectiveness Analysis of the ED-SAFE Interventions. Psychiatr Serv. 2019;70(12):1082-7.
20. Fitzgibbon KP, Plett D, Chan BCF, Hancock-Howard R, Coyte PC, Blumberger DM. Cost-Utility Analysis of Electroconvulsive Therapy and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression in Ontario. Can J Psychiatry. 2019:706743719890167.
21. Fox HM, Ramsey DC, Thompson AR, Hoekstra CJ, Mirarchi AJ, Nazir OF. Neer Type-II Distal Clavicle Fractures: A Cost-Effectiveness Analysis of Fixation Techniques. J Bone Joint Surg Am. 2019.
22. Garay OU, Nishimwe ML, Bousmah MA, Janah A, Girard PM, Chene G, et al. Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM). Pharmacoecon Open. 2019;3(4):505-15.
23. Gospodarevskaya E. "Naive" cost-utility analysis of reduction mammoplasty in Brazilian public service using BREAST-Q(): Response to the authors. J Plast Reconstr Aesthet Surg. 2019;72(12):2064-94.
24. Hill J, Paulden M, McCabe C, North SA, Venner P, Usmani N. Cost-effectiveness analysis of metformin with enzalutamide in the metastatic castrate-resistant prostate cancer setting. Can J Urol. 2019;26(6):10045-53.
25. Hu JQ, Sarkar R, Sella R, Murphy JD, Afshari NA. Cost-Effectiveness Analysis of Multifocal Intraocular Lenses Compared to Monofocal Intraocular Lenses in Cataract Surgery. Am J Ophthalmol. 2019;208:305-12.
26. Hu X, Wildman KP, Basu S, Lin PL, Rowntree C, Saha V. The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis. Health Econ Rev. 2019;9(1):40.
27. Hunt B, Hansen BB, Ericsson A, Kallenbach K, Ali SN, Dang-Tan T, et al. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States. Adv Ther. 2019;36(12):3483-93.
28. Hwang R, Morris NR, Mandrusiak A, Bruning J, Peters R, Korczyk D, et al. Cost-Utility Analysis of Home-Based Telerehabilitation Compared With Centre-Based Rehabilitation in Patients With Heart Failure. Heart Lung Circ. 2019;28(12):1795-803.
29. Innocenti M, Dell'Acqua I, Famiglietti M, Vignini L, Menichini G, Ghezzi S. Free perforator flaps vs propeller flaps in lower limb reconstruction: A cost/effectiveness analysis on a series of 179 cases. Injury. 2019;50 Suppl 5:S11-s6.
30. Jiang M, Li P, You JH, Zheng X, Deng J, Zhao M, et al. Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China. PLoS One. 2019;14(12):e0224580.
31. Kawaguchi I, Chayama K, Gonzalez YS, Virabhak S, Mitchell D, Yuen C, et al. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan. Adv Ther. 2019.
32. Kongnakorn T, Eckmann C, Bassetti M, Tichy E, Di Virgilio R, Baillon-Plot N, et al. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI). Antimicrob Resist Infect Control. 2019;8:204.
33. Kristianslund O, Dalby M, Moe MC, Drolsum L. Cost-effectiveness analysis in a randomized trial of late in-the-bag intraocular lens dislocation surgery: repositioning versus exchange. Acta Ophthalmol. 2019;97(8):771-7.
34. Krittayaphong R, Yadee J, Permsuwan U. Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction. Clinicoecon Outcomes Res. 2019;11:767-77.
35. Kurita J, Sugawara T, Matsumoto K, Ohkusa Y. Cost-effectiveness analysis of (Nursery) School Absenteeism Surveillance System. Pediatr Int. 2019;61(12):1257-60.
36. Lazzaro C, Baricich A, Picelli A, Caglioni PM, Ratti M, Santamato A. AbobotulinumtoxinA and rehabilitation vs rehabilitation alone in post-stroke spasticity: A cost-utility analysis. J Rehabil Med. 2019.
37. Leurent B, Gomes M, Cro S, Wiles N, Carpenter JR. Reference-based multiple imputation for missing data sensitivity analyses in trial-based cost-effectiveness analysis. Health Econ. 2019.
38. Li LY, Wang H, Chen X, Li WQ, Cui JW. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China. Chin Med J (Engl). 2019;132(23):2790-4.
39. Liao W, Huang J, Hutton D, Zhu G, Wu Q, Wen F, et al. Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma. Liver Int. 2019;39(12):2408-16.
40. Liao W, Huang J, Wu Q, Wen F, Zhang N, Zhou K, et al. First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis. Breast Cancer. 2019.
41. Ling XX, Jin JJ, Zhu GD, Wang WM, Cao YY, Yang MM, et al. Cost-effectiveness analysis of malaria rapid diagnostic tests: a systematic review. Infect Dis Poverty. 2019;8(1):104.
42. Lorenzoni V, Bellelli S, Caselli C, Knuuti J, Underwood SR, Neglia D, et al. Cost-effectiveness analysis of stand-alone or combined non-invasive imaging tests for the diagnosis of stable coronary artery disease: results from the EVINCI study. Eur J Health Econ. 2019;20(9):1437-49.
43. Malhotra A, Wu X, Brinjikji W, Miller T, Matouk CC, Sanelli P, et al. Pipeline Endovascular Device vs Stent-Assisted Coiling in Small Unruptured Aneurysms: A Cost-Effectiveness Analysis. Neurosurgery. 2019;85(6):E1010-e9.
44. Mattingly TJ, 2nd, Slejko JF, Onukwugha E, Perfetto EM, Kottilil S, Mullins CD. Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis. Pharmacoeconomics. 2019.
45. McCabe C, Paulden M, Awotwe I, Sutton A, Hall P. One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit. Pharmacoeconomics. 2019.
46. Mlcoch T, Hrnciarova T, Tuzil J, Zadak J, Marian M, Dolezal T. Propensity Score Weighting Using Overlap Weights: A New Method Applied to Regorafenib Clinical Data and a Cost-Effectiveness Analysis. Value Health. 2019;22(12):1370-7.
47. Nguyen CP, Dan Do TN, Bruggemann R, Ten Oever J, Kolwijck E, Adang EMM, et al. Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis. Int J Antimicrob Agents. 2019;54(6):790-7.
48. Nystrand C, Feldman I, Enebrink P, Sampaio F. Cost-effectiveness analysis of parenting interventions for the prevention of behaviour problems in children. PLoS One. 2019;14(12):e0225503.
49. Overmann KM, Robinson BRH, Eckman MH. Cervical spine evaluation in pediatric trauma: A cost-effectiveness analysis. Am J Emerg Med. 2019.
50. Padula WV, Chen YH, Santamaria N. Five-layer border dressings as part of a quality improvement bundle to prevent pressure injuries in US skilled nursing facilities and Australian nursing homes: A cost-effectiveness analysis. Int Wound J. 2019;16(6):1263-72.
51. Palmer AY, Wade AJ, Draper B, Howell J, Doyle JS, Petrie D, et al. A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment. Int J Drug Policy. 2019;76:102633.
52. Paulauskiene J, Stelemekas M, Ivanauskiene R, Petkeviciene J. The Cost-Effectiveness Analysis of Cervical Cancer Screening Using a Systematic Invitation System in Lithuania. Int J Environ Res Public Health. 2019;16(24).
53. Pecenka C, Debellut F, Bar-Zeev N, Anwari P, Nonvignon J, Clark A. Cost-effectiveness analysis for rotavirus vaccine decision-making: How can we best inform evolving and complex choices in vaccine product selection? Vaccine. 2019.
54. Pereira C, Areia M, Dinis-Ribeiro M. Cost-utility analysis of genetic polymorphism universal screening in colorectal cancer prevention by detection of high-risk individuals. Dig Liver Dis. 2019;51(12):1731-7.
55. Petrou P. Elucidating value: the role of cost-effectiveness analysis in the decision-making process for the management of BRAF V600E/K mutation-positive melanoma. J Med Econ. 2019;22(12):1241-2.
56. Pirhonen L, Bolin K, Olofsson EH, Fors A, Ekman I, Swedberg K, et al. Person-Centred Care in Patients with Acute Coronary Syndrome: Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial. Pharmacoecon Open. 2019;3(4):495-504.
57. Presa M, Perez-Ruiz F, Oyaguez I. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients. Clin Rheumatol. 2019;38(12):3521-8.
58. Ramos M, Foos V, Ustyugova A, Hau N, Gandhi P, Lamotte M. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease. Diabetes Ther. 2019;10(6):2153-67.
59. Rogers M, Dart S, Odum S, Fleischli J. A Cost-Effectiveness Analysis of Isolated Meniscal Repair Versus Partial Meniscectomy for Red-Red Zone, Vertical Meniscal Tears in the Young Adult. Arthroscopy. 2019;35(12):3280-6.
60. Sakamaki H, Nakao K, Matsumoto T, Inoue S. Cost-effectiveness analysis of percutaneous mitral valve repair with the MitraClip delivery system for patients with mitral regurgitation in Japan. J Med Econ. 2019;22(12):1312-20.
61. Serra-Burriel M, Graupera I, Toran P, Thiele M, Roulot D, Wai-Sun Wong V, et al. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J Hepatol. 2019;71(6):1141-51.
62. She L, Hu H, Liao M, Xia X, Shi Y, Yao L, et al. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. Lung Cancer. 2019;138:88-94.
63. Simons RWP, Dickman MM, van den Biggelaar F, Dirksen CD, Van Rooij J, Remeijer L, et al. Trial-based cost-effectiveness analysis of ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) versus DSAEK. Acta Ophthalmol. 2019;97(8):756-63.
64. Sung WS, Jeon SR, Hong YJ, Kim TH, Shin S, Lee HJ, et al. Efficacy, safety, and cost-effectiveness analysis of adjuvant herbal medicine treatment, Palmijihwang-hwan, for chronic low back pain: a study protocol for randomized, controlled, assessor-blinded, multicenter clinical trial. Trials. 2019;20(1):778.
65. Telford C, Bertranou E, Large S, Phelps H, Ekman M, Livings C. Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naive Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK. Pharmacoecon Open. 2019;3(4):559-70.
66. Tremblay G, Rousseau B, Marquis M, Beaubois C, Sauvageau G, Hebert J. Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting. Appl Health Econ Health Policy. 2019;17(6):827-39.
67. van den Brand FA, Nagelhout GE, Winkens B, Chavannes NH, van Schayck OCP, Evers S. Cost-effectiveness and cost-utility analysis of a work-place smoking cessation intervention with and without financial incentives. Addiction. 2019.
68. Wen F, Zheng H, Zhang P, Zhou J, Chen H, Zhou K, et al. Patient-based cost-effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4-year prospective randomised phase II study. Eur J Cancer Care (Engl). 2019:e13196.
69. Ying T, Tran A, Webster AC, Klarenbach SW, Gill J, Chadban S, et al. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis. Am J Kidney Dis. 2019.
70. Yokoya Y, Igarashi A, Uda A, Deguchi H, Takeuchi T, Higuchi K. Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD. J Gastroenterol. 2019;54(12):1083-95.
71. Yoon AY, Bozzuto L, Seto AJ, Fisher CS, Chatterjee A. ASO Author Reflections: Cost-Utility Analysis, Utility Scores, and Surgical Oncology. Ann Surg Oncol. 2019;26(Suppl 3):649-50.
72. You R, Liu J, Wu DB, Qian X, Lyu B, Zhang Y, et al. Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China. Cancer Manag Res. 2019;11:10239-48.
73. Yue M, Dickens BL, Yoong JS, M ICC, Teerawattananon Y, Cook AR. Cost-Effectiveness Analysis for Influenza Vaccination Coverage and Timing in Tropical and Subtropical Climate Settings: A Modeling Study. Value Health. 2019;22(12):1345-54.
74. Zeng X, Wan X, Peng L, Peng Y, Ma F, Liu Q, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA. BMJ Open. 2019;9(12):e031019.
75. Zhan M, Zheng H, Yang Y, Xu T, Li Q. Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial. Radiother Oncol. 2019;141:27-32.
76. Zhang M, Wen F, He X, Zhang W, Hu J, Li Q. Adjuvant Chemoradiotherapy for Gastric Cancer: Efficacy and Cost-Effectiveness Analysis. Front Oncol. 2019;9:1357.

November 2019

1. Adamson AS, Jarmul JA, Pignone MP. Screening for Melanoma in Men: a Cost-Effectiveness Analysis. J Gen Intern Med. 2019.
2. Amirlak B, Chung MH, Masrour S. Commentary on: Cost-Utility Analysis of Surgical Decompression Relative to Injection Therapy for Chronic Migraine Headaches. Aesthet Surg J. 2019;39(12):Np471-np3.
3. Bao Y, Zhao G, Qu S, Xiong T, Yao X, Wu B. A Caprini Risk Score-Based Cost-Effectiveness Analysis of Enoxaparin for the Thromboprophylaxis of Patients After Nonorthopedic Surgery in a Chinese Healthcare Setting. Clin Drug Investig. 2019.
4. Barichello S, Deng L, Ismond KP, Loomes DE, Kirwin EM, Wang H, et al. Comparative effectiveness and cost-effectiveness analysis of a urine metabolomics test vs. alternative colorectal cancer screening strategies. Int J Colorectal Dis. 2019;34(11):1953-62.
5. Beaulieu E, Rajabali F, Zheng A, Pike I. The lifetime costs of pediatric abusive head trauma and a cost-effectiveness analysis of the Period of Purple crying program in British Columbia, Canada. Child Abuse Negl. 2019;97:104133.
6. Ben AJ, Neyeloff JL, de Souza CF, Rosses APO, de Araujo AL, Szortika A, et al. Cost-utility Analysis of Opportunistic and Systematic Diabetic Retinopathy Screening Strategies from the Perspective of the Brazilian Public Healthcare System. Appl Health Econ Health Policy. 2019.
7. Booth N, Rissanen P, Tammela TLJ, Kujala P, Stenman UH, Taari K, et al. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data. PLoS One. 2019;14(11):e0224479.
8. Castillo-Rodriguez L, Ovalle-Bracho C, Diaz-Jimenez D, Sanchez-Vanegas G, Muvdi-Arenas S, Castaneda-Orjuela C. Cost-effectiveness analysis of Mucosal Leishmaniasis diagnosis with PCR-based vs parasitological tests in Colombia. PLoS One. 2019;14(11):e0224351.
9. Criss SD, Cao P, Bastani M, Ten Haaf K, Chen Y, Sheehan DF, et al. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study. Ann Intern Med. 2019.
10. Cui L, He T, Jiang Y, Li M, Wang O, Jiajue R, et al. Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data. Osteoporos Int. 2019.
11. Diaby V, Alqhtani H, van Boemmel-Wegmann S, Wang CY, Ali AA, Balkrishnan R, et al. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. Breast. 2019;49:141-8.
12. Genuino AJ, Chaikledkaew U, Guerrero AM, Reungwetwattana T, Thakkinstian A. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines. BMC Health Serv Res. 2019;19(1):874.
13. Goryakin Y, Aldea A, Lerouge A, Romano Spica V, Nante N, Vuik S, et al. Promoting sport and physical activity in Italy: a cost-effectiveness analysis of seven innovative public health policies. Ann Ig. 2019;31(6):614-25.
14. Hollier-Hann G, Curry A, Onishchenko K, Akehurst R, Ahmed F, Davies B, et al. Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK. J Med Econ. 2020;23(1):113-23.
15. Jensen AD, Debus J. Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck. Radiat Oncol. 2019;14(1):194.
16. Jin C, Zheng H, Zhan M, Wen F, Xu T. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 2019.
17. Kansal A, Reifsnider OS, Proskorovsky I, Zheng Y, Pfarr E, George JT, et al. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial. Diabet Med. 2019;36(11):1494-502.
18. Kim H, Vargo JA, Ling DC, Beriwal S, Smith KJ. Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status. Am J Clin Oncol. 2019;42(11):837-44.
19. Kim JJ, McFarlane T, Tully S, Wong WWL. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis. Oncologist. 2019.
20. Kongnakorn T, Wagenlehner F, Falcone M, Tichy E, Di Virgilio R, Baillon-Plot N, et al. Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections. Int J Antimicrob Agents. 2019;54(5):633-41.
21. Li LY, Wang H, Chen X, Li WQ, Cui JW. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China. Chin Med J (Engl). 2019.
22. Liu M, Han S, Zheng B, Cai H, Yang J, Zhuang Q, et al. Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States. Cancer Manag Res. 2019;11:9483-93.
23. Liu Q, Luo X, Peng L, Yi L, Wan X, Zeng X, et al. Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis. Clin Drug Investig. 2019.
24. Messoudi W, Elmahi T, Nejjari C, Tachfouti N, Zidouh A, Saadani G, et al. Cervical cancer prevention in Morocco: a model-based cost-effectiveness analysis. J Med Econ. 2019;22(11):1153-9.
25. Mouritsen JM, Ehlers L, Kovaleva J, Ahmad I, El-Boghdadly K. A systematic review and cost effectiveness analysis of reusable vs. single-use flexible bronchoscopes. Anaesthesia. 2019.
26. Muhlenbruch K, Zhuo X, Bardenheier B, Shao H, Laxy M, Icks A, et al. Selecting the optimal risk threshold of diabetes risk scores to identify high-risk individuals for diabetes prevention: a cost-effectiveness analysis. Acta Diabetol. 2019.
27. O'Mahony JF, Paulden M. The Joint Committee on Vaccination and Immunisation's Advice on Extending Human Papillomavirus Vaccination to Boys: Were Cost-Effectiveness Analysis Guidelines Bent to Achieve a Politically Acceptable Decision? Value Health. 2019;22(11):1227-30.
28. Otero HJ, Degnan AJ, Kadom N, Neumann PJ, Lavelle TA. Cost-Effectiveness Analysis in Pediatric Imaging: The Evidence (or Lack Thereof) Thus Far. J Am Coll Radiol. 2019.
29. Papaefthymiou A, Liatsos C, Georgopoulos SD, Apostolopoulos P, Doulberis M, Kyriakos N, et al. Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis. Helicobacter. 2019:e12666.
30. Premkumar A, Grobman WA, Terplan M, Miller ES. Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis. Obstet Gynecol. 2019;134(5):921-31.
31. Reddy KP, Horsburgh CR, Wood R, Fields NF, Girouard MP, Costantini S, et al. Shortened Tuberculosis Treatment for People with HIV in South Africa: A Model-based Evaluation and Cost-effectiveness Analysis. Ann Am Thorac Soc. 2019.
32. Rodriguez-Sanchez B, Pena-Longobardo LM, Sinclair AJ. Cost-effectiveness analysis of the Neuropad device as a screening tool for early diabetic peripheral neuropathy. Eur J Health Econ. 2019.
33. Sathianathen NJ, Alarid-Escudero F, Kuntz KM, Lawrentschuk N, Bolton DM, Murphy DG, et al. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer. Eur Urol Oncol. 2019;2(6):649-55.
34. Shaker M, Oppenheimer J, Wallace D, Lang DM, Rambasek T, Dykewicz M, et al. Optimizing Value in the Evaluation of Chronic Spontaneous Urticaria: A Cost-effectiveness Analysis. J Allergy Clin Immunol Pract. 2019.
35. Shao H, Lin J, Zhuo X, Rolka DB, Gregg EW, Zhang P. Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis. Diabetes Care. 2019;42(11):2136-42.
36. Shauly O, Gould DJ, Patel KM. Cost-Utility Analysis of Surgical Decompression Relative to Injection Therapy for Chronic Migraine Headaches. Aesthet Surg J. 2019;39(12):Np462-np70.
37. Smare C, Lakhdari K, Doan J, Posnett J, Johal S. Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes. Pharmacoeconomics. 2019.
38. Teramae F, Yamaguchi N, Makino T, Sengoku S, Kodama K. Holistic cost-effectiveness analysis of anticancer drug regimens in Japan. Drug Discov Today. 2019.
39. Tigabu BM, Davari M, Kebriaeezadeh A, Mojtahedzadeh M, Sadeghi K, Najmeddin F, et al. A Cost-effectiveness Analysis of Albumin in Septic Shock: A Patient-level Data Analysis. Clin Ther. 2019;41(11):2297-307.e2.
40. Xiao H, Huang J, Liu W, Dai Z, Peng S, Peng Z, et al. The cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a Markov model. Qual Life Res. 2019.
41. Xing N, Cheung WY, Jiang M, You JHS. Standing orders program of pneumococcal vaccination for hospitalized elderly patients in Hong Kong: A cost-effectiveness analysis. Am J Infect Control. 2019;47(11):1302-8.

October 2019

1. Barnett J, Belsey J, Tavare AN, Saini A, Patel A, Hayward M, et al. Pre-surgical lung biopsy in management of solitary pulmonary nodules: a cost effectiveness analysis. J Med Econ. 2019:1-5.
2. Bendixen M, Kronborg C, Jorgensen OD, Andersen C, Licht PB. Cost-utility analysis of minimally invasive surgery for lung cancer: a randomized controlled trial. Eur J Cardiothorac Surg. 2019;56(4):754-61.
3. Biggerstaff M, Cohen C, Reed C, Tempia S, McMorrow ML, Walaza S, et al. A cost-effectiveness analysis of antenatal influenza vaccination among HIV-infected and HIV-uninfected pregnant women in South Africa. Vaccine. 2019;37(46):6874-84.
4. Brown GC, Brown MM. Re: Hughes et al.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis (Ophthalmology. 2019;126:415-424). Ophthalmology. 2019;126(10):e76.
5. Buttermann G, Hollmann S, Arpino JM, Ferko N. Value of single-level circumferential fusion: a 10-year prospective outcomes and cost-effectiveness analysis comparing posterior facet versus pedicle screw fixation. Eur Spine J. 2019.
6. Caruso R, Vicente E, Nunez-Alfonsel J, Ferri V, Diaz E, Fabra I, et al. Robotic-assisted gastrectomy compared with open resection: a comparative study of clinical outcomes and cost-effectiveness analysis. J Robot Surg. 2019.
7. Chen J, Hu G, Chen Z, Wan X, Tan C, Zeng X, et al. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. Clin Drug Investig. 2019;39(10):931-8.
8. Cleghorn CL, Wilson N, Nair N, Kvizhinadze G, Nghiem N, McLeod M, et al. Health benefits and costs of weight-loss dietary counselling by nurses in primary care: a cost-effectiveness analysis. Public Health Nutr. 2019:1-11.
9. Collins B, Kypridemos C, Cookson R, Parvulescu P, McHale P, Guzman-Castillo M, et al. Universal or targeted cardiovascular screening? Modelling study using a sector-specific distributional cost effectiveness analysis. Prev Med. 2019:105879.
10. Connor D, Coppell K, Gray A, Sullivan T. A cost-effectiveness analysis of the Prediabetes Intervention Package (PIP) in primary care: a New Zealand pilot programme. N Z Med J. 2019;132(1504):24-34.
11. De Mil R, Guillaume E, Launay L, Guittet L, Dejardin O, Bouvier V, et al. Cost-Effectiveness Analysis of a Mobile Mammography Unit for Breast Cancer Screening to Reduce Geographic and Social Health Inequalities. Value Health. 2019;22(10):1111-8.
12. de Pouvourville G, Blin P, Karam P. The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France. Eur J Health Econ. 2019.
13. Duhig KE, Seed PT, Myers JE, Bahl R, Bambridge G, Barnfield S, et al. Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis. Bjog. 2019;126(11):1390-8.
14. Fan KL, Black CK, Song DH. Discussion: A Simplified Cost-Utility Analysis of Inpatient Flap Monitoring after Microsurgical Breast Reconstruction and Implications for Hospital Length of Stay. Plast Reconstr Surg. 2019;144(4):552e-3e.
15. Fernandes EG, Sartori AMC, de Soarez PC, Amaku M, de Azevedo Neto RS, Novaes HMD. Cost-effectiveness analysis of universal adult immunization with tetanus-diphtheria-acellular pertussis vaccine (Tdap) versus current practice in Brazil. Vaccine. 2019.
16. Fragoulakis V, Bartsakoulia M, Diaz-Villamarin X, Chalikiopoulou K, Kehagia K, Ramos JGS, et al. Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention. Pharmacogenomics J. 2019;19(5):438-45.
17. Garattini L, Padula A. Comment on: 'The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study'. Pharmacoeconomics. 2019;37(10):1301-2.
18. Gaskin J, Coyle D, Whyte J, Birkett N, Krewksi D. A cost effectiveness analysis of interventions to reduce residential radon exposure in Canada. J Environ Manage. 2019;247:449-61.
19. Gehrman J, Angenete E, Bjorholt I, Lesen E, Haglind E. Cost-effectiveness analysis of laparoscopic and open surgery in routine Swedish care for colorectal cancer. Surg Endosc. 2019.
20. Giannouchos TV, Mitsikostas DD, Ohsfeldt RL, Vozikis A, Koufopoulou P. Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece. Clin Drug Investig. 2019;39(10):979-90.
21. Gospodarevskaya E. "Naive" cost-utility analysis of reduction mammoplasty in Brazilian public service using BREAST-Q(): Response to the authors. J Plast Reconstr Aesthet Surg. 2019.
22. Han Y, Yan T, Ma H, Yao X, Lu C, Li Y, et al. Cost-Effectiveness Analysis of Helicobacter pylori Eradication Therapy for Prevention of Gastric Cancer: A Markov Model. Dig Dis Sci. 2019.
23. Hedderich DM, Ferro JM, Kunz WG. Diagnostic imaging in the management of patients with possible cerebral venous thrombosis: a cost-effectiveness analysis. Neuroradiology. 2019;61(10):1155-63.
24. Hunt B, Hansen BB, Ericsson A, Kallenbach K, Ali SN, Dang-Tan T, et al. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States. Adv Ther. 2019.
25. Hunt B, Malkin SJP, Moes RGJ, Huisman EL, Vandebrouck T, Wolffenbuttel B. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. BMJ Open Diabetes Res Care. 2019;7(1):e000705.
26. Ibrahim LF, Huang L, Hopper SM, Dalziel K, Babl FE, Bryant PA. Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis. Lancet Infect Dis. 2019;19(10):1101-8.
27. Jablonka EM, Lamelas AM, Kanchwala SK, Rhemtulla I, Smith ML. A Simplified Cost-Utility Analysis of Inpatient Flap Monitoring after Microsurgical Breast Reconstruction and Implications for Hospital Length of Stay. Plast Reconstr Surg. 2019;144(4):540e-9e.
28. Javanbakht M, Trevor M, Rezaei Hemami M, Rahimi K, Branagan-Harris M, Degener F, et al. Ticagrelor Removal by CytoSorb((R)) in Patients Requiring Emergent or Urgent Cardiac Surgery: A UK-Based Cost-Utility Analysis. Pharmacoecon Open. 2019.
29. Kongpakwattana K, Ademi Z, Chaiyasothi T, Nathisuwan S, Zomer E, Liew D, et al. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand. Pharmacoeconomics. 2019;37(10):1277-86.
30. Konijeti GG, Grandhe S, Konerman M, Lane J, Shrime M, Singh S, et al. Cost-Effectiveness Analysis of Screening for Hepatitis B Virus Infection in Patients with Solid Tumors before Initiating Chemotherapy. Clin Gastroenterol Hepatol. 2019.
31. Koto PS, Hu SX, Virani K, Simpkin WL, Christian CA, Cao H, et al. A Cost-utility Analysis of Endovascular Thrombectomy in a Real-World Setting. Can J Neurol Sci. 2019:1-34.
32. Kurita J, Sugawara T, Matsumoto K, Ohkusa Y. Cost-Effectiveness Analysis of (Nursery) School Absenteeism Surveillance System. Pediatr Int. 2019.
33. Liao W, Huang J, Zhu G, Zhou J, Wen F, Zhang P, et al. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial. Expert Rev Pharmacoecon Outcomes Res. 2019:1-6.
34. Moreno-Fernandez J. Comments on Garcia-Lorenzo et al. Cost-effectiveness analysis of real-time continuous monitoring glucose compared to self-monitoring of blood glucose for diabetes mellitus in Spain. J Eval Clin Pract. 2019;25(5):906.
35. Nemati H, Talebianpour H, Lotfi F, Sepehri NZ, Keshavarz K. Cost-Effectiveness Analysis of Topiramate versus Phenobarbital in the Treatment of Children with Febrile Seizure. Iran J Child Neurol. 2019;13(4):109-20.
36. Oostingh EC, Ophuis RH, Koster MP, Polinder S, Lingsma HF, Laven JS, et al. Mobile Health Coaching on Nutrition and Lifestyle Behaviors for Subfertile Couples Using the Smarter Pregnancy Program: Model-Based Cost-Effectiveness Analysis. JMIR Mhealth Uhealth. 2019;7(10):e13935.
37. Oyaguez I, Suarez C, Lopez-Sendon JL, Gonzalez-Juanatey JR, de Andres-Nogales F, Suarez J, et al. Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention. Pharmacoecon Open. 2019.
38. Perera K, Ademi Z, Liew D, Zomer E. Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis. Eur J Prev Cardiol. 2019:2047487319878953.
39. Permsuwan U, Thongprasert S, Sirichanchuen B. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand. Value Health Reg Issues. 2019;21:9-16.
40. Pleyer U, Minden K, Klotsche J, Heiligenhaus A, Foeldvari I. Re: Hughes et al.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis (Ophthalmology. 2019;126:415-424). Ophthalmology. 2019;126(10):e75-e6.
41. Ramos M, Foos V, Ustyugova A, Hau N, Gandhi P, Lamotte M. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease. Diabetes Ther. 2019.
42. Retat L, Pimpin L, Webber L, Jaccard A, Lewis A, Tearne S, et al. Screening and brief intervention for obesity in primary care: cost-effectiveness analysis in the BWeL trial. Int J Obes (Lond). 2019;43(10):2066-75.
43. Schwartz NRM, Flanagan MR, Babigumira JB, Steuten LM, Roth JA. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer. J Manag Care Spec Pharm. 2019;25(10):1133-9.
44. She L, Hu H, Liao M, Xia X, Shi Y, Yao L, et al. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. Lung Cancer. 2019;138:88-94.
45. Sheckter CC, Matros E. Discussion: A Simplified Cost-Utility Analysis of Inpatient Flap Monitoring after Microsurgical Breast Reconstruction and Implications for Hospital Length of Stay. Plast Reconstr Surg. 2019;144(4):550e-1e.
46. Su W, Li C, Zhang L, Lin Z, Tan J, Xuan J. Meta-Analysis and Cost-Effectiveness Analysis of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2 Diabetes in China. Diabetes Ther. 2019;10(5):1969-84.
47. Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, et al. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. JAMA Oncol. 2019.
48. Surendra NK, Abdul Manaf MR, Hooi LS, Bavanandan S, Mohamad Nor FS, Firdaus Khan SS, et al. Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis. PLoS One. 2019;14(10):e0218422.
49. Symes RJ, Zagora SL, Younan C, McCluskey PJ. Re: Hughes et al.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis (Ophthalmology. 2019;126:415-424). Ophthalmology. 2019;126(10):e77.
50. Tam-Tham H, Clement F, Hemmelgarn BR, Manns BJ, Klarenbach SW, Tonelli M, et al. A Cost Analysis and Cost-Utility Analysis of a Community Pharmacist-Led Intervention on Reducing Cardiovascular Risk: The Alberta Vascular Risk Reduction Community Pharmacy Project (RxEACH). Value Health. 2019;22(10):1128-36.
51. Taneva GT, Donas KP, Pitoulias GA, Austermann M, Veith FJ, Torsello G. Cost-effectiveness analysis of chimney/snorkel versus fenestrated endovascular repair for high-risk patients with complex abdominal aortic pathologies. J Cardiovasc Surg (Torino). 2019.
52. Tigabu BM, Davari M, Kebriaeezadeh A, Mojtahedzadeh M, Sadeghi K, Najmeddin F, et al. A Cost-effectiveness Analysis of Albumin in Septic Shock: A Patient-level Data Analysis. Clin Ther. 2019.
53. Tsukiyama I, Ando M, Tsukiyama S, Takeuchi M, Ejiri M, Kurose Y, et al. Cost-utility analysis of aprepitant for patients who truly need it in Japan. Support Care Cancer. 2019;27(10):3749-58.
54. Vargas C, Balmaceda C, Rodriguez F, Rojas R, Giglio A, Espinoza MA. Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison. Expert Rev Pharmacoecon Outcomes Res. 2019;19(5):609-17.
55. Vijayaraghavan BKT, Willaert X, Cuthbertson BH. Cost-effectiveness analysis should be mandatory in clinical-effectiveness research. Cmaj. 2019;191(41):E1140.
56. Voermans AM, Mewes JC, Broyles MR, Steuten LMG. Cost-Effectiveness Analysis of a Procalcitonin-Guided Decision Algorithm for Antibiotic Stewardship Using Real-World U.S. Hospital Data. Omics. 2019;23(10):508-15.
57. Wan X, Luo X, Tan C, Zeng X, Zhang Y, Peng L. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis. Cancer. 2019;125(20):3526-34.
58. Weng X, Luo S, Lin S, Zhong L, Li M, Xin R, et al. Cost-utility analysis of pembrolizumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer with different PD-L1 expression levels. Oncol Res. 2019.
59. Werbrouck A, Schmidt M, Putman K, Annemans L, Benhalima K, Simoens S, et al. Cost-utility analysis of lifestyle interventions to prevent type 2 diabetes in women with prior gestational diabetes. Eur J Public Health. 2019.
60. Zeevat F, van der Schans J, Boersma WG, Boersma C, Postma MJ. Cost-effectiveness analysis on elderly pneumococcal vaccination in the Netherlands: Challenging the Dutch Health Council's advice. Vaccine. 2019;37(43):6282-4.
61. Zhou K, Jiang C, Li Q. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores. Lung Cancer. 2019;136:98-101.

September 2019

1. Abramson A, Halperin F, Kim J, Traverso G. Quantifying the Value of Orally Delivered Biologic Therapies: A Cost-Effectiveness Analysis of Oral Semaglutide. J Pharm Sci. 2019;108(9):3138-45.
2. Aguilar-Serra J, Gimeno-Ballester V, Pastor-Clerigues A, Milara J, Marti-Bonmati E, Trigo-Vicente C, et al. Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis. J Comp Eff Res. 2019;8(11):853-63.
3. Akazawa M, Igarashi A, Ebata N, Murata T, Zeniya S, Haga Y, et al. A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan. J Pain Res. 2019;12:2785-97.
4. Anagnostis P, Pliakos I, Panidis S, Chorti A, Stelmach V, Michalopoulos A, et al. Should total thyroidectomies be performed by high-volume endocrine surgeons? A cost-effectiveness analysis. Endocrine. 2019.
5. Atehortua S, Senior JM, Castro P, Ceballos M, Saldarriaga C, Giraldo N, et al. Cost-utility analysis of an implantable cardioverterdefibrillator for the treatment of patients with ischemic or non-ischemic New York Heart Association class II or III heart failure in Colombia. Biomedica. 2019;39(3):502-12.
6. Avram CM, Greiner KS, Tilden E, Caughey AB. Point-of-care HIV viral load in pregnant women without prenatal care: a cost-effectiveness analysis. Am J Obstet Gynecol. 2019;221(3):265.e1-.e9.
7. Barnett J, Belsey J, Tavare AN, Saini A, Patel A, Hayward M, et al. Pre-surgical lung biopsy in management of solitary pulmonary nodules: a cost effectiveness analysis. J Med Econ. 2019:1.
8. Biggerstaff M, Cohen C, Reed C, Tempia S, McMorrow ML, Walaza S, et al. A cost-effectiveness analysis of antenatal influenza vaccination among HIV-infected and HIV-uninfected pregnant women in South Africa. Vaccine. 2019.
9. Bullard KA, Edelman AB, Williams SM, Rodriguez MI. Ulipristal acetate compared to levonorgestrel emergency contraception among current oral contraceptive users: a cost-effectiveness analysis. Contraception. 2019;100(3):222-7.
10. Byrnes J, Ball J, Gao L, Kai Chan Y, Kularatna S, Stewart S, et al. Within trial cost-utility analysis of disease management program for patients hospitalized with atrial fibrillation: results from the SAFETY trial. J Med Econ. 2019;22(9):945-52.
11. Chatterjee A, Asban A, Jonczyk M, Chen L, Czerniecki B, Fisher CS. A cost-utility analysis comparing large volume displacement oncoplastic surgery to mastectomy with free flap reconstruction in the treatment of breast cancer. Am J Surg. 2019;218(3):597-604.
12. Codispoti CD, Mahdavinia M. A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps. Ann Allergy Asthma Immunol. 2019;123(3):232-9.
13. Collins B, Kypridemos C, Pearson-Stuttard J, Huang Y, Bandosz P, Wilde P, et al. FDA Sodium Reduction Targets and the Food Industry: Are There Incentives to Reformulate? Microsimulation Cost-Effectiveness Analysis. Milbank Q. 2019;97(3):858-80.
14. Conway A, Gow J, Ralph N, Duff J, Edward KL, Alexander K, et al. Implementing a thermal care bundle for inadvertent perioperative hypothermia: A cost-effectiveness analysis. Int J Nurs Stud. 2019;97:21-7.
15. Coughlin OP, Wright ME, Thorson AG, Ternent CA. Hemorrhoid Banding: A Cost-Effectiveness Analysis. Dis Colon Rectum. 2019;62(9):1085-94.
16. Crespo C, Linhart M, Acosta J, Soto-Iglesias D, Martinez M, Jauregui B, et al. Optimisation of cardiac resynchronisation therapy device selection guided by cardiac magnetic resonance imaging: Cost-effectiveness analysis. Eur J Prev Cardiol. 2019:2047487319873149.
17. de Carvalho I, Peixoto HM, Romero GAS, de Oliveira MRF. Treatment for human visceral leishmaniasis: a cost-effectiveness analysis for Brazil. Trop Med Int Health. 2019;24(9):1064-77.
18. Del Hoyo J, Nos P, Bastida G, Faubel R, Munoz D, Garrido-Marin A, et al. Telemonitoring of Crohn's Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis. J Med Internet Res. 2019;21(9):e15505.
19. Gil-Ibanez MT, Aispuru GR. Cost-effectiveness analysis of glycaemic control of a glucose monitoring system (FreeStyle Libre(R)) for patients with type 1 diabetes in primary health care of Burgos. Enferm Clin. 2019.
20. Goranitis I, Lissauer DM, Coomarasamy A, Wilson A, Daniels J, Middleton L, et al. Antibiotic prophylaxis in the surgical management of miscarriage in low-income countries: a cost-effectiveness analysis of the AIMS trial. Lancet Glob Health. 2019;7(9):e1280-e6.
21. Habu Y. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan. Intern Med. 2019;58(17):2427-33.
22. Haji Ali Afzali H, Karnon J, Theou O, Beilby J, Cesari M, Visvanathan R. Structuring a conceptual model for cost-effectiveness analysis of frailty interventions. PLoS One. 2019;14(9):e0222049.
23. Hansen SA, Aas E, Solli O. A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction. Eur J Health Econ. 2019.
24. Hernandez L, Kuwabara H, Shah A, Yamabe K, Burnett H, Fahrbach K, et al. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naive Patients with Moderate-to-Severe Ulcerative Colitis in Japan. Pharmacoeconomics. 2019.
25. Holleman MS, Al MJ, Zaim R, Groen HJM, Uyl-de Groot CA. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. Eur J Health Econ. 2019.
26. Kaito T, Matsuyama Y, Yamashita T, Kawakami M, Takahashi K, Yoshida M, et al. Cost-effectiveness analysis of the pharmacological management of chronic low back pain with four leading drugs. J Orthop Sci. 2019;24(5):805-11.
27. Kaku K, Haneda M, Sakamaki H, Yasui A, Murata T, Ustyugova A, et al. Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian population in the EMPA-REG OUTCOME Trial. Clin Ther. 2019.
28. Leeyaphan C, Bunyaratavej S, Taychakhoonavudh S, Kulthanachairojana N, Pattanaprichakul P, Chanyachailert P, et al. Cost-effectiveness analysis and safety of erythromycin 4% gel and 4% chlorhexidine scrub for pitted keratolysis treatment. J Dermatolog Treat. 2019;30(6):627-9.
29. Liao W, Huang J, Hutton D, Zhu G, Wu Q, Wen F, et al. Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma. Liver Int. 2019.
30. Lundqvist M, Alwin J, Levin LA. Certified service dogs - A cost-effectiveness analysis appraisal. PLoS One. 2019;14(9):e0219911.
31. Mallampati D, Grobman W, Rouse DJ, Werner EF. Strategies for Prescribing Aspirin to Prevent Preeclampsia: A Cost-Effectiveness Analysis. Obstet Gynecol. 2019;134(3):537-44.
32. Manchikanti L, Pampati V, Parr Iii A, Manchikanti MV, Sanapati MR, Kaye AD, et al. Cervical Interlaminar Epidural Injections in the Treatment of Cervical Disc Herniation, Post Surgery Syndrome, or Discogenic Pain: Cost Utility Analysis from Randomized Trials. Pain Physician. 2019;22(5):421-31.
33. Meester RGS, Lansdorp-Vogelaar I, Winawer SJ, Zauber AG, Knudsen AB, Ladabaum U. High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas: A Cost-Effectiveness Analysis. Ann Intern Med. 2019.
34. Mendez LC, Moraes FY, Castilho MS, Louie AV, Qu XM. Lives and Economic Loss in Brazil due to Lack of Radiotherapy Access in Cervical Cancer: A Cost-Effectiveness Analysis. Clin Oncol (R Coll Radiol). 2019;31(9):e143-e8.
35. Mitchell BG, Fasugba O, Cheng AC, Gregory V, Koerner J, Collignon P, et al. Chlorhexidine versus saline in reducing the risk of catheter associated urinary tract infection: A cost-effectiveness analysis. Int J Nurs Stud. 2019;97:1-6.
36. Mostafa A, El-Sayed MH, El Kassas M, Elhamamsy M, Elsisi GH. Safety-Engineered Syringes: An Intervention to Decrease Hepatitis C Burden in Developing Countries-A Cost-Effectiveness Analysis From Egypt. Value Health Reg Issues. 2019;19:51-8.
37. Murphy A, Bourke J, Flynn D, Kells M, Joyce M. A cost-effectiveness analysis of dialectical behaviour therapy for treating individuals with borderline personality disorder in the community. Ir J Med Sci. 2019.
38. Nicholson KJ, Roberts MS, McCoy KL, Carty SE, Yip L. Molecular Testing Versus Diagnostic Lobectomy in Bethesda III/IV Thyroid Nodules: A Cost-Effectiveness Analysis. Thyroid. 2019;29(9):1237-43.
39. Nicholson KJ, Smith KJ, McCoy KL, Carty SE, Yip L. A comparative cost-utility analysis of postoperative calcium supplementation strategies used in the current management of hypocalcemia. Surgery. 2019.
40. Padula WV, Chen YH, Santamaria N. Five-layer border dressings as part of a quality improvement bundle to prevent pressure injuries in US skilled nursing facilities and Australian nursing homes: A cost-effectiveness analysis. Int Wound J. 2019.
41. Petrou P. Elucidating value: the role of cost-effectiveness analysis in the decision-making process for the management of BRAF V600E/K mutation-positive melanoma. J Med Econ. 2019:1.
42. Rossi SH, Blick C, Nathan P, Nicol D, Stewart GD, Wilson ECF. Expert Elicitation to Inform a Cost-Effectiveness Analysis of Screening for Renal Cancer. Value Health. 2019;22(9):981-7.
43. Sakamaki H, Nakao K, Matsumoto T, Inoue S. Cost-effectiveness analysis of percutaneous mitral valve repair with the MitraClip delivery system for patients with mitral regurgitation in Japan. J Med Econ. 2019:1-9.
44. Samsell B, McLean J, Cazzell S, Dorsch K, Moyer PM, Moore M. Health economics for treatment of diabetic foot ulcers: a cost-effectiveness analysis of eight skin substitutes. J Wound Care. 2019;28(Sup9):S14-s26.
45. Saraswat MK, Carter L, Berrigan P, Sapp JL, Gray C, Fearon A, et al. Integrated Management Approach to Atrial Fibrillation Care: A Cost Utility Analysis. Can J Cardiol. 2019;35(9):1142-8.
46. Shao H, Lin J, Zhuo X, Rolka DB, Gregg EW, Zhang P. Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-Effectiveness Analysis. Diabetes Care. 2019.
47. Shlomai A, Leshno M, Goldstein DA. Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis. Therap Adv Gastroenterol. 2019;12:1756284819878304.
48. Slade E, Daly C, Mavranezouli I, Dias S, Kearney R, Ward K, et al. Primary surgical management of anterior pelvic organ prolapse: a systematic review, network meta-analysis and cost-effectiveness analysis. Bjog. 2019.
49. Su W, Li C, Zhang L, Lin Z, Tan J, Xuan J. Meta-Analysis and Cost-Effectiveness Analysis of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2 Diabetes in China. Diabetes Ther. 2019;10(5):1969-84.
50. Sudhof LS, Shainker SA, Einerson BD. Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis. Am J Obstet Gynecol. 2019;221(3):275.e1-.e12.
51. Vadhwana B, Pouzi A, Surjus Kaneta G, Reid V, Claxton D, Pyne L, et al. Preoperative oral antibiotic bowel preparation in elective resectional colorectal surgery reduces rates of surgical site infections: a single-centre experience with a cost-effectiveness analysis. Ann R Coll Surg Engl. 2019:1-8.
52. Vallejo-Torres L, Rivero-Santana A, Martin-Saborido C, Epstein D, Perestelo-Perez L, Castellano-Fuentes CL, et al. Cost-effectiveness analysis of a surveillance program to prevent hip dislocation in children with cerebral palsy. Gac Sanit. 2019.
53. Vecoso LVZ, Silva MT, Resende MR, da Silva EN, Galvao TF. Cost-Effectiveness Analysis of Influenza A (H1N1) Chemoprophylaxis in Brazil. Front Pharmacol. 2019;10:945.
54. Viola MG, Diamantopoulos A. Determining the Baseline Strategy in a Cost-Effectiveness Analysis with Treatment Sequences. Appl Health Econ Health Policy. 2019.
55. Voermans AM, Mewes JC, Broyles MR, Steuten LMG. Cost-Effectiveness Analysis of a Procalcitonin-Guided Decision Algorithm for Antibiotic Stewardship Using Real-World U.S. Hospital Data. Omics. 2019;23(10):508-15.
56. Wei X, Sun H, Zhuang J, Weng X, Zheng B, Lin Q, et al. Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China. Clin Drug Investig. 2019.
57. Zeevat F, van der Schans J, Boersma WG, Boersma C, Postma MJ. Cost-effectiveness analysis on elderly pneumococcal vaccination in the Netherlands: Challenging the Dutch Health Council's advice. Vaccine. 2019;37(43):6282-4.
58. Zhang L, Bao Y, Riaz M, Tiller J, Liew D, Zhuang X, et al. Correction: Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. Genet Med. 2019;21(9):2162-3.
59. Zhang L, Bao Y, Riaz M, Tiller J, Liew D, Zhuang X, et al. Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. Genet Med. 2019;21(9):1958-68.
60. Zimmermann M, Frey K, Hagedorn B, Oteri AJ, Yahya A, Hamisu M, et al. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis. Vaccine. 2019;37(41):6039-47.

August 2019

1. Aguilar-Serra J, Gimeno-Ballester V, Pastor-Clerigues A, Milara J, Marti-Bonmati E, Trigo-Vicente C, et al. Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis. J Comp Eff Res. 2019;8(11):853-63.
2. Amirlak B, Chung MH, Masrour S. Commentary on: Cost-Utility Analysis of Surgical Decompression Relative to Injection Therapy for Chronic Migraine Headaches. Aesthet Surg J. 2019.
3. Avram CM, Shaffer BL, Sparks TN, Allen AJ, Caughey AB. Cell-free fetal DNA screening for detection of microdeletion syndromes: a cost-effectiveness analysis(). J Matern Fetal Neonatal Med. 2019:1-9.
4. Avram CM, Yieh L, Dukhovny D, Caughey AB. A Cost-Effectiveness Analysis of Rooming-in and Breastfeeding in Neonatal Opioid Withdrawal. Am J Perinatol. 2019.
5. Bandeiras C, Cabral JMS, Gabbay RA, Finkelstein SN, Ferreira FC. Bringing Stem Cell-Based Therapies for Type 1 Diabetes to the Clinic: Early Insights from Bioprocess Economics and Cost-Effectiveness Analysis. Biotechnol J. 2019;14(8):e1800563.
6. Bartolucci A, Walter D, Redmond T. Comparative Review on the Cost-Effectiveness Analysis of Relief Teams' Deployment to Sudden-Onset Disasters. Prehosp Disaster Med. 2019;34(4):415-21.
7. Beaulieu E, Rajabali F, Zheng A, Pike I. The lifetime costs of pediatric abusive head trauma and a cost-effectiveness analysis of the Period of Purple crying program in British Columbia, Canada. Child Abuse Negl. 2019;97:104133.
8. Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, et al. Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Pharmacoeconomics. 2019;37(8):1071.
9. Canning P, Tawfick W, Whelan N, Hynes N, Sultan S. Cost-effectiveness analysis of endovascular versus open repair of abdominal aortic aneurysm in a high-volume center. J Vasc Surg. 2019;70(2):485-96.
10. Chen DY, Hsu PN, Tang CH, Claxton L, Valluri S, Gerber RA. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan. J Med Econ. 2019;22(8):777-87.
11. Cheng LJ, Soon SS, Wu DB, Ju H, Ng K. Cost-effectiveness analysis of bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears in Singapore. PLoS One. 2019;14(8):e0220439.
12. DiStefano MJ, Levin JS. Does Incorporating Cost-Effectiveness Analysis Into Prescribing Decisions Promote Drug Access Equity? AMA J Ethics. 2019;21(8):E679-85.
13. Dunlap LJ, Orme S, Zarkin GA, Arias SA, Miller IW, Camargo CA, Jr., et al. Screening and Intervention for Suicide Prevention: A Cost-Effectiveness Analysis of the ED-SAFE Interventions. Psychiatr Serv. 2019:appips201800445.
14. Evers PD, Anderson JB, Ryan TD, Czosek RJ, Knilans TK, Spar DS. Wearable Cardioverter Defibrillators in Pediatric Cardiomyopathy: A Cost-Utility Analysis. Heart Rhythm. 2019.
15. Freeman J, Hendrie W, Jarrett L, Hawton A, Barton A, Dennett R, et al. Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis. Lancet Neurol. 2019;18(8):736-47.
16. Gaede P, Johansen P, Tikkanen CK, Pollock RF, Hunt B, Malkin SJP. Correction to: Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. Diabetes Ther. 2019;10(4):1319-21.
17. Gaede P, Johansen P, Tikkanen CK, Pollock RF, Hunt B, Malkin SJP. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. Diabetes Ther. 2019;10(4):1297-317.
18. Hu S, Han Y, Zhang W, Zhang T, Yao X, Liu L. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China. J Med Econ. 2019;22(8):742-50.
19. Ibrahim LF, Huang L, Hopper SM, Dalziel K, Babl FE, Bryant PA. Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis. Lancet Infect Dis. 2019.
20. Isaline G, Marie-Christine C, Rudy VT, Caroline D, Yvon E. An exploratory cost-effectiveness analysis: Comparison between a midwife-led birth unit and a standard obstetric unit within the same hospital in Belgium. Midwifery. 2019;75:117-26.
21. Lam J, Hay JW, Salcedo J, Kenyon NJ. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. J Asthma. 2019;56(8):872-81.
22. Lee E, Costello MF, Botha WC, Illingworth P, Chambers GM. A cost-effectiveness analysis of preimplantation genetic testing for aneuploidy (PGT-A) for up to three complete assisted reproductive technology cycles in women of advanced maternal age. Aust N Z J Obstet Gynaecol. 2019;59(4):573-9.
23. Lee H, Park SY, Clark A, Debellut F, Pecenka C, Kim DS, et al. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study. Vaccine. 2019;37(35):4987-95.
24. Li A, Manohar PM, Garcia DA, Lyman GH, Steuten LM. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. Thromb Res. 2019;180:37-42.
25. Lomas JRS. Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment. Value Health. 2019;22(8):898-905.
26. Long MW, Polacsek M, Bruno P, Giles CM, Ward ZJ, Cradock AL, et al. Cost-Effectiveness Analysis and Stakeholder Evaluation of 2 Obesity Prevention Policies in Maine, US. J Nutr Educ Behav. 2019.
27. Lorenzoni V, Bellelli S, Caselli C, Knuuti J, Underwood SR, Neglia D, et al. Cost-effectiveness analysis of stand-alone or combined non-invasive imaging tests for the diagnosis of stable coronary artery disease: results from the EVINCI study. Eur J Health Econ. 2019.
28. Ma T, Lee LY, Aw MM, Lee GH. Cost-effectiveness analysis of antiviral treatment for pregnant women with high viral load to prevent hepatitis B virus vertical transmission. Singapore Med J. 2019.
29. Malkin SJP, Russel-Szymczyk M, Psota M, Hlavinkova L, Hunt B. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. Adv Ther. 2019;36(8):2034-51.
30. Men P, Qu S, Luo W, Li C, Zhai S. Comparison of lixisenatide in combination with basal insulin versus other insulin regimens for the treatment of patients with type 2 diabetes mellitus inadequately controlled by basal insulin: systematic review, network meta-analysis and cost-effectiveness analysis. Diabetes Obes Metab. 2019.
31. Moya-Alarcon C, Gonzalez-Dominguez A, Simon S, Perez-Roman I, Gonzalez-Martin A, Bayo-Lozano E, et al. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain. Clin Transl Oncol. 2019;21(8):1076-84.
32. Nicholson K, Roberts MS, McCoy KL, Carty SE, Yip L. Molecular Testing Versus Diagnostic Lobectomy in Bethesda III/IV Thyroid Nodules: A Cost-Effectiveness Analysis. Thyroid. 2019.
33. Pereira C, Areia M, Dinis-Ribeiro M. Cost-utility analysis of genetic polymorphism universal screening in colorectal cancer prevention by detection of high-risk individuals. Dig Liver Dis. 2019.
34. Presa M, Perez-Ruiz F, Oyaguez I. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients. Clin Rheumatol. 2019.
35. Sceats LA, Ku S, Coughran A, Barnes B, Grimm E, Muffly M, et al. Operative Versus Nonoperative Management of Appendicitis: A Long-Term Cost Effectiveness Analysis. MDM Policy Pract. 2019;4(2):2381468319866448.
36. Serra-Burriel M, Graupera I, Toran P, Thiele M, Roulot D, Wong VW, et al. Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J Hepatol. 2019.
37. Snowsill TM, Ryan NAJ, Crosbie EJ, Frayling IM, Evans DG, Hyde CJ. Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting. PLoS One. 2019;14(8):e0221419.
38. Terpos E, Jamotte A, Christodoulopoulou A, Campioni M, Bhowmik D, Kennedy L, et al. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy. J Med Econ. 2019;22(8):766-76.
39. Townsend T, Blostein F, Doan T, Madson-Olson S, Galecki P, Hutton DW. Cost-effectiveness analysis of alternative naloxone distribution strategies: First responder and lay distribution in the United States. Int J Drug Policy. 2019.
40. Tremblay G, Rousseau B, Marquis M, Beaubois C, Sauvageau G, Hebert J. Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting. Appl Health Econ Health Policy. 2019.
41. van Gorp E, Adang EMM, Gultuna I, Hamm-Faber TE, Burger K, Kallewaard JW, et al. Cost-Effectiveness Analysis of Peripheral Nerve Field Stimulation as Add-On Therapy to Spinal Cord Stimulation in the Treatment of Chronic Low Back Pain in Failed Back Surgery Syndrome Patients. Neuromodulation. 2019.
42. Wang DL, Zhang XF, Wang XC, Wang YT, Zhang R, Chen YY, et al. [Cost-effectiveness analysis of rabies immunization strategy based on dynamic-decision tree model]. Zhonghua Yu Fang Yi Xue Za Zhi. 2019;53(8):804-10.
43. Windegger TM, Nghiem S, Nguyen KH, Fung YL, Scuffham PA. Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia. Blood Transfus. 2019:1-10.
44. Wolfson LJ, Daniels VJ, Pillsbury M, Kurugol Z, Yardimci C, Kyle J, et al. Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model. PLoS One. 2019;14(8):e0220921.
45. Yan C, Rittenbach K, Souri S, Silverstone PH. Cost-effectiveness analysis of a randomized study of depression treatment options in primary care suggests stepped-care treatment may have economic benefits. BMC Psychiatry. 2019;19(1):240.
46. Yokoya Y, Igarashi A, Uda A, Deguchi H, Takeuchi T, Higuchi K. Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD. J Gastroenterol. 2019.
47. Zeng X, Peng L, Tan C, Wang Y. Cost-effectiveness analysis of positron-emission tomography-computed tomography in preoperative staging for nonsmall-cell lung cancer with resected monometastatic disease. Medicine (Baltimore). 2019;98(33):e16843.
48. Zhan M, Zheng H, Yang Y, Xu T, Li Q. Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial. Radiother Oncol. 2019.
49. Zhou K, Jiang C, Li Q. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores. Lung Cancer. 2019;136:98-101.
50. Zimmermann M, Frey K, Hagedorn B, Oteri AJ, Yahya A, Hamisu M, et al. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis. Vaccine. 2019;37(41):6039-47.

July 2019

1. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. Value Health. 2019;22(7):843.
2. Al Hamarneh YN, Johnston K, Marra CA, Tsuyuki RT. Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the RxEACH study. Can Pharm J (Ott). 2019;152(4):257-66.
3. Amirsadri M, Mousavi S, Karimipour A. The cost-effectiveness and cost-utility analysis of the use of enoxaparin compared with heparin for venous thromboembolism prophylaxis in medical inpatients in Iran. Daru. 2019.
4. Bandeiras C, Cabral JMS, Gabbay RA, Finkelstein SN, Ferreira FC. Bringing Stem Cell-Based Therapies for Type 1 Diabetes to the Clinic: Early Insights from Bioprocess Economics and Cost-Effectiveness Analysis. Biotechnol J. 2019;14(8):e1800563.
5. Barnett C, Davenport MS, Montgomery JS, Kunju LP, Denton B, Piert M. (18)F-choline PET/mpMRI for Detection of Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis. J Nucl Med. 2019.
6. Bartolucci A, Walter D, Redmond T. Comparative Review on the Cost-Effectiveness Analysis of Relief Teams' Deployment to Sudden-Onset Disasters. Prehosp Disaster Med. 2019:1-7.
7. Benard A, Duroux T, Robert G. Cost-utility analysis of focal high-intensity focussed ultrasound vs active surveillance for low- to intermediate-risk prostate cancer using a Markov multi-state model. BJU Int. 2019.
8. Brown GC, Brown MM, Busbee BG. Cost-utility analysis of cataract surgery in the United States for the year 2018. J Cataract Refract Surg. 2019;45(7):927-38.
9. Bullement A, McMordie ST, Hatswell AJ, Li N, Wilson K. Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data. Pharmacoecon Open. 2019.
10. Buluc F, Agirbas I, Tulunay Kaya C. Cost Effectiveness Analysis of Stents Used in Treatment of Coronary Artery Disease. Balkan Med J. 2019.
11. Byrnes J, Ball J, Gao L, Kai Chan Y, Kularatna S, Stewart S, et al. Within trial cost-utility analysis of disease management program for patients hospitalized with atrial fibrillation: results from the SAFETY trial. J Med Econ. 2019:1-8.
12. Capel M, Ciudin A, Mareque M, Rodriguez-Rincon RM, Simon S, Oyaguez I. Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus. Pharmacoecon Open. 2019.
13. Carpenter CF, Aljassem A, Stassinopoulos J, Pisacreta G, Hutton D. A Cost-effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-herpetic Neuralgia. Open Forum Infect Dis. 2019;6(7):ofz219.
14. Castillo-Jimenez DA, Garcia-Perdomo HA. Re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.055: Standardized Reporting for Economic Analyses Should be Mandatory. Eur Urol. 2019;76(1):e9.
15. Chen X, Liang W, Wan N, Zhang L, Yang Y, Jiang J, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol. 2019;94:80-5.
16. Chiang CL, So TH, Lam TC, Choi HCW. Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective. Prostate Cancer Prostatic Dis. 2019.
17. Cicero AFG, Fogacci F, Borghi C. Cost-effectiveness analysis of different hypertension management strategies. Intern Emerg Med. 2019.
18. Codispoti CD, Mahdavinia M. A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps. Ann Allergy Asthma Immunol. 2019.
19. Collins B, Kypridemos C, Pearson-Stuttard J, Huang Y, Bandosz P, Wilde P, et al. FDA Sodium Reduction Targets and the Food Industry: Are There Incentives to Reformulate? Microsimulation Cost-Effectiveness Analysis. Milbank Q. 2019.
20. Coughlin OP, Wright ME, Thorson AG, Ternent CA. Hemorrhoid Banding: A Cost-Effectiveness Analysis. Dis Colon Rectum. 2019.
21. de Carvalho I, Peixoto HM, Romero GAS, de Oliveira MRF. Treatment for human visceral leishmaniasis: a cost-effectiveness analysis for Brazil. Trop Med Int Health. 2019.
22. Dilokthornsakul P, Kengkla K, Saokaew S, Permsuwan U, Techasaensiri C, Chotpitayasunondh T, et al. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. Vaccine. 2019;37(32):4551-60.
23. Dizbay M, Ozger HS, Bilgetekin I, Basyurt R, Yurtal O, Simsek H, et al. Cost-Effectiveness Analysis of Low-Cost, Domestic Short Peripheral Catheters Versus Higher-Priced, Imported Short Peripheral Catheters. J Infus Nurs. 2019;42(4):209-14.
24. Fonarow GC, van Hout B, Villa G, Arellano J, Lindgren P. Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019;4(7):691-5.
25. Giannouchos TV, Mitsikostas DD, Ohsfeldt RL, Vozikis A, Koufopoulou P. Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece. Clin Drug Investig. 2019.
26. Ha D, Kerr J, Ries AL, Fuster MM, Lippman SM, Murphy JD. A Model-Based Cost-Effectiveness Analysis of an Exercise Program for Lung Cancer Survivors Following Curative-Intent Treatment. Am J Phys Med Rehabil. 2019.
27. Hedderich DM, Ferro JM, Kunz WG. Diagnostic imaging in the management of patients with possible cerebral venous thrombosis: a cost-effectiveness analysis. Neuroradiology. 2019.
28. Julicher P, Chulanov VP, Pimenov NN, Chirkova E, Yankina A, Galli C. Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis. PLoS One. 2019;14(7):e0219687.
29. Kameda M, Date I. [Health Economics Studies in the Neurosurgical Field:An Introduction to Cost-Effectiveness Analysis and a Literature Review]. No Shinkei Geka. 2019;47(7):707-17.
30. Kansal A, Reifsnider OS, Proskorovsky I, Zheng Y, Pfarr E, George JT, et al. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial. Diabet Med. 2019.
31. Kashiwa M, Matsushita R. Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan. BMC Health Serv Res. 2019;19(1):438.
32. Larsen S, Holm JH, Sauer TN, Andersen C. A Cost-Effectiveness Analysis Comparing the VivaSight Double-Lumen Tube and a Conventional Double-Lumen Tube in Adult Patients Undergoing Thoracic Surgery Involving One-Lung Ventilation. Pharmacoecon Open. 2019.
33. Lau E, Salem A, Chan JCN, So WY, Kong A, Lamotte M, et al. Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis. Cost Eff Resour Alloc. 2019;17:13.
34. Lee DJ, Kumarasamy N, Resch SC, Sivaramakrishnan GN, Mayer KH, Tripathy S, et al. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector. PLoS One. 2019;14(7):e0218890.
35. Lee H, Park SY, Clark A, Debellut F, Pecenka C, Kim DS, et al. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study. Vaccine. 2019;37(35):4987-95.
36. Leurent B, Gomes M, Faria R, Morris S, Grieve R, Carpenter JR. Correction to: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial. Pharmacoeconomics. 2019;37(7):971.
37. Nguyen CP, Dan Do TN, Bruggemann R, Oever JT, Kolwijck E, Adang EMM, et al. Clinical cure rate and cost-effectiveness of carbapenem sparing beta-lactams versus meropenem for Gram-negative infections: a systematic review, meta-analysis, and cost-effectiveness analysis. Int J Antimicrob Agents. 2019.
38. Nogueras A, Chinchilla Fernandez MI, Martinez F, Maria Jose F, Martinez Sesmero JM, Poveda Andres JL, et al. Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model. Eur J Hosp Pharm. 2019;26(4):242-3.
39. Oderda M, Antolini J, Falcone M, Lacquaniti S, Fasolis G. Cost-effectiveness analysis of a single-use digital flexible cystoscope for double J removal. Urologia. 2019:391560319859797.
40. Phelps CE. A New Method to Determine the Optimal Willingness to Pay in Cost-Effectiveness Analysis. Value Health. 2019;22(7):785-91.
41. Rennert-May E, Conly J, Smith S, Puloski S, Henderson E, Au F, et al. A cost-effectiveness analysis of mupirocin and chlorhexidine gluconate for Staphylococcus aureus decolonization prior to hip and knee arthroplasty in Alberta, Canada compared to standard of care. Antimicrob Resist Infect Control. 2019;8:113.
42. Sathianathen NJ, Konety BR. Reply to Diana A. Castillo-Jimenez and Herney A. Garcia-Perdomo's Letter to the Editor re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.055. Standardized Reporting for Economic Analyses Should be Mandatory. Eur Urol. 2019;76(1):e10-e1.
43. Sawaya GF, Sanstead E, Alarid-Escudero F, Smith-McCune K, Gregorich SE, Silverberg MJ, et al. Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis. JAMA Intern Med. 2019;179(7):867-78.
44. Shine B, James T, Adler A. In primary care, is measuring free-thyroxine plus thyroid-stimulating hormone to detect hypopituitarism cost-effective? A cost utility analysis using Markov chain models. BMJ Open. 2019;9(7):e029369.
45. Stein MJ, Arnaout A, Thavorn K, Van Katwyk S, Zhang J. A cost effectiveness analysis of paravertebral blocks in immediate breast reconstruction following mastectomy. J Plast Reconstr Aesthet Surg. 2019;72(7):1219-43.
46. Stokes EA, Doble B, Pufulete M, Reeves BC, Bucciarelli-Ducci C, Dorman S, et al. Cardiovascular magnetic resonance in emergency patients with multivessel disease or unobstructed coronary arteries: a cost-effectiveness analysis in the UK. BMJ Open. 2019;9(7):e025700.
47. Tanaka K, Tachi T, Hori A, Osawa T, Nagaya K, Makino T, et al. Cost utility analysis of pharmacist counseling care for breast cancer chemotherapy outpatients. Pharmazie. 2019;74(7):439-42.
48. Tew M, Clarke P, Thursky K, Dalziel K. Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients. Pharmacoeconomics. 2019;37(7):931-41.
49. Torchia MT, Austin DC, Kunkel ST, Dwyer KW, Moschetti WE. Next-Generation Sequencing vs Culture-Based Methods for Diagnosing Periprosthetic Joint Infection After Total Knee Arthroplasty: A Cost-Effectiveness Analysis. J Arthroplasty. 2019;34(7):1333-41.
50. Wan X, Luo X, Tan C, Zeng X, Zhang Y, Peng L. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis. Cancer. 2019.
51. Xie X, Falk L, Brophy JM, Tu HA, Guo J, Gajic-Veljanoski O, et al. A Non-inferiority Framework for Cost-Effectiveness Analysis. Int J Technol Assess Health Care. 2019:1-7.
52. Zhang X, Liao H, Shi D, Li X, Chen X, He S. Cost-effectiveness analysis of different hypertension management strategies in a community setting. Intern Emerg Med.


June 2019

1. Abecassis IJ, Sen R, Kelly CM, Levy S, Barber J, Ghodke B, et al. Clinical outcomes and cost-effectiveness analysis for the treatment of basilar tip aneurysms. J Neurointerv Surg. 2019.
2. Avram CM, Greiner KS, Tilden E, Caughey AB. Point-of-care HIV Viral Load in Pregnant Women Without Prenatal Care: A Cost-Effectiveness Analysis. Am J Obstet Gynecol. 2019.
3. Bahin FF, Heitman SJ, Bourke MJ. Wide-field endoscopic mucosal resection versus endoscopic submucosal dissection for laterally spreading colorectal lesions: a cost-effectiveness analysis. Gut. 2019;68(6):1130.
4. Benucci M, Damiani A, Manfredi M, Infantino M, Grossi V, Li Gobbi F. Abatacept: from a budget impact model to cost-effectiveness analysis - data from RCT and real life. Clinicoecon Outcomes Res. 2019;11:405-9.
5. Cai H, Zhang L, Li N, Zheng B, Liu M. Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma. Leuk Lymphoma. 2019:1-9.
6. Chen J, Hu G, Chen Z, Wan X, Tan C, Zeng X, et al. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. Clin Drug Investig. 2019.
7. Davoudi-Monfared E, Taghizadeh-Ghehi M. Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia: a comment. Int J Clin Pharm. 2019;41(3):621-2.
8. Desai M, Bentley A, Keck WA, Haag T, Taylor RS, Dakin H. Cooled radiofrequency ablation of the genicular nerves for chronic pain due to osteoarthritis of the knee: a cost-effectiveness analysis based on trial data. BMC Musculoskelet Disord. 2019;20(1):302.
9. Dopp AR, Mundey P, Silovsky JF, Hunter M, Slemaker A. Economic value of community-based services for problematic sexual behaviors in youth: A mixed-method cost-effectiveness analysis. Child Abuse Negl. 2019:104043.
10. Dowd B, Nyman JA. Cost-Effectiveness Analysis in the Context of US Commercial Health Insurance. Pharmacoeconomics. 2019;37(6):743-4.
11. Duhig KE, Seed PT, Myers J, Bahl R, Bambridge G, Barnfield S, et al. Placental Growth Factor Testing for Suspected Preeclampsia: a Cost-Effectiveness Analysis. Bjog. 2019.
12. Fawsitt CG, Vickerman P, Cooke G, Welton NJ. A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. Value Health. 2019;22(6):693-703.
13. Fonarow GC, van Hout B, Villa G, Arellano J, Lindgren P. Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019.
14. Furneri G, Santoni L, Ricella C, Prosperini L. Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy. BMC Health Serv Res. 2019;19(1):436.
15. Fusco F, Campbell H, Barker K. Rehabilitation after resurfacing hip arthroplasty: cost-utility analysis alongside a randomized controlled trial. Clin Rehabil. 2019;33(6):1003-14.
16. Garattini L, Padula A. Comment on: 'The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study'. Pharmacoeconomics. 2019.
17. Gaskin J, Coyle D, Whyte J, Birkett N, Krewksi D. A cost effectiveness analysis of interventions to reduce residential radon exposure in Canada. J Environ Manage. 2019;247:449-61.
18. Gong CL, Zangwill KM, Hay JW, Meeker D, Doctor JN. Behavioral Economics Interventions to Improve Outpatient Antibiotic Prescribing for Acute Respiratory Infections: a Cost-Effectiveness Analysis. J Gen Intern Med. 2019;34(6):846-54.
19. Habu Y. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan. Intern Med. 2019.
20. Haonga BT, Areu MMM, Challa ST, Liu MB, Elieza E, Morshed S, et al. Early treatment of open diaphyseal tibia fracture with intramedullary nail versus external fixator in Tanzania: Cost effectiveness analysis using preliminary data from Muhimbili Orthopaedic Institute. Sicot j. 2019;5:20.
21. Hersh AR, Skeith AE, Sargent JA, Caughey AB. Induction of labor at 39 weeks of gestation versus expectant management for low-risk nulliparous women: a cost-effectiveness analysis. Am J Obstet Gynecol. 2019;220(6):590.e1-.e10.
22. Homan J, Schijns W, Janssen IMC, Berends FJ, Aarts EO. Correction to: Adequate Multivitamin Supplementation after Roux-En-Y Gastric Bypass Results in a Decrease of National Health Care Costs: a Cost-Effectiveness Analysis. Obes Surg. 2019;29(6):2007.
23. Igarashi A, Furusyo N, Ogawa E, Nomura H, Dohmen K, Higashi N, et al. Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan. BMJ Open. 2019;9(6):e023405.
24. Jablonka EM, Lamelas AM, Kanchwala SK, Rhemtulla I, Smith ML. A Simplified Cost-Utility Analysis of Inpatient Flap Monitoring after Microsurgical Breast Reconstruction and Implications for Hospital Length of Stay. Plast Reconstr Surg. 2019.
25. Kaito T, Matsuyama Y, Yamashita T, Kawakami M, Takahashi K, Yoshida M, et al. Cost-effectiveness analysis of the pharmacological management of chronic low back pain with four leading drugs. J Orthop Sci. 2019.
26. Keshmiri R, Coyte PC, Laporte A, Sheth PM, Loutfy M. Cost-effectiveness analysis of infant feeding modalities for virally suppressed mothers in Canada living with HIV. Medicine (Baltimore). 2019;98(23):e15841.
27. Khan I, Petrou S, Khan K, Mistry D, Lall R, Sheehan B, et al. Does Structured Exercise Improve Cognitive Impairment in People with Mild to Moderate Dementia? A Cost-Effectiveness Analysis from a Confirmatory Randomised Controlled Trial: The Dementia and Physical Activity (DAPA) Trial. Pharmacoecon Open. 2019;3(2):215-27.
28. Kobayashi M, Kudo M, Izumi N, Kaneko S, Azuma M, Copher R, et al. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol. 2019;54(6):558-70.
29. Kongnakorn T, Wagenlehner F, Falcone M, Tichy E, Di Virgilio R, Baillon-Plot N, et al. Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections. Int J Antimicrob Agents. 2019.
30. Kongpakwattana K, Ademi Z, Chaiyasothi T, Nathisuwan S, Zomer E, Liew D, et al. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand. Pharmacoeconomics. 2019.
31. Kouis P, Papatheodorou SI, Middleton N, Giallouros G, Kyriacou K, Cohen JT, et al. Cost-effectiveness analysis of three algorithms for diagnosing primary ciliary dyskinesia: a simulation study. Orphanet J Rare Dis. 2019;14(1):142.
32. Leal J, Manetti S, Buchanan J. Correction to: The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study. Pharmacoeconomics. 2019;37(6):867.
33. Liao M, Jiang Q, Hu H, Han J, She L, Yao L, et al. Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China. J Med Econ. 2019;22(6):584-92.
34. Liao W, Huang J, Wu Q, Zhu G, Wang X, Wen F, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis. Oral Oncol. 2019;93:15-20.
35. Lin CH, Fann JC, Chen SL, Chen HH, Yang KC. Heterogeneity in cost-effectiveness analysis of vaccination for mild and moderate Alzheimer's disease. Curr Alzheimer Res. 2019.
36. Londono Trujillo D, Sandoval Reyes NF, Taborda Restrepo A, Chamorro Velasquez CL, Dominguez Torres MT, Romero Ducuara SV, et al. Cost-effectiveness analysis of newborn pulse oximetry screening to detect critical congenital heart disease in Colombia. Cost Eff Resour Alloc. 2019;17:11.
37. Malkin SJP, Russel-Szymczyk M, Psota M, Hlavinkova L, Hunt B. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. Adv Ther. 2019.
38. Messoudi W, Elmahi T, Nejjari C, Tachfouti N, Zidouh A, Saadani G, et al. Cervical cancer prevention in Morocco: a model-based cost-effectiveness analysis. J Med Econ. 2019:1-7.
39. Moayeri F, Dunt D, Hsueh YA, Doyle C. Cost-utility analysis of telephone-based cognitive behavior therapy in chronic obstructive pulmonary disease (COPD) patients with anxiety and depression comorbidities: an application for willingness to accept concept. Expert Rev Pharmacoecon Outcomes Res. 2019;19(3):331-40.
40. Negoescu DM, Enns EA, Swanhorst B, Baumgartner B, Campbell JP, Osterman MT, et al. Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Inflamm Bowel Dis. 2019.
41. Park SK, Hong SH, Kim H, Kim S, Lee EK. Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea. Clin Ther. 2019;41(6):1066-79.
42. Phi XA, Greuter MJW, Obdeijn IM, Oosterwijk JC, Feenstra TL, Houssami N, et al. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis. Breast. 2019;45:82-8.
43. Pickering K, Gallos ID, Williams H, Price MJ, Merriel A, Lissauer D, et al. Uterotonic Drugs for the Prevention of Postpartum Haemorrhage: A Cost-Effectiveness Analysis. Pharmacoecon Open. 2019;3(2):163-76.
44. Psaltikidis EM, Silva END, Moretti ML, Trabasso P, Stucchi RSB, Aoki FH, et al. Cost-utility analysis of outpatient parenteral antimicrobial therapy (OPAT) in the Brazilian national health system. Expert Rev Pharmacoecon Outcomes Res. 2019;19(3):341-52.
45. Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA. Advantage of inhaled corticosteroids as additional therapy to systemic corticosteroids for pediatric acute asthma exacerbations: a cost-effectiveness analysis. J Asthma. 2019:1-10.
46. Rubio-Terres C, Aguado JM, Almirante B, Cobo J, Grau S, Salavert M, et al. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain. Eur J Clin Microbiol Infect Dis. 2019;38(6):1105-11.
47. Ruggeri M, Rolli FR, Kondili LA, Drago C, De Solda F, Nappi C, et al. Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy. Expert Rev Pharmacoecon Outcomes Res. 2019;19(3):363-74.
48. Sathianathen NJ, Konety BR, Alarid-Escudero F, Lawrentschuk N, Bolton DM, Kuntz KM. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. 2019;75(6):910-7.
49. Schlueter M, Finn E, Diaz S, Dilla T, Inciarte-Mundo J, Fakhouri W. Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain. Clinicoecon Outcomes Res. 2019;11:395-403.
50. Seko T, Tachi T, Hatakeyama H, Noguchi Y, Teramachi H. Cost-effectiveness analysis and effectiveness of pharmacist-managed outpatient clinics in Helicobacter pylori eradication therapy. Int J Clin Pract. 2019;73(6):e13349.
51. Selva-Sevilla C, Ferrara P, Geronimo-Pardo M. Cost-utility Analysis for Recurrent Lumbar Disc Herniation: Conservative Treatment Versus Discectomy Versus Discectomy With Fusion. Clin Spine Surg. 2019;32(5):E228-e34.
52. Sohrt A, Maerkedahl A, Padula WV. Correction to: Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes. Pharmacoecon Open. 2019;3(2):275.
53. Sohrt A, Maerkedahl A, Padula WV. Correction to: Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes. Pharmacoecon Open. 2019;3(2):273.
54. Sohrt A, Maerkedahl A, Padula WV. Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes. Pharmacoecon Open. 2019;3(2):265-72.
55. Sudhof LS, Shainker SA, Einerson BD. Tranexamic Acid in the Routine Treatment of Post-Partum Hemorrhage in the United States: A Cost-Effectiveness Analysis. Am J Obstet Gynecol. 2019.
56. Wang S, Wen F, Zhang P, Wang X, Li Q. Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiotherapy vs. 5x5Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancer. Radiat Oncol. 2019;14(1):113.
57. Xing N, Cheung WY, Jiang M, You JHS. Standing orders program of pneumococcal vaccination for hospitalized elderly patients in Hong Kong: A cost-effectiveness analysis. Am J Infect Control. 2019.
58. Yang YT, Ortendahl J. How does the Cox maze procedure compare? Cost-effectiveness analysis of alternative treatments of atrial fibrillation. Curr Med Res Opin. 2019;35(6):957-61.
59. Yoon AY, Bozzuto L, Seto AJ, Fisher CS, Chatterjee A. ASO Author Reflections: Cost-Utility Analysis, Utility Scores, and Surgical Oncology. Ann Surg Oncol. 2019.
60. Zarca K, Durand-Zaleski I, Loriot MA, Chatellier G, Pallet N. Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis. Mol Diagn Ther. 2019;23(3):429-38.
61. Zhang B, Long EF. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Breast Cancer Res Treat. 2019;175(3):775-9.
62. Zhang Y, Zeng X, Deng H, Ma F, Peng Y, Yi L, et al. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR(+)/HER2(-) Metastatic Breast Cancer From the US and Chinese Perspectives. Clin Ther. 2019;41(6):1175-85.

May 2019

1. Abreha SK. Model-based cost-effectiveness analysis of external beam radiation therapy for the treatment of localized prostate cancer: a systematic review. Cost effectiveness and resource allocation : C/E. 2019;17:10.
2. Bandeiras C, Cabral JMS, Gabbay RA, Finkelstein SN, Ferreira FC. Bringing stem cell-based therapies for type 1 diabetes to the clinic: early insights from bioprocess economics and cost-effectiveness analysis. Biotechnology journal. 2019:e1800563.
3. Barrington DA, Dilley SE, Smith HJ, Straughn JM, Jr. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. Gynecologic oncology. 2019;153(2):381-4.
4. Berber A, Del-Rio-Navarro BE. Cost-effectiveness analysis of OM-85 vs placebo in the prevention of acute respiratory tract infections (ARTIs) in children that attend day-care centers. Health economics review. 2019;9(1):12.
5. Bhadhuri A, Al-Janabi H, Jowett S, Jolly K. Incorporating Household Spillovers in Cost Utility Analysis: A Case Study Using Behavior Change in COPD. International journal of technology assessment in health care. 2019:1-9.
6. Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, et al. Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. PharmacoEconomics. 2019.
7. Brown H, D'Amico F, Knapp M, Orrell M, Rehill A, Vale L, et al. A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements. Aging & mental health. 2019;23(5):602-7.
8. Bullard KA, Edelman AB, Williams SM, Rodriguez MI. Ulipristal acetate compared to levonorgestrel emergency contraception among current oral contraceptive users: a cost-effectiveness analysis. Contraception. 2019.
9. Butt T, Liu GG, Kim DD, Neumann PJ. Taking stock of cost-effectiveness analysis of healthcare in China. BMJ global health. 2019;4(3):e001418.
10. Caicedo JI, Taborda A, Robledo D, Bravo-Balado A, Dominguez C, Trujillo CG, et al. Photovaporization of the prostate with GreenLight laser 180 W XPS versus transurethral resection of the prostate with monopolar energy for the treatment of benign prostatic enlargement: a cost-utility analysis from a healthcare perspective. World journal of urology. 2019;37(5):861-6.
11. Chan KH, Whittam BM, Krambeck A, Downs SM, Misseri R, Cain MP, et al. Cost-Effectiveness Analysis of the Management of Distal Ureteral Stones in Children. Urology. 2019;127:107-12.
12. Chen X, Liang W, Wan N, Zhang L, Yang Y, Jiang J, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. Oral oncology. 2019;94:80-5.
13. Clennon EK, Pare E, Amato P, Caughey AB. Use of gestational surrogates for women with Eisenmenger syndrome: a cost-effectiveness analysis. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2019:1-6.
14. Conway A, Gow J, Ralph N, Duff J, Edward KL, Alexander K, et al. Implementing a thermal care bundle for inadvertent perioperative hypothermia: A cost-effectiveness analysis. International journal of nursing studies. 2019;97:21-7.
15. da Silva LR, Vianna CMM, Mosegui GBG, Peregrino AAF, Marinho V, Laks J. Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer's disease in Brazil. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2019;41(3):218-24.
16. Daar DA, Shah A, Mirrer JT, Thanik V, Hacquebord J. Proximal Row Carpectomy versus Four-Corner Arthrodesis for the Treatment of Scapholunate Advanced Collapse/Scaphoid Nonunion Advanced Collapse Wrist: A Cost-Utility Analysis. Plastic and reconstructive surgery. 2019;143(5):1432-45.
17. Dalziel K, Cheek JA, Fanning L, Borland ML, Phillips N, Kochar A, et al. A Cost-Effectiveness Analysis Comparing Clinical Decision Rules PECARN, CATCH, and CHALICE With Usual Care for the Management of Pediatric Head Injury. Annals of emergency medicine. 2019;73(5):429-39.
18. De Carlo M. Cost-effectiveness analysis: A tool in the hands of the clinician. European journal of preventive cardiology. 2019;26(8):855-7.
19. Doan TN, Barendregt J. Adjuvant trastuzumab chemotherapy in early breast cancer: meta-analysis of randomised trials and cost-effectiveness analysis. Swiss medical weekly. 2019;149:w20082.
20. Du X, He X, Jia Y, Wu J, Long D, Yu R, et al. A Long-Term Cost-Effectiveness Analysis Comparing Radiofrequency Catheter Ablation with Antiarrhythmic Drugs in Treatment of Chinese Patients with Atrial Fibrillation. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2019.
21. Estrella J, Simmons D. Comment on Johnson et al. Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life. Diabetes Care 2019;42:69-76. Diabetes care. 2019;42(5):e78.
22. Finch AP, van Velzen P, Ter Riet G, Sterk PJ, Prins JM, Bosmans JE. Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial. PharmacoEconomics. 2019;37(5):689-99.
23. Franklin M, Lomas J, Walker S, Young T. An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis. PharmacoEconomics. 2019;37(5):631-43.
24. Gaede P, Johansen P, Tikkanen CK, Pollock RF, Hunt B, Malkin SJP. Correction to: Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2019.
25. Gaede P, Johansen P, Tikkanen CK, Pollock RF, Hunt B, Malkin SJP. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2019.
26. Galper BZ, Reynolds MR, Garg P, Secemsky EA, Valsdottir LR, Cohen DJ, et al. Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention. Coronary artery disease. 2019;30(3):177-82.
27. Gandola AE, Dainelli L, Zimmermann D, Dahlui M, Detzel P. Milk Powder Fortified with Potassium and Phytosterols to Decrease the Risk of Cardiovascular Events among the Adult Population in Malaysia: A Cost-Effectiveness Analysis. Nutrients. 2019;11(6).
28. Gui Q, Zhang X, Liu L, Zhao F, Cheng W, Zhang Y. Cost-utility analysis of total knee arthroplasty for osteoarthritis in a regional medical center in China. Health economics review. 2019;9(1):15.
29. Guzman-de la Garza FJ, Laredo-Flores AD, Cardenas-Del Castillo B, Cordero-Franco HF, Salinas-Martinez AM, Fernandez-Garza NE, et al. [Ultrasound-guided umbilical venous catheterisation: A cost-effectiveness analysis]. Anales de pediatria (Barcelona, Spain : 2003). 2019.
30. Hannouf MB, Zaric GS, Blanchette P, Brezden-Masley C, Paulden M, McCabe C, et al. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer. The pharmacogenomics journal. 2019.
31. Homan J, Schijns W, Janssen IMC, Berends FJ, Aarts EO. Adequate Multivitamin Supplementation after Roux-En-Y Gastric Bypass Results in a Decrease of National Health Care Costs: a Cost-Effectiveness Analysis. Obesity surgery. 2019;29(5):1638-43.
32. Isaline G, Marie-Christine C, Rudy VT, Caroline D, Yvon E. An exploratory cost-effectiveness analysis: Comparison between a midwife-led birth unit and a standard obstetric unit within the same hospital in Belgium. Midwifery. 2019;75:117-26.
33. Johnson SR, Carter HE, Leo P, Hollingworth SA, Davis EA, Jones TW, et al. Response to Comment on Johnson et al. Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life. Diabetes Care 2019;42:69-76. Diabetes care. 2019;42(5):e79-e80.
34. Kashiwa M, Matsushita R. Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan. Clinical therapeutics. 2019;41(5):929-42.
35. Kimaro GD, Guinness L, Shiri T, Kivuyo S, Chanda D, Bottomley C, et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: a cost-effectiveness analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019.
36. Krishnan A, Finkelstein EA, Levine E, Foley P, Askew S, Steinberg D, et al. A Digital Behavioral Weight Gain Prevention Intervention in Primary Care Practice: Cost and Cost-Effectiveness Analysis. Journal of medical Internet research. 2019;21(5):e12201.
37. Lee E, Costello MF, Botha WC, Illingworth P, Chambers GM. A cost-effectiveness analysis of preimplantation genetic testing for aneuploidy (PGT-A) for up to three complete assisted reproductive technology cycles in women of advanced maternal age. The Australian & New Zealand journal of obstetrics & gynaecology. 2019.
38. Liyanage P, Rocklov J, Tissera H, Palihawadana P, Wilder-Smith A, Tozan Y. Evaluation of intensified dengue control measures with interrupted time series analysis in the Panadura Medical Officer of Health division in Sri Lanka: a case study and cost-effectiveness analysis. The Lancet Planetary health. 2019;3(5):e211-e8.
39. Lopez-Villegas A, Catalan-Matamoros D, Robles-Musso E, Bautista-Mesa R, Peiro S. Cost-utility analysis on telemonitoring of users with pacemakers: The PONIENTE study. Journal of telemedicine and telecare. 2019;25(4):204-12.
40. Love-Koh J, Cookson R, Gutacker N, Patton T, Griffin S. Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2019;22(5):518-26.
41. Malhotra A, Wu X, Forman HP, Matouk CC, Hughes DR, Gandhi D, et al. Management of Unruptured Intracranial Aneurysms in Older Adults: A Cost-effectiveness Analysis. Radiology. 2019;291(2):411-7.
42. Malhotra A, Wu X, Matouk CC, Forman HP, Gandhi D, Sanelli P. MR Angiography Screening and Surveillance for Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Cost-effectiveness Analysis. Radiology. 2019;291(2):400-8.
43. Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. Journal of market access & health policy. 2019;7(1):1601484.
44. Mar J, Anton-Ladislao A, Ibarrondo O, Arrospide A, Lazaro-Aramburu S, Gonzalez N, et al. Stage- and age-adjusted cost-effectiveness analysis of laparoscopic surgery in rectal cancer. Surgical endoscopy. 2019.
45. Memirie ST, Tolla MT, Desalegn D, Hailemariam M, Norheim OF, Verguet S, et al. A cost-effectiveness analysis of maternal and neonatal health interventions in Ethiopia. Health policy and planning. 2019.
46. Mendez LC, Moraes FY, Castilho MS, Louie AV, Qu XM. Lives and Economic Loss in Brazil due to Lack of Radiotherapy Access in Cervical Cancer: A Cost-Effectiveness Analysis. Clinical oncology (Royal College of Radiologists (Great Britain)). 2019.
47. Messoudi W, Elmahi T, Nejjari C, Tachfouti N, Zidouh A, Saadani G, et al. Cervical cancer prevention in Morocco: a model-based cost-effectiveness analysis. Journal of medical economics. 2019:1.
48. Mosegui GG, Vianna CM, Rodrigues MS, Valle PM, Silva FV. Cost-effectiveness analysis of oral rehydration therapy compared to intravenous rehydration for acute gastroenteritis without severe dehydration treatment. Journal of infection and public health. 2019.
49. Park SK, Hong SH, Kim H, Kim S, Lee EK. Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea. Clinical therapeutics. 2019;41(6):1066-79.
50. Peral C, Cordido F, Gimeno-Ballester V, Mir N, Sanchez-Cenizo L, Rubio-Rodriguez D, et al. Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain. Expert review of pharmacoeconomics & outcomes research. 2019:1-10.
51. Podlipnik S, Moreno-Ramirez D, Carrera C, Barreiro A, Manubens E, Ferrandiz-Pulido L, et al. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma. The British journal of dermatology. 2019;180(5):1190-7.
52. Pollit V, Graham D, Leonard C, Filby A, McMaster J, Mealing SJ, et al. A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett's oesophagus in the United Kingdom. Current medical research and opinion. 2019;35(5):805-15.
53. Sawaya GF, Sanstead E, Alarid-Escudero F, Smith-McCune K, Gregorich SE, Silverberg MJ, et al. Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis. JAMA internal medicine. 2019.
54. Shaker M, Greenhawt M. Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-effectiveness Analysis. JAMA network open. 2019;2(5):e193242.
55. Tang CH, Cheng WF, Jiang JH, You SL, Huang LW, Hsieh JY, et al. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan. Asian Pacific journal of cancer prevention : APJCP. 2019;20(5):1377-87.
56. Wright ME, Beaty JS, Thorson AG, Rojas R, Ternent CA. Cost-Effectiveness Analysis of Total Neoadjuvant Therapy Followed by Radical Resection Versus Conventional Therapy for Locally Advanced Rectal Cancer. Diseases of the colon and rectum. 2019;62(5):568-78.
57. Xu Y, Wei Y, Ming J, Li N, Xu N, Pong RW, et al. Cost-Effectiveness Analysis of Non-invasive Prenatal Testing for Down Syndrome in China. International journal of technology assessment in health care. 2019:1-6.
58. Zhang PF, Wen F, Zhou J, Huang JX, Zhou KX, Wu QJ, et al. Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2019.
59. Zhang Y, Zeng X, Deng H, Ma F, Peng Y, Yi L, et al. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR(+)/HER2(-) Metastatic Breast Cancer From the US and Chinese Perspectives. Clinical therapeutics. 2019;41(6):1175-85.

April 2019

1.    Abramson A, Halperin F, Kim J, Traverso G. Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide. Journal of pharmaceutical sciences. 2019.
2.    Assis TSM, Rabello A, Cota G, Werneck GL, Azeredo-da-Silva ALF. Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil. Revista da Sociedade Brasileira de Medicina Tropical. 2019;52:e20180272.
3.    Bandurska E, Damps-Konstanska I, Popowski P, Jedrzejczyk T, Janowiak P, Swietnicka K, et al. Cost-Effectiveness Analysis of Integrated Care in Management of Advanced Chronic Obstructive Pulmonary Disease (COPD). Medical science monitor : international medical journal of experimental and clinical research. 2019;25:2879-85.
4.    Becares-Martinez C, Lopez-Llames A, Arroyo-Domingo MM, Marco-Algarra J, Morales Suarez-Varela MM. [What do MRI and CT scan provide us in patients with vertigo and dizziness? A cost-utility analysis]. Revista de neurologia. 2019;68(8):326-32.
5.    Brown GC, Brown MM. Patient Preference-Based Comparative Effectiveness and Cost-Utility Analysis of the Prostamides for Open-Angle Glaucoma. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2019;35(3):145-60.
6.    Cai X, Shi L, Yang W, Gu S, Chen Y, Nie L, et al. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. Journal of medical economics. 2019;22(4):336-43.
7.    Canning P, Tawfick W, Kamel K, Hynes N, Sultan S. Q-TWiST and Cost-Effectiveness Analysis of Endovascular versus Open Repair for Ruptured Abdominal Aortic Aneurysms in a High Deliberate Practice Volume Center. Annals of vascular surgery. 2019;56:163-74.
8.    Chen DY, Hsu PN, Tang CH, Claxton L, Valluri S, Gerber RA. Tofacitinib in the treatment of moderate to severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan. Journal of medical economics. 2019:1.
9.    Chen Q, Liang X, Long X, Yu L, Liu W, Lu H. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases. Helicobacter. 2019;24(2):e12563.
10.    D'Andrea E, Choudhry NK, Raby B, Weinhouse GL, Najafzadeh M. A bronchial-airway gene-expression classifier to improve the diagnosis of lung cancer: clinical outcomes and cost-effectiveness analysis. International journal of cancer. 2019.
11.    Davoudi-Monfared E, Taghizadeh-Ghehi M. Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia: a comment. International journal of clinical pharmacy. 2019.
12.    de Jong LA, Gout-Zwart JJ, van den Bosch M, Koops M, Postma MJ. Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis. Journal of medical economics. 2019;22(4):306-18.
13.    Dekker ARJ, van der Velden AW, Luijken J, Verheij TJM, van Giessen A. Cost-effectiveness analysis of a GP- and parent-directed intervention to reduce antibiotic prescribing for children with respiratory tract infections in primary care. The Journal of antimicrobial chemotherapy. 2019;74(4):1137-42.
14.    Dottino JA, Moss HA, Lu KH, Secord AA, Havrilesky LJ. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2019;133(4):795-802.
15.    Duvetorp A, Levin LA, Engerstedt Mattsson E, Ryttig L. A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden. Acta dermato-venereologica. 2019;99(4):393-9.
16.    Epstein DM, Gohel MS, Heatley F, Liu X, Bradbury A, Bulbulia R, et al. Cost-effectiveness analysis of a randomized clinical trial of early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration. The British journal of surgery. 2019;106(5):555-62.
17.    Fatima A, Hackman TG, Wood JS. Cost-Effectiveness Analysis of Virtual Surgical Planning in Mandibular Reconstruction. Plastic and reconstructive surgery. 2019;143(4):1185-94.
18.    Garay OU, Nishimwe ML, Bousmah MA, Janah A, Girard PM, Chene G, et al. Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM). PharmacoEconomics - open. 2019.
19.    Garrison LP, Jr., Babigumira J, Tournier C, Goertz HP, Lubinga SJ, Perez EA. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2019;22(4):408-15.
20.    Geitona M, Stamuli E, Giannakodimos S, Kimiskidis VK, Kountouris V, Charokopou M, et al. Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system. Journal of medical economics. 2019;22(4):359-64.
21.    Goodall G, Lamotte M, Ramos M, Maunoury F, Pejchalova B, de Pouvourville G. Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients. Journal of medical economics. 2019;22(4):289-96.
22.    Grochtdreis T, Brettschneider C, Bjerregaard F, Bleich C, Boczor S, Harter M, et al. Cost-effectiveness analysis of collaborative treatment of late-life depression in primary care (GermanIMPACT). European psychiatry : the journal of the Association of European Psychiatrists. 2019;57:10-8.
23.    Hamilton TD, MacNeill AJ, Lim H, Hunink MGM. Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer. Annals of surgical oncology. 2019;26(4):1110-7.
24.    Han S, Kim S, Kim H, Suh HS. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting beta2-agonists in South Korea. Current medical research and opinion. 2019:1.
25.    Healey A, Roberts S, Sevdalis N, Goulding L, Wilson S, Shaw K, et al. A Cost-Effectiveness Analysis of Stop Smoking Interventions in Substance-Use Disorder Populations. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. 2019;21(5):623-30.
26.    Hu S, Han Y, Zhang W, Zhang T, Yao X, Liu L. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China. Journal of medical economics. 2019:1-9.
27.    Hua LH, Hersh CM, Morten P, Kusel J, Lin F, Cave J, et al. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis. Journal of managed care & specialty pharmacy. 2019;25(4):490-8.
28.    Kabore N, Marnat G, Rouanet F, Barreau X, Verpillot E, Menegon P, et al. Cost-effectiveness analysis of mechanical thrombectomy plus tissue-type plasminogen activator compared with tissue-type plasminogen activator alone for acute ischemic stroke in France. Revue neurologique. 2019;175(4):252-60.
29.    Kadom N, Itri JN, Trofimova A, Otero HJ, Horny M. Cost-Effectiveness Analysis: An Overview of Key Concepts, Recommendations, Controversies, and Pitfalls. Academic radiology. 2019;26(4):534-41.
30.    Kashiwa M, Matsushita R. Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan. Clinical therapeutics. 2019.
31.    Kristianslund O, Dalby M, Moe MC, Drolsum L. Cost-effectiveness analysis in a randomized trial of late in-the-bag intraocular lens dislocation surgery: repositioning versus exchange. Acta ophthalmologica. 2019.
32.    Ladabaum U. How I do it: Does this cost-effectiveness analysis convince me about screening for Barrett's esophagus? Gastrointestinal endoscopy. 2019;89(4):723-5.
33.    Liao W, Huang J, Hutton D, Li Q. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China. Journal of medical economics. 2019;22(4):344-9.
34.    Lima PH, Fan B, Berube J, Cerny M, Olivie D, Giard JM, et al. Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma. AJR American journal of roentgenology. 2019:1-9.
35.    Marseille E, Kahn JG. Utilitarianism and the ethical foundations of cost-effectiveness analysis in resource allocation for global health. Philosophy, ethics, and humanities in medicine : PEHM. 2019;14(1):5.
36.    Mostafa A, El-Sayed MH, El Kassas M, Elhamamsy M, Elsisi GH. Safety-Engineered Syringes: An Intervention to Decrease Hepatitis C Burden in Developing Countries-A Cost-Effectiveness Analysis from Egypt. Value in health regional issues. 2019;19:51-8.
37.    Patel V, Ahmed I, Podbielski D, Falvey H, Murray J, Goeree R. Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada. Journal of medical economics. 2019;22(4):390-401.
38.    Pullagura GR, Waite NM, Houle SKD, Violette R, Wong WWL. Cost-utility analysis of offering a novel remunerated community pharmacist consultation service on influenza vaccination for seniors in Ontario, Canada. Journal of the American Pharmacists Association : JAPhA. 2019.
39.    Rubio-Terres C, Aguado JM, Almirante B, Cobo J, Grau S, Salavert M, et al. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2019.
40.    Seleznova Y, Brass P, Hellmich M, Stock S, Muller D. Cost-effectiveness-analysis of ultrasound guidance for central venous catheterization compared with landmark method: a decision-analytic model. BMC anesthesiology. 2019;19(1):51.
41.    Simons RWP, Dickman MM, van den Biggelaar F, Dirksen CD, Van Rooij J, Remeijer L, et al. Trial-based cost-effectiveness analysis of ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) versus DSAEK. Acta ophthalmologica. 2019.
42.    Smith AD, Carson JD, Sirous R, Sanyal R, Remer EM, Allen BC, et al. Active Surveillance Versus Nephron-Sparing Surgery for a Bosniak IIF or III Renal Cyst: A Cost-Effectiveness Analysis. AJR American journal of roentgenology. 2019;212(4):830-8.
43.    Telford C, Bertranou E, Large S, Phelps H, Ekman M, Livings C. Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naive Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK. PharmacoEconomics - open. 2019.
44.    Terpos E, Jamotte A, Christodoulopoulou A, Campioni M, Bhowmik D, Kennedy L, et al. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy. Journal of medical economics. 2019:1-11.
45.    Torrejon Torres R, Saunders R, Ho KM. A comparative cost-effectiveness analysis of mechanical and pharmacological VTE prophylaxis after lower limb arthroplasty in Australia. Journal of orthopaedic surgery and research. 2019;14(1):93.
46.    Tubeuf S, Saloniki EC, Cottrell D. Parental Health Spillover in Cost-Effectiveness Analysis: Evidence from Self-Harming Adolescents in England. PharmacoEconomics. 2019;37(4):513-30.
47.    Vossen RJ, Philipszoon PC, Vahl AC, Montauban van Swijndregt AD, Leijdekkers VJ, Balm R. A Comparative Cost-Effectiveness Analysis of Percutaneous Transluminal Angioplasty With Optional Stenting and Femoropopliteal Bypass Surgery for Medium-Length TASC II B and C Femoropopliteal Lesions. Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists. 2019;26(2):172-80.
48.    Wang D, Xie W, Cao W, He S, Fan G, Zhang H. A Cost-utility Analysis of Percutaneous Endoscopic Lumbar Discectomy for L5-S1 Lumbar Disc Herniation: Transforaminal versus Interlaminar. Spine. 2019;44(8):563-70.
49.    Wastlund D, Moraitis AA, Dacey A, Sovio U, Wilson ECF, Smith GCS. Screening for breech presentation using universal late-pregnancy ultrasonography: A prospective cohort study and cost effectiveness analysis. PLoS medicine. 2019;16(4):e1002778.
50.    Windegger TM, Nghiem S, Nguyen KH, Fung YL, Scuffham PA. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency. Vox sanguinis. 2019;114(3):237-46.
51.    Zarca K, Durand-Zaleski I, Loriot MA, Chatellier G, Pallet N. Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis. Molecular diagnosis & therapy. 2019.
52.    Zhang L, Bao Y, Riaz M, Tiller J, Liew D, Zhuang X, et al. Correction: Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. Genetics in medicine : official journal of the American College of Medical Genetics. 2019.
53.    Zhou K, Zhou J, Huang J, Zhang N, Bai L, Yang Y, et al. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2019;130:1-4.

March 2019

1.    Abel L, Dakin HA, Roberts N, Ashdown HF, Butler CC, Hayward G, et al. Is stratification testing for treatment of chronic obstructive pulmonary disease exacerbations cost-effective in primary care? an early cost-utility analysis. International journal of technology assessment in health care. 2019:1-10.
2.    Aguiar PN, Jr., Roitberg F, Noia Barreto CM, Adashek JJ, Del Giglio A, Lopes GL, Jr. Back to the Future: In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments. Value in health regional issues. 2019;20:47-50.
3.    Aguiar PN, Jr., Tan PS, Simko S, Barreto CMN, Gutierres BS, Giglio AD, et al. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer. Einstein (Sao Paulo, Brazil). 2019;17(2):eGS4414.
4.    Bayon JC, Orruno E, Portillo MI, Asua J. The consequences of implementing non-invasive prenatal testing with cell-free foetal DNA for the detection of Down syndrome in the Spanish National Health Service: a cost-effectiveness analysis. Cost effectiveness and resource allocation : C/E. 2019;17:6.
5.    Bendixen M, Kronborg C, Jorgensen OD, Andersen C, Licht PB. Cost-utility analysis of minimally invasive surgery for lung cancer: a randomized controlled trial. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2019.
6.    Berkovits SM, Alvero AM. The Effects of Monetary Incentives on Planned and Unplanned Absences in Adolescent Part-Time Employees: a Cost-Effectiveness Analysis. Behavior analysis in practice. 2019;12(1):162-6.
7.    Blach S, Schaetti C, Bruggmann P, Negro F, Razavi H. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland. Swiss medical weekly. 2019;149:w20026.
8.    Bolkenstein HE, de Wit GA, Consten ECJ, Van de Wall BJM, Broeders I, Draaisma WA. Cost-effectiveness analysis of a multicentre randomized clinical trial comparing surgery with conservative management for recurrent and ongoing diverticulitis (DIRECT trial). The British journal of surgery. 2019;106(4):448-57.
9.    Brain D, Tulleners R, Lee X, Cheng Q, Graves N, Pacella R. Cost-effectiveness analysis of an innovative model of care for chronic wounds patients. PloS one. 2019;14(3):e0212366.
10.    Brown GC, Brown MM. Patient Preference-Based Comparative Effectiveness and Cost-Utility Analysis of the Prostamides for Open-Angle Glaucoma. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2019;35(3):145-60.
11.    Chanthawong S, Lim YH, Subongkot S, Chan A, Andalusia R, Ahmad Bustamam RS, et al. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2019;27(3):1109-19.
12.    Chomsky-Higgins K, Kahn JG. Interventions and Innovation to Prevent Surgical Site Infection in Colorectal Surgery: A Cost-Effectiveness Analysis. The Journal of surgical research. 2019;235:373-82.
13.    Dowd B, Nyman JA. Cost-Effectiveness Analysis in the Context of US Commercial Health Insurance. PharmacoEconomics. 2019.
14.    Fawsitt CG, Thom HHZ, Hunt LP, Nemes S, Blom AW, Welton NJ, et al. Choice of Prosthetic Implant Combinations in Total Hip Replacement: Cost-Effectiveness Analysis Using UK and Swedish Hip Joint Registries Data. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2019;22(3):303-12.
15.    Ganzer N, Feldmann I, Petren S, Bondemark L. A cost-effectiveness analysis of anchorage reinforcement with miniscrews and molar blocks in adolescents: a randomized controlled trial. European journal of orthodontics. 2019;41(2):180-7.
16.    Gomes M, Pennington M, Black N, Smith S. Cost-effectiveness analysis of English memory assessment services 2 years after first consultation for patients with dementia. International journal of geriatric psychiatry. 2019;34(3):439-46.
17.    Gong CL, Studdert AL, Liedtke M. Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis. American journal of hematology. 2019;94(3):E68-e70.
18.    Griffiths PD. Turning cost effectiveness analysis on its head. Reviews in medical virology. 2019;29(2):e2040.
19.    Homan J, Schijns W, Janssen IMC, Berends FJ, Aarts EO. Correction to: Adequate Multivitamin Supplementation after Roux-En-Y Gastric Bypass Results in a Decrease of National Health Care Costs: a Cost-Effectiveness Analysis. Obesity surgery. 2019.
20.    Hopkins MK, Grotegut CA, Swamy GK, Myers ER, Havrilesky LJ. Induction of Labor versus Scheduled Cesarean in Morbidly Obese Women: A Cost-Effectiveness Analysis. American journal of perinatology. 2019;36(4):399-405.
21.    Hu JQ, Sarkar R, Sella R, Murphy JD, Afshari NA. Cost-effectiveness Analysis of Multifocal Intraocular Lenses Compared to Monofocal Intraocular Lenses in Cataract Surgery. American journal of ophthalmology. 2019.
22.    Huang SJ, Galarraga O, Smith KA, Fuimaono S, McGarvey ST. Cost-effectiveness analysis of a cluster-randomized, culturally tailored, community health worker home-visiting diabetes intervention versus standard care in American Samoa. Human resources for health. 2019;17(1):17.
23.    Hughes DA, Culeddu G, Plumpton CO, Wood E, Dick AD, Jones AP, et al. Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. Ophthalmology. 2019;126(3):415-24.
24.    Hwang JP, Huang D, Vierling JM, Suarez-Almazor ME, Shih YT, Chavez-MacGregor M, et al. Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. JCO clinical cancer informatics. 2019;3:1-12.
25.    Idrees JJ, Rosinski BF, Merath K, Chen Q, Bagante F, Pawlik TM. Readmission after pancreatic resection: causes, costs and cost-effectiveness analysis of high versus low quality hospitals using the Nationwide Readmission Database. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2019;21(3):291-300.
26.    Jain A, Marks MC, Kelly MP, Lenke LG, Errico TJ, Lonner BS, et al. Cost-Utility Analysis of Operative Versus Nonoperative Treatment of Thoracic Adolescent Idiopathic Scoliosis. Spine. 2019;44(5):309-17.
27.    Jendle J, Pohlmann J, de Portu S, Smith-Palmer J, Roze S. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes. Diabetes technology & therapeutics. 2019;21(3):110-8.
28.    Jones DA, Whittaker P, Rathod KS, Richards AJ, Andiapen M, Antoniou S, et al. Sodium Nitrite-Mediated Cardioprotection in Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Cost-Effectiveness Analysis. Journal of cardiovascular pharmacology and therapeutics. 2019;24(2):113-9.
29.    Kalabina S, Belsey J, Pivonka D, Mohamed B, Thomas C, Paterson B. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales. Journal of medical economics. 2019;22(3):215-25.
30.    Kang SY, DiStefano MJ, Yehia F, Koszalka MV, Padula WV. Critical Care Beds With Continuous Lateral Rotation Therapy to Prevent Ventilator-Associated Pneumonia and Hospital-Acquired Pressure Injury: A Cost-effectiveness Analysis. Journal of patient safety. 2019.
31.    Ker H, Al-Murrani A, Rolfe G, Martin R. WOUND Study: A Cost-Utility Analysis of Negative Pressure Wound Therapy After Split-Skin Grafting for Lower Limb Skin Cancer. The Journal of surgical research. 2019;235:308-14.
32.    Leal J, Manetti S, Buchanan J. Correction to: The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study. PharmacoEconomics. 2019.
33.    Leurent B, Gomes M, Faria R, Morris S, Grieve R, Carpenter JR. Correction to: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial. PharmacoEconomics. 2019.
34.    Lightman S, Niederer R, Sharma S, Hooper C, Tomkins-Netzer O, Kramer M, et al. Re: Hughes et al.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis (Ophthalmology. 2019;126:415-424). Ophthalmology. 2019;126(3):e22-e4.
35.    Malhotra A, Wu X, Forman HP, Matouk CC, Hughes DR, Gandhi D, et al. Management of Unruptured Intracranial Aneurysms in Older Adults: A Cost-effectiveness Analysis. Radiology. 2019:182353.
36.    Meenan RT, Coronado GD, Petrik A, Green BB. A cost-effectiveness analysis of a colorectal cancer screening program in safety net clinics. Preventive medicine. 2019;120:119-25.
37.    Phi XA, Greuter MJW, Obdeijn IM, Oosterwijk JC, Feenstra TL, Houssami N, et al. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis. Breast (Edinburgh, Scotland). 2019;45:82-8.
38.    Pirhonen L, Bolin K, Olofsson EH, Fors A, Ekman I, Swedberg K, et al. Person-Centred Care in Patients with Acute Coronary Syndrome: Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial. PharmacoEconomics - open. 2019.
39.    Pollock RF, Norrbacka K, Cameron C, Mancillas-Adame L, Jeddi M. A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada. Journal of comparative effectiveness research. 2019;8(4):229-40.
40.    Pruis SL, Aziz MIA, Pearce F, Tan MH, Wu DB, Ng K. Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore. International journal of technology assessment in health care. 2019:1-8.
41.    Reinhorn D, Sarfaty M, Leshno M, Moore A, Neiman V, Rosenbaum E, et al. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma. The oncologist. 2019;24(3):366-71.
42.    Rossler R, Verhagen E, Rommers N, Dvorak J, Junge A, Lichtenstein E, et al. Comparison of the '11+ Kids' injury prevention programme and a regular warmup in children's football (soccer): a cost effectiveness analysis. British journal of sports medicine. 2019;53(5):309-14.
43.    Sanders GD, Maciejewski ML, Basu A. Overview of Cost-effectiveness Analysis. Jama. 2019.
44.    Sarmiento S, Pierre JA, Jr., Dellon AL, Frick KD. Tibial nerve decompression for the prevention of the diabetic foot: a cost-utility analysis using Markov model simulations. BMJ open. 2019;9(3):e024816.
45.    Seko T, Tachi T, Hatakeyama H, Noguchi Y, Teramachi H. Cost-effectiveness analysis and effectiveness of pharmacist-managed outpatient clinics in Helicobacter pylori eradication therapy. International journal of clinical practice. 2019:e13349.
46.    Shauly O, Gould DJ, Patel KM. Cost-Utility Analysis of Surgical Decompression Relative to Injection Therapy for Chronic Migraine Headaches. Aesthetic surgery journal. 2019.
47.    Stein MJ, Arnaout A, Thavorn K, Van Katwyk S, Zhang J. A cost effectiveness analysis of paravertebral blocks in immediate breast reconstruction following mastectomy. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2019.
48.    Tan MG, Isaranuwatchai W, DeLyzer T, Butler K, Hofer SOP, O'Neill AC, et al. A cost-effectiveness analysis of DIEP vs free MS-TRAM flap for microsurgical breast reconstruction. Journal of surgical oncology. 2019;119(3):388-96.
49.    Termrungruanglert W, Khemapech N, Tantitamit T, Havanond P. Cost effectiveness analysis of HPV primary screening and dual stain cytology triage compared with cervical cytology. Journal of gynecologic oncology. 2019;30(2):e17.
50.    Tew M, Clarke P, Thursky K, Dalziel K. Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients. PharmacoEconomics. 2019.
51.    Waller K, Furber S, Bauman A, Allman-Farinelli M, van den Dolder P, Hayes A, et al. DTEXT - text messaging intervention to improve outcomes of people with type 2 diabetes: protocol for randomised controlled trial and cost-effectiveness analysis. BMC public health. 2019;19(1):262.
52.    Walter E, Berger T, Bajer-Kornek B, Deisenhammer F. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria. Journal of medical economics. 2019;22(3):226-37.
53.    Wei X, Cai J, Sun H, Li N, Xu C, Zhang G, et al. Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients. Pharmacogenomics. 2019;20(4):241-9.
54.    Windegger TM, Nghiem S, Nguyen KH, Fung YL, Scuffham PA. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency. Vox sanguinis. 2019.
55.    Zhang B, Long EF. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Breast cancer research and treatment. 2019.


February 2019
1.    Response to the Article "Comparison of the Cost-Utility Analysis of Electroacupuncture and Nonsteroidal Antiinflammatory Drugs in the Treatment of Chronic Low Back Pain". Journal of acupuncture and meridian studies. 2019;12(1):1-2.
2.    Amin N, McIntyre L, Carter T, Xerogeanes J, Voigt J. Cost-Effectiveness Analysis of Needle Arthroscopy Versus Magnetic Resonance Imaging in the Diagnosis and Treatment of Meniscal Tears of the Knee. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2019;35(2):554-62.e13.
3.    Areia M, Fuccio L, Hassan C, Dekker E, Dias-Pereira A, Dinis-Ribeiro M. Cost-utility analysis of colonoscopy or faecal immunochemical test for population-based organised colorectal cancer screening. United European gastroenterology journal. 2019;7(1):105-13.
4.    Barrington DA, Dilley SE, Smith HJ, Straughn JM, Jr. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. Gynecologic oncology. 2019.
5.    Basu S, Wagner RG, Sewpaul R, Reddy P, Davies J. Implications of scaling up cardiovascular disease treatment in South Africa: a microsimulation and cost-effectiveness analysis. The Lancet Global health. 2019;7(2):e270-e80.
6.    Bhattacharyya A, Tahir A, Chandrashekar A, Vasisht S, Stinson L, Omatseye J. A cost-utility analysis of decompressive hemicraniectomy versus medical treatment in the management of space-occupying brain oedema post middle cerebral artery infarction. European journal of neurology. 2019;26(2):313-e19.
7.    Bordewijk EM, Weiss NS, Nahuis MJ, Bayram N, van Hooff MHA, Boks DES, et al. Gonadotrophins versus clomiphene citrate with or without IUI in women with normogonadotropic anovulation and clomiphene failure: a cost-effectiveness analysis. Human reproduction (Oxford, England). 2019;34(2):276-84.
8.    Bourel G, Pelletier-Fleury N, Bouyer J, Delbarre A, Fernandez H, Capmas P. Cost-effectiveness analysis of medical management versus conservative surgery for early tubal pregnancy. Human reproduction (Oxford, England). 2019;34(2):261-7.
9.    Canning P, Tawfick W, Whelan N, Hynes N, Sultan S. Cost-effectiveness analysis of endovascular versus open repair of abdominal aortic aneurysm in a high-volume center. Journal of vascular surgery. 2019.
10.    Castagna A, Garofalo R, Maman E, Gray AC, Brooks EA. Comparative cost-effectiveness analysis of the subacromial spacer for irreparable and massive rotator cuff tears. International orthopaedics. 2019;43(2):395-403.
11.    Cavany SM, Vynnycky E, Anderson CS, Maguire H, Sandmann F, Thomas HL, et al. Should NICE reconsider the 2016 UK guidelines on TB contact tracing? A cost-effectiveness analysis of contact investigations in London. Thorax. 2019;74(2):185-93.
12.    Chan KH, Whittam BM, Krambeck A, Downs SM, Misseri R, Cain MP, et al. Cost-effectiveness analysis of the management of distal ureteral stones in children. Urology. 2019.
13.    Daar DA, Shah A, Mirrer JT, Thanik V, Hacquebord J. "Proximal Row Carpectomy versus Four-Corner Arthrodesis for the Treatment of SLAC/SNAC Wrist: A Cost-Utility Analysis". Plastic and reconstructive surgery. 2019.
14.    Depreitere B, Turner I, Vandoren C, Choi D. Cost-Utility Analysis of Surgery and Radiotherapy for Symptomatic Spinal Metastases in a Belgian Specialist Center. World neurosurgery. 2019.
15.    Epstein DM, Gohel MS, Heatley F, Liu X, Bradbury A, Bulbulia R, et al. Cost-effectiveness analysis of a randomized clinical trial of early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration. The British journal of surgery. 2019.
16.    Floros L, Kuessner D, Posthumus J, Bagshaw E, Sjolin J. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden. BMC infectious diseases. 2019;19(1):134.
17.    Franklin M, Lomas J, Walker S, Young T. An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis. PharmacoEconomics. 2019.
18.    Fusco F, Campbell H, Barker K. Rehabilitation after resurfacing hip arthroplasty: cost-utility analysis alongside a randomized controlled trial. Clinical rehabilitation. 2019:269215519827628.
19.    Gallego-Delgado M, Villacorta E, Valenzuela-Vicente MC, Walias-Sanchez A, Avila C, Velasco-Canedo MJ, et al. Start-up of a Cardiology Day Hospital: Activity, Quality Care and Cost-effectiveness Analysis of the First Year of Operation. Revista espanola de cardiologia (English ed). 2019;72(2):130-7.
20.    Gibbons A, Leung EH, Yoo SH. Cost-Effectiveness Analysis of Descemet's Membrane Endothelial Keratoplasty Versus Descemet's Stripping Endothelial Keratoplasty in the United States. Ophthalmology. 2019;126(2):207-13.
21.    Girardin F, Hearmon N, Negro F, Eddowes L, Bruggmann P, Castro E. Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis. Journal of viral hepatitis. 2019;26(2):236-45.
22.    Griffiths PD. Turning cost effectiveness analysis on its head. Reviews in medical virology. 2019:e2040.
23.    Hersh AR, Skeith AE, Sargent JA, Caughey AB. Induction of Labor at 39 Weeks of Gestation vs. Expectant Management for Low-Risk Nulliparous Women: A Cost-Effectiveness Analysis. American journal of obstetrics and gynecology. 2019.
24.    Hojjat H, Svider PF, Hong R, Folbe AJ, Eloy JA, Shkoukani MA. In Response to To Image or Not to Image? A Cost-effectiveness Analysis of MRI for Patients With Asymmetric Sensorineural Hearing Loss. The Laryngoscope. 2019;129(2):E50.
25.    Homan J, Schijns W, Janssen IMC, Berends FJ, Aarts EO. Adequate Multivitamin Supplementation after Roux-En-Y Gastric Bypass Results in a Decrease of National Health Care Costs: a Cost-Effectiveness Analysis. Obesity surgery. 2019.
26.    Huang CC, Lin CN, Chung CH, Hwang JS, Tsai ST, Wang JD. Cost-effectiveness analysis of the oral cancer screening program in Taiwan. Oral oncology. 2019;89:59-65.
27.    Jendle J, Pohlmann J, de Portu S, Smith-Palmer J, Roze S. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes. Diabetes technology & therapeutics. 2019;21(3):110-8.
28.    Khalifeh JM, Dibble CF, Dy CJ, Ray WZ. Cost-Effectiveness Analysis of Combined Dual Motor Nerve Transfers versus Alternative Surgical and Nonsurgical Management Strategies to Restore Shoulder Function Following Upper Brachial Plexus Injury. Neurosurgery. 2019;84(2):362-77.
29.    Klebanoff MJ, Corey KE, Samur S, Choi JG, Kaplan LM, Chhatwal J, et al. Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis. JAMA network open. 2019;2(2):e190047.
30.    Kobayashi M, Kudo M, Izumi N, Kaneko S, Azuma M, Copher R, et al. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. Journal of gastroenterology. 2019.
31.    Le QA, Hay JW, Becker R, Wang Y. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States. The Annals of pharmacotherapy. 2019;53(2):134-43.
32.    Liao M, Jiang Q, Hu H, Han J, She L, Yao L, et al. Cost effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China. Journal of medical economics. 2019:1.
33.    Malhotra A, Wu X, Matouk CC, Forman HP, Gandhi D, Sanelli P. MR Angiography Screening and Surveillance for Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Cost-effectiveness Analysis. Radiology. 2019:181399.
34.    Malkin SJP, Russel-Szymczyk M, Liidemann G, Volke V, Hunt B. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2019;10(1):159-76.
35.    Moreno-Fernandez J. Comments on Garcia-Lorenzo et al. Cost-effectiveness analysis of real-time continuous monitoring glucose compared to self-monitoring of blood glucose for diabetes mellitus in Spain. Journal of evaluation in clinical practice. 2019.
36.    Mostafa A, Elsisi GH. A cost-effectiveness analysis of the use of safety-engineered syringes in reducing HBV, HCV, and HIV burden in Egypt. Expert review of medical devices. 2019;16(2):155-63.
37.    Myckatyn TM, Hall B, Pierce A. Discussion: Cost-Effectiveness Analysis of Silicone versus Saline Implant-Based Breast Reconstruction Using the BREAST-Q. Plastic and reconstructive surgery. 2019;143(2):285e-6e.
38.    Ordonez JE, Ordonez A, Osorio UM. Cost-effectiveness analysis of iStent trabecular micro-bypass stent for patients with open-angle glaucoma in Colombia. Current medical research and opinion. 2019;35(2):329-40.
39.    Padula WV, Pronovost PJ, Makic MBF, Wald HL, Moran D, Mishra MK, et al. Value of hospital resources for effective pressure injury prevention: a cost-effectiveness analysis. BMJ quality & safety. 2019;28(2):132-41.
40.    Pan YJ, Kuo KH, Chan HY, Yeh LL. Cost-effectiveness and cost-utility analysis of outpatient follow-up frequency in relation to three-year mortality in discharged patients with bipolar disorder. Psychiatry research. 2019;272:61-8.
41.    Pizzo E, Dumba M, Lobotesis K. Cost-utility analysis of mechanical thrombectomy between 6 and 24 hours in acute ischemic stroke. International journal of stroke : official journal of the International Stroke Society. 2019:1747493019830587.
42.    Prosser LA, Harpaz R, Rose AM, Gebremariam A, Guo A, Ortega-Sanchez IR, et al. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. Annals of internal medicine. 2019.
43.    Qiu X, Nasser JS, Sue GR, Chang J, Chung KC. Cost-Effectiveness Analysis of Humanitarian Hand Surgery Trips According to WHO-CHOICE Thresholds. The Journal of hand surgery. 2019;44(2):93-103.
44.    Rattanachotphanit T, Limwattananon C, Waleekhachonloet O, Limwattananon P, Sawanyawisuth K. Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding. PharmacoEconomics. 2019;37(2):279-89.
45.    Reinhorn D, Sarfaty M, Leshno M, Moore A, Neiman V, Rosenbaum E, et al. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma. The oncologist. 2019.
46.    Saxena A, Koon AD, Lagrada-Rombaua L, Angeles-Agdeppa I, Johns B, Capanzana M. Modelling the impact of a tax on sweetened beverages in the Philippines: an extended cost-effectiveness analysis. Bulletin of the World Health Organization. 2019;97(2):97-107.
47.    Selva-Sevilla C, Ferrara P, Geronimo-Pardo M. Cost-utility Analysis for Recurrent Lumbar Disc Herniation: Conservative Treatment Versus Discectomy Versus Discectomy With Fusion. Clinical spine surgery. 2019.
48.    Shiri T, Loyse A, Mwenge L, Chen T, Lakhi S, Chanda D, et al. Addition of flucytosine to fluconazole for the treatment of cryptococcal meningitis in Africa: a multi-country cost-effectiveness analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019.
49.    Simons RWP, Visser N, van den Biggelaar F, Nuijts R, Webers CAB, Bauer NJC, et al. Trial-based cost-effectiveness analysis of toric versus monofocal intraocular lenses in cataract patients with bilateral corneal astigmatism in the Netherlands. Journal of cataract and refractive surgery. 2019;45(2):146-52.
50.    Siotos C, Sarmiento S, McColl M, Sacks JM, Manahan MA, Rosson GD, et al. Cost-Effectiveness Analysis of Silicone versus Saline Implant-Based Breast Reconstruction Using the BREAST-Q. Plastic and reconstructive surgery. 2019;143(2):276e-84e.
51.    Smith AD, Carson JD, Sirous R, Sanyal R, Remer EM, Allen BC, et al. Active Surveillance Versus Nephron-Sparing Surgery for a Bosniak IIF or III Renal Cyst: A Cost-Effectiveness Analysis. AJR American journal of roentgenology. 2019:1-9.
52.    Tsukiyama I, Ando M, Tsukiyama S, Takeuchi M, Ejiri M, Kurose Y, et al. Cost-utility analysis of aprepitant for patients who truly need it in Japan. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2019.
53.    Ulrich LR, Petersen JJ, Mergenthal K, Berghold A, Pregartner G, Holle R, et al. Cost-effectiveness analysis of case management for optimized antithrombotic treatment in German general practices compared to usual care - results from the PICANT trial. Health economics review. 2019;9(1):4.
54.    van Baal P, Morton A, Meltzer D, Brouwer W. Future unrelated medical costs need to be considered in cost effectiveness analysis. The European journal of health economics : HEPAC : health economics in prevention and care. 2019;20(1):1-5.
55.    Vargas C, Balmaceda C, Rodriguez F, Rojas R, Giglio A, Espinoza MA. Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison. Expert review of pharmacoeconomics & outcomes research. 2019.
56.    Wan X, Zhang Y, Tan C, Zeng X, Peng L. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis. JAMA oncology. 2019.
57.    Yang F, Devlin N, Luo N. Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments. The European journal of health economics : HEPAC : health economics in prevention and care. 2019;20(1):99-105.
58.    Zhang L, Bao Y, Riaz M, Tiller J, Liew D, Zhuang X, et al. Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. Genetics in medicine : official journal of the American College of Medical Genetics. 2019.

January 2019

1.    Developing Research to Change Policy: Design of a Multicenter Cost-Effectiveness Analysis Comparing Intramedullary Nailing to Skeletal Traction in Malawi: Erratum. Journal of orthopaedic trauma. 2019;33(1):e35.
2.    Bussabawalai T, Thiboonboon K, Teerawattananon Y. Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand. Cost effectiveness and resource allocation : C/E. 2019;17:1.
3.    Cai X, Shi L, Yang W, Gu S, Chen Y, Nie L, et al. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. Journal of medical economics. 2019:1-8.
4.    Campbell JR, Johnston JC, Ronald LA, Sadatsafavi M, Balshaw RF, Cook VJ, et al. Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2019;73(1):39-50.
5.    Castillo-Jimenez DA, Garcia-Perdomo HA. Re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.055: Standardized Reporting for Economic Analyses Should be Mandatory. European urology. 2019.
6.    Chen Q, Liang X, Long X, Yu L, Liu W, Lu H. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases. Helicobacter. 2019:e12563.
7.    Chouaid C, Bensimon L, Clay E, Millier A, Levy-Bachelot L, Huang M, et al. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung cancer (Amsterdam, Netherlands). 2019;127:44-52.
8.    Culyer AJ, Chalkidou K. Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis? Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2019;22(1):99-103.
9.    Daly AT, Deshmukh AA, Vidrine DJ, Prokhorov AV, Frank SG, Tahay PD, et al. Cost-effectiveness analysis of smoking cessation interventions using cell phones in a low-income population. Tobacco control. 2019;28(1):88-94.
10.    de Jong LA, Gout-Zwart JJ, van den Bosch M, Koops M, Postma MJ. Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis. Journal of medical economics. 2019:1-10.
11.    Dekker ARJ, van der Velden AW, Luijken J, Verheij TJM, van Giessen A. Cost-effectiveness analysis of a GP- and parent-directed intervention to reduce antibiotic prescribing for children with respiratory tract infections in primary care. The Journal of antimicrobial chemotherapy. 2019.
12.    den Broeder N, Bouman CAM, Kievit W, van Herwaarden N, van den Hoogen FHJ, van Vollenhoven RF, et al. Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is key. Annals of the rheumatic diseases. 2019;78(1):141-2.
13.    Driessen MT, Whalen J, Buguth BS, Vallejo-Aparicio LA, Naya IP, Asukai Y, et al. Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respiratory research. 2019;20(1):18.
14.    Duvetorp A, Levin LA, Engerstedt Mattsson E, Ryttig L. A Cost-utility Analysis of Calcipotriol/betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden. Acta dermato-venereologica. 2019.
15.    Fatima A, Hackman TG, Wood JS. "Cost-Effectiveness Analysis of Virtual Surgical Planning in Mandibular Reconstruction.". Plastic and reconstructive surgery. 2019.
16.    Federer AE, Mather RC, 3rd, Ramsey ML, Garrigues GE. Cost-effectiveness analysis of total elbow arthroplasty versus open reduction-internal fixation for distal humeral fractures. Journal of shoulder and elbow surgery. 2019;28(1):102-11.
17.    Fragoulakis V, Bartsakoulia M, Diaz-Villamarin X, Chalikiopoulou K, Kehagia K, Ramos JGS, et al. Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention. The pharmacogenomics journal. 2019.
18.    Gakis G, Volkmer B, Qvick B, Marteau F, Stenzl A. [Cost-effectiveness analysis of blue light cystoscopy with hexylaminolevulinate in transurethral resection of the bladder]. Der Urologe Ausg A. 2019;58(1):34-40.
19.    Galper BZ, Reynolds MR, Garg P, Secemsky EA, Valsdottir LR, Cohen DJ, et al. Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention. Coronary artery disease. 2019.
20.    Gandhoke GS, Smith KJ, Niranjan A, Sekula RF, Lunsford LD. Comparing Microvascular Decompression with Gamma Knife Radiosurgery for Trigeminal Neuralgia A Cost-effectiveness Analysis. World neurosurgery. 2019.
21.    Geitona M, Stamuli E, Giannakodimos S, Kimiskidis VK, Kountouris V, Charokopou M, et al. Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system. Journal of medical economics. 2019:1-6.
22.    Go DS, Kim SH, Park J, Ryu DR, Lee HJ, Jo MW. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea. Nephrology (Carlton, Vic). 2019;24(1):56-64.
23.    Goeree R, Chiva-Razavi S, Gunda P, Jain M, Jugl SM. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective. Journal of medical economics. 2019;22(1):45-52.
24.    Grochtdreis T, Brettschneider C, Bjerregaard F, Bleich C, Boczor S, Harter M, et al. Cost-effectiveness analysis of collaborative treatment of late-life depression in primary care (GermanIMPACT). European psychiatry : the journal of the Association of European Psychiatrists. 2019;57:10-8.
25.    Hamilton TD, MacNeill AJ, Lim H, Hunink MGM. Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer. Annals of surgical oncology. 2019.
26.    Kabore N, Marnat G, Rouanet F, Barreau X, Verpillot E, Menegon P, et al. Cost-effectiveness analysis of mechanical thrombectomy plus tissue-type plasminogen activator compared with tissue-type plasminogen activator alone for acute ischemic stroke in France. Revue neurologique. 2019.
27.    Kleineruschkamp A, Meybohm P, Straub N, Zacharowski K, Choorapoikayil S. A model-based cost-effectiveness analysis of Patient Blood Management. Blood transfusion = Trasfusione del sangue. 2019;17(1):16-26.
28.    Kloos RQH, van Litsenburg RRL, Wolf S, Wismans L, Kaspers GJL, Uyl-de Groot CA, et al. A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia. Pediatric blood & cancer. 2019;66(1):e27458.
29.    Lee H, Kim UC, Oh JK, Kim T, Park S, Ha Y. Cost-Effectiveness Analysis of Cervical Anterior Fusion and Cervical Artificial Disc Replacement in the Korean Medical System. Journal of Korean Neurosurgical Society. 2019;62(1):83-9.
30.    Liao W, Huang J, Hutton D, Li Q. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China. Journal of medical economics. 2019:1-6.
31.    Matchar DB, Eom K, Duncan PW, Lee M, Sim R, Sivapragasam NR, et al. A Cost-Effectiveness Analysis of a Randomized Control Trial of a Tailored, Multifactorial Program to Prevent Falls Among the Community-Dwelling Elderly. Archives of physical medicine and rehabilitation. 2019;100(1):1-8.
32.    Mattingly TJ, 2nd, Meninger S, Heil EL. Penicillin skin testing in methicillin-sensitive staphylococcus aureus bacteremia: A cost-effectiveness analysis. PloS one. 2019;14(1):e0210271.
33.    Meenan RT, Coronado GD, Petrik A, Green BB. A cost-effectiveness analysis of a colorectal cancer screening program in safety net clinics. Preventive medicine. 2019;120:119-25.
34.    Moriarty F, Cahir C, Bennett K, Fahey T. Economic impact of potentially inappropriate prescribing and related adverse events in older people: a cost-utility analysis using Markov models. BMJ open. 2019;9(1):e021832.
35.    Mostafa A, Elsisi GH. A cost-effectiveness analysis of the use of safety-engineered syringes in reducing HBV, HCV, and HIV burden in Egypt. Expert review of medical devices. 2019;16(2):155-63.
36.    Moya-Alarcon C, Gonzalez-Dominguez A, Simon S, Perez-Roman I, Gonzalez-Martin A, Bayo-Lozano E, et al. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2019.
37.    Narayen IC, Te Pas AB, Blom NA, van den Akker-van Marle ME. Cost-effectiveness analysis of pulse oximetry screening for critical congenital heart defects following homebirth and early discharge. European journal of pediatrics. 2019;178(1):97-103.
38.    Patel V, Ahmed I, Podbielski D, Falvey H, Murray J, Goeree R. Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada. Journal of medical economics. 2019:1-12.
39.    Pollock RF, Norrbacka K, Cameron C, Mancillas-Adame L, Jeddi M. A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada. Journal of comparative effectiveness research. 2019.
40.    Quintella EF, Ferreira E, Azevedo VMP, Araujo DV, Sant'Anna FM, Amorim B, et al. Clinical Outcomes and Cost-Effectiveness Analysis of FFR Compared with Angiography in Multivessel Disease Patient. Arquivos brasileiros de cardiologia. 2019;112(1):40-7.
41.    Retat L, Pimpin L, Webber L, Jaccard A, Lewis A, Tearne S, et al. Screening and brief intervention for obesity in primary care: cost-effectiveness analysis in the BWeL trial. International journal of obesity (2005). 2019.
42.    Rombach I, Merritt N, Shirkey BA, Rees JL, Cook JA, Cooper C, et al. Cost-effectiveness analysis of a placebo-controlled randomized trial evaluating the effectiveness of arthroscopic subacromial decompression in patients with subacromial shoulder pain. The bone & joint journal. 2019;101-b(1):55-62.
43.    Russell WA, Stramer SL, Busch MP, Custer B. Screening the Blood Supply for Zika Virus in the 50 U.S. States and Puerto Rico: A Cost-Effectiveness Analysis. Annals of internal medicine. 2019.
44.    Sathianathen NJ, Konety BR. Reply to Diana A. Castillo-Jimenez and Herney A. Garcia-Perdomo's Letter to the Editor re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.055. Standardized Reporting for Economic Analyses Should be Mandatory. European urology. 2019.
45.    Schneeberger S, Phillips S, Huang LC, Pierce RA, Etemad SA, Poulose BK. Cost-Utility Analysis of Biologic and Biosynthetic Mesh in Ventral Hernia Repair: When Are They Worth It? Journal of the American College of Surgeons. 2019;228(1):66-71.
46.    Sekiguchi M, Igarashi A, Sakamoto T, Saito Y, Esaki M, Matsuda T. Cost-effectiveness analysis of postpolypectomy colonoscopy surveillance using Japanese data. Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society. 2019;31(1):40-50.
47.    Simpson AN, Garbens A, Dossa F, Coyte PC, Baxter NN, McDermott CD. A Cost-Utility Analysis of Nonsurgical Treatments for Stress Urinary Incontinence in Women. Female pelvic medicine & reconstructive surgery. 2019;25(1):49-55.
48.    Sohrt A, Maerkedahl A, Padula WV. Correction to: Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes. PharmacoEconomics - open. 2019.
49.    Sun XR, He SN, Lin ZY, Zhang L, Wang YJ, Zeng LJ, et al. Radiofrequency Catheter Ablation Versus Cryoballoon Ablation in the Treatment of Paroxysmal Atrial Fibrillation: A Cost-effectiveness Analysis in China. Clinical therapeutics. 2019;41(1):78-91.
50.    Teranishi Y, Arai K, Baba S. Cost-Utility Analysis of Molar Single Implant Versus Fixed Dental Prosthesis. The International journal of prosthodontics. 2019;32(1):75-81.
51.    Wang SY, Chen T, Dang W, Mougalian SS, Evans SB, Gross CP. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis. Journal of the National Comprehensive Cancer Network : JNCCN. 2019;17(1):39-46.
52.    Wang Y, Shi JF, Wang L, Yan Y, Yao H, Dai M, et al. Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2019;78:130-9.
53.    Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK, et al. An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis. Human vaccines & immunotherapeutics. 2019.
54.    Wei X, Cai J, Sun H, Li N, Xu C, Zhang G, et al. Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients. Pharmacogenomics. 2019.
55.    Whittington MD, McQueen RB, Ollendorf DA, Chapman RH, Kumar VM, Synnott PG, et al. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. Journal of managed care & specialty pharmacy. 2019;25(1):80-7.
56.    Yang F, Devlin N, Luo N. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter? Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2019;22(1):45-9.
57.    Zhang J, Ge L, Hill M, Liang Y, Xie J, Cui D, et al. Standard-Dose Proton Pump Inhibitors in the Initial Non-eradication Treatment of Duodenal Ulcer: Systematic Review, Network Meta-Analysis, and Cost-Effectiveness Analysis. Frontiers in pharmacology. 2018;9:1512.


December 2018

1.    Altawalbeh SM, Alshogran OY, Smith KJ. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018;21(12):1365-72.
2.    Aronsson L, Ansari D, Andersson B, Persson U, Fridhammar A, Andersson R. Intraductal papillary mucinous neoplasms of the pancreas - a cost-effectiveness analysis of management strategies for the branch-duct subtype. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2018;20(12):1206-14.
3.    Atehortua SC, Lugo LH, Ceballos M, Orozco E, Castro PA, Arango JC, et al. Cost-Effectiveness Analysis of Diagnosis of Duchenne/Becker Muscular Dystrophy in Colombia. Value in health regional issues. 2018;17:1-6.
4.    Basu S, Wagner RG, Sewpaul R, Reddy P, Davies J. Implications of scaling up cardiovascular disease treatment in South Africa: a microsimulation and cost-effectiveness analysis. The Lancet Global health. 2018.
5.    Bolkenstein HE, de Wit GA, Consten ECJ, Van de Wall BJM, Broeders I, Draaisma WA. Cost-effectiveness analysis of a multicentre randomized clinical trial comparing surgery with conservative management for recurrent and ongoing diverticulitis (DIRECT trial). The British journal of surgery. 2018.
6.    Bordewijk EM, Weiss NS, Nahuis MJ, Bayram N, van Hooff MHA, Boks DES, et al. Gonadotrophins versus clomiphene citrate with or without IUI in women with normogonadotropic anovulation and clomiphene failure: a cost-effectiveness analysis. Human reproduction (Oxford, England). 2018.
7.    Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, et al. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. PharmacoEconomics. 2018;36(12):1463-73.
8.    Bourel G, Pelletier-Fleury N, Bouyer J, Delbarre A, Fernandez H, Capmas P. Cost-effectiveness analysis of medical management versus conservative surgery for early tubal pregnancy. Human reproduction (Oxford, England). 2018.
9.    Chanatittarat C, Chaikledkaew U, Prayoonwiwat N, Siritho S, Pasogpakdee P, Apiwattanakul M, et al. COST-UTILITY ANALYSIS OF MULTIPLE SCLEROSIS TREATMENT IN THAILAND. International journal of technology assessment in health care. 2018:1-9.
10.    Chhatwal J, Chen Q, Bethea ED, Ladd MA, Mueller PP, Hutin Y, et al. Hep C Calculator: an online tool for cost-effectiveness analysis of DAAs. The lancet Gastroenterology & hepatology. 2018;3(12):819.
11.    Cho SK, Hay JW, Barzi A. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. Clinical colorectal cancer. 2018;17(4):e751-e61.
12.    Degeling K, Franken MD, May AM, van Oijen MGH, Koopman M, Punt CJA, et al. Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. Cancer epidemiology. 2018;57:60-7.
13.    Finch AP, van Velzen P, Ter Riet G, Sterk PJ, Prins JM, Bosmans JE. Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial. PharmacoEconomics. 2018.
14.    Ginsberg GM, Somekh E, Schlesinger Y. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis. Israel journal of health policy research. 2018;7(1):63.
15.    Gong CL, Studdert AL, Liedtke M. Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis. American journal of hematology. 2018.
16.    Goodall G, Lamotte M, Ramos M, Maunoury F, Pejchalova B, de Pouvourville G. Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients. Journal of medical economics. 2018:1-23.
17.    Gozlan G, Lecardeur L, Monfort AS, Doz M, Ortiz I, Larroumets P, et al. [Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France]. L'Encephale. 2018;44(6):496-503.
18.    Holmes EAF, Harris SD, Hughes A, Craine N, Hughes DA. Cost-Effectiveness Analysis of the Use of Point-of-Care C-Reactive Protein Testing to Reduce Antibiotic Prescribing in Primary Care. Antibiotics (Basel, Switzerland). 2018;7(4).
19.    Hwang R, Morris NR, Mandrusiak A, Bruning J, Peters R, Korczyk D, et al. Cost-Utility Analysis of Home-based Telerehabilitation Compared with Centre-based Rehabilitation in Patients with Heart Failure. Heart, lung & circulation. 2018.
20.    Ionescu AM, Mpobela Agnarson A, Kambili C, Metz L, Kfoury J, Wang S, et al. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis. Expert review of pharmacoeconomics & outcomes research. 2018;18(6):677-89.
21.    Johnson SR, Carter HE, Leo P, Hollingworth SA, Davis EA, Jones TW, et al. Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life. Diabetes care. 2018.
22.    Kigozi J, Jowett S, Nicholl BI, Lewis M, Bartlam B, Green D, et al. Cost-Utility Analysis of Routine Anxiety and Depression Screening in Patients Consulting for Osteoarthritis: Results From a Clinical, Randomized Controlled Trial. Arthritis care & research. 2018;70(12):1787-94.
23.    Kulaylat AS, Hollenbeak CS, Soybel DI. Cost-utility analysis of smoking cessation to prevent operative complications following elective abdominal colon surgery. American journal of surgery. 2018;216(6):1082-9.
24.    Lara C, De Graeve D, Franco F. Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia. Value in health regional issues. 2018;17:21-31.
25.    Lim SL, Moss HA, Secord AA, Lee PS, Havrilesky LJ, Davidson BA. Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis. Gynecologic oncology. 2018;151(3):506-12.
26.    Malkin SJP, Russel-Szymczyk M, Liidemann G, Volke V, Hunt B. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2018.
27.    Mar J, Anton-Ladislao A, Ibarrondo O, Arrospide A, Lazaro S, Gonzalez N, et al. Cost-effectiveness analysis of laparoscopic versus open surgery in colon cancer. Surgical endoscopy. 2018;32(12):4912-22.
28.    Mehta Z, English M, Trybus C, Magda V, Kamal K. Comment on the article "Comparison of the Cost-Utility Analysis of Electroacupuncture and Nonsteroidal Antiinflammatory Drugs in the Treatment of Chronic Low Back Pain". Journal of acupuncture and meridian studies. 2018;11(6):341-2.
29.    Mostafa A, Elsisi GH. A cost-effectiveness analysis of the use of safety-engineered syringes in reducing HBV, HCV, and HIV burden in Egypt. Expert review of medical devices. 2018.
30.    Nguyen E, Coleman CI, Kohn CG, Weeda ER. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life. International journal of cardiology. 2018;273:34-8.
31.    Pan YJ, Kuo KH, Chan HY, Yeh LL. Cost-effectiveness and cost-utility analysis of outpatient follow-up frequency in relation to three-year mortality in discharged patients with bipolar disorder. Psychiatry research. 2018;272:61-8.
32.    Qiu X, Nasser JS, Sue GR, Chang J, Chung KC. Cost-Effectiveness Analysis of Humanitarian Hand Surgery Trips According to WHO-CHOICE Thresholds. The Journal of hand surgery. 2018.
33.    Quintella EF, Ferreira E, Azevedo VMP, Araujo DV, Sant'Anna FM, Amorim B, et al. Clinical Outcomes and Cost-Effectiveness Analysis of FFR Compared with Angiography in Multivessel Disease Patient. Arquivos brasileiros de cardiologia. 2018.
34.    Raphael J, Sun Z, Bjarnason GA, Helou J, Sander B, Naimark DM. Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma: A Cost-Utility Analysis. American journal of clinical oncology. 2018;41(12):1235-42.
35.    Sanz-Granda A, Marti MJ, Catalan MJ. [Cost-utility analysis of two formulations of botulinum toxin type A in the treatment of blepharospasm and cervical dystonia in Spain]. Revista de neurologia. 2018;67(12):465-72.
36.    Sathianathen NJ, Kuntz KM, Alarid-Escudero F, Lawrentschuk NL, Bolton DM, Murphy DG, et al. Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis. The Journal of urology. 2018;200(6):1215-20.
37.    Segal L, Twizeyemariya A, Zarnowiecki D, Niyonsenga T, Bogomolova S, Wilson A, et al. Cost effectiveness and cost-utility analysis of a group-based diet intervention for treating major depression - the HELFIMED trial. Nutritional neuroscience. 2018:1-9.
38.    Sun XR, He SN, Lin ZY, Zhang L, Wang YJ, Zeng LJ, et al. Radiofrequency Catheter Ablation Versus Cryoballoon Ablation in the Treatment of Paroxysmal Atrial Fibrillation: A Cost-Effectiveness Analysis in China. Clinical therapeutics. 2018.
39.    Taheri S, Heidari E, Aivazi MA, Shams-Beyranvand M, Varmaghani M. COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN TREATMENT OF PATIENTS WITH HEART FAILURE IN IRAN. International journal of technology assessment in health care. 2018:1-8.
40.    Tan MG, Isaranuwatchai W, DeLyzer T, Butler K, Hofer SOP, O'Neill AC, et al. A cost-effectiveness analysis of DIEP vs free MS-TRAM flap for microsurgical breast reconstruction. Journal of surgical oncology. 2018.
41.    Tedesco Silva H, Jr., Evans RW, Gavaghan MB, Vazquez VC. A Cost-Effectiveness Analysis of Organ Preservation Methods for Deceased Donor Kidneys at High Risk for Delayed Graft Function in Brazil. Transplantation proceedings. 2018;50(10):3121-7.
42.    Walter E, Berger T, Bajer-Kornek B, Deisenhammer F. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria. Journal of medical economics. 2018:1-19.
43.    Wu J, Deaton S, Jiao B, Rosen Z, Muennig PA. The cost-effectiveness analysis of the New Rural Cooperative Medical Scheme in China. PloS one. 2018;13(12):e0208297.
44.    Zhang L, Lin Z, Yin H, Liu J, Xuan J. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective. Clinical therapeutics. 2018;40(12):2125-37.
45.    Zimmermann M, Brouwer E, Tice JA, Seidner M, Loos AM, Liu S, et al. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis. CNS drugs. 2018;32(12):1145-57.

November 2018

1.    Amin EE, Ten Cate-Hoek AJ, Bouman AC, Meijer K, Tick L, Middeldorp S, et al. Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis. The Lancet Haematology. 2018;5(11):e512-e9.
2.    Bahin FF, Heitman SJ, Rasouli KN, Mahajan H, McLeod D, Lee EYT, et al. Wide-field endoscopic mucosal resection versus endoscopic submucosal dissection for laterally spreading colorectal lesions: a cost-effectiveness analysis. Gut. 2018;67(11):1965-73.
3.    Bloemen A, Daniels AM, Samyn MG, Janssen RJ, Elshof JW. Electrocardiographic-guided tip positioning technique for peripherally inserted central catheters in a Dutch teaching hospital: Feasibility and cost-effectiveness analysis in a prospective cohort study. The journal of vascular access. 2018;19(6):578-84.
4.    Butterworth JFt, Cassano AD. Pitfalls in cost-effectiveness analysis in surgery. The Journal of thoracic and cardiovascular surgery. 2018;156(5):1933.
5.    Canning P, Tawfick W, Kamel K, Hynes N, Sultan S. Q-TWiST and Cost-Effectiveness Analysis of Endovascular vs. Open Repair in Ruptured Abdominal Aortic Aneurysms in a High Deliberate Practice Volume Centre. Annals of vascular surgery. 2018.
6.    da Silva LR, Vianna CMM, Mosegui GBG, Peregrino AAF, Marinho V, Laks J. Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer's disease in Brazil. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2018:0.
7.    Dalziel K, Cheek JA, Fanning L, Borland ML, Phillips N, Kochar A, et al. A Cost-Effectiveness Analysis Comparing Clinical Decision Rules PECARN, CATCH, and CHALICE With Usual Care for the Management of Pediatric Head Injury. Annals of emergency medicine. 2018.
8.    Dempsey M, Mocarski M, Langer J, Hunt B. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. Journal of medical economics. 2018;21(11):1110-8.
9.    Driessen MT, Whalen J, Seewoodharry Buguth B, Vallejo-Aparicio LA, Naya IP, Asukai Y, et al. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respiratory research. 2018;19(1):224.
10.    Dunlap LJ, Zarkin GA, Orme S, Meinhofer A, Kelly SM, O'Grady KE, et al. Re-engineering methadone-Cost-effectiveness analysis of a patient-centered approach to methadone treatment. Journal of substance abuse treatment. 2018;94:81-90.
11.    Entringer AP, Pinto M, Gomes M. Cost-effectiveness analysis of natural birth and elective C-section in supplemental health. Revista de saude publica. 2018;52:91.
12.    Erman A, Masucci L, Krahn MD, Elterman DS. Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis. BJU international. 2018;122(5):879-88.
13.    Gao L, Li SC. Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation. Breast cancer (Tokyo, Japan). 2018;25(6):671-80.
14.    Giorgakoudi K, O'Sullivan C, Heath PT, Ladhani S, Lamagni T, Ramsay M, et al. Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study. Vaccine. 2018;36(46):7033-42.
15.    Goeree R, Chiva-Razavi S, Gunda P, Jain M, Jugl SM. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective. Journal of medical economics. 2018:1-8.
16.    Gomes M, Pennington M, Black N, Smith S. Cost-effectiveness analysis of English memory assessment services two years after first consultation for patients with dementia. International journal of geriatric psychiatry. 2018.
17.    Graham CN, Christodoulopoulou A, Knox HN, Sabatelli L, Hechmati G, Garawin T, et al. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. Journal of medical economics. 2018;21(11):1075-83.
18.    Grynberg M, Murphy C, Dore C, Fresneau L, Paillet S, Petrica N, et al. A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective. Journal of medical economics. 2018:1-15.
19.    Hojjat H, Svider PF, Hong R, Folbe AJ, Eloy JA, Shkoukani MA. In Response to To Image or Not to Image? A Cost-effectiveness Analysis of MRI for Patients With Asymmetric Sensorineural Hearing Loss. The Laryngoscope. 2018.
20.    Ibarrondo O, Alvarez-Lopez I, Freundlich F, Arrospide A, Galve-Calvo E, Gutierrez-Toribio M, et al. Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model. Gaceta sanitaria. 2018.
21.    Jain A, Marks MC, Kelly MP, Lenke LG, Errico TJ, Lonner BS, et al. Cost-Utility Analysis of Operative vs. Nonoperative Treatment of Thoracic AIS. Spine. 2018.
22.    Kadom N, Itri JN, Trofimova A, Otero HJ, Horny M. Cost-Effectiveness Analysis: An Overview of Key Concepts, Recommendations, Controversies, and Pitfalls. Academic radiology. 2018.
23.    Kalabina S, Belsey J, Pivonka D, Mohamed B, Thomas C, Paterson B. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's Disease in patients in Scotland and Wales. Journal of medical economics. 2018:1-33.
24.    Kumdee C, Kulpeng W, Teerawattananon Y. Cost-utility analysis of the screening program for early oral cancer detection in Thailand. PloS one. 2018;13(11):e0207442.
25.    Lee H, Kim UC, Oh JK, Kim T, Park S, Ha Y. Cost-Effectiveness Analysis of Cervical Anterior Fusion and Cervical Artificial Disc Replacement in the Korean Medical System. Journal of Korean Neurosurgical Society. 2018.
26.    Leeyaphan C, Bunyaratavej S, Taychakhoonavudh S, Kulthanachairojana N, Pattanaprichakul P, Chanyachailert P, et al. Cost-effectiveness Analysis and Safety of Erythromycin 4%Gel and 4% Chlorhexidine Scrub for Pitted Keratolysis Treatment. The Journal of dermatological treatment. 2018:1-11.
27.    Li X, Li W, Hou L. A Trial-Based Cost-Effectiveness Analysis of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Nonsquamous Non-Small-Cell Lung Cancer in China. Value in health regional issues. 2018;18:1-7.
28.    Merritt MW, Sutherland CS, Tediosi F. Ethical Considerations for Global Health Decision-Making: Justice-Enhanced Cost-Effectiveness Analysis of New Technologies for Trypanosoma brucei gambiense. Public health ethics. 2018;11(3):275-92.
29.    Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, et al. A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018;129(2):257-63.
30.    Pickering K, Gallos ID, Williams H, Price MJ, Merriel A, Lissauer D, et al. Uterotonic Drugs for the Prevention of Postpartum Haemorrhage: A Cost-Effectiveness Analysis. PharmacoEconomics - open. 2018.
31.    Pollit V, Graham D, Leonard C, Filby A, McMaster J, Mealing SJ, et al. A cost-effectiveness analysis of endoscopic eradication therapy (EET) for management of dysplasia arising in patients with Barrett's esophagus in the United Kingdom. Current medical research and opinion. 2018:1-29.
32.    Purmonen T, Puolakka K, Bhattacharyya D, Jain M, Martikainen J. Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective. Cost effectiveness and resource allocation : C/E. 2018;16:56.
33.    Rattanachotphanit T, Limwattananon C, Waleekhachonloet O, Limwattananon P, Sawanyawisuth K. Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding. PharmacoEconomics. 2018.
34.    Robin P, Kumar S, Salaun PY, Le Roux PY, Couturaud F, Planquette B, et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis research. 2018;171:97-102.
35.    Rosenbloom JI, Lewkowitz AK, Sondgeroth KE, Hudson JL, Macones GA, Cahill AG, et al. Antenatal corticosteroid administration in late-preterm gestations: a cost-effectiveness analysis. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2018:1-7.
36.    Salavert M, Cobo J, Pascual A, Aragon B, Maratia S, Jiang Y, et al. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain. Advances in therapy. 2018;35(11):1920-34.
37.    Sathianathen NJ, Konety BR, Alarid-Escudero F, Lawrentschuk N, Bolton DM, Kuntz KM. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. European urology. 2018.
38.    Shedrawy J, Henriksson M, Hergens MP, Askling HH. Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: A cost-effectiveness analysis. Vaccine. 2018;36(50):7659-65.
39.    Shlomai A, Leshno M, Goldstein DA. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis. PloS one. 2018;13(11):e0207132.
40.    Simons RWP, Visser N, van den Biggelaar F, Nuijts R, Webers CAB, Bauer NJC, et al. Trial-based cost-effectiveness analysis of toric versus monofocal intraocular lenses in cataract patients with bilateral corneal astigmatism in the Netherlands. Journal of cataract and refractive surgery. 2018.
41.    Siotos C, Sarmiento S, McColl M, Sacks JM, Manahan MA, Rosson GD, et al. Cost-Effectiveness Analysis of Silicone vs. Saline Implant-Based Breast Reconstruction Using the BREAST-Q. Plastic and reconstructive surgery. 2018.
42.    Sluiter RL, Kievit W, van der Wilt GJ, Schene AH, Teichert M, Coenen MJH, et al. Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprosate, Using a Modeling Approach. European addiction research. 2018;24(5):245-54.
43.    Wang Y, Shi JF, Wang L, Yan Y, Yao H, Dai M, et al. Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2018.
44.    Weeks CA, Marsh JD, MacDonald SJ, Graves S, Vasarhelyi EM. Patellar Resurfacing in Total Knee Arthroplasty: A Cost-Effectiveness Analysis. The Journal of arthroplasty. 2018;33(11):3412-5.
45.    Yang YT, Ortendahl J. How does the Cox maze procedure compare? Cost-effectiveness analysis of alternative treatments of atrial fibrillation. Current medical research and opinion. 2018:1-21.
46.    Yap A, Muzira A, Cheung M, Healy J, Kakembo N, Kisa P, et al. A Cost-Effectiveness Analysis of a Pediatric Operating Room in Uganda. Surgery. 2018;164(5):953-9.
47.    Zhang L, Lin Z, Yin H, Liu J, Xuan J. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective. Clinical therapeutics. 2018.
48.    Zhou A, Yousem DM, Alvin MD. Cost-Effectiveness Analysis in Radiology: A Systematic Review. Journal of the American College of Radiology : JACR. 2018;15(11):1536-46.
49.    Zhou GQ, Wu CF, Zhang J, Mao YP, Tang LL, Chen L, et al. Cost-Effectiveness Analysis of Routine Magnetic Resonance Imaging in the Follow-Up of Patients With Nasopharyngeal Carcinoma After Intensity Modulated Radiation Therapy. International journal of radiation oncology, biology, physics. 2018;102(4):1382-91.


October 2018

1.    Ahern S, Burke LA, McElroy B, Corcoran P, McMahon EM, Keeley H, et al. A cost-effectiveness analysis of school-based suicide prevention programmes. European child & adolescent psychiatry. 2018;27(10):1295-304.
2.    Amin EE, Ten Cate-Hoek AJ, Bouman AC, Meijer K, Tick L, Middeldorp S, et al. Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis. The Lancet Haematology. 2018;5(11):e512-e9.
3.    Asban A, Homsy C, Chen L, Fisher C, Losken A, Chatterjee A. A cost-utility analysis comparing large volume displacement oncoplastic surgery to mastectomy with single stage implant reconstruction in the treatment of breast cancer. Breast (Edinburgh, Scotland). 2018;41:159-64.
4.    Cara AKS, Zaidi STR, Suleman F. Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia in Saudi Arabia. International journal of clinical pharmacy. 2018;40(5):1051-8.
5.    Degeling K, Franken MD, May AM, van Oijen MGH, Koopman M, Punt CJA, et al. Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. Cancer epidemiology. 2018;57:60-7.
6.    Drummond R, Malkin S, Du Preez M, Lee XY, Hunt B. The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting. Diabetes, obesity & metabolism. 2018;20(10):2371-8.
7.    Flowers CR, Ramsey SD. What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018:Jco2018793570.
8.    Giorgakoudi K, O'Sullivan C, Heath PT, Ladhani S, Lamagni T, Ramsay M, et al. Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study. Vaccine. 2018.
9.    Girardin F, Hearmon N, Negro F, Eddowes L, Bruggmann P, Castro E. Increasing Hepatitis C Virus Screening in People Who Inject Drugs in Switzerland Using Rapid Antibody Saliva and Dried Blood Spot Testing: a Cost-Effectiveness Analysis. Journal of viral hepatitis. 2018.
10.    Goeree R, Chiva-Razavi S, Gunda P, Jain M, Jugl SM. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective. Journal of medical economics. 2018:1-18.
11.    Hale A, Merlo G, Nissen L, Coombes I, Graves N. Cost-effectiveness analysis of doctor-pharmacist collaborative prescribing for venous thromboembolism in high risk surgical patients. BMC health services research. 2018;18(1):749.
12.    Hernandez L, O'Donnell M, Postma M. Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. PharmacoEconomics. 2018;36(10):1223-52.
13.    Hofer F, Kauczor HU, Stargardt T. Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach. Lung cancer (Amsterdam, Netherlands). 2018;124:189-98.
14.    Huang J, Liao W, Zhou J, Zhang P, Wen F, Wang X, et al. Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial. Cancer management and research. 2018;10:4065-72.
15.    Hughes DA, Culeddu G, Plumpton C, Wood E, Dick AD, Jones AP, et al. Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with Juvenile Idiopathic Arthritis. Ophthalmology. 2018.
16.    Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018:Jco1800122.
17.    Lau BC, Wu HH, Mustafa M, Ibrahim J, Conway D, Agarwal-Harding K, et al. Developing Research to Change Policy: Design of a Multicenter Cost-Effectiveness Analysis Comparing Intramedullary Nailing to Skeletal Traction in Malawi. Journal of orthopaedic trauma. 2018;32 Suppl 7:S52-s7.
18.    Le KD, Vuong LN, Ho TM, Dang VQ, Pham TD, Pham CT, et al. A cost-effectiveness analysis of freeze-only or fresh embryo transfer in IVF of non-PCOS women. Human reproduction (Oxford, England). 2018;33(10):1907-14.
19.    Leal J, Manetti S, Buchanan J. The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study. PharmacoEconomics. 2018;36(10):1263-72.
20.    Lee SR, Kwok KL, Ng DKK, Hon KL. Palivizumab for Infants < 29 Weeks in Hong Kong without a Clear-Cut Season for Respiratory Syncytial Virus Infection-A Cost-Effectiveness Analysis. Journal of tropical pediatrics. 2018;64(5):418-25.
21.    Leurent B, Gomes M, Carpenter J. Comment on: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial. PharmacoEconomics. 2018;36(10):1297.
22.    Mistry H, Mason J. Diagnostic Assessment Reviews: is cost-effectiveness analysis helpful or necessary? Journal of health services research & policy. 2018;23(4):222-42.
23.    Moayeri F, Dunt D, Hsueh YA, Doyle C. Cost-utility analysis of telephone-based cognitive behavior therapy in chronic obstructive pulmonary disease (COPD) patients with anxiety and depression comorbidities: an application for willingness to accept concept. Expert review of pharmacoeconomics & outcomes research. 2018:1-10.
24.    Morrow EH, Chen J, Patel R, Bellows B, Nirula R, Glasgow R, et al. Watchful waiting versus elective repair for asymptomatic and minimally symptomatic paraesophageal hernias: A cost-effectiveness analysis. American journal of surgery. 2018;216(4):760-3.
25.    Narayen IC, Te Pas AB, Blom NA, van den Akker-van Marle ME. Cost-effectiveness analysis of pulse oximetry screening for critical congenital heart defects following homebirth and early discharge. European journal of pediatrics. 2018.
26.    Nherera LM, Trueman P, Schmoeckel M, Fatoye FA. Cost-effectiveness analysis of single use negative pressure wound therapy dressings (sNPWT) compared to standard of care in reducing surgical site complications (SSC) in patients undergoing coronary artery bypass grafting surgery. Journal of cardiothoracic surgery. 2018;13(1):103.
27.    Pattamatta M, Smeets BJJ, Evers S, Rutten HJT, Luyer MDP, Hiligsmann M. Health-related quality of life and cost-effectiveness analysis of gum chewing in patients undergoing colorectal surgery: results of a randomized controlled trial. Acta chirurgica Belgica. 2018;118(5):299-306.
28.    Pinto SM, Yassin M, Galang G. Cost-Effectiveness Analysis of Routine Venous Doppler Ultrasound for Diagnosis of Deep Venous Thrombosis at Admission to Inpatient Rehabilitation. American journal of physical medicine & rehabilitation. 2018;97(10):747-53.
29.    Psaltikidis EM, Silva END, Moretti ML, Trabasso P, Stucchi RSB, Aoki FH, et al. Cost-utility analysis of outpatient parenteral antimicrobial therapy (OPAT) in the Brazilian national health system. Expert review of pharmacoeconomics & outcomes research. 2018:1-12.
30.    Rosenbloom J, Lewkowitz A, Sondgeroth K, Hudson J, Macones G, Cahill A, et al. Antenatal corticosteroid administration in late-preterm gestations: a cost-effectiveness analysis. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2018:1-191.
31.    Ruggeri M, Rolli FR, Kondili LA, Drago C, De Solda F, Nappi C, et al. Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy. Expert review of pharmacoeconomics & outcomes research. 2018:1-12.
32.    Ruggeri M, Romano F, Basile M, Coretti S, Rolli FR, Drago C, et al. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy. Applied health economics and health policy. 2018;16(5):711-22.
33.    Salavert M, Cobo J, Pascual A, Aragon B, Maratia S, Jiang Y, et al. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain. Advances in therapy. 2018;35(11):1920-34.
34.    Saramago P, Yang H, Llewellyn A, Palmer S, Simmonds M, Griffin S. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2018;125(11):1414-22.
35.    Schlemm L. Disability Adjusted Life Years due to Ischaemic Stroke Preventable by Real-Time Stroke Detection-A Cost-Utility Analysis of Hypothetical Stroke Detection Devices. Frontiers in neurology. 2018;9:814.
36.    Schneeberger S, Phillips S, Huang LC, Pierce RA, Etemad SA, Poulose BK. Cost-Utility Analysis of Biologic and Biosynthetic Mesh in Ventral Hernia Repair: When Are They Worth It? Journal of the American College of Surgeons. 2018.
37.    Schwendicke F, Stolpe M. Restoring root-canal treated molars: Cost-effectiveness-analysis of direct versus indirect restorations. Journal of dentistry. 2018;77:37-42.
38.    Shedrawy J, Henriksson M, Hergens MP, Askling HH. Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: A cost-effectiveness analysis. Vaccine. 2018.
39.    Sinkey RG, Odibo AO. Vasa previa screening strategies: decision and cost-effectiveness analysis. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2018;52(4):522-9.
40.    Tarhini A, Benedict A, McDermott D, Rao S, Ambavane A, Gupte-Singh K, et al. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. Immunotherapy. 2018;10(14):1241-52.
41.    Teng M, Zhao YJ, Khoo AL, Ananthakrishna R, Yeo TC, Lim BP, et al. Cost-effectiveness analysis of biodegradable polymer versus durable polymer drug-eluting stents incorporating real-world evidence. Cardiovascular therapeutics. 2018;36(5):e12442.
42.    Tremblay G, Dolph M, Patel S, Brandt P, Forsythe A. Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom. Cost effectiveness and resource allocation : C/E. 2018;16:33.
43.    Tubeuf S, Saloniki EC, Cottrell D. Parental Health Spillover in Cost-Effectiveness Analysis: Evidence from Self-Harming Adolescents in England. PharmacoEconomics. 2018.
44.    Verhaeghe N, Schepers J, van Dun P, Annemans L. Osteopathic care for low back pain and neck pain: A cost-utility analysis. Complementary therapies in medicine. 2018;40:207-13.
45.    Wang D, Xie W, Cao W, He S, Fan G, Zhang H. A Cost-Utility Analysis of Percutaneous Endoscopic Lumbar Discectomy for L5-S1 Lumbar Disc Herniation: Transforaminal vs Interlaminar. Spine. 2018.
46.    Westin O, Svensson M, Nilsson Helander K, Samuelsson K, Gravare Silbernagel K, Olsson N, et al. Cost-effectiveness analysis of surgical versus non-surgical management of acute Achilles tendon ruptures. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA. 2018;26(10):3074-82.
47.    Xuan D, Chen G, Wang C, Yao X, Yin H, Zhang L, et al. A Cost-effectiveness Analysis of Rabbit Antithymocyte Globulin Versus Antithymocyte Globulin-fresenius as Induction Therapy for Patients With Kidney Transplantation From Donation After Cardiac Death in China. Clinical therapeutics. 2018;40(10):1741-51.
48.    Zaca V. Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis. Journal of cardiovascular medicine (Hagerstown, Md). 2018;19(10):597-605.
49.    Zhang Z, Dawkins B, Hicks JP, Walley JD, Hulme C, Elsey H, et al. Cost-effectiveness analysis of a multi-dimensional intervention to reduce inappropriate antibiotic prescribing for children with upper respiratory tract infections in China. Tropical medicine & international health : TM & IH. 2018;23(10):1092-100.


September 2018

1.    Basora M, Pereira A, Coca M, Tio M, Lozano L. Cost-effectiveness analysis of ferric carboxymaltose in pre-operative haemoglobin optimisation in patients undergoing primary knee arthroplasty. Blood transfusion = Trasfusione del sangue. 2018;16(5):438-42.
2.    Bhattacharyya A, Tahir A, Chandrashekar A, Vasisht S, Stinson L, Omatseye J. A cost utility analysis of decompressive hemicraniectomy vs. medical treatment in the management of space occupying brain oedema post middle cerebral artery infarction. European journal of neurology. 2018.
3.    Borisenko O, Lukyanov V, Ahmed AR. Cost-utility analysis of bariatric surgery. The British journal of surgery. 2018;105(10):1328-37.
4.    Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, et al. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. PharmacoEconomics. 2018.
5.    Campbell JR, Johnston JC, Ronald LA, Sadatsafavi M, Balshaw RF, Cook VJ, et al. Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2018.
6.    Cui S, Tobe RG, Mo X, Liu X, Xu L, Li S. Correction to: Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option. BMC infectious diseases. 2018;18(1):487.
7.    Debals-Gonthier M, Siani C, Faucher C, Touzani R, Lemarie-Basset C, Chabannon C, et al. Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years. Bone marrow transplantation. 2018;53(9):1096-104.
8.    Dempsey M, Mocarski M, Langer J, Hunt B. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. Journal of medical economics. 2018:1-9.
9.    Gibbons A, Leung EH, Yoo SH. Cost-Effectiveness Analysis of Descemet Membrane Endothelial Keratoplasty Compared to Descemet Stripping Endothelial Keratoplasty in the United States of America. Ophthalmology. 2018.
10.    Graham CN, Christodoulopoulou A, Knox HN, Sabatelli L, Hechmati G, Garawin T, et al. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. Journal of medical economics. 2018:1-9.
11.    Heath K. Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C. ClinicoEconomics and outcomes research : CEOR. 2018;10:539-50.
12.    Hersh AR, Megli CJ, Caughey AB. Repeat Screening for Syphilis in the Third Trimester of Pregnancy: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2018;132(3):699-707.
13.    Hopper RA, Kapadia H. Discussion: Cost-Effectiveness Analysis of Demineralized Bone Matrix and rhBMP-2 versus Autologous Iliac Crest Bone Grafting in Alveolar Cleft Patients. Plastic and reconstructive surgery. 2018;142(3):744-5.
14.    Hu X, Hay JW. First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective. Lung cancer (Amsterdam, Netherlands). 2018;123:166-71.
15.    Idrees JJ, Rosinski BF, Merath K, Chen Q, Bagante F, Pawlik TM. Readmission after pancreatic resection: causes, costs and cost-effectiveness analysis of high versus low quality hospitals using the Nationwide Readmission Database. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2018.
16.    Inderhaug E, Schelp CH, Glambek I, Kristiansen IS. Cost-effectiveness analysis of five procedures for great saphenous vein reflux in a Norwegian healthcare setting or societal setting. SAGE open medicine. 2018;6:2050312118801709.
17.    Khan I, Petrou S, Khan K, Mistry D, Lall R, Sheehan B, et al. Does Structured Exercise Improve Cognitive Impairment in People with Mild to Moderate Dementia? A Cost-Effectiveness Analysis from a Confirmatory Randomised Controlled Trial: The Dementia and Physical Activity (DAPA) Trial. PharmacoEconomics - open. 2018.
18.    Kloos RQH, van Litsenburg RRL, Wolf S, Wismans L, Kaspers GJL, Uyl-de Groot CA, et al. A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia. Pediatric blood & cancer. 2018:e27458.
19.    Leung HW, Chan AL, Wang SY. RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer - real world claim data. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2018;24(6):Np2-np8.
20.    Lim SL, Moss HA, Secord AA, Lee PS, Havrilesky LJ, Davidson BA. Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis. Gynecologic oncology. 2018.
21.    MacMonegle AJ, Nonnemaker J, Duke JC, Farrelly MC, Zhao X, Delahanty JC, et al. Cost-Effectiveness Analysis of The Real Cost Campaign's Effect on Smoking Prevention. American journal of preventive medicine. 2018;55(3):319-25.
22.    Mehta S, Blagg R, Willcockson J, Gociman B, Yamashiro D, Siddiqi F. Cost-Effectiveness Analysis of Demineralized Bone Matrix and rhBMP-2 versus Autologous Iliac Crest Bone Grafting in Alveolar Cleft Patients. Plastic and reconstructive surgery. 2018;142(3):737-43.
23.    Menger RP, Savardekar AR, Farokhi F, Sin A. A Cost-Effectiveness Analysis of the Integration of Robotic Spine Technology in Spine Surgery. Neurospine. 2018;15(3):216-24.
24.    Michaud TL, Kane RL, McCarten JR, Gaugler JE, Nyman JA, Kuntz KM. Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis. PharmacoEconomics - open. 2018;2(3):309-23.
25.    Morfin-Otero R, Alvarado-Ibarra M, Rodriguez-Noriega E, Resendiz-Sanchez J, Patel DA, Stephens JM, et al. Cost-effectiveness analysis of voriconazole, fluconazole, and amphotericin B for invasive fungal infections following allogeneic hematopoietic stem cell transplantation in Mexico. ClinicoEconomics and outcomes research : CEOR. 2018;10:511-20.
26.    Mujica-Mota R, Varley-Campbell J, Tikhonova I, Cooper C, Griffin E, Haasova M, et al. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Health technology assessment (Winchester, England). 2018;22(49):1-326.
27.    Nguyen E, Coleman CI, Kohn CG, Weeda ER. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life. International journal of cardiology. 2018.
28.    Paix A, Noel G, Falcoz PE, Levy P. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018;128(3):534-40.
29.    Poorman GW, Passias PG, Qureshi R, Hassanzadeh H, Horn S, Bortz C, et al. Cost-utility analysis of cervical deformity surgeries using 1-year outcome. The spine journal : official journal of the North American Spine Society. 2018;18(9):1552-7.
30.    Robin P, Kumar S, Salaun PY, Le Roux PY, Couturaud F, Planquette B, et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis research. 2018;171:97-102.
31.    Ruggeri M, Basile M, Zini A, Mangiafico S, Agostoni EC, Lobotesis K, et al. Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy. Journal of medical economics. 2018;21(9):902-11.
32.    Shamout S, Nazha S, Dragomir A, Campeau L. A cost-utility analysis of artificial urinary sphincter versus AdVance male sling in post prostatectomy stress urinary incontinence: A publicly funded health care perspective. Neurourology and urodynamics. 2018;37(7):2195-203.
33.    Sharma D, Xing S, Hung YT, Caskey RN, Dowell ML, Touchette DR. Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States. Orphanet journal of rare diseases. 2018;13(1):172.
34.    Sinkey RG, Odibo AO. Vasa previa screening strategies: decision and cost-effectiveness analysis. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2018;52(4):522-9.
35.    Sohrt A, Maerkedahl A, Padula WV. Correction to: Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes. PharmacoEconomics - open. 2018.
36.    Sussman M, Benner J, Neumann P, Menzin J. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives. Cephalalgia : an international journal of headache. 2018;38(10):1644-57.
37.    Tarhini A, Benedict A, McDermott D, Rao S, Ambavane A, Gupte-Singh K, et al. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. Immunotherapy. 2018.
38.    Tsevat J, Moriates C. Value-Based Health Care Meets Cost-Effectiveness Analysis. Annals of internal medicine. 2018;169(5):329-32.
39.    Wordsworth S, Doble B, Payne K, Buchanan J, Marshall DA, McCabe C, et al. Using "Big Data" in the Cost-Effectiveness Analysis of Next-Generation Sequencing Technologies: Challenges and Potential Solutions. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018;21(9):1048-53.
40.    Xuan D, Chen G, Wang C, Yao X, Yin H, Zhang L, et al. A Cost-Effectiveness Analysis of Rabbit Antithymocyte Globulin Versus Antithymocyte Globulin-Fresenius as Induction Therapy for Patients With Kidney Transplantation From Donation After Cardiac Death in China. Clinical therapeutics. 2018.
41.    Yalniz FF, Murad MH, Lee SJ, Pavletic SZ, Khera N, Shah ND, et al. Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018;24(9):1920-7.
42.    Zuur MA, van Asselt ADI, van 't Boveneind-Vrubleuskaya N, Aleksa A, Postma MJ, Alffenaar JWC. Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patients. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2018;22(9):991-9.


August 2018

1.    Abdelrahman A. Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder. International urogynecology journal. 2018;29(8):1221.
2.    Aigbogun MS, Liu S, Kamat SA, Sapin C, Duhig AM, Citrome L. Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. ClinicoEconomics and outcomes research : CEOR. 2018;10:443-56.
3.    Ali A, Kaplan CM, Derefinko KJ, Klesges RC. Smoking Cessation for Smokers Not Ready to Quit: Meta-analysis and Cost-effectiveness Analysis. American journal of preventive medicine. 2018;55(2):253-62.
4.    Alsumali A, Eguale T, Bairdain S, Samnaliev M. Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity. Obesity surgery. 2018;28(8):2203-14.
5.    Antonides CFJ, Cohen DJ, Osnabrugge RLJ. Statistical primer: a cost-effectiveness analysis. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2018;54(2):209-13.
6.    Asban A, Homsy C, Chen L, Fisher C, Losken A, Chatterjee A. A cost-utility analysis comparing large volume displacement oncoplastic surgery to mastectomy with single stage implant reconstruction in the treatment of breast cancer. Breast (Edinburgh, Scotland). 2018;41:159-64.
7.    Bagwell K, Wu X, Baum ED, Malhotra A. Cost-Effectiveness Analysis of Intracapsular Tonsillectomy and Total Tonsillectomy for Pediatric Obstructive Sleep Apnea. Applied health economics and health policy. 2018;16(4):527-35.
8.    Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis. Diabetes, obesity & metabolism. 2018;20(8):1921-7.
9.    Buse S, Hach CE, Klumpen P, Schmitz K, Mager R, Mottrie A, et al. Cost-effectiveness analysis of robot-assisted vs. open partial nephrectomy. The international journal of medical robotics + computer assisted surgery : MRCAS. 2018;14(4):e1920.
10.    Caicedo JI, Taborda A, Robledo D, Bravo-Balado A, Dominguez C, Trujillo CG, et al. Photovaporization of the prostate with GreenLight laser 180 W XPS versus transurethral resection of the prostate with monopolar energy for the treatment of benign prostatic enlargement: a cost-utility analysis from a healthcare perspective. World journal of urology. 2018.
11.    Cara AKS, Zaidi STR, Suleman F. Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia in Saudi Arabia. International journal of clinical pharmacy. 2018.
12.    Cavany SM, Vynnycky E, Anderson CS, Maguire H, Sandmann F, Thomas HL, et al. Should NICE reconsider the 2016 UK guidelines on TB contact tracing? A cost-effectiveness analysis of contact investigations in London. Thorax. 2018.
13.    Chanthawong S, Lim YH, Subongkot S, Chan A, Andalusia R, Ahmad Bustamam RS, et al. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2018.
14.    Chen YI, Barkun AN, Adam V, Bai G, Singh VK, Bukhari M, et al. Cost-effectiveness analysis comparing lumen-apposing metal stents with plastic stents in the management of pancreatic walled-off necrosis. Gastrointestinal endoscopy. 2018;88(2):267-76.e1.
15.    Cheng Q, Kinner SA, Lee XJ, Snow KJ, Graves N. Cost-utility analysis of low-intensity case management to increase contact with health services among ex-prisoners in Australia. BMJ open. 2018;8(8):e023082.
16.    Crosland P, Maconachie R, Buckner S, McGuire H, Humphries SE, Qureshi N. Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales. Atherosclerosis. 2018;275:80-7.
17.    den Broeder N, Bouman CAM, Kievit W, van Herwaarden N, van den Hoogen FHJ, van Vollenhoven RF, et al. Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is key. Annals of the rheumatic diseases. 2018.
18.    Eckman MH, Woodle ES, Thakar CV, Paterno F, Sherman KE. Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis. Annals of internal medicine. 2018;169(4):214-23.
19.    Erman A, Masucci L, Krahn MD, Elterman DS. Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis. BJU international. 2018.
20.    Ford DC, Schroeder MC, Ince D, Ernst EJ. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate Clostridium difficile infection in hospitalized patients. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2018;75(15):1110-21.
21.    Garcia-Lorenzo B, Rivero-Santana A, Vallejo-Torres L, Castilla-Rodriguez I, Garcia-Perez S, Garcia-Perez L, et al. Cost-effectiveness analysis of real-time continuous monitoring glucose compared to self-monitoring of blood glucose for diabetes mellitus in Spain. Journal of evaluation in clinical practice. 2018;24(4):772-81.
22.    Geskin L, Malone DC. An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma. The Journal of dermatological treatment. 2018;29(5):522-30.
23.    Graham CN, Christodoulopoulou A, Knox HN, Sabatelli L, Hechmati G, Garawin T, et al. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. Journal of medical economics. 2018:1-23.
24.    Herzel BJ, Samuel SP, Bulfone TC, Raj CS, Lewin M, Kahn JG. Snakebite: An Exploratory Cost-Effectiveness Analysis of Adjunct Treatment Strategies. The American journal of tropical medicine and hygiene. 2018;99(2):404-12.
25.    Hopkins MK, Grotegut CA, Swamy GK, Myers ER, Havrilesky LJ. Induction of Labor versus Scheduled Cesarean in Morbidly Obese Women: A Cost-Effectiveness Analysis. American journal of perinatology. 2018.
26.    Hoshi SL, Seposo X, Okubo I, Kondo M. Cost-effectiveness analysis of pertussis vaccination during pregnancy in Japan. Vaccine. 2018;36(34):5133-40.
27.    Ionescu AM, Mpobela Agnarson A, Kambili C, Metz L, Kfoury J, Wang S, et al. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis. Expert review of pharmacoeconomics & outcomes research. 2018:1-13.
28.    Johansson EC, Hartz S, Kiri SH, Kumar G, Svedbom A. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. Journal of medical economics. 2018;21(8):810-20.
29.    Jones DA, Whittaker P, Rathod KS, Richards AJ, Andiapen M, Antoniou S, et al. Sodium Nitrite-Mediated Cardioprotection in Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Cost-Effectiveness Analysis. Journal of cardiovascular pharmacology and therapeutics. 2018:1074248418784940.
30.    Kim H, Vargo JA, Beriwal S, Clump DA, Ohr JP, Ferris RL, et al. Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer. Head & neck. 2018;40(8):1743-51.
31.    Lam J, Hay JW, Salcedo J, Kenyon NJ. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. The Journal of asthma : official journal of the Association for the Care of Asthma. 2018:1-10.
32.    Lazzaro C, Barone C, Caprioni F, Cascinu S, Falcone A, Maiello E, et al. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert review of pharmacoeconomics & outcomes research. 2018;18(4):435-46.
33.    Le QA, Hay JW, Becker R, Wang Y. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States. The Annals of pharmacotherapy. 2018:1060028018798034.
34.    Leung EH, Gibbons A, Stout JT, Koch DD. Intracameral moxifloxacin for endophthalmitis prophylaxis after cataract surgery: Cost-effectiveness analysis. Journal of cataract and refractive surgery. 2018;44(8):971-8.
35.    Leurent B, Gomes M, Faria R, Morris S, Grieve R, Carpenter JR. Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial. PharmacoEconomics. 2018;36(8):889-901.
36.    Li N, Zheng B, Cai HF, Chen YH, Qiu MQ, Liu MB. Cost-effectiveness analysis of oral probiotics for the prevention of Clostridium difficile-associated diarrhoea in children and adolescents. The Journal of hospital infection. 2018;99(4):469-74.
37.    Mahmoud O, Vikatmaa P, Rasanen J, Peltola E, Sihvo E, Vikatmaa L, et al. Catheter-Directed Thrombolysis Versus Pharmacomechanical Thrombectomy for Upper Extremity Deep Venous Thrombosis: A Cost-Effectiveness Analysis. Annals of vascular surgery. 2018;51:246-53.
38.    Matchar DB, Eom K, Duncan PW, Lee M, Sim R, Sivapragasam NR, et al. A Cost-Effectiveness Analysis Of A Randomized Control Trial Of A Tailored, Multifactorial Program To Prevent Falls Among The Community-Dwelling Elderly. Archives of physical medicine and rehabilitation. 2018.
39.    McGrady ME, Eckman MH, O'Brien MM, Pai ALH. Cost-Effectiveness Analysis of an Adherence-Promotion Intervention for Children With Leukemia: A Markov Model-Based Simulation. Journal of pediatric psychology. 2018;43(7):758-68.
40.    McKay AJ, Hogan H, Humphries SE, Marks D, Ray KK, Miners A. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis. Atherosclerosis. 2018;275:434-43.
41.    Menger RP, Savardekar AR, Farokhi F, Sin A. A Cost-Effectiveness Analysis of the Integration of Robotic Spine Technology in Spine Surgery. Neurospine. 2018.
42.    Ordonez JE, Ordonez A, Osorio UM. Cost-effectiveness analysis of iStent trabecular micro-bypass stent for patients with open-angle glaucoma in Colombia. Current medical research and opinion. 2018:1-12.
43.    Padula WV, Pronovost PJ, Makic MBF, Wald HL, Moran D, Mishra MK, et al. Value of hospital resources for effective pressure injury prevention: a cost-effectiveness analysis. BMJ quality & safety. 2018.
44.    Pan M, Huang LY, Zhen L, Li DZ. A cost-effectiveness analysis comparing two different strategies in advanced maternal age: Combined first-trimester screening and maternal blood cell-free DNA testing. Taiwanese journal of obstetrics & gynecology. 2018;57(4):536-40.
45.    Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, et al. A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018.
46.    Qin S, Kruger E, Tan SC, Cheng S, Wang N, Liang J. Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. Cost effectiveness and resource allocation : C/E. 2018;16:29.
47.    Rossler R, Verhagen E, Rommers N, Dvorak J, Junge A, Lichtenstein E, et al. Comparison of the '11+ Kids' injury prevention programme and a regular warmup in children's football (soccer): a cost effectiveness analysis. British journal of sports medicine. 2018.
48.    Shepherd JP, Carter-Brooks CM, Chermanksy C. A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder. International urogynecology journal. 2018;29(8):1213-9.
49.    Sohrt A, Maerkedahl A, Padula WV. Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes. PharmacoEconomics - open. 2018.
50.    Souche R, Herrero A, Bourel G, Chauvat J, Pirlet I, Guillon F, et al. Robotic versus laparoscopic distal pancreatectomy: a French prospective single-center experience and cost-effectiveness analysis. Surgical endoscopy. 2018;32(8):3562-9.
51.    Sussman M, Benner J, Neumann P, Menzin J. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives. Cephalalgia : an international journal of headache. 2018:333102418796842.
52.    Tsai PC, Liu TW, Huang CF, Yeh ML, Dai CY, Chuang WL, et al. A real world cost effectiveness analysis of interferon-based therapy for HCV naive super-responders. Journal of the Chinese Medical Association : JCMA. 2018;81(8):670-5.
53.    Tsevat J, Moriates C. Value-Based Health Care Meets Cost-Effectiveness Analysis. Annals of internal medicine. 2018;169(5):329-32.
54.    Westwood M, Ramaekers B, Lang S, Grimm S, Deshpande S, de Kock S, et al. Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis. Health technology assessment (Winchester, England). 2018;22(44):1-264.
55.    Yang KC, Hung HF, Chen MK, Chen SL, Fann JC, Chiu SY, et al. Cost-effectiveness analysis of universal influenza vaccination: Application of the susceptible-infectious-complication-recovery model. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2018;73:102-8.
56.    Yoshizawa T, Nishino T, Okubo I, Yamazaki M. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate. Archives of osteoporosis. 2018;13(1):94.
57.    Zimmermann M, Brouwer E, Tice JA, Seidner M, Loos AM, Liu S, et al. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis. CNS drugs. 2018.


July 2018

1.    Aronsson L, Ansari D, Andersson B, Persson U, Fridhammar A, Andersson R. Intraductal papillary mucinous neoplasms of the pancreas - a cost-effectiveness analysis of management strategies for the branch-duct subtype. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2018.
2.    Brooks EA, Massanari M. Cost-Effectiveness Analysis of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in the Management of Asthma. Managed care (Langhorne, Pa). 2018;27(7):42-8.
3.    Castagna A, Garofalo R, Maman E, Gray AC, Brooks EA. Comparative cost-effectiveness analysis of the subacromial spacer for irreparable and massive rotator cuff tears. International orthopaedics. 2018.
4.    Cortesi PA, Belli LS, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, et al. The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities. Journal of viral hepatitis. 2018;25(7):791-801.
5.    den Hollander M, Heijnders N, de Jong JR, Vlaeyen JWS, Smeets R, Goossens M. EXPOSURE IN VIVO VERSUS PAIN-CONTINGENT PHYSICAL THERAPY IN COMPLEX REGIONAL PAIN SYNDROME TYPE I: A COST-EFFECTIVENESS ANALYSIS. International journal of technology assessment in health care. 2018:1-10.
6.    Eckman MH, Woodle ES, Thakar CV, Paterno F, Sherman KE. Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis. Annals of internal medicine. 2018.
7.    Foley P, Garrett S, Ryttig L. A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis. Current medical research and opinion. 2018;34(7):1277-83.
8.    Gamst-Klaussen T, Lamu AN, Chen G, Olsen JA. Assessment of outcome measures for cost-utility analysis in depression: mapping depression scales onto the EQ-5D-5L. BJPsych open. 2018;4(4):160-6.
9.    Garcia-Lorenzo B, Rivero-Santana A, Vallejo-Torres L, Castilla-Rodriguez I, Garcia-Perez S, Garcia-Perez L, et al. Cost-effectiveness analysis of real-time continuous monitoring glucose compared to self-monitoring of blood glucose for diabetes mellitus in Spain. Journal of evaluation in clinical practice. 2018.
10.    Grustam AS, Severens JL, De Massari D, Buyukkaramikli N, Koymans R, Vrijhoef HJM. Cost-Effectiveness Analysis in Telehealth: A Comparison between Home Telemonitoring, Nurse Telephone Support, and Usual Care in Chronic Heart Failure Management. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018;21(7):772-82.
11.    Hernandez L, Lanitis T, Cele C, Toro-Diaz H, Gibson A, Kuznik A. Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis. Journal of managed care & specialty pharmacy. 2018;24(7):608-16.
12.    Hernandez L, O'Donnell M, Postma M. Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. PharmacoEconomics. 2018.
13.    Holko P, Kawalec P, Pilc A. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-alpha Antagonist. PharmacoEconomics. 2018;36(7):853-65.
14.    Hoshi SL, Seposo X, Okubo I, Kondo M. Cost-effectiveness analysis of pertussis vaccination during pregnancy in Japan. Vaccine. 2018.
15.    Iragorri N, Spackman E. Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis. Public health reviews. 2018;39:17.
16.    Jiang M, Leung NH, Ip M, You JHS. Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe Clostridium difficile infection. PloS one. 2018;13(7):e0201539.
17.    Jiang Y, Yang X, Taniguchi K, Petigara T, Abe M. A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan. Journal of medical economics. 2018;21(7):687-97.
18.    Lam J, Hay J, Salcedo J, Kenyon NJ. A Cost-Effectiveness Analysis of Reslizumab in the Treatment of Poorly Controlled Eosinophilic Asthma. The Journal of asthma : official journal of the Association for the Care of Asthma. 2018:1-29.
19.    Leech AA, Kim DD, Cohen JT, Neumann PJ. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018;21(7):759-61.
20.    LeFevre A, Cabrera-Escobar MA, Mohan D, Eriksen J, Rogers D, Neo Parsons A, et al. Forecasting the Value for Money of Mobile Maternal Health Information Messages on Improving Utilization of Maternal and Child Health Services in Gauteng, South Africa: Cost-Effectiveness Analysis. JMIR mHealth and uHealth. 2018;6(7):e153.
21.    Leung EH, Gibbons A, Stout JT, Koch DD. Intracameral moxifloxacin for endophthalmitis prophylaxis after cataract surgery: Cost-effectiveness analysis. Journal of cataract and refractive surgery. 2018.
22.    Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood advances. 2018;2(14):1792-8.
23.    Mennini FS, Marcellusi A, Viti R, Bini C, Carosso A, Revelli A, et al. Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with recombinant FSH plus recombinant LH vs. human menopausal gonadotropin for women undergoing IVF. Reproductive biology and endocrinology : RB&E. 2018;16(1):68.
24.    Morrow EH, Chen J, Patel R, Bellows B, Nirula R, Glasgow R, et al. Watchful waiting versus elective repair for asymptomatic and minimally symptomatic paraesophageal hernias: A cost-effectiveness analysis. American journal of surgery. 2018.
25.    Nishimura S, Nakao M. Cost-effectiveness analysis of suvorexant for the treatment of Japanese elderly patients with chronic insomnia in a virtual cohort. Journal of medical economics. 2018;21(7):698-703.
26.    O'Brien GL, O'Mahony D, Gillespie P, Mulcahy M, Walshe V, O'Connor MN, et al. Cost-Effectiveness Analysis of a Physician-Implemented Medication Screening Tool in Older Hospitalised Patients in Ireland. Drugs & aging. 2018.
27.    Ordonez JE, Ordonez A, Osorio UM. Cost-effectiveness analysis of iStent trabecular micro-bypass stent for patients with open-angle glaucoma in Colombia. Current medical research and opinion. 2018:1-37.
28.    Orlando S, Triulzi I, Ciccacci F, Palla I, Palombi L, Marazzi MC, et al. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF. PloS one. 2018;13(7):e0200523.
29.    Paoli AR, Gold HT, Mahure SA, Mai DH, Agten CA, Rokito AS, et al. Treatment for Symptomatic SLAP Tears in Middle-Aged Patients Comparing Repair, Biceps Tenodesis, and Nonoperative Approaches: A Cost-Effectiveness Analysis. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2018;34(7):2019-29.
30.    Ramkumar DB, Ramkumar N, Tapp SJ, Moschetti WE. Pharmacologic Hemostatic Agents in Total Joint Arthroplasty-A Cost-Effectiveness Analysis. The Journal of arthroplasty. 2018;33(7):2092-9.e9.
31.    Ricci G, Ciccone MM, Giordano P, Cortese F. Statins: pharmacokinetics, pharmacodynamics, and cost-effectiveness analysis. Current vascular pharmacology. 2018.
32.    Ruggeri M, Romano F, Basile M, Coretti S, Rolli FR, Drago C, et al. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy. Applied health economics and health policy. 2018.
33.    Schwendicke F, Stolpe M. Restoring root-canal treated molars: Cost-effectiveness-analysis of direct versus indirect restorations. Journal of dentistry. 2018.
34.    Sekiguchi M, Igarashi A, Sakamoto T, Saito Y, Esaki M, Matsuda T. Cost-effectiveness analysis of post-polypectomy colonoscopy surveillance using Japanese data. Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society. 2018.
35.    Sher DJ, Tishler RB, Pham NL, Punglia RS. Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus Proton Therapy for Oropharyngeal Squamous Cell Carcinoma. International journal of radiation oncology, biology, physics. 2018;101(4):875-82.
36.    Singh K, Crossan C, Laba TL, Roy A, Hayes A, Salam A, et al. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. International journal of cardiology. 2018;262:71-8.
37.    Suidan RS, Sun CC, Cantor SB, Mariani A, Soliman PT, Westin SN, et al. Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2018;132(1):52-8.
38.    Suraratdecha C, Stuart RM, Manopaiboon C, Green D, Lertpiriyasuwat C, Wilson DP, et al. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand. Journal of the International AIDS Society. 2018;21 Suppl 5:e25129.
39.    van der Spek N, Jansen F, Holtmaat K, Vos J, Breitbart W, van Uden-Kraan CF, et al. Cost-utility analysis of meaning-centered group psychotherapy for cancer survivors. Psycho-oncology. 2018;27(7):1772-9.
40.    van Mens K, Lokkerbol J, Janssen R, van Orden ML, Kloos M, Tiemens B. A Cost-Effectiveness Analysis to Evaluate a System Change in Mental Healthcare in the Netherlands for Patients with Depression or Anxiety. Administration and policy in mental health. 2018;45(4):530-7.
41.    Yi Y, Bryce CL, Adambekov S, Edwards RP, Goughnour SL, Linkov F. Cost-effectiveness analysis of biopsy strategies for endometrial cancer diagnosis in women with postmenopausal bleeding: Pipelle sampling curette versus dilatation & curettage. Gynecologic oncology. 2018;150(1):112-8.
42.    Zhang Z, Dawkins B, Hicks JP, Walley JD, Hulme C, Elsey H, et al. Cost-effectiveness analysis of a multi-dimensional intervention to reduce inappropriate antibiotic prescribing for children with upper respiratory tract infections in China. Tropical medicine & international health : TM & IH. 2018.
43.    Zhou A, Yousem DM, Alvin MD. Cost-Effectiveness Analysis in Radiology: A Systematic Review. Journal of the American College of Radiology : JACR. 2018.
44.    Zimmermann M, Rind D, Chapman R, Kumar V, Kahn S, Carlson J. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis. Journal of drugs in dermatology : JDD. 2018;17(7):750-6.


June 2018

1.    Aas E, Iversen T, Holt T, Ormhaug SM, Jensen TK. Cost-Effectiveness Analysis of Trauma-Focused Cognitive Behavioral Therapy: A Randomized Control Trial among Norwegian Youth. Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53. 2018:1-14.
2.    Ali A, Kaplan CM, Derefinko KJ, Klesges RC. Smoking Cessation for Smokers Not Ready to Quit: Meta-analysis and Cost-effectiveness Analysis. American journal of preventive medicine. 2018.
3.    Andiesta NS, Hamid MA, Lee K, Pau A. Dental Home Visits for Caries Prevention Among Preschool Children: Protocol for a Cost-Effectiveness Analysis on a Randomized Control Trial. JMIR research protocols. 2018;7(6):e10053.
4.    Barnhoorn K, Staal JB, van Dongen RT, Frolke JPM, Klomp FP, van de Meent H, et al. Pain Exposure Physical Therapy versus conventional treatment in complex regional pain syndrome type 1-a cost-effectiveness analysis alongside a randomized controlled trial. Clinical rehabilitation. 2018;32(6):790-8.
5.    Borse RH, Kachroo S, Brown C, McCann E, Insinga RP. Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland. Rheumatology and therapy. 2018;5(1):57-73.
6.    Capri S, Barbieri M, de Waure C, Boccalini S, Panatto D. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population. Human vaccines & immunotherapeutics. 2018;14(6):1331-41.
7.    Chen G, Garcia-Gordillo MA, Collado-Mateo D, Del Pozo-Cruz B, Adsuar JC, Cordero-Ferrera JM, et al. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis. The patient. 2018.
8.    Cheng Q, Gibb M, Graves N, Finlayson K, Pacella RE. Cost-effectiveness analysis of guideline-based optimal care for venous leg ulcers in Australia. BMC health services research. 2018;18(1):421.
9.    Choi MJ, Kang SO, Oh JJ, Park SB, Kim MJ, Cheong HJ. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea. Human vaccines & immunotherapeutics. 2018:1-9.
10.    Daly AT, Deshmukh AA, Vidrine DJ, Prokhorov AV, Frank SG, Tahay PD, et al. Cost-effectiveness analysis of smoking cessation interventions using cell phones in a low-income population. Tobacco control. 2018.
11.    De Mil R, Guillaume E, Guittet L, Dejardin O, Bouvier V, Pornet C, et al. Cost-Effectiveness Analysis of a Navigation Program for Colorectal Cancer Screening to Reduce Social Health Inequalities: A French Cluster Randomized Controlled Trial. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018;21(6):685-91.
12.    Dwommoh R, Sorsdahl K, Myers B, Asante KP, Naledi T, Stein DJ, et al. Brief interventions to address substance use among patients presenting to emergency departments in resource poor settings: a cost-effectiveness analysis. Cost effectiveness and resource allocation : C/E. 2018;16:24.
13.    Eaton Turner E, Jenks M. Cost-effectiveness analysis of the use of high-flow oxygen through nasal cannula in intensive care units in NHS England. Expert review of pharmacoeconomics & outcomes research. 2018;18(3):331-7.
14.    Ford DC, Schroeder MC, Ince D, Ernst EJ. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate Clostridium difficile infection in hospitalized patients. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2018.
15.    Geessinck FAJ, Pleijhuis RG, Mentink RJ, van der Palen J, Koffijberg H. Cost-Effectiveness Analysis of the DiagnOSAS Screening Tool Compared With Polysomnography Diagnosis in Dutch Primary Care. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2018;14(6):1005-15.
16.    Grochtdreis T, Brettschneider C, Shedden-Mora M, Piontek K, Konig HH, Lowe B. Cost-effectiveness Analysis of a Stepped, Collaborative and Coordinated Health Care Network for Patients with Somatoform Disorders (Sofu-Net). The journal of mental health policy and economics. 2018;21(2):59-69.
17.    Herzel B, Samuel SP, Bulfone TC, Raj CS, Lewin M, Kahn JG. Snakebite: An Exploratory Cost-Effectiveness Analysis of Adjunct Treatment Strategies. The American journal of tropical medicine and hygiene. 2018.
18.    Holst A, Bjorkelund C, Metsini A, Madsen JH, Hange D, Petersson EL, et al. Cost-effectiveness analysis of internet-mediated cognitive behavioural therapy for depression in the primary care setting: results based on a controlled trial. BMJ open. 2018;8(6):e019716.
19.    Johansson EC, Hartz S, Kiri SH, Kumar G, Svedbom A. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. Journal of medical economics. 2018:1-11.
20.    Krittayaphong R, Permsuwan U. Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2018.
21.    Lai T, Zhao Q, Li F, Zhou XG, Song P, Wang LP, et al. [Cost-Effectiveness Analysis of Different Chemotherapy Regimens in the Treatment of Patients with Multiple Myeloma]. Zhongguo shi yan xue ye xue za zhi. 2018;26(3):824-8.
22.    Leurent B, Gomes M, Carpenter JR. Missing data in trial-based cost-effectiveness analysis: An incomplete journey. Health economics. 2018;27(6):1024-40.
23.    Limwattananon C, Limwattananon S, Waleekhachonloet O, Rattanachotphanit T. Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand. Lung cancer (Amsterdam, Netherlands). 2018;120:91-7.
24.    Mar J, Anton-Ladislao A, Ibarrondo O, Arrospide A, Lazaro S, Gonzalez N, et al. Cost-effectiveness analysis of laparoscopic versus open surgery in colon cancer. Surgical endoscopy. 2018.
25.    McKay AJ, Hogan H, Humphries SE, Marks D, Ray KK, Miners A. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis. Atherosclerosis. 2018.
26.    Mezei AK, Pedersen HN, Sy S, Regan C, Mitchell-Foster SM, Byamugisha J, et al. Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial. BMJ open. 2018;8(6):e020484.
27.    Munoz Romo R, A MBP, M AM, Carballo Cardona C, Cobo Mora J, Carcas Sansuan AJ. Efficient diagnosis and treatment of acute paracetamol poisoning: cost-effectiveness analysis of approaches based on a hospital toxicovigilance program. Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias. 2018;30(3):169-76.
28.    Peng J, Tan C, Zeng X, Liu S. Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. PloS one. 2018;13(6):e0199553.
29.    Podlipnik S, Moreno-Ramirez D, Carrera C, Barreiro A, Manubens E, Ferrandiz-Pulido L, et al. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with AJCC stage IIB, IIC and III malignant melanoma. The British journal of dermatology. 2018.
30.    Qerimi V, Nestorovska AK, Sterjev Z, Genadieva-Stavric S, Suturkova L. Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia. ClinicoEconomics and outcomes research : CEOR. 2018;10:327-38.
31.    Rampaul M, Edun B, Gaskin M, Albrecht H, Weissman S. Cost-Effectiveness Analysis of Early vs Late Diagnosis of HIV-Infected Patients in South Carolina. Southern medical journal. 2018;111(6):355-8.
32.    Ramsey DC, Friess DM. Cost-Effectiveness Analysis of Syndesmotic Screw Versus Suture Button Fixation in Tibiofibular Syndesmotic Injuries. Journal of orthopaedic trauma. 2018;32(6):e198-e203.
33.    Reyes-Uruena J, Campbell C, Diez E, Ortun V, Casabona J. Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment. AIDS care. 2018;30(6):784-92.
34.    Romero Prada M, Roa C, Alfonso P, Acero G, Huerfano L, Vivas-Consuelo D. Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers. Diabetic foot & ankle. 2018;9(1):1480249.
35.    Ruggeri M, Basile M, Zini A, Mangiafico S, Agostoni EC, Lobotesis K, et al. Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy. Journal of medical economics. 2018:1-10.
36.    Sanchez-Santos R, Padin EM, Adam D, Borisenko O, Fernandez SE, Dacosta EC, et al. Bariatric surgery versus conservative management for morbidly obese patients in Spain: a cost-effectiveness analysis. Expert review of pharmacoeconomics & outcomes research. 2018;18(3):305-14.
37.    Sathianathen NJ, Kuntz KM, Alarid-Escudero F, Lawrentschuk NL, Bolton DM, Murphy DG, et al. Incorporating biomarkers into the primary prostate biopsy setting: a cost-effectiveness analysis. The Journal of urology. 2018.
38.    Shafrin J, Skornicki M, Brauer M, Villeneuve J, Lees M, Hertel N, et al. An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference? Health policy (Amsterdam, Netherlands). 2018;122(6):607-13.
39.    Svensson M, Barregard L, Axelsson G, Andersson E. A cost-effectiveness analysis of lowering residential radon levels in Sweden-Results from a modelling study. Health policy (Amsterdam, Netherlands). 2018;122(6):687-92.
40.    Taneja SS. Re: Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-Effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). The Journal of urology. 2018;199(6):1397-8.
41.    Teng M, Zhao YJ, Khoo AL, Ananthakrishna R, Yeo TC, Lim BP, et al. Cost-effectiveness analysis of biodegradable polymer versus durable polymer drug-eluting stents incorporating real-world evidence. Cardiovascular therapeutics. 2018:e12442.
42.    Trigo-Vicente C, Gimeno-Ballester V, Montoiro-Allue R, Lopez-Del Val A. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain. Expert review of pharmacoeconomics & outcomes research. 2018;18(3):321-9.
43.    Tsai PC, Liu TW, Huang CF, Yeh ML, Dai CY, Chuang WL, et al. A real world cost effectiveness analysis of interferon-based therapy for HCV naive super-responders. Journal of the Chinese Medical Association : JCMA. 2018;81(8):670-5.
44.    van Boven JFM, Cushen B, Sulaiman I, Greene G, MacHale E, Mokoka MC, et al. Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis. NPJ primary care respiratory medicine. 2018;28(1):24.
45.    Varghese L, Talbot L, Govender A, Zhang XH, Mungall BA. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand. Applied health economics and health policy. 2018;16(3):331-45.
46.    Wan Z, Li C, Long F, Zhang Y, Wang B, Wu Y, et al. Cost-Effectiveness Analysis of a Standardized Management Program for Ischemic Stroke Patients in Hainan Province, China. Population health management. 2018;21(3):253-4.
47.    Xie X, He T, Kang J, Siscovick DS, Li Y, Pagan JA. Cost-effectiveness analysis of intensive hypertension control in China. Preventive medicine. 2018;111:110-4.
48.    Xuan J, Huang M, Lu Y, Tao L. Economic Evaluation of Safflower Yellow Injection for the Treatment of Patients with Stable Angina Pectoris in China: A Cost-Effectiveness Analysis. Journal of alternative and complementary medicine (New York, NY). 2018;24(6):564-9.
49.    Yang F, Devlin N, Luo N. Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments. The European journal of health economics : HEPAC : health economics in prevention and care. 2018.
50.    Yang KC, Hung HF, Chen MK, Chen LS, Fann JC, Chiu SY, et al. Cost-Effectiveness Analysis of Universal Influenza Vaccination: Application of Susceptible-Infectious-Complication-Recovery Model. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2018.
51.    Zhou H, He J, Wu B, Che D. Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants. Human vaccines & immunotherapeutics. 2018;14(6):1444-52.
52.    Zhou K, Wen F, Zhang P, Zhou J, Zheng H, Sun L, et al. Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2018;20(6):768-74.


May 2018

1.    Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ (Clinical research ed). 2018;361:k2295.
2.    Cost-effectiveness of a Ceramide-Infused Skin Barrier Versus a Standard Barrier: Findings From a Long-Term Cost-effectiveness Analysis: Erratum. Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society. 2018;45(3):278.
3.    Antonides CFJ, Cohen DJ, Osnabrugge RLJ. Statistical primer: a cost-effectiveness analysis. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2018.
4.    Bagwell K, Wu X, Baum ED, Malhotra A. Cost-Effectiveness Analysis of Intracapsular Tonsillectomy and Total Tonsillectomy for Pediatric Obstructive Sleep Apnea. Applied health economics and health policy. 2018.
5.    Bahin FF, Heitman SJ, Bourke MJ. Wide-field endoscopic mucosal resection versus endoscopic submucosal dissection for laterally spreading colorectal lesions: a cost-effectiveness analysis. Gut. 2018.
6.    Boujaoude MA, Mirelman AJ, Dalziel K, Carvalho N. Accounting for equity considerations in cost-effectiveness analysis: a systematic review of rotavirus vaccine in low- and middle-income countries. Cost effectiveness and resource allocation : C/E. 2018;16:18.
7.    Buse S, Hach CE, Klumpen P, Schmitz K, Mager R, Mottrie A, et al. Cost-effectiveness analysis of robot-assisted vs. open partial nephrectomy. The international journal of medical robotics + computer assisted surgery : MRCAS. 2018:e1920.
8.    Cheng XS, Kim WR, Tan JC, Chertow GM, Goldhaber-Fiebert J. Comparing Simultaneous Liver-Kidney Transplant Strategies: A Modified Cost-Effectiveness Analysis. Transplantation. 2018;102(5):e219-e28.
9.    Conget I, Martin-Vaquero P, Roze S, Elias I, Pineda C, Alvarez M, et al. Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain. Endocrinologia, diabetes y nutricion. 2018.
10.    Drummond RS, Malkin S, Du Preez M, Lee XY, Hunt B. Management of type 2 diabetes with Fixed-Ratio combination insulin degludec/liraglutide (IDEGLIRA) versus Basal-Bolus therapy (INSULIN GLARGINE U100 PLUS INSULIN ASPART): A Short-Term Cost-Effectiveness analysis in the UK setting. Diabetes, obesity & metabolism. 2018.
11.    Elliott J, McCoy B, Clifford T, Wells GA, Coyle D. Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis. PharmacoEconomics. 2018.
12.    Entringer AP, Pinto M, Dias MAB, Gomes M. [Cost-effectiveness analysis of spontaneous vaginal delivery and elective cesarean for normal risk pregnant women in the Brazilian Unified National Health System]. Cadernos de saude publica. 2018;34(5):e00022517.
13.    Forster R, Ratcliffe A, Lewis M, Crossley A, Bastida JL, Dunlop WCN. Cost-utility analysis of an intervention designed to reduce the critical handling error of insufficient inspiratory effort. The European journal of health economics : HEPAC : health economics in prevention and care. 2018.
14.    Gallego-Delgado M, Villacorta E, Valenzuela-Vicente MC, Walias-Sanchez A, Avila C, Velasco-Canedo MJ, et al. Start-up of a Cardiology Day Hospital: Activity, Quality Care and Cost-effectiveness Analysis of the First Year of Operation. Revista espanola de cardiologia (English ed). 2018.
15.    Gao L, Li SC. Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation. Breast cancer (Tokyo, Japan). 2018.
16.    Geessinck FAJ, Pleijhuis RG, Mentink RJ, van der Palen J, Koffijberg H. Cost-Effectiveness Analysis of the DiagnOSAS Screening Tool Compared With Polysomnography Diagnosis in Dutch Primary Care. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2018.
17.    Gong CL, Zangwill KM, Hay JW, Meeker D, Doctor JN. Behavioral Economics Interventions to Improve Outpatient Antibiotic Prescribing for Acute Respiratory Infections: a Cost-Effectiveness Analysis. Journal of general internal medicine. 2018.
18.    Healey A, Roberts S, Sevdalis N, Goulding L, Wilson S, Shaw K, et al. A Cost-Effectiveness Analysis of Stop Smoking Interventions in Substance Use Disorder Populations undergoing treatment. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. 2018.
19.    Huang L, Roberts CT, Manley BJ, Owen LS, Davis PG, Dalziel KM. Cost-Effectiveness Analysis of Nasal Continuous Positive Airway Pressure Versus Nasal High Flow Therapy as Primary Support for Infants Born Preterm. The Journal of pediatrics. 2018;196:58-64.e2.
20.    Jiang Y, Yang X, Taniguchi K, Petigara T, Abe M. A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan. Journal of medical economics. 2018:1-11.
21.    Klijn SL, van den Reek J, van de Wetering G, van der Kolk A, de Jong E, Kievit W. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE. The British journal of dermatology. 2018;178(5):1181-9.
22.    Leal J, Manetti S, Buchanan J. The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study. PharmacoEconomics. 2018.
23.    Mar PL, Chen G, Gandhi G, Tang ZZ, Leiserowitz A, Tripuraneni A, et al. Cost-effectiveness Analysis of Magnetic Resonance Imaging-Conditional Pacemaker Implantation: Insights from a Multicenter Study and Implications in the Current Era. Heart rhythm. 2018.
24.    Maunoury F, Farinetto C, Ruckly S, Guenezan J, Lucet JC, Lepape A, et al. Cost-effectiveness analysis of chlorhexidine-alcohol versus povidone iodine-alcohol solution in the prevention of intravascular-catheter-related bloodstream infections in France. PloS one. 2018;13(5):e0197747.
25.    McGrady ME, Eckman MH, O'Brien MM, Pai ALH. Cost-Effectiveness Analysis of an Adherence-Promotion Intervention for Children With Leukemia: A Markov Model-Based Simulation. Journal of pediatric psychology. 2018.
26.    Moretti ME, Lato DF, Berger H, Koren G, Ito S, Ungar WJ. A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events. The pharmacogenomics journal. 2018;18(3):391-7.
27.    Nishimura S, Nakao M. Cost-effectiveness analysis of suvorexant for the treatment of Japanese elderly patients with chronic insomnia in a virtual cohort. Journal of medical economics. 2018:1-6.
28.    Pattanaprateep O, Ingsathit A, McEvoy M, Attia J, Thakkinstian A. Cost-Effectiveness Analysis of Renin-Angiotensin Aldosterone System Blockade in Progression of Chronic Kidney Disease. Value in health regional issues. 2018;15:155-60.
29.    Pinto SM, Yassin M, Galang G. Cost-Effectiveness Analysis of Routine Venous Doppler Ultrasound for Diagnosis of Deep Venous Thrombosis at Admission to Inpatient Rehabilitation. American journal of physical medicine & rehabilitation. 2018.
30.    Raje N, Roodman GD, Willenbacher W, Shimizu K, Garcia-Sanz R, Terpos E, et al. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. Journal of medical economics. 2018;21(5):525-36.
31.    Raphael J, Sun Z, Bjarnason GA, Helou J, Sander B, Naimark DM. Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma: A Cost-Utility Analysis. American journal of clinical oncology. 2018.
32.    Ruggeri M, Basile M, Drago C, Rolli FR, Cicchetti A. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy. PharmacoEconomics. 2018;36(5):625-36.
33.    Sinkey RG, Odibo AO. Vasa previa screening strategies: a decision and cost-effectiveness analysis. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2018.
34.    Sobral APT, Godoy CLH, Fernandes KPS, Bussadori SK, Ferrari RAM, Horliana A, et al. Photomodulation in the treatment of chronic pain in patients with temporomandibular disorder: protocol for cost-effectiveness analysis. BMJ open. 2018;8(5):e018326.
35.    Tam DY, Hughes A, Fremes SE, Youn S, Hancock-Howard RL, Coyte PC, et al. A cost-utility analysis of transcatheter versus surgical aortic valve replacement for the treatment of aortic stenosis in the population with intermediate surgical risk. The Journal of thoracic and cardiovascular surgery. 2018;155(5):1978-88.e1.
36.    Thakar S, Rajagopal N, Mani S, Shyam M, Aryan S, Rao AS, et al. Comparison of telemedicine with in-person care for follow-up after elective neurosurgery: results of a cost-effectiveness analysis of 1200 patients using patient-perceived utility scores. Neurosurgical focus. 2018;44(5):E17.
37.    Tringale KR, Carroll KT, Zakeri K, Sacco AG, Barnachea L, Murphy JD. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Journal of the National Cancer Institute. 2018;110(5):479-85.
38.    Tsai PC, Liu TW, Huang CF, Yeh ML, Dai CY, Chuang WL, et al. A real world cost effectiveness analysis of interferon-based therapy for HCV naive super-responders. Journal of the Chinese Medical Association : JCMA. 2018.
39.    van Asten F, Michels CTJ, Hoyng CB, van der Wilt GJ, Klevering BJ, Rovers MM, et al. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective. PloS one. 2018;13(5):e0197670.
40.    Vilsboll AW, Mouritsen JM, Jensen LP, Bodker N, Holst AW, Pennisi CP, et al. Cell-based therapy for the treatment of female stress urinary incontinence: an early cost-effectiveness analysis. Regenerative medicine. 2018;13(3):321-30.
41.    Whittington MD, McQueen RB, Campbell JD. Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies. JAMA pediatrics. 2018;172(5):409-10.
42.    Yaghoubi M, Nojomi M, Vaezi A, Erfani V, Mahmoudi S, Ezoji K, et al. Cost-Effectiveness Analysis of the Introduction of HPV Vaccination of 9-Year-Old-Girls in Iran. Value in health regional issues. 2018;15:112-9.
43.    Yap A, Muzira A, Kakembo N, Kisa P, Sekabira J, Cheung M, et al. A Cost-Effectiveness Analysis of a Pediatric Operating Room in Uganda. Surgery. 2018.
44.    Yi Y, Bryce CL, Adambekov S, Edwards RP, Goughnour SL, Linkov F. Cost-effectiveness analysis of biopsy strategies for endometrial cancer diagnosis in women with postmenopausal bleeding: Pipelle sampling curette versus dilatation & curettage. Gynecologic oncology. 2018.

April 2018

1.    Abdelrahman A. Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder. International urogynecology journal. 2018.
2.    Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis. Diabetes, obesity & metabolism. 2018.
3.    Borisenko O, Lukyanov V, Ahmed AR. Cost-utility analysis of bariatric surgery. The British journal of surgery. 2018.
4.    Borisenko O, Lukyanov V, Debergh I, Dillemans B. Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium. Journal of medical economics. 2018;21(4):365-73.
5.    Borse RH, Kachroo S, Brown C, McCann E, Insinga RP. Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland. Rheumatology and therapy. 2018;5(1):57-73.
6.    Bulsei J, Darlington M, Durand-Zaleski I, Azizi M. How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example. Blood pressure. 2018;27(2):66-72.
7.    Chan MC, Tan EC, Yang MC. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD. International journal of chronic obstructive pulmonary disease. 2018;13:1079-88.
8.    Chen S, Peng Z, Wei M, Liu W, Dai Z, Wang H, et al. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis. BMC cancer. 2018;18(1):392.
9.    Cohen JT, Neumann PJ, Wong JB. A Call for Open-Source Cost-Effectiveness Analysis. Annals of internal medicine. 2018;168(7):529.
10.    Cosse C, Rebibo L, Brazier F, Hakim S, Delcenserie R, Regimbeau JM. Cost-effectiveness analysis of stent type in endoscopic treatment of gastric leak after laparoscopic sleeve gastrectomy. The British journal of surgery. 2018;105(5):570-7.
11.    Dawkins BR, Mirelman AJ, Asaria M, Johansson KA, Cookson RA. Distributional cost-effectiveness analysis in low- and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia. Health policy and planning. 2018;33(3):456-63.
12.    Ferket BS, Oxman JM, Iribarne A, Gelijns AC, Moskowitz AJ. Cost-effectiveness analysis in cardiac surgery: A review of its concepts and methodologies. The Journal of thoracic and cardiovascular surgery. 2018;155(4):1671-81.e11.
13.    Fobelets M, Beeckman K, Faron G, Daly D, Begley C, Putman K. Vaginal birth after caesarean versus elective repeat caesarean delivery after one previous caesarean section: a cost-effectiveness analysis in four European countries. BMC pregnancy and childbirth. 2018;18(1):92.
14.    Gakis G, Volkmer B, Qvick B, Marteau F, Stenzl A. [Cost-effectiveness analysis of blue light cystoscopy with hexylaminolevulinate in transurethral resection of the bladder]. Der Urologe Ausg A. 2018.
15.    Heemskerk SCM, Rotteveel AH, Benninga MA, Baeten CIM, Masclee AAM, Melenhorst J, et al. Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis. International journal of colorectal disease. 2018;33(4):493-501.
16.    Henry N, Jovanovic J, Schlueter M, Kritikou P, Wilson K, Myren KJ. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden. Journal of medical economics. 2018;21(4):318-25.
17.    Holko P, Kawalec P, Pilc A. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-alpha Antagonist. PharmacoEconomics. 2018.
18.    House LK, Lewis AF, Ashmead MG. A cost-effectiveness analysis of the up-front use of balloon catheter dilation in the treatment of pediatric chronic rhinosinusitis. American journal of otolaryngology. 2018.
19.    Itoga NK, Minami HR, Chelvakumar M, Pearson K, Mell MM, Bendavid E, et al. Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test. Vascular medicine (London, England). 2018;23(2):97-106.
20.    Jarmul J, Pletcher MJ, Hassmiller Lich K, Wheeler SB, Weinberger M, Avery CL, et al. Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis. Circulation Cardiovascular quality and outcomes. 2018;11(4):e004171.
21.    Kassebaum NJ, McQueen K. The Role of Cost-Effectiveness Analysis in Global Anesthesia. Anesthesia and analgesia. 2018;126(4):1397-9.
22.    Kennedy L, Bhatta S, Hechmati G, Buchanan J. Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018;36(10):1051.
23.    Kigozi J, Jowett S, Nicholl BI, Lewis M, Bartlam B, Green D, et al. Cost-utility Analysis of Routine Anxiety and Depression Screening in Patients Consulting for Osteoarthritis: results from the POST Trial. Arthritis care & research. 2018.
24.    Kim CH, Chung CK, Kim MJ, Choi Y, Kim MJ, Hahn S, et al. Increased Volume of Lumbar Surgeries for Herniated Intervertebral Disc Disease and Cost-Effectiveness Analysis: A Nationwide Cohort Study. Spine. 2018;43(8):585-93.
25.    Lara C, De Graeve D, Franco F. Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia. Value in health regional issues. 2018;17:21-31.
26.    Lazzaro C, Barone C, Caprioni F, Cascinu S, Falcone A, Maiello E, et al. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert review of pharmacoeconomics & outcomes research. 2018:1-12.
27.    Leurent B, Gomes M, Faria R, Morris S, Grieve R, Carpenter JR. Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial. PharmacoEconomics. 2018.
28.    Li N, Zheng B, Cai HF, Chen YH, Qiu MQ, Liu MB. Cost-effectiveness analysis of oral probiotics for the prevention of Clostridium difficile-associated diarrhoea in children and adolescents. The Journal of hospital infection. 2018.
29.    Lindholm L, Stenling A, Norberg M, Stenlund H, Weinehall L. A cost-effectiveness analysis of a community based CVD program in Sweden based on a retrospective register cohort. BMC public health. 2018;18(1):452.
30.    Martini A, Gupta A, Cumarasamy S, Tewari AK. Re: Rita Faria, Marta O. Soares, Eldon Spackman, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). Eur Urol 2018;73:23-30. European urology. 2018;73(4):e108-e9.
31.    McQueen RB, Padula WV, Campbell JD. A Call for Open-Source Cost-Effectiveness Analysis. Annals of internal medicine. 2018;168(7):528-9.
32.    Neslusan C, Teschemaker A, Willis M, Johansen P, Vo L. Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2018;9(2):565-81.
33.    Neyt M, Vlayen J, Devriese S, Camberlin C. First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis. PloS one. 2018;13(4):e0195134.
34.    Norum J, Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Undlien DE, et al. BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer. ESMO open. 2018;3(3):e000328.
35.    Paix A, Noel G, Falcoz PE, Levy P. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018.
36.    Paoli AR, Gold HT, Mahure SA, Mai DH, Agten CA, Rokito AS, et al. Treatment for Symptomatic SLAP Tears in Middle-Aged Patients Comparing Repair, Biceps Tenodesis, and Nonoperative Approaches: A Cost-Effectiveness Analysis. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2018.
37.    Pearson-Stuttard J, Kypridemos C, Collins B, Mozaffarian D, Huang Y, Bandosz P, et al. Estimating the health and economic effects of the proposed US Food and Drug Administration voluntary sodium reformulation: Microsimulation cost-effectiveness analysis. PLoS medicine. 2018;15(4):e1002551.
38.    Raphael J, Sun Z, Bjarnason GA, Helou J, Sander B, Naimark DM. Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma: A Cost-Utility Analysis. American journal of clinical oncology. 2018.
39.    Sampson CJ. A Call for Open-Source Cost-Effectiveness Analysis. Annals of internal medicine. 2018;168(7):528.
40.    Shafrin J, Skornicki M, Brauer M, Villeneuve J, Lees M, Hertel N, et al. An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference? Health policy (Amsterdam, Netherlands). 2018.
41.    Shamout S, Nazha S, Dragomir A, Campeau L. A cost-utility analysis of artificial urinary sphincter versus AdVance male sling in post prostatectomy stress urinary incontinence: A publicly funded health care perspective. Neurourology and urodynamics. 2018.
42.    Shepherd JP, Carter-Brooks CM, Chermanksy C. A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder. International urogynecology journal. 2018.
43.    Simpson E, Hock E, Stevenson M, Wong R, Dracup N, Wailoo A, et al. What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. Health technology assessment (Winchester, England). 2018;22(20):1-258.
44.    Stamuli E, Kesornsak W, Grevitt MP, Posnett J, Claxton K. A Cost-Effectiveness Analysis of Intradiscal Electrothermal Therapy Compared with Circumferential Lumbar Fusion. Pain practice : the official journal of World Institute of Pain. 2018;18(4):515-22.
45.    Toroski M, Nikfar S, Mojahedian MM, Ayati MH. Comparison of the Cost-utility Analysis of Electroacupuncture and Nonsteroidal Antiinflammatory Drugs in the Treatment of Chronic Low Back Pain. Journal of acupuncture and meridian studies. 2018;11(2):62-6.
46.    van Baal P, Morton A, Meltzer D, Brouwer W. Future unrelated medical costs need to be considered in cost effectiveness analysis. The European journal of health economics : HEPAC : health economics in prevention and care. 2018.
47.    van der Spek N, Jansen F, Holtmaat K, Vos J, Breitbart W, van Uden-Kraan CF, et al. Cost-utility analysis of meaning-centered group psychotherapy for cancer survivors. Psycho-oncology. 2018.
48.    Van Kriekinge G, Sohn WY, Aljunid SM, Soon R, Yong CM, Chen J, et al. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia. Asian Pacific journal of cancer prevention : APJCP. 2018;19(4):933-40.
49.    Vilsboll AW, Mouritsen JM, Jensen LP, Bodker N, Holst AW, Pennisi CP, et al. Cell-based therapy for the treatment of female stress urinary incontinence: an early cost-effectiveness analysis. Regenerative medicine. 2018;13(3):321-30.
50.    Wen F, Zheng H, Zhang P, Hutton D, Li Q. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer. BMJ open. 2018;8(4):e020128.
51.    Westin O, Svensson M, Nilsson Helander K, Samuelsson K, Gravare Silbernagel K, Olsson N, et al. Cost-effectiveness analysis of surgical versus non-surgical management of acute Achilles tendon ruptures. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA. 2018.
52.    Yaghoubi M, Nojomi M, Vaezi A, Erfani V, Mahmoudi S, Ezoji K, et al. Cost-Effectiveness Analysis of the Introduction of HPV Vaccination of 9-Year-Old-Girls in Iran. Value in health regional issues. 2018;15:112-9.


March 2018

1.    Comparing the Air Medical Prehospital Triage Score With Current Practice for Triage of Injured Patients to Helicopter Emergency Medical Services: A Cost-effectiveness Analysis. JAMA surgery. 2018;153(3):261-8.
2.    Agus A, Phair G, Page VJ, McAuley DF. Simvastatin for the prevention and treatment of delirium in critically ill, mechanically ventilated patients (MoDUS): a cost-effectiveness analysis. The Lancet Respiratory medicine. 2018;6(3):e9-e10.
3.    Amiri A, Goudarzi R, Amiresmaili M, Iranmanesh F. Cost-effectiveness analysis of tissue plasminogen activator in acute ischemic stroke in Iran. Journal of medical economics. 2018;21(3):282-7.
4.    Areia M, Spaander MC, Kuipers EJ, Dinis-Ribeiro M. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk. United European gastroenterology journal. 2018;6(2):192-202.
5.    Atehortua SC, Lugo LH, Ceballos M, Orozco E, Castro PA, Arango JC, et al. Cost-Effectiveness Analysis of Diagnosis of Duchenne/Becker Muscular Dystrophy in Colombia. Value in health regional issues. 2018;17:1-6.
6.    Berger A, Inglese G, Skountrianos G, Karlsmark T, Oguz M. Cost-effectiveness of a Ceramide-Infused Skin Barrier Versus a Standard Barrier: Findings From a Long-Term Cost-effectiveness Analysis. Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society. 2018;45(2):146-55.
7.    Bethea ED, Chen Q, Hur C, Chung RT, Chhatwal J. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology (Baltimore, Md). 2018;67(3):837-46.
8.    Bloemen A, Daniels AM, Samyn MG, Janssen RJ, Elshof JW. Electrocardiographic-guided tip positioning technique for peripherally inserted central catheters in a Dutch teaching hospital: Feasibility and cost-effectiveness analysis in a prospective cohort study. The journal of vascular access. 2018:1129729818764051.
9.    Brown H, D'Amico F, Knapp M, Orrell M, Rehill A, Vale L, et al. A cost effectiveness analysis of maintenance cognitive stimulation therapy (MCST) for people with dementia: examining the influence of cognitive ability and living arrangements. Aging & mental health. 2018:1-6.
10.    Bullard KA, Shaffer BL, Greiner KS, Skeith AE, Rodriguez MI, Caughey AB. Twenty-Week Abortion Bans on Pregnancies With a Congenital Diaphragmatic Hernia: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2018;131(3):581-90.
11.    Casado LF, Hernandez JA, Jarque I, Echave M, Casado MA, Castro A. Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia. European journal of haematology. 2018;100(3):264-72.
12.    Cazarim MS, Pereira LRL. Cost-effectiveness analysis of pharmaceutical care for hypertensive patients from the perspective of the public health system in Brazil. PloS one. 2018;13(3):e0193567.
13.    Chen YI, Barkun AN, Adam V, Bai G, Singh VK, Bukhari M, et al. Cost-Effectiveness Analysis Comparing Lumen Apposing Metal Stents with Plastic Stents in the Management of Pancreatic Walled-Off Necrosis. Gastrointestinal endoscopy. 2018.
14.    Cheng XS, Kim WR, Tan JC, Chertow GM, Goldhaber-Fiebert J. Comparing Simultaneous Liver-Kidney Transplant Strategies: A Modified Cost-Effectiveness Analysis. Transplantation. 2018.
15.    Connolly P, Miller S, Kee F, Sloan S, Gildea A, McIntosh E, et al. Public Health Research.  A cluster randomised controlled trial and evaluation and cost-effectiveness analysis of the Roots of Empathy schools-based programme for improving social and emotional well-being outcomes among 8- to 9-year-olds in Northern Ireland. Southampton (UK): NIHR Journals Library
16.    Coyle S, Kinsella S, Lenehan B, Queally JM. Cost-utility analysis in orthopaedic trauma; what pays? A systematic review. Injury. 2018;49(3):575-84.
17.    Debals-Gonthier M, Siani C, Faucher C, Touzani R, Lemarie-Basset C, Chabannon C, et al. Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years. Bone marrow transplantation. 2018.
18.    Dorji K, Phuntsho S, Pempa, Kumluang S, Khuntha S, Kulpeng W, et al. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option. Vaccine. 2018;36(13):1757-65.
19.    Fong Soe Khioe R, Skedgel C, Hart A, Lewis MPN, Alexandre L. Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis. PharmacoEconomics. 2018;36(3):349-58.
20.    Ghabri S, Mauskopf J. The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges. The European journal of health economics : HEPAC : health economics in prevention and care. 2018;19(2):173-5.
21.    Huang L, Roberts CT, Manley BJ, Owen LS, Davis PG, Dalziel KM. Cost-Effectiveness Analysis of Nasal Continuous Positive Airway Pressure Versus Nasal High Flow Therapy as Primary Support for Infants Born Preterm. The Journal of pediatrics. 2018.
22.    Hunter RM, Fulop NJ, Boaden RJ, McKevitt C, Perry C, Ramsay AIG, et al. The potential role of cost-utility analysis in the decision to implement major system change in acute stroke services in metropolitan areas in England. Health research policy and systems. 2018;16(1):23.
23.    Ikeme S, Weltert L, Lewis KM, Bothma G, Cianciulli D, Pay N, et al. Cost-effectiveness analysis of a sealing hemostat patch (HEMOPATCH) vs standard of care in cardiac surgery. Journal of medical economics. 2018;21(3):273-81.
24.    Kajinami K. Towards Effective Cost-Effectiveness Analysis in Atherosclerotic Cardiovascular Disease Prevention. Circulation journal : official journal of the Japanese Circulation Society. 2018;82(4):954-5.
25.    Kay E, Owen L, Taylor M, Claxton L, Sheppard L. The use of cost-utility analysis for the evaluation of caries prevention: an exploratory case study of two community-based public health interventions in a high-risk population in the UK. Community dental health. 2018;35(1):30-6.
26.    Kim H, Vargo JA, Beriwal S, Clump DA, Ohr JP, Ferris RL, et al. Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer. Head & neck. 2018.
27.    Leurent B, Gomes M, Carpenter JR. Missing data in trial-based cost-effectiveness analysis: An incomplete journey. Health economics. 2018.
28.    Mahmoud O, Vikatmaa P, Rasanen J, Peltola E, Sihvo E, Vikatmaa L, et al. Catheter-Directed Thrombolysis vs. Pharmacomechanical Thrombectomy for Upper Extremity Deep Venous Thrombosis: Cost-Effectiveness Analysis. Annals of vascular surgery. 2018.
29.    Maunoury F, Clement A, Nwankwo C, Levy-Bachelot L, Abergel A, Di Martino V, et al. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France. PloS one. 2018;13(3):e0194329.
30.    Pandey S, Tyagi R. Re: Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis: Cost-effectiveness in recurrent endometriosis prevention. BJOG : an international journal of obstetrics and gynaecology. 2018;125(4):503-4.
31.    Penaloza-Ramos MC, Jowett S, Sutton AJ, McManus RJ, Barton P. The Importance of Model Structure in the Cost-Effectiveness Analysis of Primary Care Interventions for the Management of Hypertension. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018;21(3):351-63.
32.    Raje N, Roodman GD, Willenbacher W, Shimizu K, Garcia-Sanz R, Terpos E, et al. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. Journal of medical economics. 2018:1-12.
33.    Ramkumar DB, Ramkumar N, Tapp SJ, Moschetti WE. Pharmacologic Hemostatic Agents in Total Joint Arthroplasty-A Cost-Effectiveness Analysis. The Journal of arthroplasty. 2018.
34.    Rao C, Smith FM, Martin AP, Dhadda AS, Stewart A, Gollins S, et al. A Cost-Effectiveness Analysis of Contact X-ray Brachytherapy for the Treatment of Patients with Rectal Cancer Following a Partial Response to Chemoradiotherapy. Clinical oncology (Royal College of Radiologists (Great Britain)). 2018;30(3):166-77.
35.    Rognoni C, Ciani O, Sommariva S, Tarricone R. Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma. Journal of comparative effectiveness research. 2018;7(3):209-21.
36.    Ruggeri M, Basile M, Drago C, Rolli FR, Cicchetti A. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy. PharmacoEconomics. 2018.
37.    Ruiz-Rodriguez P, Cano-Vindel A, Munoz-Navarro R, Wood CM, Medrano LA, Moretti LS. Cost-Effectiveness and Cost-Utility Analysis of the Treatment of Emotional Disorders in Primary Care: PsicAP Clinical Trial. Description of the Sub-study Design. Frontiers in psychology. 2018;9:281.
38.    Sacino MF, Huang SS, Keating RF, Gaillard WD, Oluigbo CO. An initial cost-effectiveness analysis of intraoperative magnetic resonance imaging (iMRI) in pediatric epilepsy surgery. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 2018;34(3):495-502.
39.    Singh K, Crossan C, Laba TL, Roy A, Hayes A, Salam A, et al. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. International journal of cardiology. 2018.
40.    Svensson M, Barregard L, Axelsson G, Andersson E. A cost-effectiveness analysis of lowering residential radon levels in Sweden-Results from a modelling study. Health policy (Amsterdam, Netherlands). 2018.
41.    Tan PT, Aziz MIA, Pearce F, Lim WT, Wu DB, Ng K. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective. BMC cancer. 2018;18(1):352.
42.    Telford C. RE: "Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer," by Ding H., et al. European journal of cancer care. 2018;27(2):e12834.
43.    Tseng CC, Lai MT, Wu CC, Yuan SP, Ding YF. Cost-effectiveness analysis of endoscopic tympanoplasty versus microscopic tympanoplasty for chronic otitis media in Taiwan. Journal of the Chinese Medical Association : JCMA. 2018;81(3):284-90.
44.    Tullberg M, Persson J, Petersen J, Hellstrom P, Wikkelso C, Lundgren-Nilsson A. Shunt surgery in idiopathic normal pressure hydrocephalus is cost-effective-a cost utility analysis. Acta neurochirurgica. 2018;160(3):509-18.
45.    Walter E, Dellago H, Grillari J, Dimai HP, Hackl M. Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population. Bone. 2018;108:44-54.
46.    Walzer S, Droschel D, Vollmer L, Atkin L, Ousey K. A cost-effectiveness analysis of a hydration response technology dressing in the treatment of venous leg ulcers in the UK. Journal of wound care. 2018;27(3):166-72.
47.    Whittington MD, McQueen RB, Campbell JD. Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies. JAMA pediatrics. 2018.
48.    Wu B, Wang Y. Authors' reply re: Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2018;125(4):504.
49.    Wu B, Yang Z, Tobe RG, Wang Y. Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2018;125(4):469-77.
50.    Wu DBC, Chaiyakunapruk N, Pratoomsoot C, Lee KKC, Chong HY, Nelson RE, et al. Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and heath economics. Epidemiology and infection. 2018;146(4):496-507.
51.    Xie X, He T, Kang J, Siscovick DS, Li Y, Pagan JA. Cost-effectiveness analysis of intensive hypertension control in China. Preventive medicine. 2018;111:110-4.
52.    Yalniz FF, Murad MH, Lee SJ, Pavletic SZ, Khera N, Shah ND, et al. Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018.
53.    You JHS, Li HK, Ip M. Surveillance-guided selective digestive decontamination of carbapenem-resistant Enterobacteriaceae in the intensive care unit: A cost-effectiveness analysis. American journal of infection control. 2018;46(3):291-6.
54.    Zheng H, Xie L, Zhan M, Wen F, Xu T, Li Q. Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2018;20(3):286-93.
55.    Zueger PM, Kumar VM, Harrington RL, Rigoni GC, Atwood A, DiDomenico RJ, et al. Cost-Effectiveness Analysis of Sacubitril-Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States. Pharmacotherapy. 2018.


February 2018

1.    Ahern S, Burke LA, McElroy B, Corcoran P, McMahon EM, Keeley H, et al. A cost-effectiveness analysis of school-based suicide prevention programmes. European child & adolescent psychiatry. 2018.
2.    Alemao E, Johal S, Al MJ, Rutten-van Molken M. Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018;21(2):193-202.
3.    Avsar P, Karadag A. Efficacy and Cost-Effectiveness Analysis of Evidence-Based Nursing Interventions to Maintain Tissue Integrity to Prevent Pressure Ulcers and Incontinence-Associated Dermatitis. Worldviews on evidence-based nursing. 2018;15(1):54-61.
4.    Barnhoorn K, Staal JB, van Dongen RT, Frolke JPM, Klomp FP, van de Meent H, et al. Pain Exposure Physical Therapy versus conventional treatment in complex regional pain syndrome type 1-a cost-effectiveness analysis alongside a randomized controlled trial. Clinical rehabilitation. 2018:269215518757050.
5.    Barriere P, Porcu-Buisson G, Hamamah S. Cost-Effectiveness Analysis of the Gonadotropin Treatments HP-hMG and rFSH for Assisted Reproductive Technology in France: A Markov Model Analysis. Applied health economics and health policy. 2018;16(1):65-77.
6.    Berger A, Inglese G, Skountrianos G, Karlsmark T, Oguz M. Cost-effectiveness of a Ceramide-Infused Skin Barrier Versus a Standard Barrier: Findings From a Long-Term Cost-effectiveness Analysis. Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society. 2018.
7.    Capri S, Barbieri M, de Waure C, Boccalini S, Panatto D. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population. Human vaccines & immunotherapeutics. 2018:1-11.
8.    Chong HY, Lim YH, Prawjaeng J, Tassaneeyakul W, Mohamed Z, Chaiyakunapruk N. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population. Pharmacogenetics and genomics. 2018;28(2):56-67.
9.    Combariza JF, Toro LF, Orozco JJ, Arango M. Cost-effectiveness analysis of interventions for prevention of invasive aspergillosis among leukemia patients during hospital construction activities. European journal of haematology. 2018;100(2):140-6.
10.    Cortesi PA, Belli LS, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, et al. The optimal timing of Hepatitis C therapy in liver transplant eligible patients: cost-effectiveness analysis of new opportunities. Journal of viral hepatitis. 2018.
11.    Cosse C, Rebibo L, Brazier F, Hakim S, Delcenserie R, Regimbeau JM. Cost-effectiveness analysis of stent type in endoscopic treatment of gastric leak after laparoscopic sleeve gastrectomy. The British journal of surgery. 2018.
12.    Dorji K, Phuntsho S, Pempa, Kumluang S, Khuntha S, Kulpeng W, et al. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option. Vaccine. 2018;36(13):1757-65.
13.    Freund R, Granger B, Francois C, Carcelain G, Ravaud P, Mariette X, et al. Cost-effectiveness analysis of strategies using new immunological diagnostic tests of latent tuberculosis infection before TNF-blockers therapy. Presse medicale (Paris, France : 1983). 2018.
14.    Garcia SL, Smith KJ, Palmer C. Cost-Effectiveness Analysis of a Military Hearing Conservation Program. Military medicine. 2018.
15.    Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, et al. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. Journal of medical economics. 2018;21(2):163-73.
16.    Gokani SA, Elmqvist KO, El-Koubani O, Ash J, Biswas SK, Rigaudy M. A cost-utility analysis of small bite sutures versus large bite sutures in the closure of midline laparotomies in the United Kingdom National Health Service. ClinicoEconomics and outcomes research : CEOR. 2018;10:105-17.
17.    Gregory ST, Kay B, Smith J, Hall K, De Nadai AS, Quast T, et al. Treatment-Refractory Obsessive-Compulsive Disorder in Adults: A Cost-Effectiveness Analysis of Treatment Strategies. The Journal of clinical psychiatry. 2018;79(2).
18.    Guo K, Zheng X, Li D, Wu Y, Ji Q, Wang Z. Cost-effectiveness analysis in papillary thyroid carcinoma patients with different neck dissection strategy: A retrospective cohort study. International journal of surgery (London, England). 2018;50:1-5.
19.    Haerling KA. Cost-Utility Analysis of Virtual and Mannequin-Based Simulation. Simulation in healthcare : journal of the Society for Simulation in Healthcare. 2018;13(1):33-40.
20.    Heemskerk SCM, Rotteveel AH, Benninga MA, Baeten CIM, Masclee AAM, Melenhorst J, et al. Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis. International journal of colorectal disease. 2018.
21.    Hernandez L, Lanitis T, Cele C, Toro-Diaz H, Gibson A, Kuznik A. Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-effectiveness Analysis. Journal of managed care & specialty pharmacy. 2018:1-9.
22.    Hong JC, Padula WV, Hollin IL, Hussain T, Dietz KB, Halbert JP, et al. Care Management to Reduce Disparities and Control Hypertension in Primary Care: A Cost-effectiveness Analysis. Medical care. 2018;56(2):179-85.
23.    Jendle J, Ericsson A, Hunt B, Valentine WJ, Pollock RF. Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2018;9(1):87-99.
24.    Joish VN, Frech F, Lapuerta P. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. Journal of medical economics. 2018;21(2):182-8.
25.    Kantito S, Saokaew S, Yamwong S, Vathesatogkit P, Katekao W, Sritara P, et al. Cost-effectiveness analysis of patient self-testing therapy of oral anticoagulation. Journal of thrombosis and thrombolysis. 2018;45(2):281-90.
26.    Karnon J, Haghighi BM, Sajjad B, Yem S, Gamage A, Thorpe A. COST-UTILITY ANALYSIS OF PRIVATE CONTRACTING TO REDUCE PUBLIC WAITING TIMES FOR JOINT REPLACEMENT SURGERY. International journal of technology assessment in health care. 2018:1-9.
27.    Kennedy L, Bhatta S, Hechmati G, Buchanan J. Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018:Jco2017770115.
28.    Kumar V, Cohen JT, van Klaveren D, Soeteman DI, Wong JB, Neumann PJ, et al. Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis. Annals of internal medicine. 2018;168(3):161-9.
29.    Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. BMC health services research. 2018;18(1):78.
30.    Laiteerapong N, Cooper JM, Skandari MR, Clarke PM, Winn AN, Naylor RN, et al. Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. Annals of internal medicine. 2018;168(3):170-8.
31.    Li B, Miners A, Shakur H, Roberts I. Tranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial. The Lancet Global health. 2018;6(2):e222-e8.
32.    Lim G, Melnyk V, Facco FL, Waters JH, Smith KJ. Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage. Anesthesiology. 2018;128(2):328-37.
33.    Marino R, Traub F, Lekfuangfu P, Niyomsilp K. Cost-effectiveness analysis of a school-based dental caries prevention program using fluoridated milk in Bangkok, Thailand. BMC oral health. 2018;18(1):24.
34.    Mason JM, Chalmers JR, Godec T, Nunn AJ, Kirtschig G, Wojnarowska F, et al. Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial. The British journal of dermatology. 2018;178(2):415-23.
35.    Neslusan C, Teschemaker A, Willis M, Johansen P, Vo L. Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2018.
36.    Panca M, Christie D, Cole TJ, Costa S, Gregson J, Holt R, et al. Cost-effectiveness of a community-delivered multicomponent intervention compared with enhanced standard care of obese adolescents: cost-utility analysis alongside a randomised controlled trial (the HELP trial). BMJ open. 2018;8(2):e018640.
37.    Plavinskii SL, Barinova AN. [Use of Highly Concentrated Polyunsaturated Fatty Acids for Prevention of Complications After Myocardial Infarction. Cost-Utility Analysis]. Kardiologiia. 2018(2):77-82.
38.    Poorman GW, Passias PG, Qureshi R, Hassanzadeh H, Horn S, Bortz C, et al. Cost-utility analysis of cervical deformity surgeries using one-year outcome. The spine journal : official journal of the North American Spine Society. 2018.
39.    Risor BW, Lisby M, Sorensen J. Comparative Cost-Effectiveness Analysis of Three Different Automated Medication Systems Implemented in a Danish Hospital Setting. Applied health economics and health policy. 2018;16(1):91-106.
40.    Russell LB, Bhanot G, Kim SY, Sinha A. Using Cluster Analysis to Group Countries for Cost-effectiveness Analysis: An Application to Sub-Saharan Africa. Medical decision making : an international journal of the Society for Medical Decision Making. 2018;38(2):139-49.
41.    Saramago P, Yang H, Llewellyn A, Palmer S, Simmonds M, Griffin S. High-throughput, non-invasive prenatal testing for fetal RHD genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2018.
42.    Silver RM, Einerson BD. Cost-effectiveness analysis and obstetrics: the time has come. BJOG : an international journal of obstetrics and gynaecology. 2018;125(3):384.
43.    Souche R, Herrero A, Bourel G, Chauvat J, Pirlet I, Guillon F, et al. Robotic versus laparoscopic distal pancreatectomy: a French prospective single-center experience and cost-effectiveness analysis. Surgical endoscopy. 2018.
44.    Suh CH, Kim KW, Park SH, Kim SY, Woo DC, Shin S, et al. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. AJR American journal of roentgenology. 2018;210(2):W63-w9.
45.    Tam DY, Hughes A, Fremes SE, Youn S, Hancock-Howard RL, Coyte PC, et al. A cost-utility analysis of transcatheter versus surgical aortic valve replacement for the treatment of aortic stenosis in the population with intermediate surgical risk. The Journal of thoracic and cardiovascular surgery. 2018.
46.    Ten Eikelder M, van Baaren GJ, Oude Rengerink K, Jozwiak M, de Leeuw JW, Kleiverda G, et al. Comparing induction of labour with oral misoprostol or Foley catheter at term: cost-effectiveness analysis of a randomised controlled multi-centre non-inferiority trial. BJOG : an international journal of obstetrics and gynaecology. 2018;125(3):375-83.
47.    Toroski M, Nikfar S, Mojahedian MM, Ayati MH. Cost-Utility Analysis of Electro acupuncture Comparing Non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of Chronic Low Back Pain. Journal of acupuncture and meridian studies. 2018.
48.    Wang Y, Xing Y, Chen L, Meng T, Li Y, Xie J, et al. Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis. International journal of hematology. 2018;107(2):235-43.
49.    Wu DBC, Chaiyakunapruk N, Pratoomsoot C, Lee KKC, Chong HY, Nelson RE, et al. Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and heath economics. Epidemiology and infection. 2018;146(4):496-507.
50.    Xuan J, Huang M, Lu Y, Tao L. Economic Evaluation of Safflower Yellow Injection for the Treatment of Patients with Stable Angina Pectoris in China: A Cost-Effectiveness Analysis. Journal of alternative and complementary medicine (New York, NY). 2018.
51.    Zhou H, He J, Wu B, Che D. Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants. Human vaccines & immunotherapeutics. 2018:0.


January 2018

1.    Alsumali A, Eguale T, Bairdain S, Samnaliev M. Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity. Obesity surgery. 2018.
2.    Anderson D, Villagra V, Coman EN, Zlateva I, Hutchinson A, Villagra J, et al. A cost-effectiveness analysis of cardiology eConsults for Medicaid patients. The American journal of managed care. 2018;24(1):e9-e16.
3.    Baker CL, Pietri G. A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trial. ClinicoEconomics and outcomes research : CEOR. 2018;10:67-74.
4.    Borisenko O, Lukyanov V, Debergh I, Dillemans B. Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium. Journal of medical economics. 2018:1-9.
5.    Bove AM, Smith KJ, Bise CG, Fritz JM, Childs J, Brennan GP, et al. Exercise, Manual Therapy, and Booster Sessions in Knee Osteoarthritis: Cost-Effectiveness Analysis From a Multicenter Randomized Controlled Trial. Physical therapy. 2018;98(1):16-27.
6.    Cho JH, Jang HM, Jung HY, Choi JY, Park SH, Kim CD, et al. A Real-world Cost-effectiveness Analysis of Sevelamer Versus Calcium Acetate in Korean Dialysis Patients. Clinical therapeutics. 2018;40(1):123-34.
7.    Chomsky-Higgins K, Seib C, Rochefort H, Gosnell J, Shen WT, Kahn JG, et al. Less is more: cost-effectiveness analysis of surveillance strategies for small, nonfunctional, radiographically benign adrenal incidentalomas. Surgery. 2018;163(1):197-204.
8.    Clarke M, Fursse J, Brown-Connolly NE, Sharma U, Jones R. Evaluation of the National Health Service (NHS) Direct Pilot Telehealth Program: Cost-Effectiveness Analysis. Telemedicine journal and e-health : the official journal of the American Telemedicine Association. 2018;24(1):67-76.
9.    Dawkins BR, Mirelman AJ, Asaria M, Johansson KA, Cookson RA. Distributional cost-effectiveness analysis in low-and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia. Health policy and planning. 2018.
10.    DiazOrdaz K, Franchini AJ, Grieve R. Methods for estimating complier average causal effects for cost-effectiveness analysis. Journal of the Royal Statistical Society Series A, (Statistics in Society). 2018;181(1):277-97.
11.    Dubin JM, Greer AB, Kohn TP, Masterson TA, Ji L, Ramasamy R. Men With Severe Oligospermia Appear to Benefit From Varicocele Repair: A Cost-effectiveness Analysis of Assisted Reproductive Technology. Urology. 2018;111:99-103.
12.    Faria R, Soares MO, Spackman E, Ahmed HU, Brown LC, Kaplan R, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). European urology. 2018;73(1):23-30.
13.    Foley P, Garrett S, Ryttig L. A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis. Current medical research and opinion. 2018:1-7.
14.    Hermans J, Reijman M, Goossens LMA, Verburg H, Bierma-Zeinstra SMA, Koopmanschap MA. Cost-Utility Analysis of High Molecular Weight Hyaluronic Acid for Knee Osteoarthritis in Everyday Clinical Care in Patients at a Working Age: An Economic Evaluation of a Randomized Clinical Trial. Arthritis care & research. 2018;70(1):89-97.
15.    Hong JC, Saraswat MK, Ellison TA, Magruder JT, Crawford T, Gardner JM, et al. Staphylococcus Aureus Prevention Strategies in Cardiac Surgery: A Cost-Effectiveness Analysis. The Annals of thoracic surgery. 2018;105(1):47-53.
16.    Itoga NK, Minami HR, Chelvakumar M, Pearson K, Mell MM, Bendavid E, et al. Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test. Vascular medicine (London, England). 2018:1358863x17745371.
17.    Jansons P, Robins L, O'Brien L, Haines T. Gym-based exercise was more costly compared with home-based exercise with telephone support when used as maintenance programs for adults with chronic health conditions: cost-effectiveness analysis of a randomised trial. Journal of physiotherapy. 2018;64(1):48-54.
18.    Kassebaum NJ, McQueen K. The Role of Cost-Effectiveness Analysis in Global Anesthesia. Anesthesia and analgesia. 2018.
19.    Kumar S, Jones Bell M, Juusola JL. Mobile and traditional cognitive behavioral therapy programs for generalized anxiety disorder: A cost-effectiveness analysis. PloS one. 2018;13(1):e0190554.
20.    Kumar V, Cohen JT, van Klaveren D, Soeteman DI, Wong JB, Neumann PJ, et al. Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis. Annals of internal medicine. 2018;168(3):161-9.
21.    Lee TH, Kim W, Shin J, Park EC, Park S, Kim TH. Strategic Distributional Cost-Effectiveness Analysis for Improving National Cancer Screening Uptake in Cervical Cancer: A Focus on Regional Inequality in South Korea. Cancer research and treatment : official journal of Korean Cancer Association. 2018;50(1):212-21.
22.    Leung HW, Chan AL, Wang SY. Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer - real world claim data. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2018:1078155218755548.
23.    Li J, Yip BHK, Leung C, Chung W, Kwok KO, Chan EYY, et al. Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area. PloS one. 2018;13(1):e0189531.
24.    Manchikanti L, Pampati V, Kaye AD, Hirsch JA. Therapeutic lumbar facet joint nerve blocks in the treatment of chronic low back pain: cost utility analysis based on a randomized controlled trial. The Korean journal of pain. 2018;31(1):27-38.
25.    Miyayasu A, Kanazawa M, Jo A, Sato Y, Minakuchi S. Cost-effectiveness analysis of two impression methods for the fabrication of mandibular complete dentures. Journal of dentistry. 2018;68:98-103.
26.    Mohr NM, Stoltze A, Ahmed A, Kiscaden E, Shane D. Using continuous quantitative capnography for emergency department procedural sedation: a systematic review and cost-effectiveness analysis. Internal and emergency medicine. 2018;13(1):75-85.
27.    Nshimyumukiza L, Beaumont JA, Duplantie J, Langlois S, Little J, Audibert F, et al. Cell-Free DNA-Based Non-invasive Prenatal Screening for Common Aneuploidies in a Canadian Province: A Cost-Effectiveness Analysis. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 2018;40(1):48-60.
28.    Patel R, Powell JT, Sweeting MJ, Epstein DM, Barrett JK, Greenhalgh RM. The UK EndoVascular Aneurysm Repair (EVAR) randomised controlled trials: long-term follow-up and cost-effectiveness analysis. Health technology assessment (Winchester, England). 2018;22(5):1-132.
29.    Pattamatta M, Smeets BJJ, Evers S, Rutten HJT, Luyer MDP, Hiligsmann M. Health-related quality of life and cost-effectiveness analysis of gum chewing in patients undergoing colorectal surgery: results of a randomized controlled trial. Acta chirurgica Belgica. 2018:1-8.
30.    Peng S, Deger KA, Ustyugova A, Gandhi P, Qiao N, Wang C, et al. Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries. Current medical research and opinion. 2018;34(1):55-63.
31.    Restelli U, Alberti A, Lazzarin A, Bonfanti M, Nappi C, Croce D. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. The European journal of health economics : HEPAC : health economics in prevention and care. 2018;19(1):37-44.
32.    Sarker AR, Sultana M, Mahumud RA, Van Der Meer R, Morton A. Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh. Human vaccines & immunotherapeutics. 2018;14(1):189-98.
33.    Scangas GA, Lehmann AE, Remenschneider AK, Su BM, Shrime MG, Metson R. The value of frontal sinusotomy for chronic rhinosinusitis with nasal polyps-A cost utility analysis. The Laryngoscope. 2018;128(1):43-51.
34.    Sridharan ND, Boitet A, Smith K, Noorbakhsh K, Avgerinos E, Eslami MH, et al. Cost-effectiveness analysis of drug-coated therapies in the superficial femoral artery. Journal of vascular surgery. 2018;67(1):343-52.
35.    Suh CH, Kim KW, Park SH, Shin S, Ahn J, Pyo J, et al. A cost-effectiveness analysis of the diagnostic strategies for differentiating focal nodular hyperplasia from hepatocellular adenoma. European radiology. 2018;28(1):214-25.
36.    Tuffaha HW, Mitchell A, Ward RL, Connelly L, Butler JRG, Norris S, et al. Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers. Genetics in medicine : official journal of the American College of Medical Genetics. 2018.
37.    Turner I, Kennedy J, Morris S, Crockard A, Choi D. Surgery and Radiotherapy for Symptomatic Spinal Metastases Is More Cost Effective Than Radiotherapy Alone: A Cost Utility Analysis in a U.K. Spinal Center. World neurosurgery. 2018;109:e389-e97.
38.    Ulchaker JC, Martinson MS. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. ClinicoEconomics and outcomes research : CEOR. 2018;10:29-43.
39.    Voon HY, Shafie AA, Bujang MA, Suharjono HN. Cost effectiveness analysis of carbetocin during cesarean section in a high volume maternity unit. The journal of obstetrics and gynaecology research. 2018;44(1):109-16.
40.    Wein B, Kaiser C. Prasugrel vs clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts - Response to the letter to the Editor. International journal of cardiology. 2018;251:33.
41.    Wu B, Zhang S, Lin H, Mou S. Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: A cost-effectiveness analysis. Journal of diabetes investigation. 2018;9(1):152-61.
42.    Zemplenyi AT, Kalo Z, Kovacs G, Farkas R, Beothe T, Banyai D, et al. Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. European journal of cancer care. 2018;27(1).
43.    Zhang XH, Leeuwenkamp O, Oh KB, Lee YE, Kim CM. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea. Human vaccines & immunotherapeutics. 2018;14(1):85-94.
44.    Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA. A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK. The European journal of health economics : HEPAC : health economics in prevention and care. 2018;19(1):21-35.


December 2017

1.    Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ (Clinical research ed). 2017;359:j5631.
2.    Albright RH, Haller S, Klein E, Baker JR, Weil L, Jr., Weil LS, Sr., et al. Cost-Effectiveness Analysis of Primary Arthrodesis Versus Open Reduction Internal Fixation for Primarily Ligamentous Lisfranc Injuries. The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons. 2017.
3.    Avsar P, Karadag A. Efficacy and Cost-Effectiveness Analysis of Evidence-Based Nursing Interventions to Maintain Tissue Integrity to Prevent Pressure Ulcers and Incontinence-Associated Dermatitis. Worldviews on evidence-based nursing. 2017.
4.    Bierbaum M, Schoffski O, Schliemann B, Kosters C. Cost-utility analysis of dynamic intraligamentary stabilization versus early reconstruction after rupture of the anterior cruciate ligament. Health economics review. 2017;7(1):8.
5.    Casado LF, Hernandez JA, Jarque I, Echave M, Casado MA, Castro A. Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia. European journal of haematology. 2017.
6.    Cazarim MS, da Cruz-Cazarim ELC, Baldoni AO, Dos Santos TBE, de Souza PG, Silva IA, et al. Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus. Diabetes & metabolic syndrome. 2017;11 Suppl 2:S859-s65.
7.    Chang HH, Chen PL, Chen IM, Kuo TT, Weng ZC, Huang PJ, et al. Cost-utility analysis of direct ventricular assist device vs double bridges to heart transplantation in patients with refractory heart failure. Clinical transplantation. 2017;31(12).
8.    Dawoud D, Fenu E, Higgins B, Wonderling D, Amiel SA. Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Cost-Utility Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(10):1279-87.
9.    Eaton Turner E, Jenks M. Cost-effectiveness analysis of the use of high-flow oxygen through nasal cannula in intensive care units in NHS England. Expert review of pharmacoeconomics & outcomes research. 2017:1-7.
10.    Einerson BD, Stehlikova Z, Nelson RE, Bellows BK, Kawamoto K, Clark EAS. Transfusion Preparedness Strategies for Obstetric Hemorrhage: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2017;130(6):1347-55.
11.    Felipe C, Tedesco-Silva H, Ferreira Brigido A, Bessa A, Ruppel P, Hiramoto L, et al. Cost-Effectiveness Analysis of Everolimus versus Mycophenolate in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis for Cytomegalovirus Infection: A Short-Term Pharmacoeconomic Evaluation (12 Months). Value in health regional issues. 2017;14:108-15.
12.    Fong Soe Khioe R, Skedgel C, Hart A, Lewis MPN, Alexandre L. Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis. PharmacoEconomics. 2017.
13.    Geskin L, Malone DC. An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma. The Journal of dermatological treatment. 2017:1-9.
14.    Go DS, Kim SH, Park J, Ryu DR, Lee HJ, Jo MW. Cost-utility Analysis of the National Health Screening Program for Chronic Kidney Disease in Korea. Nephrology (Carlton, Vic). 2017.
15.    Gordon LG, Hyland CA, Hyett JA, O'Brien H, Millard G, Flower RL, et al. Noninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia: A cost-effectiveness analysis. Prenatal diagnosis. 2017;37(12):1245-53.
16.    Guo K, Zheng X, Li D, Wu Y, Ji Q, Wang Z. Cost-effectiveness analysis in papillary thyroid carcinoma patients with different neck dissection strategy: A retrospective cohort study. International journal of surgery (London, England). 2017;50:1-5.
17.    Hansen KS, Clarke SE, Lal S, Magnussen P, Mbonye AK. Cost-effectiveness analysis of introducing malaria diagnostic testing in drug shops: A cluster-randomised trial in Uganda. PloS one. 2017;12(12):e0189758.
18.    Henry N, Jovanovic J, Schlueter M, Kritikou P, Wilson K, Myren KJ. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden. Journal of medical economics. 2017:1-8.
19.    Hong JC, Padula WV, Hollin IL, Hussain T, Dietz KB, Halbert JP, et al. Care Management to Reduce Disparities and Control Hypertension in Primary Care: A Cost-effectiveness Analysis. Medical care. 2017.
20.    Hugo A, Makinde OD, Kumar S, Chibwana FF. Optimal control and cost effectiveness analysis for Newcastle disease eco-epidemiological model in Tanzania. Journal of biological dynamics. 2017;11(1):190-209.
21.    Ikeme S, Weltert L, Lewis KM, Bothma G, Cianciulli D, Pay N, et al. Cost-effectiveness analysis of a sealing hemostat patch (HEMOPATCH) vs standard of care in cardiac surgery. Journal of medical economics. 2017:1-9.
22.    James R, Salton RI, Byrnes JM, Scuffham PA. Cost-utility analysis for bariatric surgery compared with usual care for the treatment of obesity in Australia. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2017;13(12):2012-20.
23.    Jansons P, Robins L, O'Brien L, Haines T. Gym-based exercise was more costly compared with home-based exercise with telephone support when used as maintenance programs for adults with chronic health conditions: cost-effectiveness analysis of a randomised trial. Journal of physiotherapy. 2018;64(1):48-54.
24.    Jendle J, Ericsson A, Hunt B, Valentine WJ, Pollock RF. Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2017.
25.    Kamphuis EI, Naber SK, Danhof NA, Habbema JDF, de Groot CJM, Mol BWJ. Effect of Cervical Cancer Screening Programs on Preterm Birth: A Decision and Cost-Effectiveness Analysis. Obstetrics and gynecology. 2017;130(6):1207-17.
26.    Keskey RC, LaJoie AS, Sutton BS, Kim IK, Cheadle WG, McMasters KM, et al. Cost-effectiveness Analysis of Contralateral Prophylactic Mastectomy Compared to Unilateral Mastectomy with Routine Surveillance for Unilateral, Sporadic Breast Cancer. Annals of surgical oncology. 2017;24(13):3903-10.
27.    Klijn SL, van den Reek J, van de Wetering G, van der Kolk A, de Jong E, Kievit W. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE. The British journal of dermatology. 2017.
28.    Kodera S, Kiyosue A, Ando J, Akazawa H, Morita H, Watanabe M, et al. Cost-Effectiveness Analysis of Cardiovascular Disease Treatment in Japan. International heart journal. 2017;58(6):847-52.
29.    Laiteerapong N, Cooper JM, Skandari MR, Clarke PM, Winn AN, Naylor RN, et al. Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. Annals of internal medicine. 2017.
30.    Li K, Cannon JGD, Jiang SY, Sambare TD, Owens DK, Bendavid E, et al. Diagnostic staging laparoscopy in gastric cancer treatment: A cost-effectiveness analysis. Journal of surgical oncology. 2017.
31.    Lim G, Melnyk V, Facco FL, Waters JH, Smith KJ. Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage. Anesthesiology. 2017.
32.    Mandeville KL, Hanson K, Muula AS, Dzowela T, Ulaya G, Lagarde M. Specialty training for the retention of Malawian doctors: A cost-effectiveness analysis. Social science & medicine (1982). 2017;194:87-95.
33.    Mason JM, Thomas KS, Ormerod AD, Craig FE, Mitchell E, Norrie J, et al. Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial. The British journal of dermatology. 2017;177(6):1527-36.
34.    Mezquita-Raya P, Darba J, Ascanio M, Ramirez de Arellano A. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective. Expert review of pharmacoeconomics & outcomes research. 2017;17(6):587-95.
35.    Mori AT, Kampata L, Musonda P, Johansson KA, Robberstad B, Sandoy I. Cost-benefit and extended cost-effectiveness analysis of a comprehensive adolescent pregnancy prevention program in Zambia: study protocol for a cluster randomized controlled trial. Trials. 2017;18(1):604.
36.    Morina D, de Sanjose S, Diaz M. Impact of model calibration on cost-effectiveness analysis of cervical cancer prevention. Scientific reports. 2017;7(1):17208.
37.    Okafor CE, Ekwunife OI. Cost-effectiveness analysis of diarrhoea management approaches in Nigeria: A decision analytical model. PLoS neglected tropical diseases. 2017;11(12):e0006124.
38.    Olmedo D, Brotons-Segui M, Del Toro C, Gonzalez M, Requena C, Traves V, et al. Use of Lymph Node Ultrasound Prior to Sentinel Lymph Node Biopsy in 384 Patients with Melanoma: A Cost-Effectiveness Analysis. Actas dermo-sifiliograficas. 2017;108(10):931-8.
39.    Parker B, Buchanan J, Wordsworth S, Keshav S, George B, East JE. Surgery versus surveillance in ulcerative colitis patients with endoscopically invisible low-grade dysplasia: a cost-effectiveness analysis. Gastrointestinal endoscopy. 2017;86(6):1088-99.e5.
40.    Psota M, Psenkova MB, Racekova N, Ramirez de Arellano A, Vandebrouck T, Hunt B. Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system. ClinicoEconomics and outcomes research : CEOR. 2017;9:749-62.
41.    Rao C, Smith FM, Martin AP, Dhadda AS, Stewart A, Gollins S, et al. A Cost-Effectiveness Analysis of Contact X-ray Brachytherapy for the Treatment of Patients with Rectal Cancer Following a Partial Response to Chemoradiotherapy. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017.
42.    Reyes-Uruena J, Campbell C, Diez E, Ortun V, Casabona J. Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment. AIDS care. 2017:1-9.
43.    Rognoni C, Ciani O, Sommariva S, Tarricone R. Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma. Journal of comparative effectiveness research. 2017.
44.    Schrader AJ, Tribble DR, Riddle MS. Strategies to Improve Management of Acute Watery Diarrhea during a Military Deployment: A Cost Effectiveness Analysis. The American journal of tropical medicine and hygiene. 2017;97(6):1857-66.
45.    Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, et al. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(35):3949-55.
46.    Skeith AE, Niu B, Valent AM, Tuuli MG, Caughey AB. Adding Azithromycin to Cephalosporin for Cesarean Delivery Infection Prophylaxis: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2017;130(6):1279-84.
47.    Spackman E, Hinde S, Bojke L, Payne K, Sculpher M. Using Cost-Effectiveness Analysis to Quantify the Value of Genomic-Based Diagnostic Tests: Recommendations for Practice and Research. Genetic testing and molecular biomarkers. 2017;21(12):705-16.
48.    Tesar T, Szilberhorn L, Nemeth B, Nagy B, Wawruch M, Kalo Z. Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer. Frontiers in pharmacology. 2017;8:946.
49.    Trigo-Vicente C, Gimeno-Ballester V, Montoiro-Allue R, Lopez-Del Val A. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain. Expert review of pharmacoeconomics & outcomes research. 2017:1-9.
50.    Tseng CC, Lai MT, Wu CC, Yuan SP, Ding YF. Cost-effectiveness analysis of endoscopic tympanoplasty versus microscopic tympanoplasty for chronic otitis media in Taiwan. Journal of the Chinese Medical Association : JCMA. 2017.
51.    Tsukiyama I, Ejiri M, Yamamoto Y, Nakao H, Yoneda M, Matsuura K, et al. A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan. Journal of gastrointestinal cancer. 2017;48(4):326-32.
52.    van Mens K, Lokkerbol J, Janssen R, van Orden ML, Kloos M, Tiemens B. A Cost-Effectiveness Analysis to Evaluate a System Change in Mental Healthcare in the Netherlands for Patients with Depression or Anxiety. Administration and policy in mental health. 2017.
53.    van Tilborg TC, Oudshoorn SC, Eijkemans MJC, Mochtar MH, van Golde RJT, Hoek A, et al. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis. Human reproduction (Oxford, England). 2017;32(12):2485-95.
54.    Walter E, Dellago H, Grillari J, Dimai HP, Hackl M. Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population. Bone. 2017;108:44-54.
55.    Wein B, Coslovsky M, Jabbari R, Galatius S, Pfisterer M, Kaiser C. Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts. International journal of cardiology. 2017;248:20-7.
56.    Zaraca F, Vaccarili M, Zaccagna G, Maniscalco P, Dolci G, Feil B, et al. Cost-effectiveness analysis of sealant impact in management of moderate intraoperative alveolar air leaks during video-assisted thoracoscopic surgery lobectomy: a multicentre randomised controlled trial. Journal of thoracic disease. 2017;9(12):5230-8.


November 2017

1.    In Errata: Cost Utility Analysis of Lumbar Interlaminar Epidural Injections in the Treatment of Lumbar Disc Herniation, Central Spinal Stenosis, and Axial or Discogenic Low Back Pain. Pain physician. 2017;20(7):711.
2.    Pershad J, Taylor A, Hall MK, Klimo P. Imaging Strategies for Suspected Acute Cranial Shunt Failure: A Cost-Effectiveness Analysis. Pediatrics. 2017;140(2):e20164263. Pediatrics. 2017;140(5).
3.    Ademi Z, Sutherland CS, Van Stiphout J, Michaud J, Tanackovic G, Schwenkglenks M. A systematic review of cost-effectiveness analysis of screening interventions for assessing the risk of venous thromboembolism in women considering combined oral contraceptives. Journal of thrombosis and thrombolysis. 2017;44(4):494-506.
4.    Aiello A, D'Ausilio A, Lo Muto R, Randon F, Laurenti L. Cost-effectiveness analysis of ibrutinib in patients with Waldenstrom macroglobulinemia in Italy. Journal of market access & health policy. 2017;5(1):1393308.
5.    Amiri A, Goudarzi R, Amiresmaili M, Iranmanesh F. Cost-effectiveness analysis of tissue plasminogen activator in acute ischemic stroke in Iran. Journal of medical economics. 2017:1-6.
6.    Bajre MK, Pennington M, Woznitza N, Beardmore C, Radhakrishnan M, Harris R, et al. Expanding the role of radiographers in reporting suspected lung cancer: A cost-effectiveness analysis using a decision tree model. Radiography (London, England : 1995). 2017;23(4):273-8.
7.    Barriere P, Porcu-Buisson G, Hamamah S. Cost-Effectiveness Analysis of the Gonadotropin Treatments HP-hMG and rFSH for Assisted Reproductive Technology in France: A Markov Model Analysis. Applied health economics and health policy. 2017.
8.    Brown JB, Smith KJ, Gestring ML, Rosengart MR, Billiar TR, Peitzman AB, et al. Comparing the Air Medical Prehospital Triage Score With Current Practice for Triage of Injured Patients to Helicopter Emergency Medical Services: A Cost-effectiveness Analysis. JAMA surgery. 2017.
9.    Candia R, Naimark D, Sander B, Nguyen GC. Cost-utility Analysis: Thiopurines Plus Endoscopy-guided Biological Step-up Therapy is the Optimal Management of Postoperative Crohn's Disease. Inflammatory bowel diseases. 2017;23(11):1930-40.
10.    Choi SE, Brandeau ML, Basu S. Dynamic treatment selection and modification for personalised blood pressure therapy using a Markov decision process model: a cost-effectiveness analysis. BMJ open. 2017;7(11):e018374.
11.    Chomsky-Higgins K, Seib C, Rochefort H, Gosnell J, Shen WT, Kahn JG, et al. Less is more: cost-effectiveness analysis of surveillance strategies for small, nonfunctional, radiographically benign adrenal incidentalomas. Surgery. 2017.
12.    Chong HY, Lim YH, Prawjaeng J, Tassaneeyakul W, Mohamed Z, Chaiyakunapruk N. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population. Pharmacogenetics and genomics. 2017.
13.    Cohen AB. Point-Counterpoint: Cost-Effectiveness Analysis in Medical Care and the Issue of Economic Model Transparency. Medical care. 2017;55(11):907-8.
14.    Cohen JT, Wong JB. Can Economic Model Transparency Improve Provider Interpretation of Cost-Effectiveness Analysis? A Response. Medical care. 2017;55(11):912-4.
15.    Combariza JF, Toro LF, Orozco JJ, Arango M. Cost-effectiveness analysis of interventions for prevention of invasive aspergillosis among leukemia patients during hospital construction activities. European journal of haematology. 2017.
16.    Deshmukh AA, Shirvani SM, Lal L, Swint JM, Cantor SB, Smith BD, et al. Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer. Journal of the National Cancer Institute. 2017;109(11).
17.    Ding H, Fang L, Xin W, Tong Y, Zhou Q, Huang P. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer. European journal of cancer care. 2017;26(6).
18.    Dunning L, Francke JA, Mallampati D, MacLean RL, Penazzato M, Hou T, et al. The value of confirmatory testing in early infant HIV diagnosis programmes in South Africa: A cost-effectiveness analysis. PLoS medicine. 2017;14(11):e1002446.
19.    Geale K, Saridogan E, Lehmann M, Arriagada P, Hultberg M, Henriksson M. Repeated intermittent ulipristal acetate in the treatment of uterine fibroids: a cost-effectiveness analysis. ClinicoEconomics and outcomes research : CEOR. 2017;9:669-76.
20.    Gordon LG, Hyland C, Hyett J, O'Brien H, Millard G, Flower R, et al. Non-invasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia: a cost-effectiveness analysis. Prenatal diagnosis. 2017.
21.    Helou J, Torres S, Musunuru HB, Raphael J, Cheung P, Vesprini D, et al. Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost-Utility Analysis. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017;29(11):718-31.
22.    Hunter R, Wallace P, Struzzo P, Vedova RD, Scafuri F, Tersar C, et al. Randomised controlled non-inferiority trial of primary care-based facilitated access to an alcohol reduction website: cost-effectiveness analysis. BMJ open. 2017;7(11):e014577.
23.    Kantito S, Saokaew S, Yamwong S, Vathesatogkit P, Katekao W, Sritara P, et al. Cost-effectiveness analysis of patient self-testing therapy of oral anticoagulation. Journal of thrombosis and thrombolysis. 2017.
24.    Kardas-Sloma L, Lucet JC, Perozziello A, Pelat C, Birgand G, Ruppe E, et al. Universal or targeted approach to prevent the transmission of extended-spectrum beta-lactamase-producing Enterobacteriaceae in intensive care units: a cost-effectiveness analysis. BMJ open. 2017;7(11):e017402.
25.    Kato MG, Erkul E, Nguyen SA, Day TA, Hornig JD, Lentsch EJ, et al. Extracapsular Dissection vs Superficial Parotidectomy of Benign Parotid Lesions: Surgical Outcomes and Cost-effectiveness Analysis. JAMA otolaryngology-- head & neck surgery. 2017;143(11):1092-7.
26.    Kodera S, Kiyosue A, Ando J, Akazawa H, Morita H, Watanabe M, et al. Cost-Effectiveness Analysis of Cardiovascular Disease Treatment in Japan. International heart journal. 2017.
27.    Lee SR, Kwok KL, Ng DKK, Hon KL. Palivizumab for Infants < 29 Weeks in Hong Kong without a Clear-Cut Season for Respiratory Syncytial Virus Infection-A Cost-Effectiveness Analysis. Journal of tropical pediatrics. 2017.
28.    Liu K, Sun W, Lu Q, Chen J, Tang J. A cost-utility analysis of Dynesys dynamic stabilization versus instrumented fusion for the treatment of degenerative lumbar spine diseases. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association. 2017;22(6):982-7.
29.    Lopez-Lopez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ (Clinical research ed). 2017;359:j5058.
30.    Martini A, Gupta A, Cumarasamy S, Tewari AK. Re: Rita Faria, Marta O. Soares, Eldon Spackman, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.08.018. European urology. 2017.
31.    Neoh CF, Senol E, Kara A, Dinleyici EC, Turner SJ, Kong DCM. Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey. Mycoses. 2017;60(11):714-22.
32.    Padula WV, McQueen RB, Pronovost PJ. Can Economic Model Transparency Improve Provider Interpretation of Cost-effectiveness Analysis? Evaluating Tradeoffs Presented by the Second Panel on Cost-effectiveness in Health and Medicine. Medical care. 2017;55(11):909-11.
33.    Patel R, Ivanov O, Voigt J. Lifetime cost-effectiveness analysis of intraoperative radiation therapy versus external beam radiation therapy for early stage breast cancer. Cost effectiveness and resource allocation : C/E. 2017;15:22.
34.    Raphael J, Helou J, Pritchard KI, Naimark DM. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis. European journal of cancer (Oxford, England : 1990). 2017;85:146-54.
35.    Risor BW, Lisby M, Sorensen J. Comparative Cost-Effectiveness Analysis of Three Different Automated Medication Systems Implemented in a Danish Hospital Setting. Applied health economics and health policy. 2017.
36.    Sacino MF, Huang SS, Keating RF, Gaillard WD, Oluigbo CO. An initial cost-effectiveness analysis of intraoperative magnetic resonance imaging (iMRI) in pediatric epilepsy surgery. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 2017.
37.    Sanchez-Santos R, Padin EM, Adam D, Borisenko O, Fernandez SE, Dacosta EC, et al. Bariatric surgery versus conservative management for morbidly obese patients in Spain: a cost-effectiveness analysis. Expert review of pharmacoeconomics & outcomes research. 2017:1-10.
38.    Sarker AR, Sultana M, Mahumud RA, Van Der Meer R, Morton A. Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh. Human vaccines & immunotherapeutics. 2017:1-10.
39.    Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Kawahara T, et al. Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial. BMC cancer. 2017;17(1):773.
40.    Smith AF, Hall PS, Hulme CT, Dunn JA, McConkey CC, Rahman JK, et al. Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer. European journal of cancer (Oxford, England : 1990). 2017;85:6-14.
41.    Suh CH, Kim KW, Park SH, Kim SY, Woo DC, Shin S, et al. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. AJR American journal of roentgenology. 2017:W1-w7.
42.    Termrungruanglert W, Khemapech N, Tantitamit T, Sangrajrang S, Havanond P, Laowahutanont P. Cost-effectiveness analysis study of HPV testing as a primary cervical cancer screening in Thailand. Gynecologic oncology reports. 2017;22:58-63.
43.    Tobe RG, Martin GR, Li F, Moriichi A, Wu B, Mori R. Cost-effectiveness analysis of neonatal screening of critical congenital heart defects in China. Medicine. 2017;96(46):e8683.
44.    Tringale KR, Carroll KT, Zakeri K, Sacco AG, Barnachea L, Murphy JD. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Journal of the National Cancer Institute. 2017.
45.    Tullberg M, Persson J, Petersen J, Hellstrom P, Wikkelso C, Lundgren-Nilsson A. Shunt surgery in idiopathic normal pressure hydrocephalus is cost-effective-a cost utility analysis. Acta neurochirurgica. 2017.
46.    Wailoo A, Hock ES, Stevenson M, Martyn-St James M, Rawdin A, Simpson E, et al. The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis. Health technology assessment (Winchester, England). 2017;21(71):1-258.
47.    You JHS, Li HK, Ip M. Surveillance-guided selective digestive decontamination of carbapenem-resistant Enterobacteriaceae in the intensive care unit: A cost-effectiveness analysis. American journal of infection control. 2017.
48.    Zhang XH, Leeuwenkamp O, Oh KB, Lee YE, Kim CM. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea. Human vaccines & immunotherapeutics. 2017:1-10.
49.    Zheng HR, Wen F, Wu YF, Wheeler JRC, Li Q. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective. European journal of cancer care. 2017;26(6).
50.    Zhou K, Wen F, Zhang P, Zhou J, Zheng H, Sun L, et al. Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2017.
51.    Zwerling A, Dowdy D, von Delft A, Taylor H, Merritt MW. Incorporating social justice and stigma in cost-effectiveness analysis: drug-resistant tuberculosis treatment. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2017;21(11):69-74.




 October 2017

1.    Erratum to "The impact of nutrition support on clinical outcome and cost-effectiveness analysis in patients at nutritional risk: a prospective cohort study with propensity score matching," Nutrition (2017) 37C, 53-59. Nutrition (Burbank, Los Angeles County, Calif). 2017;42:121.
2.    Aronsson M, Svennberg E, Rosenqvist M, Engdahl J, Al-Khalili F, Friberg L, et al. Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2017;19(10):1650-6.
3.    Bahin FF, Heitman SJ, Rasouli KN, Mahajan H, McLeod D, Lee EYT, et al. Wide-field endoscopic mucosal resection versus endoscopic submucosal dissection for laterally spreading colorectal lesions: a cost-effectiveness analysis. Gut. 2017.
4.    Bethea E, Chen Q, Hur C, Chung RT, Chhatwal J. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology (Baltimore, Md). 2017.
5.    Bove AM, Smith KJ, Bise CG, Fritz JM, Childs J, Brennan GP, et al. Exercise, Manual Therapy, and Booster Sessions in Knee Osteoarthritis: Cost-Effectiveness Analysis from a Multicenter Randomized Controlled Trial. Physical therapy. 2017.
6.    Bulsei J, Darlington M, Durand-Zaleski I, Azizi M. How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example. Blood pressure. 2017:1-7.
7.    Chatroux LR, Savitsky LM, Zwerling B, Williams J, Cahill AG, Caughey AB. Standardizing the Response to Category II Tracings during Induction with Oxytocin: A Cost-Effectiveness Analysis. American journal of perinatology. 2017;34(12):1255-63.
8.    Chouaid C, Luciani L, LeLay K, Do P, Bennouna J, Perol M, et al. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017;12(10):1496-502.
9.    Dubin JM, Greer AB, Kohn TP, Masterson TA, Ji L, Ramasamy R. Men with Severe Oligospermia Appear to Benefit From Varicocele Repair: a Cost-Effectiveness Analysis of Assisted Reproductive Technology. Urology. 2017.
10.    Ghabri S, Mauskopf J. The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges. The European journal of health economics : HEPAC : health economics in prevention and care. 2017.
11.    Godefrooij DA, Mangen MJ, Chan E, O'Brart DPS, Imhof SM, de Wit GA, et al. Cost-Effectiveness Analysis of Corneal Collagen Crosslinking for Progressive Keratoconus. Ophthalmology. 2017;124(10):1485-95.
12.    Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, et al. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. Journal of medical economics. 2017:1-11.
13.    Greuter MJE, de Klerk CM, Meijer GA, Dekker E, Coupe VMH. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis. Annals of internal medicine. 2017;167(8):544-54.
14.    Hajizadeh N, Stevens ER, Applegate M, Huang KY, Kamboukos D, Braithwaite RS, et al. Potential return on investment of a family-centered early childhood intervention: a cost-effectiveness analysis. BMC public health. 2017;17(1):796.
15.    Hong JC, Saraswat MK, Ellison TA, Magruder JT, Crawford T, Gardner JM, et al. Staphylococcus Aureus Prevention Strategies in Cardiac Surgery: A Cost-Effectiveness Analysis. The Annals of thoracic surgery. 2017.
16.    Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, et al. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer. 2017;123(19):3763-71.
17.    Jahn B, Rochau U, Kurzthaler C, Hubalek M, Miksad R, Sroczynski G, et al. Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online. BMC cancer. 2017;17(1):685.
18.    Joish VN, Frech F, Lapuerta P. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. Journal of medical economics. 2017:1-7.
19.    Kim CH, Chung CK, Kim MJ, Choi Y, Kim MJ, Hahn S, et al. Increased volume of lumbar surgeries for herniated intervertebral disc disease and cost-effectiveness analysis: a nationwide cohort study. Spine. 2017.
20.    Kim H, Rajagopalan MS, Beriwal S, Smith KJ. Cost-effectiveness Analysis of Stereotactic Radiosurgery Alone Versus Stereotactic Radiosurgery with Upfront Whole Brain Radiation Therapy for Brain Metastases. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017;29(10):e157-e64.
21.    Mandeville KL, Hanson K, Muula AS, Dzowela T, Ulaya G, Lagarde M. Specialty training for the retention of Malawian doctors: A cost-effectiveness analysis. Social science & medicine (1982). 2017;194:87-95.
22.    Mathewos B, Owen H, Sitrin D, Cousens S, Degefie T, Wall S, et al. Community-Based Interventions for Newborns in Ethiopia (COMBINE): Cost-effectiveness analysis. Health policy and planning. 2017;32(suppl_1):i21-i32.
23.    Miyayasu A, Kanazawa M, Jo A, Sato Y, Minakuchi S. Cost-effectiveness Analysis of Two Impression Methods for the Fabrication of Mandibular Complete Dentures. Journal of dentistry. 2017.
24.    Padula WV, Phelps CE, Moran D, Earley C. Allocating provider resources to diagnose and treat restless legs syndrome: a cost-utility analysis. Sleep medicine. 2017;38:44-9.
25.    Plumpton CO, Alfirevic A, Pirmohamed M, Hughes DA. Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. Rheumatology (Oxford, England). 2017;56(10):1729-39.
26.    Sanchez-Luna M, Burgos-Pol R, Oyaguez I, Figueras-Aloy J, Sanchez-Solis M, Martinon-Torres F, et al. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. BMC infectious diseases. 2017;17(1):687.
27.    Shaikh N, Dando EE, Dunleavy ML, Curran DL, Martin JM, Hoberman A, et al. A Cost-Utility Analysis of 5 Strategies for the Management of Acute Otitis Media in Children. The Journal of pediatrics. 2017;189:54-60.e3.
28.    Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, et al. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017:Jco2017737437.
29.    Simpson AN, Garbens A, Dossa F, Coyte PC, Baxter NN, McDermott CD. A Cost-Utility Analysis of Nonsurgical Treatments for Stress Urinary Incontinence in Women. Female pelvic medicine & reconstructive surgery. 2017.
30.    Spackman E, Hinde S, Bojke L, Payne K, Sculpher M. Using Cost-Effectiveness Analysis to Quantify the Value of Genomic-Based Diagnostic Tests: Recommendations for Practice and Research. Genetic testing and molecular biomarkers. 2017.
31.    Thein HH, Qiao Y, Zaheen A, Jembere N, Sapisochin G, Chan KKW, et al. Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting. PloS one. 2017;12(10):e0185198.
32.    Trenaman L, Stacey D, Bryan S, Taljaard M, Hawker G, Dervin G, et al. Decision aids for patients considering total joint replacement: a cost-effectiveness analysis alongside a randomised controlled trial. Osteoarthritis and cartilage. 2017;25(10):1615-22.
33.    Turner I, Kennedy J, Morris S, Crockard A, Choi D. Surgery and radiotherapy for symptomatic spinal metastases is more cost effective than radiotherapy alone: a cost utility analysis in a UK spinal center. World neurosurgery. 2017.
34.    Udkoff J, Eichenfield LF. Cost-Effectiveness Analysis of Ixekizumab vs Etanercept and Their Manufacturer-Recommended Dosing Regimens in Moderate to Severe Plaque Psoriasis. Journal of drugs in dermatology : JDD. 2017;16(10):964-70.
35.    Ungari AQ, Pereira LRL, Nunes AA, Peria FM. Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school. BMC cancer. 2017;17(1):691.
36.    van den Akker-van Marle ME, Brouwer PA, Brand R, Koes B, van den Hout WB, van Buchem MA, et al. Percutaneous laser disc decompression versus microdiscectomy for sciatica: Cost utility analysis alongside a randomized controlled trial. Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences. 2017;23(5):538-45.
37.    van Klaveren D, Wong JB, Kent DM, Steyerberg EW. Biases in Individualized Cost-effectiveness Analysis: Influence of Choices in Modeling Short-Term, Trial-Based, Mortality Risk Reduction and Post-Trial Life Expectancy. Medical decision making : an international journal of the Society for Medical Decision Making. 2017;37(7):770-8.
38.    Voigt J, Carpenter L, Leuchter A. Cost effectiveness analysis comparing repetitive transcranial magnetic stimulation to antidepressant medications after a first treatment failure for major depressive disorder in newly diagnosed patients - A lifetime analysis. PloS one. 2017;12(10):e0186950.
39.    Voon HY, Shafie AA, Bujang MA, Suharjono HN. Cost effectiveness analysis of carbetocin during cesarean section in a high volume maternity unit. The journal of obstetrics and gynaecology research. 2017.
40.    Walsh TS, Stanworth S, Boyd J, Hope D, Hemmatapour S, Burrows H, et al. The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up. Health technology assessment (Winchester, England). 2017;21(62):1-118.
41.    Wang Y, Xing Y, Chen L, Meng T, Li Y, Xie J, et al. Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis. International journal of hematology. 2017.
42.    Yang H, Duchesneau E, Foster R, Guerin A, Ma E, Thomas NP. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. Journal of medical economics. 2017;20(10):1056-65.
43.    Zhao RC, Zhou J, Wei YG, Liu F, Chen KF, Li Q, et al. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma. Hepatobiliary & pancreatic diseases international : HBPD INT. 2017;16(5):493-8.


September 2017

1.    Ademi Z, Sutherland CS, Van Stiphout J, Michaud J, Tanackovic G, Schwenkglenks M. A systematic review of cost-effectiveness analysis of screening interventions for assessing the risk of venous thromboembolism in women considering combined oral contraceptives. Journal of thrombosis and thrombolysis. 2017.
2.    Akpo EIH, Jansen IR, Maes E, Simoens S. Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer. Frontiers in pharmacology. 2017;8:614.
3.    Barfar E, Sharifi V, Amini H, Mottaghipour Y, Yunesian M, Tehranidoost M, et al. Cost-effectiveness Analysis of an Aftercare Service vs Treatment-As-Usual for Patients with Severe Mental Disorders. The journal of mental health policy and economics. 2017;20(3):101-10.
4.    Borrelli J, Jr. Invited Commentary related to: Cost-Utility Analysis of Reconstruction Compared With Primary Amputation for Patients With Severe Lower Limb Trauma in Colombia. Journal of orthopaedic trauma. 2017;31(9):e294-e5.
5.    Buti M, Dominguez-Hernandez R, Oyaguez I, Casado MA, Esteban R. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. Journal of viral hepatitis. 2017;24(9):750-8.
6.    Ceballos M, Valderrama CO, Orozco LE, Sanchez L, Valderrama JP, Lugo LH. Cost-Utility Analysis of Reconstruction Compared With Primary Amputation for Patients With Severe Lower Limb Trauma in Colombia. Journal of orthopaedic trauma. 2017;31(9):e288-e94.
7.    Chang HH, Chen PL, Chen IM, Kuo TT, Weng ZC, Huang PJ, et al. Cost-utility analysis of direct VAD versus double bridges to heart transplantation in patients with refractory heart failure. Clinical transplantation. 2017.
8.    Chatroux LR, Savitsky LM, Zwerling B, Williams J, Cahill AG, Caughey AB. Standardizing the Response to Category II Tracings during Induction with Oxytocin: A Cost-Effectiveness Analysis. American journal of perinatology. 2017;34(12):1255-63.
9.    Cohen JT, Neumann PJ, Wong JB. A Call for Open-Source Cost-Effectiveness Analysis. Annals of internal medicine. 2017;167(6):432-3.
10.    Faria R, Soares MO, Spackman E, Ahmed HU, Brown LC, Kaplan R, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). European urology. 2017.
11.    Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, et al. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. Journal of medical economics. 2017:1-21.
12.    Goranitis I, Bellanca L, Daley AJ, Thomas A, Stokes-Lampard H, Roalfe AK, et al. Aerobic exercise for vasomotor menopausal symptoms: A cost-utility analysis based on the Active Women trial. PloS one. 2017;12(9):e0184328.
13.    Gray E, Donten A, Karssemeijer N, van Gils C, Evans DG, Astley S, et al. Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(8):1100-9.
14.    Griffin EA, Wonderling D, Ludman AJ, Al-Mohammad A, Cowie MR, Hardman SMC, et al. Cost-Effectiveness Analysis of Natriuretic Peptide Testing and Specialist Management in Patients with Suspected Acute Heart Failure. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(8):1025-33.
15.    Heinzel A, Muller D, Yekta-Michael SS, Ceccon G, Langen KJ, Mottaghy FM, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis. Neuro-oncology. 2017;19(9):1271-8.
16.    Helou J, Torres S, Musunuru HB, Raphael J, Cheung P, Vesprini D, et al. Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost-Utility Analysis. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017;29(11):718-31.
17.    Iannazzo S, Cortesi PA, Crea R, Steinitz K, Mantovani LG, Gringeri A. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2017;28(6):425-30.
18.    Isaranuwatchai W, Perdrizet J, Markle-Reid M, Hoch JS. Cost-effectiveness analysis of a multifactorial fall prevention intervention in older home care clients at risk for falling. BMC geriatrics. 2017;17(1):199.
19.    Jendle J, Smith-Palmer J, Delbaere A, de Portu S, Papo N, Valentine W, et al. Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2017.
20.    Jowett S, Barton P, Roalfe A, Fletcher K, Hobbs FDR, McManus RJ, et al. Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease. PloS one. 2017;12(9):e0182625.
21.    Kato MG, Erkul E, Nguyen SA, Day TA, Hornig JD, Lentsch EJ, et al. Extracapsular Dissection vs Superficial Parotidectomy of Benign Parotid Lesions: Surgical Outcomes and Cost-effectiveness Analysis. JAMA otolaryngology-- head & neck surgery. 2017.
22.    Mason JM, Chalmers JR, Godec T, Nunn AJ, Kirtschig G, Wojnarowska F, et al. Doxycycline compared to prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial. The British journal of dermatology. 2017.
23.    Moreno Guillen S, Losa Garcia JE, Berenguer Berenguer J, Martinez Sesmero JM, Cenoz Gomis S, Graefenhain R, et al. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2017;41(5):601-10.
24.    Pearson-Stuttard J, Hooton W, Critchley J, Capewell S, Collins M, Mason H, et al. Cost-effectiveness analysis of eliminating industrial and all trans fats in England and Wales: modelling study. Journal of public health (Oxford, England). 2017;39(3):574-82.
25.    Peng S, Deger KA, Ustyugova A, Gandhi P, Qiao N, Wang C, et al. Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries. Current medical research and opinion. 2017:1-9.
26.    Raphael J, Helou J, Pritchard KI, Naimark DM. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis. European journal of cancer (Oxford, England : 1990). 2017;85:146-54.
27.    Sadler S, Tosh J, Pennington R, Rawdin A, Squires H, Romero C, et al. A cost-effectiveness analysis of condom distribution programmes for the prevention of sexually transmitted infections in England. Journal of epidemiology and community health. 2017;71(9):897-904.
28.    Schawo S, Bouwmans C, van der Schee E, Hendriks V, Brouwer W, Hakkaart L. The search for relevant outcome measures for cost-utility analysis of systemic family interventions in adolescents with substance use disorder and delinquent behavior: a systematic literature review. Health and quality of life outcomes. 2017;15(1):179.
29.    Schrader AJ, Tribble DR, Riddle MS. Strategies to Improve Management of Acute Watery Diarrhea during a Military Deployment: A Cost Effectiveness Analysis. The American journal of tropical medicine and hygiene. 2017.
30.    Shechter SM, Chandler T, Skandari MR, Zalunardo N. Cost-effectiveness Analysis of Vascular Access Referral Policies in CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2017;70(3):368-76.
31.    Smith AF, Hall PS, Hulme CT, Dunn JA, McConkey CC, Rahman JK, et al. Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer. European journal of cancer (Oxford, England : 1990). 2017;85:6-14.
32.    Sridharan ND, Boitet A, Smith K, Noorbakhsh K, Avgerinos E, Eslami MH, et al. Cost-effectiveness analysis of drug-coated therapies in the superficial femoral artery. Journal of vascular surgery. 2017.
33.    Stamuli E, Kesornsak W, Grevitt MP, Posnett J, Claxton K. A Cost-Effectiveness Analysis of Intradiscal Electrothermal Therapy (IDET) Compared with Circumferential Lumbar Fusion. Pain practice : the official journal of World Institute of Pain. 2017.
34.    Surendrakumar V, Hossain MA, Pettigrew G. Regarding "A randomized controlled trial and cost-effectiveness analysis of early cannulation arteriovenous grafts versus tunneled central venous catheters in patients requiring urgent vascular access for hemodialysis". Journal of vascular surgery. 2017;66(3):969.
35.    Thein HH, Isaranuwatchai W, Qiao Y, Wong K, Sapisochin G, Chan KKW, et al. Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting. Cancer medicine. 2017;6(9):2017-33.
36.    Thorrington D, van Leeuwen E, Ramsay M, Pebody R, Baguelin M. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England. BMC medicine. 2017;15(1):166.
37.    Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, et al. Corrigendum to "Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy" [Eur J Cancer 67 (2016) 38-45]. European journal of cancer (Oxford, England : 1990). 2017;82:247.
38.    van Katwyk S, Jin YP, Trope GE, Buys Y, Masucci L, Wedge R, et al. Cost-Utility Analysis of Extending Public Health Insurance Coverage to Include Diabetic Retinopathy Screening by Optometrists. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(8):1034-40.
39.    Watanabe T, Yamamoto S, Gotoh M, Saitoh T, Yokoyama O, Murata T, et al. Cost-Effectiveness Analysis of Long-Term Intermittent Self-Catheterization with Hydrophilic-Coated and Uncoated Catheters in Patients with Spinal Cord Injury in Japan. Lower urinary tract symptoms. 2017;9(3):142-50.
40.    Wein AJ. Re: Cost-Effectiveness Analysis of Anticholinergics versus Botox for Urgency Urinary Incontinence: Results from the Anticholinergic versus Botox Comparison Randomized Trial. The Journal of urology. 2017;198(3):487-92.


August 2017

1.    Arora M, Harvey LA, Glinsky JV, Chhabra HS, Hossain MS, Arumugam N, et al. Cost-effectiveness analysis of telephone-based support for the management of pressure ulcers in people with spinal cord injury in India and Bangladesh. Spinal cord. 2017.
2.    Borisenko O, Mann O, Dupree A. Cost-utility analysis of bariatric surgery compared with conventional medical management in Germany: a decision analytic modeling. BMC surgery. 2017;17(1):87.
3.    Borse MS, Dong OM, Polasek MJ, Farley JF, Stouffer GA, Lee CR. CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. Pharmacogenomics. 2017;18(12):1155-66.
4.    Cheng Q, Lazzarini PA, Gibb M, Derhy PH, Kinnear EM, Burn E, et al. A cost-effectiveness analysis of optimal care for diabetic foot ulcers in Australia. International wound journal. 2017;14(4):616-28.
5.    Cohen JT, Neumann PJ, Wong JB. A Call for Open-Source Cost-Effectiveness Analysis. Annals of internal medicine. 2017.
6.    Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. The Lancet Public health. 2017;2(8):e367-e74.
7.    Crowson MG, Rocke DJ, Hoang JK, Weissman JL, Kaylie DM. Cost-effectiveness analysis of a non-contrast screening MRI protocol for vestibular schwannoma in patients with asymmetric sensorineural hearing loss. Neuroradiology. 2017;59(8):727-36.
8.    Devine A, Harvey R, Min AM, Gilder MET, Paw MK, Kang J, et al. Strategies for the prevention of perinatal hepatitis B transmission in a marginalized population on the Thailand-Myanmar border: a cost-effectiveness analysis. BMC infectious diseases. 2017;17(1):552.
9.    Elhennawy K, Jost-Brinkmann PG, Manton DJ, Paris S, Schwendicke F. Managing molars with severe molar-incisor hypomineralization: A cost-effectiveness analysis within German healthcare. Journal of dentistry. 2017;63:65-71.
10.    Garrido G, Penades R, Barrios M, Aragay N, Ramos I, Valles V, et al. Computer-assisted cognitive remediation therapy in schizophrenia: Durability of the effects and cost-utility analysis. Psychiatry research. 2017;254:198-204.
11.    Heisen M, Treur MJ, Heemstra HE, Giesen EBW, Postma MJ. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands. Journal of medical economics. 2017;20(8):813-24.
12.    Hong JC, Blankstein R, Shaw LJ, Padula WV, Arrieta A, Fialkow JA, et al. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines: A Cost-Effectiveness Analysis. JACC Cardiovascular imaging. 2017;10(8):938-52.
13.    Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, et al. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. Jama. 2017;318(8):748-50.
14.    Khouja T, Smith KJ. Cost-effectiveness analysis of two caries prevention methods in the first permanent molar in children. Journal of public health dentistry. 2017.
15.    Kiatos E, Armstrong JJ, Hutnik CM, Tsioros SM, Malvankar-Mehta MS, Hodge WG. The value of corneoscleral rim cultures in keratoplasty: a systematic review and cost-effectiveness analysis. ClinicoEconomics and outcomes research : CEOR. 2017;9:459-74.
16.    Lee HD, Jeon CH, Chung NS, Seo YW. Cost-Utility Analysis of Pedicle Screw Removal After Successful Posterior Instrumented Fusion in Thoracolumbar Burst Fractures. Spine. 2017;42(15):E926-e32.
17.    Leung VC, Pechlivanoglou P, Chew HF, Hatch W. Corneal Collagen Cross-Linking in the Management of Keratoconus in Canada: A Cost-Effectiveness Analysis. Ophthalmology. 2017;124(8):1108-19.
18.    Lindemark F, Haaland OA, Kvale R, Flaatten H, Norheim OF, Johansson KA. Costs and expected gain in lifetime health from intensive care versus general ward care of 30,712 individual patients: a distribution-weighted cost-effectiveness analysis. Critical care (London, England). 2017;21(1):220.
19.    Liu K, Sun W, Lu Q, Chen J, Tang J. A cost-utility analysis of Dynesys dynamic stabilization versus instrumented fusion for the treatment of degenerative lumbar spine diseases. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association. 2017.
20.    Meulen MPV, Kapidzic A, Leerdam MEV, van der Steen A, Kuipers EJ, Spaander MCW, et al. Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2017;26(8):1328-36.
21.    Nakamura A, Kojima Y, Miyazawa K, Matsumoto S, Iida H, Nagai H. Clinical Impact of Aprepitant in Patients Receiving High-Dose Chemotherapy prior to Autologous Peripheral Blood Stem Cell Transplantation: A Cost-Effectiveness Analysis. Oncology. 2017.
22.    Ngalesoni F, Ruhago G, Mayige M, Oliveira TC, Robberstad B, Norheim OF, et al. Cost-effectiveness analysis of population-based tobacco control strategies in the prevention of cardiovascular diseases in Tanzania. PloS one. 2017;12(8):e0182113.
23.    Nshimyumukiza L, Beaumont JA, Duplantie J, Langlois S, Little J, Audibert F, et al. Cell-Free DNA-Based Non-invasive Prenatal Screening for Common Aneuploidies in a Canadian Province: A Cost-Effectiveness Analysis. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 2017.
24.    Olmedo D, Brotons-Segui M, Del Toro C, Gonzalez M, Requena C, Traves V, et al. Use of Lymph Node Ultrasound Prior to Sentinel Lymph Node Biopsy in 384 Patients with Melanoma: A Cost-Effectiveness Analysis. Actas dermo-sifiliograficas. 2017.
25.    Pandey S, Tyagi R. Re: Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis: Cost-effectiveness in recurrent endometriosis prevention. BJOG : an international journal of obstetrics and gynaecology. 2017.
26.    Paquete AT, Miguel LS, Becker U, Pereira C, Pinto CG. Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy. Applied health economics and health policy. 2017;15(4):501-12.
27.    Pershad J, Taylor A, Hall MK, Klimo P, Jr. Imaging Strategies for Suspected Acute Cranial Shunt Failure: A Cost-Effectiveness Analysis. Pediatrics. 2017;140(2).
28.    Russell LB, Bhanot G, Kim SY, Sinha A. Using Cluster Analysis to Group Countries for Cost-Effectiveness Analysis: An Application to Sub-Saharan Africa. Medical decision making : an international journal of the Society for Medical Decision Making. 2017:272989x17724773.
29.    Sanchez Fernandez I, Gainza-Lein M, Loddenkemper T. Nonintravenous rescue medications for pediatric status epilepticus: A cost-effectiveness analysis. Epilepsia. 2017;58(8):1349-59.
30.    Scangas GA, Lehmann AE, Remenschneider AK, Su BM, Shrime MG, Metson R. The value of frontal sinusotomy for chronic rhinosinusitis with nasal polyps-A cost utility analysis. The Laryngoscope. 2017.
31.    Seagle BL, Miller ES, Strohl AE, Hoekstra A, Shahabi S. Transversus abdominis plane block with liposomal bupivacaine compared to oral opioids alone for acute postoperative pain after laparoscopic hysterectomy for early endometrial cancer: a cost-effectiveness analysis. Gynecologic oncology research and practice. 2017;4:12.
32.    Taipale K, Winfree KB, Boye M, Basson M, Sleilaty G, Eaton J, et al. A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France. ClinicoEconomics and outcomes research : CEOR. 2017;9:505-18.
33.    Thavorn K, Coyle D, Hoch JS, Vandermeer L, Mazzarello S, Wang Z, et al. A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017;25(8):2505-13.
34.    Thein HH, Isaranuwatchai W, Qiao Y, Wong K, Sapisochin G, Chan KKW, et al. Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting. Cancer medicine. 2017.
35.    Truzzi JC, Teich V, Pepe C. Can hydrophilic coated catheters be beneficial for the public healthcare system in Brazil? - A cost-effectiveness analysis in patients with spinal cord injuries. International braz j urol : official journal of the Brazilian Society of Urology. 2017;43.
36.    Vaidya A, Vaidya P, Both B, Brew-Graves C, Bulsara M, Vaidya JS. Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ open. 2017;7(8):e014944.
37.    Wang XJ, Saha A, Zhang XH. Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia. Cost effectiveness and resource allocation : C/E. 2017;15:17.
38.    Wein B, Coslovsky M, Jabbari R, Galatius S, Pfisterer M, Kaiser C. Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts. International journal of cardiology. 2017.
39.    Whittington MD, Atherly AJ, Curtis DJ, Lindrooth RC, Bradley CJ, Campbell JD. Recommendations for Methicillin-Resistant Staphylococcus aureus Prevention in Adult ICUs: A Cost-Effectiveness Analysis. Critical care medicine. 2017;45(8):1304-10.
40.    Zhan M, Zheng H, Xu T, Yang Y, Li Q. Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial. Lung cancer (Amsterdam, Netherlands). 2017;110:1-6.
41.    Zheng H, Xie L, Zhan M, Wen F, Xu T, Li Q. Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2017.




 July 2017

1.    Bansback N, Phibbs CS, Sun H, O'Dell JR, Brophy M, Keystone EC, et al. Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. Annals of internal medicine. 2017;167(1):8-16.
2.    Borrelli J, Jr. Invited Commentary: Cost-Utility Analysis of Reconstruction Versus Primary Amputation for Type IIIB and Type C Open Tibia Fractures. Journal of orthopaedic trauma. 2017.
3.    Borse MS, Dong OM, Polasek MJ, Farley JF, Stouffer GA, Lee CR. CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. Pharmacogenomics. 2017;18(12):1155-66.
4.    Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren's Syndrome. Arthritis & rheumatology (Hoboken, NJ). 2017;69(7):1440-50.
5.    Buchanan J, Wordsworth S, Clifford R, Robbe P, Taylor JC, Schuh A, et al. Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis. PharmacoEconomics. 2017.
6.    Burgers LT, Redekop WK, Al MJ, Lhachimi SK, Armstrong N, Walker S, et al. Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients. The European journal of health economics : HEPAC : health economics in prevention and care. 2017;18(6):731-42.
7.    Cazarim MS, da Cruz-Cazarim ELC, Baldoni AO, Dos Santos TBE, de Souza PG, Silva IA, et al. Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus. Diabetes & metabolic syndrome. 2017.
8.    Chouaid C, Luciani L, LeLay K, Do P, Bennouna J, Perol M, et al. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for first line treatment of advanced EGFR-Mutated Advanced Non-Small-Cell Lung Cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017.
9.    Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, et al. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis. Liver international : official journal of the International Association for the Study of the Liver. 2017;37(7):982-94.
10.    Clarke M, Fursse J, Connolly N, Sharma U, Jones R. Evaluation of the National Health Service (NHS) Direct Pilot Telehealth Program: Cost-Effectiveness Analysis. Telemedicine journal and e-health : the official journal of the American Telemedicine Association. 2017.
11.    Ding H, Fang L, Xin W, Tong Y, Zhou Q, Huang P. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer. European journal of cancer care. 2017.
12.    Dobie RA. In reference to To image or not to Image? A cost-effectiveness analysis of MRI for patients with asymmetric sensorineural hearing loss. The Laryngoscope. 2017.
13.    Escribano Ferrer B, Hansen KS, Gyapong M, Bruce J, Narh Bana SA, Narh CT, et al. Cost-effectiveness analysis of the national implementation of integrated community case management and community-based health planning and services in Ghana for the treatment of malaria, diarrhoea and pneumonia. Malaria journal. 2017;16(1):277.
14.    Goto D, Shih YT, Lecomte P, Olson M, Udeze C, Park Y, et al. Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis. PharmacoEconomics. 2017;35(7):685-95.
15.    Gunda R, Chimbari MJ. Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review. Cost effectiveness and resource allocation : C/E. 2017;15:10.
16.    Jiang M, You JHS. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome. Clinical cardiology. 2017.
17.    Kolesar RJ, Audibert M, Comfort AB. Cost-effectiveness analysis and mortality impact estimation of scaling-up pregnancy test kits in Madagascar, Ethiopia and Malawi. Health policy and planning. 2017;32(6):869-81.
18.    Kortz TB, Herzel B, Marseille E, Kahn JG. Bubble continuous positive airway pressure in the treatment of severe paediatric pneumonia in Malawi: a cost-effectiveness analysis. BMJ open. 2017;7(7):e015344.
19.    Lamsal R, Stalker CA, Cait CA, Riemer M, Horton S. Cost-effectiveness analysis of single-session walk-in counselling. Journal of mental health (Abingdon, England). 2017:1-7.
20.    Long LC, Maskew M, Brennan AT, Mongwenyana C, Nyoni C, Malete G, et al. Initiating antiretroviral therapy for HIV at a patient's first clinic visit: a cost-effectiveness analysis of the rapid initiation of treatment randomized controlled trial. AIDS (London, England). 2017;31(11):1611-9.
21.    Mennini FS, Bonanni P, Bianic F, de Waure C, Baio G, Plazzotta G, et al. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. Cost effectiveness and resource allocation : C/E. 2017;15:11.
22.    Mezquita-Raya P, Darba J, Ascanio M, Ramirez de Arellano A. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective. Expert review of pharmacoeconomics & outcomes research. 2017:1-9.
23.    Mo X, Gai Tobe R, Wang L, Liu X, Wu B, Luo H, et al. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. BMC infectious diseases. 2017;17(1):502.
24.    Moretti ME, Lato DF, Berger H, Koren G, Ito S, Ungar WJ. A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events. The pharmacogenomics journal. 2017.
25.    Mukerji S, MacIntyre CR, Seale H, Wang Q, Yang P, Wang X, et al. Cost-effectiveness analysis of N95 respirators and medical masks to protect healthcare workers in China from respiratory infections. BMC infectious diseases. 2017;17(1):464.
26.    Neoh CF, Senol E, Kara A, Dinleyici EC, Turner SJ, Kong DCM. Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey. Mycoses. 2017.
27.    Offodile AC, 2nd, Sheckter CC, Tucker A, Watzker A, Ottino K, Zammert M, et al. Preoperative paravertebral blocks for the management of acute pain following mastectomy: a cost-effectiveness analysis. Breast cancer research and treatment. 2017.
28.    Pershad J, Taylor A, Hall MK, Klimo P, Jr. Imaging Strategies for Suspected Acute Cranial Shunt Failure: A Cost-Effectiveness Analysis. Pediatrics. 2017;140(2).
29.    Pinsky MR, Valentin A, Rubenfeld G. Intensive Care Medicine in 2050: cost-effectiveness analysis. Intensive care medicine. 2017;43(7):1039-40.
30.    Sadler S, Tosh J, Pennington R, Rawdin A, Squires H, Romero C, et al. A cost-effectiveness analysis of condom distribution programmes for the prevention of sexually transmitted infections in England. Journal of epidemiology and community health. 2017.
31.    Shi CR, Nambudiri VE. Research Techniques Made Simple: Cost-Effectiveness Analysis. The Journal of investigative dermatology. 2017;137(7):e143-e7.
32.    Suh CH, Kim KW, Park SH, Shin S, Ahn J, Pyo J, et al. A cost-effectiveness analysis of the diagnostic strategies for differentiating focal nodular hyperplasia from hepatocellular adenoma. European radiology. 2017.
33.    Timmermans MJC, van den Brink GT, van Vught A, Adang E, van Berlo CLH, Boxtel KV, et al. The involvement of physician assistants in inpatient care in hospitals in the Netherlands: a cost-effectiveness analysis. BMJ open. 2017;7(7):e016405.
34.    Toohill J, Callander E, Gamble J, Creedy DK, Fenwick J. A cost effectiveness analysis of midwife psycho-education for fearful pregnant women - a health system perspective for the antenatal period. BMC pregnancy and childbirth. 2017;17(1):217.
35.    van Kampen RJW, Ramaekers BLT, Lobbezoo DJA, de Boer M, Dercksen MW, van den Berkmortel F, et al. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. European journal of cancer (Oxford, England : 1990). 2017;79:238-46.
36.    Wali AR, Santiago-Dieppa DR, Brown JM, Mandeville R. Nerve transfer versus muscle transfer to restore elbow flexion after pan-brachial plexus injury: a cost-effectiveness analysis. Neurosurgical focus. 2017;43(1):E4.
37.    Watt M, Dinh A, Le Monnier A, Tilleul P. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. Journal of medical economics. 2017;20(7):678-86.
38.    Yang H, Duchesneau E, Foster R, Guerin A, Ma E, Thomas NP. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. Journal of medical economics. 2017:1-10.
39.    Zhang P, Wen F, Fu P, Yang Y, Li Q. Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis. Tumori. 2017;103(4):380-6.
40.    Zheng J, Zhang H, Chen H. Group B Streptococci Screening Before Repeat Cesarean Delivery: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2017;130(1):217.


June 2017

1.            Antillon M, Bilcke J, Paltiel AD, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine. 2017;35(27):3506-14.
2.            April MD, Murray BP. Cost-effectiveness Analysis Appraisal and Application: An Emergency Medicine Perspective. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2017;24(6):754-68.
3.            Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren's Syndrome. Arthritis & rheumatology (Hoboken, NJ). 2017;69(7):1440-50.
4.            Clement RC, Lang PJ, Pettett BJ, Overman RA, Ostrum RF, Tennant JN. Sanders II/III Calcaneus Fractures in Laborers: A Cost-Effectiveness Analysis and Call for Effectiveness Research. Journal of orthopaedic trauma. 2017;31(6):299-304.
5.            Cortesi PA, D'Angiolella LS, Vellucci R, Allegri M, Casale G, Favaretti C, et al. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment. PloS one. 2017;12(6):e0179523.
6.            Cotton CC, Erim D, Eluri S, Palmer SH, Green DJ, Wolf WA, et al. Cost Utility Analysis of Topical Steroids Compared With Dietary Elimination for Treatment of Eosinophilic Esophagitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2017;15(6):841-9.e1.
7.            Crowson MG, Rocke DJ, Hoang JK, Weissman JL, Kaylie DM. Cost-effectiveness analysis of a non-contrast screening MRI protocol for vestibular schwannoma in patients with asymmetric sensorineural hearing loss. Neuroradiology. 2017.
8.            Cutti AG, Lettieri E, Del Maestro M, Radaelli G, Luchetti M, Verni G, et al. Stratified cost-utility analysis of C-Leg versus mechanical knees: Findings from an Italian sample of transfemoral amputees. Prosthetics and orthotics international. 2017;41(3):227-36.
9.            Elhennawy K, Jost-Brinkmann PG, Manton DJ, Paris S, Schwendicke F. Managing molars with severe molar-incisor hypomineralization: A cost-effectiveness analysis within German healthcare. Journal of dentistry. 2017.
10.          Evers PD, Ranade D, Lewin M, Arya B. Diagnostic Approach in Fetal Coarctation of the Aorta: A Cost-Utility Analysis. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2017;30(6):589-94.
11.          Goldstein DA, Chen Q, Ayer T, Chan KKW, Virik K, Hammerman A, et al. Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. The oncologist. 2017;22(6):694-9.
12.          Gourzoulidis G, Kourlaba G, Kakisis J, Matsagkas M, Giannakoulas G, Gourgoulianis KI, et al. Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece. Clinical drug investigation. 2017.
13.          Hall RK, Myers ER, Rosas SE, O'Hare AM, Colon-Emeric CS. Choice of Hemodialysis Access in Older Adults: A Cost-Effectiveness Analysis. Clinical journal of the American Society of Nephrology : CJASN. 2017;12(6):947-54.
14.          Hansen KS, Ndyomugyenyi R, Magnussen P, Lal S, Clarke SE. Cost-effectiveness analysis of malaria rapid diagnostic tests for appropriate treatment of malaria at the community level in Uganda. Health policy and planning. 2017;32(5):676-89.
15.          Heisen M, Treur MJ, Heemstra HE, Giesen EBW, Postma MJ. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands. Journal of medical economics. 2017:1-12.
16.          Hernaes UJV, Johansson KA, Ottersen T, Norheim OF. Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss. PharmacoEconomics. 2017.
17.          Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, et al. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer. 2017.
18.          Hunt B, Mocarski M, Valentine WJ, Langer J. IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2017;8(3):531-44.
19.          Julicher P, Greenslade JH, Parsonage WA, Cullen L. The organisational value of diagnostic strategies using high-sensitivity troponin for patients with possible acute coronary syndromes: a trial-based cost-effectiveness analysis. BMJ open. 2017;7(6):e013653.
20.          Kameda M, Yamada S, Atsuchi M, Kimura T, Kazui H, Miyajima M, et al. Cost-effectiveness analysis of shunt surgery for idiopathic normal pressure hydrocephalus based on the SINPHONI and SINPHONI-2 trials. Acta neurochirurgica. 2017;159(6):995-1003.
21.          Ke CH, Chung WH, Wen YH, Huang YB, Chuang HY, Tain YL, et al. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions. The Journal of rheumatology. 2017;44(6):835-43.
22.          Krog AH, Sahba M, Pettersen EM, Wisloff T, Sundhagen JO, Kazmi SS. Cost-utility analysis comparing laparoscopic vs open aortobifemoral bypass surgery. Vascular health and risk management. 2017;13:217-24.
23.          Lapointe-Shaw L, Voruganti T, Kohler P, Thein HH, Sander B, McGeer A. Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2017;36(6):1047-55.
24.          Lucchese M, Borisenko O, Mantovani LG, Cortesi PA, Cesana G, Adam D, et al. Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling. Obesity facts. 2017;10(3):261-72.
25.          McGuffin M, Merino T, Keller B, Pignol JP. Response to: 'Reply to: Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer'. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017;29(6):393-4.
26.          Mercier G, Loureiro M, Georgescu V, Skalli EM, Nedelcu M, Ramadan M, et al. Surgical glue in laparoscopic sleeve gastrectomy: An initial experience and cost-effectiveness analysis. Journal of evaluation in clinical practice. 2017;23(3):614-9.
27.          Mezquita-Raya P, Darba J, Ascanio M, Ramirez de Arellano A. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective. Expert review of pharmacoeconomics & outcomes research. 2017:1-9.
28.          Michael J, Crook J, Morton D, Batchelar D, Hilts M, Fenster A. Reply to: Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017;29(6):392-3.
29.          Moriwaki K, Mouri M, Hagino H. Erratum to: Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2017;28(6):1951-2.
30.          Moriwaki K, Mouri M, Hagino H. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2017;28(6):1939-50.
31.          Rivera F, Valladares M, Gea S, Lopez-Martinez N. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Journal of medical economics. 2017;20(6):574-84.
32.          Ruiz-Ramos J, Frasquet J, Roma E, Poveda-Andres JL, Salavert-Leti M, Castellanos A, et al. Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units. Journal of medical economics. 2017;20(6):652-9.
33.          Sanchez Fernandez I, Gainza-Lein M, Loddenkemper T. Nonintravenous rescue medications for pediatric status epilepticus: A cost-effectiveness analysis. Epilepsia. 2017.
34.          Shaikh N, Dando EE, Dunleavy ML, Curran DL, Martin JM, Hoberman A, et al. A Cost-Utility Analysis of 5 Strategies for the Management of Acute Otitis Media in Children. The Journal of pediatrics. 2017.
35.          Shechter SM, Chandler T, Skandari MR, Zalunardo N. Cost-effectiveness Analysis of Vascular Access Referral Policies in CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2017.
36.          Shillcutt SD, LeFevre AE, Fischer-Walker CL, Taneja S, Black RE, Mazumder S. Cost-effectiveness analysis of the diarrhea alleviation through zinc and oral rehydration therapy (DAZT) program in rural Gujarat India: an application of the net-benefit regression framework. Cost effectiveness and resource allocation : C/E. 2017;15:9.
37.          Tamoschus D, Draexler K, Chang J, Ngai C, Madin-Warburton M, Pitcher A. Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany. Clinical drug investigation. 2017;37(6):525-33.
38.          Thomas KH, Caldwell D, Dalili MN, Gunnell D, Munafo MR, Stevenson M, et al. How do smoking cessation medicines compare with respect to their neuropsychiatric safety? A protocol for a systematic review, network meta-analysis and cost-effectiveness analysis. BMJ open. 2017;7(6):e015414.
39.          Trenaman L, Stacey D, Bryan S, Taljaard M, Hawker G, Dervin G, et al. Patient decision aids for patients considering total joint replacement: a cost-effectiveness analysis alongside a randomised controlled trial (RCT). Osteoarthritis and cartilage. 2017.
40.          Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, et al. Corrigendum to "Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy" [Eur J Cancer 67 (2016) 38-45]. European journal of cancer (Oxford, England : 1990). 2017.
41.          Turnes J, Dominguez-Hernandez R, Casado MA. Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. Gastroenterologia y hepatologia. 2017.
42.          Wali AR, Park CC, Santiago-Dieppa DR, Vaida F, Murphy JD, Khalessi AA. Pipeline embolization device versus coiling for the treatment of large and giant unruptured intracranial aneurysms: a cost-effectiveness analysis. Neurosurgical focus. 2017;42(6):E6.
43.          Wikman-Jorgensen PE, Llenas-Garcia J, Perez-Porcuna TM, Hobbins M, Ehmer J, Mussa MA, et al. Microscopic observation drug-susceptibility assay vs. Xpert(R) MTB/RIF for the diagnosis of tuberculosis in a rural African setting: a cost-utility analysis. Tropical medicine & international health : TM & IH. 2017;22(6):734-43.
44.          Wu B, Yang Z, Tobe RG, Wang Y. Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2017.
45.          Xu B, Wang Q, Jin H, Li JX, Liu HN, Mao YJ, et al. [Internal fixation and hemiarthroplasty for the treatment of displaced femoral neck fracture: a cost-utility analysis]. Zhonghua yi xue za zhi. 2017;97(21):1650-4.
46.          Zhang S, Incardona B, Qazi SA, Stenberg K, Campbell H, Nair H. Cost-effectiveness analysis of revised WHO guidelines for management of childhood pneumonia in 74 Countdown countries. Journal of global health. 2017;7(1):010409.


May 2017

1.    Erratum to "The impact of nutrition support on clinical outcome and cost-effectiveness analysis in patients at nutritional risk: a prospective cohort study with propensity score matching," Nutrition (2017) 37C, 53-59. Nutrition (Burbank, Los Angeles County, Calif). 2017.
2.    Expression of Concern: Adaptive Pacing, Cognitive Behaviour Therapy, Graded Exercise, and Specialist Medical Care for Chronic Fatigue Syndrome: A Cost-Effectiveness Analysis. PloS one. 2017;12(5):e0177037.
3.    Antillon M, Bilcke J, Paltiel AD, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine. 2017;35(27):3506-14.
4.    April MD, Murray BP. Cost-effectiveness Analysis Appraisal and Application: An Emergency Medicine Perspective. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2017;24(6):754-68.
5.    Bansback N, Phibbs CS, Sun H, O'Dell JR, Brophy M, Keystone EC, et al. Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. Annals of internal medicine. 2017.
6.    Bojke L, Manca A, Asaria M, Mahon R, Ren S, Palmer S. How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis. PharmacoEconomics. 2017.
7.    Breeze PR, Thomas C, Squires H, Brennan A, Greaves C, Diggle PJ, et al. The impact of Type 2 diabetes prevention programmes based on risk-identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis. Diabetic medicine : a journal of the British Diabetic Association. 2017;34(5):632-40.
8.    Cardona-Arias JA, Lopez-Carvajal L, Tamayo Plata MP, Velez ID. Cost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis. Journal of evidence-based medicine. 2017;10(2):81-90.
9.    Ceballos M, Valderrama CO, Orozco LE, Sanchez L, Valderrama JP, Lugo LH. Cost-utility analysis of reconstruction compared with primary amputation for patients with severe lower limb trauma in Colombia. Journal of orthopaedic trauma. 2017.
10.    Coppola A, D'Ausilio A, Aiello A, Amoresano S, Toumi M, Mathew P, et al. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. Haemophilia : the official journal of the World Federation of Hemophilia. 2017;23(3):422-9.
11.    Davis SA, Himmler S, Feldman SR. Cost-effectiveness analysis of using dermatologists versus pediatricians to treat mild to moderate acne. Dermatology online journal. 2017;23(5).
12.    De Groot S, Blommestein HM, Redekop WK, Sleijfer S, Kiemeney L, Oosterwijk E, et al. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. PloS one. 2017;12(5):e0177364.
13.    Devine A, Parmiter M, Chu CS, Bancone G, Nosten F, Price RN, et al. Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis. PLoS neglected tropical diseases. 2017;11(5):e0005602.
14.    El-Saiedi SA, El Sisi AM, Mandour RS, Abdel-Aziz DM, Attia WA. Cost-effectiveness analysis of different devices used for the closure of small-to-medium-sized patent ductus arteriosus in pediatric patients. Annals of pediatric cardiology. 2017;10(2):144-51.
15.    Filby A, Taylor M, Lipman G, Lovat L, Haidry R. Cost-effectiveness analysis of endoscopic eradication therapy for treatment of high-grade dysplasia in Barrett's esophagus. Journal of comparative effectiveness research. 2017.
16.    Germar MJ, Purugganan C, Bernardino MS, Cuenca B, Chen YC, Li X, et al. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule. Human vaccines & immunotherapeutics. 2017;13(5):1158-66.
17.    Godefrooij DA, Mangen MJ, Chan E, O'Brart DPS, Imhof SM, de Wit GA, et al. Cost-Effectiveness Analysis of Corneal Collagen Crosslinking for Progressive Keratoconus. Ophthalmology. 2017.
18.    Gordon LG, James R, Tuffaha HW, Lowe A, Yaxley J. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia. Journal of magnetic resonance imaging : JMRI. 2017;45(5):1304-15.
19.    Grover R, Rueda S, Gurunluoglu R. Is Single-Stage Prosthetic Reconstruction Cost Effective? A Cost-Utility Analysis for the Use of Direct-to-Implant Breast Reconstruction Relative to Expander-Implant Reconstruction in Postmastectomy Patients. Plastic and reconstructive surgery. 2017;139(5):1204e-5e.
20.    Hall RK, Myers ER, Rosas SE, O'Hare AM, Colon-Emeric CS. Choice of Hemodialysis Access in Older Adults: A Cost-Effectiveness Analysis. Clinical journal of the American Society of Nephrology : CJASN. 2017;12(6):947-54.
21.    Hansen TB, Zwisler AD, Berg SK, Sibilitz KL, Thygesen LC, Kjellberg J, et al. Cost-utility analysis of cardiac rehabilitation after conventional heart valve surgery versus usual care. European journal of preventive cardiology. 2017;24(7):698-707.
22.    Haukaas FS, Arnesen TM, Winje BA, Aas E. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis. The European journal of health economics : HEPAC : health economics in prevention and care. 2017;18(4):405-15.
23.    Heisen M, Treur MJ, Heemstra HE, Giesen EBW, Postma MJ. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands. Journal of medical economics. 2017:1-27.
24.    Johri M, Ng ESW, Bermudez-Tamayo C, Hoch JS, Ducruet T, Chaillet N. A cluster-randomized trial to reduce caesarean delivery rates in Quebec: cost-effectiveness analysis. BMC medicine. 2017;15(1):96.
25.    Kim H, Rajagopalan MS, Beriwal S, Smith KJ. Cost-effectiveness Analysis of Stereotactic Radiosurgery Alone Versus Stereotactic Radiosurgery with Upfront Whole Brain Radiation Therapy for Brain Metastases. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017.
26.    Krishnan NM, Fischer JP, Basta MN, Nahabedian MY. Reply: Is Single-Stage Prosthetic Reconstruction Cost Effective? A Cost-Utility Analysis for the Use of Direct-to-Implant Breast Reconstruction Relative to Expander-Implant Reconstruction in Postmastectomy Patients. Plastic and reconstructive surgery. 2017;139(5):1205e-6e.
27.    Long LC, Maskew M, Brennan AT, Mongwenyana C, Nyoni C, Malete G, et al. Initiating antiretroviral therapy for HIV at a patient's first clinic visit: A cost-effectiveness analysis of the RapIT randomized controlled trial. AIDS (London, England). 2017.
28.    Manchikanti L, Pampati V, Benyamin RM, Hirsch JA. Cost Utility Analysis of Lumbar Interlaminar Epidural Injections in the Treatment of Lumbar Disc Herniation, Central Spinal Stenosis, and Axial or Discogenic Low Back Pain. Pain physician. 2017;20(4):219-28.
29.    Mullie GA, Schwartzman K, Zwerling A, N'Diaye DS. Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis. BMC medicine. 2017;15(1):104.
30.    Pepe A, Rossi G, Bentley A, Putti MC, Frizziero L, D'Ascola DG, et al. Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in beta-Thalassaemia Major Patients: An Italian Perspective. Clinical drug investigation. 2017;37(5):453-64.
31.    Schrock JB, Kraeutler MJ, Houck DA, McQueen MB, McCarty EC. A Cost-Effectiveness Analysis of Surgical Treatment Modalities for Chondral Lesions of the Knee: Microfracture, Osteochondral Autograft Transplantation, and Autologous Chondrocyte Implantation. Orthopaedic journal of sports medicine. 2017;5(5):2325967117704634.
32.    Silverstein A, Costas-Chavarri A, Gakwaya MR, Lule J, Mukhopadhyay S, Meara JG, et al. Laparoscopic Versus Open Cholecystectomy: A Cost-Effectiveness Analysis at Rwanda Military Hospital. World journal of surgery. 2017;41(5):1225-33.
33.    Sjostrom M, Lindholm L, Samuelsson E. Mobile App for Treatment of Stress Urinary Incontinence: A Cost-Effectiveness Analysis. Journal of medical Internet research. 2017;19(5):e154.
34.    Tapper EB, Hughes MS, Buti M, Dufour JF, Flamm S, Firdoos S, et al. The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Transplantation. 2017;101(5):987-95.
35.    Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, et al. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece. Rheumatology international. 2017.
36.    van der Meulen MP, Kapidzic A, van Leerdam ME, van der Steen A, Kuipers EJ, Spaander MC, et al. Do men and women need to be screened differently with faecal immunochemical testing? A cost-effectiveness analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2017.
37.    Van Minh H, My NTT, Jit M. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study. BMC health services research. 2017;17(1):353.
38.    van Oers AM, Mutsaerts MAQ, Burggraaff JM, Kuchenbecker WKH, Perquin DAM, Koks CAM, et al. Cost-effectiveness analysis of lifestyle intervention in obese infertile women. Human reproduction (Oxford, England). 2017:1-9.
39.    Vinten A, Sample J, Ibiyemi A, Abdul-Salam Y, Stutter M. A tool for cost-effectiveness analysis of field scale sediment-bound phosphorus mitigation measures and application to analysis of spatial and temporal targeting in the Lunan Water catchment, Scotland. The Science of the total environment. 2017;586:631-41.
40.    Whittington MD, Atherly AJ, Curtis DJ, Lindrooth RC, Bradley CJ, Campbell JD. Recommendations for Methicillin-Resistant Staphylococcus aureus Prevention in Adult ICUs: A Cost-Effectiveness Analysis. Critical care medicine. 2017.
41.    Wikman-Jorgensen PE, Llenas-Garcia J, Perez-Porcuna TM, Hobbins M, Ehmer J, Mussa MA, et al. Microscopic observation drug-susceptibility assay vs. Xpert(R) MTB/RIF for the diagnosis of tuberculosis in a rural African setting: a cost-utility analysis. Tropical medicine & international health : TM & IH. 2017;22(6):734-43.
42.    Williams C, Lewsey JD, Briggs AH, Mackay DF. Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial. Medical decision making : an international journal of the Society for Medical Decision Making. 2017;37(4):340-52.
43.    Wong CKH, Liao Q, Guo VYW, Xin Y, Lam CLK. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review. Vaccine. 2017;35(24):3153-61.
44.    Wysham WZ, Schaffer EM, Coles T, Roque DR, Wheeler SB, Kim KH. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial. Gynecologic oncology. 2017;145(2):340-5.
45.    Zhang H, Wang Y, Jiang ZM, Kondrup J, Fang H, Andrews M, et al. Impact of nutrition support on clinical outcome and cost-effectiveness analysis in patients at nutritional risk: A prospective cohort study with propensity score matching. Nutrition (Burbank, Los Angeles County, Calif). 2017;37:53-9.


April 2017

1.    Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I, et al. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology (Baltimore, Md). 2017;65(4):1237-48.
2.    Ceballos M, Orozco LE, Valderrama CO, Londono DI, Lugo LH. Cost-Effectiveness Analysis of the Use of a Prophylactic Antibiotic for Patients Undergoing Lower Limb Amputation due to Diabetes or Vascular Illness in Colombia. Annals of vascular surgery. 2017;40:327-34.
3.    Coyle D, Ko YJ, Coyle K, Saluja R, Shah K, Lien K, et al. Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(4):586-92.
4.    Evers PD, Ranade D, Lewin M, Arya B. Diagnostic Approach in Fetal Coarctation of the Aorta: A Cost-Utility Analysis. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2017.
5.    Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, et al. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. PharmacoEconomics. 2017;35(4):425-38.
6.    Garrido G, Penades R, Barrios M, Aragay N, Ramos I, Valles V, et al. Computer-assisted cognitive remediation therapy in schizophrenia: Durability of the effects and cost-utility analysis. Psychiatry research. 2017;254:198-204.
7.    Gordon LG, Brynes J, Baade PD, Neale RE, Whiteman DC, Youl PH, et al. Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(4):593-601.
8.    Goto D, Shih YT, Lecomte P, Olson M, Udeze C, Park Y, et al. Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis. PharmacoEconomics. 2017.
9.    Green AL, Gregory R. Cost-utility analysis alongside the PD SURG trial. Movement disorders : official journal of the Movement Disorder Society. 2017;32(4):631-2.
10.    Heller S, White D, Lee E, Lawton J, Pollard D, Waugh N, et al. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. Health technology assessment (Winchester, England). 2017;21(20):1-278.
11.    Hojjat H, Svider PF, Davoodian P, Hong RS, Folbe AJ, Eloy JA, et al. To image or not to image? A cost-effectiveness analysis of MRI for patients with asymmetric sensorineural hearing loss. The Laryngoscope. 2017;127(4):939-44.
12.    Johansson KA, Strand KB, Fekadu A, Chisholm D. Health Gains and Financial Protection Provided by the Ethiopian Mental Health Strategy: an Extended Cost-Effectiveness Analysis. Health policy and planning. 2017;32(3):376-83.
13.    Ke CH, Chung WH, Wen YH, Huang YB, Chuang HY, Tain YL, et al. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions. The Journal of rheumatology. 2017.
14.    Kempfle JS, BuSaba NY, Dobrowski JM, Westover MB, Bianchi MT. A cost-effectiveness analysis of nasal surgery to increase continuous positive airway pressure adherence in sleep apnea patients with nasal obstruction. The Laryngoscope. 2017;127(4):977-83.
15.    Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. Hepatology (Baltimore, Md). 2017;65(4):1156-64.
16.    Kolesar RJ, Audibert M, Comfort AB. Cost-effectiveness analysis and mortality impact estimation of scaling-up pregnancy test kits in Madagascar, Ethiopia and Malawi. Health policy and planning. 2017.
17.    Leung VC, Pechlivanoglou P, Chew HF, Hatch W. Corneal Collagen Cross-Linking in the Management of Keratoconus in Canada: A Cost-Effectiveness Analysis. Ophthalmology. 2017.
18.    Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, et al. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data. Journal of medical economics. 2017;20(4):328-36.
19.    Mantravadi S. Cost-Effectiveness Analysis of Interventions to Reduce Risk of Aspiration in Elderly Cancer Survivors Residing in Skilled Nursing Facilities. Cancer control : journal of the Moffitt Cancer Center. 2017;24(2):187-92.
20.    Mason JM, Thomas KS, Ormerod AD, Craig FE, Mitchell E, Norrie J, et al. Ciclosporin compared to prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial. The British journal of dermatology. 2017.
21.    Mason SE, Kinross JM, Hendricks J, Arulampalam TH. Postoperative hypothermia and surgical site infection following peritoneal insufflation with warm, humidified carbon dioxide during laparoscopic colorectal surgery: a cohort study with cost-effectiveness analysis. Surgical endoscopy. 2017;31(4):1923-9.
22.    McGuffin M, Merino T, Keller B, Pignol JP. Response to: 'Reply to: Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer'. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017;29(6):393-4.
23.    Miller HJ, Neupane R, Fayezizadeh M, Majumder A, Marks JM. POEM is a cost-effective procedure: cost-utility analysis of endoscopic and surgical treatment options in the management of achalasia. Surgical endoscopy. 2017;31(4):1636-42.
24.    Miyano S, Syakantu G, Komada K, Endo H, Sugishita T. Cost-effectiveness analysis of the national decentralization policy of antiretroviral treatment programme in Zambia. Cost effectiveness and resource allocation : C/E. 2017;15:4.
25.    Muthukumar M, Desai K, Abogunrin S, Harrower T, Gabriel S, Dinet J. Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom. ClinicoEconomics and outcomes research : CEOR. 2017;9:211-29.
26.    Nherera LM, Trueman P, Karlakki SL. Cost-effectiveness analysis of single-use negative pressure wound therapy dressings (sNPWT) to reduce surgical site complications (SSC) in routine primary hip and knee replacements. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 2017.
27.    Othus M, Bansal A, Koepl L, Wagner S, Ramsey S. Accounting for Cured Patients in Cost-Effectiveness Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(4):705-9.
28.    Phisalprapa P, Supakankunti S, Charatcharoenwitthaya P, Apisarnthanarak P, Charoensak A, Washirasaksiri C, et al. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. Medicine. 2017;96(17):e6585.
29.    Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, et al. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. PharmacoEconomics. 2017;35(4):479-91.
30.    Ruiz-Ramos J, Frasquet J, Roma E, Poveda-Andres JL, Salavert-Leti M, Castellanos A, et al. Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units. Journal of medical economics. 2017:1-8.
31.    Seagle BL, Shahabi S. Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. Gynecologic oncology. 2017;145(1):9-14.
32.    Sheng G, Chen S, Dong C, Zhang R, Miao M, Wu D, et al. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis. Journal of medical economics. 2017;20(4):371-81.
33.    Silver RM, Einerson BD. Cost-effectiveness analysis and Obstetrics: The time has come. BJOG : an international journal of obstetrics and gynaecology. 2017.
34.    Spolverato G, Vitale A, Bagante F, Connolly R, Pawlik TM. Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis. Annals of surgery. 2017;265(4):792-9.
35.    Suarez-Llanos JP, Benitez-Brito N, Vallejo-Torres L, Delgado-Brito I, Rosat-Rodrigo A, Hernandez-Carballo C, et al. Clinical and cost-effectiveness analysis of early detection of patients at nutrition risk during their hospital stay through the new screening method CIPA: a study protocol. BMC health services research. 2017;17(1):292.
36.    Takura T, Tachibana K, Isshiki T, Sumitsuji S, Kuroda T, Mizote I, et al. Preliminary report on a cost-utility analysis of revascularization by percutaneous coronary intervention for ischemic heart disease. Cardiovascular intervention and therapeutics. 2017;32(2):127-36.
37.    Takura T, Yoshimatsu M, Sugimori H, Takizawa K, Furumatsu Y, Ikeda H, et al. Cost-Effectiveness Analysis of Percutaneous Vertebroplasty for Osteoporotic Compression Fractures. Clinical spine surgery. 2017;30(3):E205-e10.
38.    Ten Eikelder MLG, van Baaren GJ, Rengerink KO, Jozwiak M, de Leeuw JW, Kleiverda G, et al. Comparing induction of labour with oral misoprostol or Foley catheter at term: cost effectiveness analysis of a randomised controlled multi-centre non-inferiority trial. BJOG : an international journal of obstetrics and gynaecology. 2017.
39.    Wikman-Jorgensen PE, Llenas-Garcia J, Perez-Porcuna TM, Hobbins M, Ehmer J, Mussa MA, et al. Microscopic observation drug-susceptibility assay vs. Xpert(R) MTB/RIF for the diagnosis of tuberculosis in a rural African setting: a cost-utility analysis. Tropical medicine & international health : TM & IH. 2017.
40.    Wilkinson A, Anderson S, Wheeler SB. Screening for and Treating Postpartum Depression and Psychosis: A Cost-Effectiveness Analysis. Maternal and child health journal. 2017;21(4):903-14.
41.    Wu B, Yao Y, Zhang K, Ma X. RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources. Oncotarget. 2017.
42.    Zhang L, Hu P. Cost-effectiveness analysis of oral versus intravenous drip infusion of levofloxacin in the treatment of acute lower respiratory tract infection in Chinese elderly patients. Clinical interventions in aging. 2017;12:673-8.
43.    Zygourakis CC, Imber BS, Chen R, Han SJ, Blevins L, Molinaro A, et al. Cost-Effectiveness Analysis of Surgical versus Medical Treatment of Prolactinomas. Journal of neurological surgery Part B, Skull base. 2017;78(2):125-31.


March 2017

1.    Aitken E, Thomson P, Bainbridge L, Kasthuri R, Mohr B, Kingsmore D. A randomized controlled trial and cost-effectiveness analysis of early cannulation arteriovenous grafts versus tunneled central venous catheters in patients requiring urgent vascular access for hemodialysis. Journal of vascular surgery. 2017;65(3):766-74.
2.    April MD, Murray BP. Cost-effectiveness analysis appraisal and application: an emergency medicine perspective. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2017.
3.    Aronsson M, Svennberg E, Rosenqvist M, Engdahl J, Al-Khalili F, Friberg L, et al. Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2017.
4.    Bove AM, Clohisy J, DeWitt J, Di Stasi S, Enseki K, Harris-Hayes M, et al. Cost-effectiveness Analysis of Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Individuals With Hip Labral Tears: Letter to the Editor. The American journal of sports medicine. 2017;45(3):Np1-np2.
5.    Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. Randomized Controlled Trial of Rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's Syndrome. Arthritis & rheumatology (Hoboken, NJ). 2017.
6.    Buti M, Dominguez-Hernandez R, Oyaguez I, Casado MA, Esteban R. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. Journal of viral hepatitis. 2017.
7.    Cho JH, Jang HM, Jung HY, Choi JY, Park SH, Kim CD, et al. A Real-world Cost-effectiveness Analysis of Sevelamer Versus Calcium Acetate in Korean Dialysis Patients. Clinical therapeutics. 2017.
8.    Clarke CS, Hunter RM, Shemilt I, Serra-Sastre V. Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective. PloS one. 2017;12(3):e0172731.
9.    Estades-Rubio FJ, Reyes-Martin A, Morales-Marcos V, Garcia-Piriz M, Garcia-Vera JJ, Peran M, et al. Knee Viscosupplementation: Cost-Effectiveness Analysis between Stabilized Hyaluronic Acid in a Single Injection versus Five Injections of Standard Hyaluronic Acid. International journal of molecular sciences. 2017;18(3).
10.    Ferket BS, Feldman Z, Zhou J, Oei EH, Bierma-Zeinstra SM, Mazumdar M. Impact of total knee replacement practice: cost effectiveness analysis of data from the Osteoarthritis Initiative. BMJ (Clinical research ed). 2017;356:j1131.
11.    Garrison LP, Jr., Zimmermann MR, Young CH, Crittendon J, Genereux P. Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-up. Cardiovascular revascularization medicine : including molecular interventions. 2017;18(2):86-90.
12.    Hermans J, Reijman M, Goossens LM, Verburg H, Bierma-Zeinstra SM, Koopmanschap MA. A cost utility analysis of high molecular weight hyaluronic acid for knee osteoarthritis in everyday clinical care in patients in the working age. An economic evaluation of a randomized clinical trial. Arthritis care & research. 2017.
13.    Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq SF. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. Journal of medical economics. 2017;20(3):228-38.
14.    Hunt B, Mocarski M, Valentine WJ, Langer J. IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2017.
15.    Hwang HJ, Guidi MA, Curvale C, Lasa J, Matano R. Post-ERCP pancreatitis: early precut or pancreatic duct stent? A multicenter, randomized-controlled trial and cost-effectiveness analysis. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 2017;109(3):174-9.
16.    Kameda M, Yamada S, Atsuchi M, Kimura T, Kazui H, Miyajima M, et al. Cost-effectiveness analysis of shunt surgery for idiopathic normal pressure hydrocephalus based on the SINPHONI and SINPHONI-2 trials. Acta neurochirurgica. 2017.
17.    Lee TH, Kim W, Shin J, Park EC, Park S, Kim TH. Strategic Distributional Cost-Effectiveness Analysis for Improving National Cancer Screening Uptake in Cervical Cancer: A Focus on Regional Inequality in South Korea. Cancer research and treatment : official journal of Korean Cancer Association. 2017.
18.    Liow MH, Agrawal K, Anderson DW, Freiberg AA, Rubash HE, Kwon YM. Unsuspected Malignancies in Routine Femoral Head Histopathologic Examination During Primary Total Hip Arthroplasty: Cost-Effectiveness Analysis. The Journal of arthroplasty. 2017;32(3):735-42.
19.    Liu CY, Chen HC. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan. Clinical drug investigation. 2017;37(3):285-93.
20.    Lodhia P, Gui C, Chandrasekaran S, Suarez-Ahedo C, Dirschl DR, Domb BG. Cost-effectiveness Analysis of Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Individuals With Hip Labral Tears: Response. The American journal of sports medicine. 2017;45(3):Np2-np4.
21.    May AM, Bosch MJ, Velthuis MJ, van der Wall E, Steins Bisschop CN, Los M, et al. Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study. BMJ open. 2017;7(3):e012187.
22.    McGuffin M, Merino T, Keller B, Pignol JP. Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017;29(3):e57-e63.
23.    Mercier G, Loureiro M, Georgescu V, Skalli EM, Nedelcu M, Ramadan M, et al. Surgical glue in laparoscopic sleeve gastrectomy: An initial experience and cost-effectiveness analysis. Journal of evaluation in clinical practice. 2017.
24.    Michael J, Crook J, Morton D, Batchelar D, Hilts M, Fenster A. Reply to: Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 2017.
25.    Moriwaki K, Mouri M, Hagino H. Erratum to: Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2017.
26.    Moriwaki K, Mouri M, Hagino H. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2017.
27.    Osterhoff G, O'Hara NN, D'Cruz J, Sprague SA, Bansback N, Evaniew N, et al. A Cost-Effectiveness Analysis of Reverse Total Shoulder Arthroplasty versus Hemiarthroplasty for the Management of Complex Proximal Humeral Fractures in the Elderly. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(3):404-11.
28.    Padula WV, Millis MA, Worku AD, Pronovost PJ, Bridges JF, Meltzer DO. Individualized cost-effectiveness analysis of patient-centered care: a case series of hospitalized patient preferences departing from practice-based guidelines. Journal of medical economics. 2017;20(3):288-96.
29.    Paquete AT, Miguel LS, Becker U, Pereira C, Pinto CG. Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy. Applied health economics and health policy. 2017.
30.    Pollock RF, Tikkanen CK. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. Journal of medical economics. 2017;20(3):213-20.
31.    Roberts K, Cannon J, Atkinson D, Brown A, Maguire G, Remenyi B, et al. Echocardiographic Screening for Rheumatic Heart Disease in Indigenous Australian Children: A Cost-Utility Analysis. Journal of the American Heart Association. 2017;6(3).
32.    Rodin D, Caulley L, Burger E, Kim J, Johnson-Obaseki S, Palma D, et al. Cost-Effectiveness Analysis of Radiation Therapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. International journal of radiation oncology, biology, physics. 2017;97(4):709-17.
33.    Rognoni C, Ciani O, Sommariva S, Tarricone R. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(3):336-44.
34.    Ruiz-Ramos J, Frasquet J, Roma E, Poveda-Andres JL, Salavert-Leti M, Catellanos A, et al. Cost-effectiveness analysis of implementing an antimicrobial stewardship programme in critical care units. Journal of medical economics. 2017:1-16.
35.    Sterne JA, Bodalia PN, Bryden PA, Davies PA, Lopez-Lopez JA, Okoli GN, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health technology assessment (Winchester, England). 2017;21(9):1-386.
36.    Tamoschus D, Draexler K, Chang J, Ngai C, Madin-Warburton M, Pitcher A. Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany. Clinical drug investigation. 2017.
37.    Thavorn K, Coyle D, Hoch JS, Vandermeer L, Mazzarello S, Wang Z, et al. A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017.
38.    Visser JJ, Oei EH, Hunink MG. Using Cost-Effectiveness Analysis to Measure Value in Musculoskeletal Imaging. Seminars in musculoskeletal radiology. 2017;21(1):37-42.
39.    Watt M, Dinh A, Le Monnier A, Tilleul P. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. Journal of medical economics. 2017:1-9.
40.    Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. International journal of chronic obstructive pulmonary disease. 2017;12:997-1008.
41.    Wu B, Zhang S, Lin H, Mou S. Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: a cost-effectiveness analysis. Journal of diabetes investigation. 2017.
42.    Wysham WZ, Schaffer EM, Coles T, Roque DR, Wheeler SB, Kim KH. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial. Gynecologic oncology. 2017.
43.    Xuan JW, Zhang ZY, Wang YF, Mao ZG, Lu YJ, Wang RZ. [Cost-effectiveness analysis of octreotide long acting release and lanreotide slow release for the treatment of postoperative patients with active acromegaly in China]. Zhonghua yi xue za zhi. 2017;97(10):765-9.


February 2017

1.    Bierbaum M, Schoffski O, Schliemann B, Kosters C. Cost-utility analysis of dynamic intraligamentary stabilization versus early reconstruction after rupture of the anterior cruciate ligament. Health economics review. 2017;7(1):8.
2.    Bugiantella W, Rondelli F, Mariani L, Polistena A, Sanguinetti A, Avenia N, et al. Cost-effectiveness analysis of the temporary percutaneous ileostomy for faecal diversion after colorectal resection in elderly. Aging clinical and experimental research. 2017;29(Suppl 1):47-53.
3.    Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I, et al. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology (Baltimore, Md). 2017.
4.    Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, et al. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. Journal of cancer research and clinical oncology. 2017;143(2):361-8.
5.    Connell NT, Abel GA, Connors JM. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. Thrombosis research. 2017;150:53-8.
6.    Cookson R, Mirelman AJ, Griffin S, Asaria M, Dawkins B, Norheim OF, et al. Using Cost-Effectiveness Analysis to Address Health Equity Concerns. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(2):206-12.
7.    Coppola A, D'Ausilio A, Aiello A, Amoresano S, Toumi M, Mathew P, et al. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. Haemophilia : the official journal of the World Federation of Hemophilia. 2017.
8.    Coyle D. Increasing the methodological quality and relevance of cost effectiveness analysis. Thrombosis research. 2017;150:121-2.
9.    Cradock AL, Barrett JL, Kenney EL, Giles CM, Ward ZJ, Long MW, et al. Using cost-effectiveness analysis to prioritize policy and programmatic approaches to physical activity promotion and obesity prevention in childhood. Preventive medicine. 2017;95s:S17-s27.
10.    de Jong LA, Dvortsin E, Janssen KJ, Postma MJ. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands. Clinical therapeutics. 2017;39(2):288-302.e4.
11.    Fontaine C, Daures JP, Landais P. On the censored cost-effectiveness analysis using copula information. BMC medical research methodology. 2017;17(1):27.
12.    Garrison LP, Jr., Kamal-Bahl S, Towse A. Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(2):213-6.
13.    Green AL, Gregory R. Cost-utility analysis alongside the PD SURG trial. Movement disorders : official journal of the Movement Disorder Society. 2017.
14.    Hansen KS, Ndyomugyenyi R, Magnussen P, Lal S, Clarke SE. Cost-effectiveness analysis of malaria rapid diagnostic tests for appropriate treatment of malaria at the community level in Uganda. Health policy and planning. 2017.
15.    Hassmiller Lich K, Cornejo DA, Mayorga ME, Pignone M, Tangka FK, Richardson LC, et al. Cost-Effectiveness Analysis of Four Simulated Colorectal Cancer Screening Interventions, North Carolina. Preventing chronic disease. 2017;14:E18.
16.    Heard C, Chaboyer W, Anderson V, Gillespie BM, Whitty JA. Cost-effectiveness analysis alongside a pilot study of prophylactic negative pressure wound therapy. Journal of tissue viability. 2017;26(1):79-84.
17.    Heinzel A, Muller D, Yekta-Michael SS, Ceccon G, Langen KJ, Mottaghy FM, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis. Neuro-oncology. 2017.
18.    Jenks M, Taylor M, Shore J. Cost-utility analysis of the insufflation of warmed humidified carbon dioxide during open and laparoscopic colorectal surgery. Expert review of pharmacoeconomics & outcomes research. 2017;17(1):99-107.
19.    Keller A, Gericke C, Whitty JA, Yaxley J, Kua B, Coughlin G, et al. A Cost-Utility Analysis of Prostate Cancer Screening in Australia. Applied health economics and health policy. 2017;15(1):95-111.
20.    Kotirum S, Chongmelaxme B, Chaiyakunapruk N. A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand. Journal of thrombosis and thrombolysis. 2017;43(2):252-62.
21.    Landfeldt E, Alfredsson L, Straub V, Lochmuller H, Bushby K, Lindgren P. Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis. PharmacoEconomics. 2017;35(2):249-58.
22.    Larsen B, Marcus B, Pekmezi D, Hartman S, Gilmer T. A Web-Based Physical Activity Intervention for Spanish-Speaking Latinas: A Costs and Cost-Effectiveness Analysis. Journal of medical Internet research. 2017;19(2):e43.
23.    Le P, Rothberg MB. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis. Journal of general internal medicine. 2017;32(2):159-67.
24.    Muhlbacher AC, Sadler A. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(2):266-72.
25.    Oksman E, Linna M, Horhammer I, Lammintakanen J, Talja M. Cost-effectiveness analysis for a tele-based health coaching program for chronic disease in primary care. BMC health services research. 2017;17(1):138.
26.    Pedersen K, Sorbye SW, Kristiansen IS, Burger EA. Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2017;124(3):474-84.
27.    Pepe A, Rossi G, Bentley A, Putti MC, Frizziero L, D'Ascola DG, et al. Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in beta-Thalassaemia Major Patients: An Italian Perspective. Clinical drug investigation. 2017.
28.    Qu XM, Louie AV, Ashman J, Wasif N. Cost-Effectiveness Analysis of Preoperative Versus Postoperative Radiation Therapy in Extremity Soft Tissue Sarcoma. International journal of radiation oncology, biology, physics. 2017;97(2):339-46.
29.    Schechner V, Carmeli Y, Leshno M. A mathematical model of Clostridium difficile transmission in medical wards and a cost-effectiveness analysis comparing different strategies for laboratory diagnosis and patient isolation. PloS one. 2017;12(2):e0171327.
30.    Seagle BL, Shahabi S. Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. Gynecologic oncology. 2017.
31.    Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, et al. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Current medical research and opinion. 2017;33(2):359-69.
32.    Simmons SF, Hollingsworth EK, Long EA, Liu X, Shotwell MS, Keeler E, et al. Training Nonnursing Staff to Assist with Nutritional Care Delivery in Nursing Homes: A Cost-Effectiveness Analysis. Journal of the American Geriatrics Society. 2017;65(2):313-22.
33.    Swart E, Laratta J, Slobogean G, Mehta S. Operative Treatment of Rib Fractures in Flail Chest Injuries: A Meta-analysis and Cost-Effectiveness Analysis. Journal of orthopaedic trauma. 2017;31(2):64-70.
34.    Teng AM, Kvizhinadze G, Nair N, McLeod M, Wilson N, Blakely T. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity. BMC infectious diseases. 2017;17(1):156.
35.    Twiner MJ, Marinica AL, Kuper K, Goodman A, Mahn JJ, Burla MJ, et al. Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost-effectiveness Analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2017;24(2):168-76.
36.    Vaidya V, Gangan N, Comerota A, Lurie F. Cost-Effectiveness Analysis of Initial Treatment Strategies for Nonembolic Acute Limb Ischemia Using Real-Word Data. Annals of vascular surgery. 2017;39:276-83.
37.    van Kampen RJ, Ramaekers BL, Lobbezoo DJ, de Boer M, Dercksen MW, van den Berkmortel F, et al. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. European journal of cancer (Oxford, England : 1990). 2017.
38.    Vinten A, Sample J, Ibiyemi A, Abdul-Salam Y, Stutter M. A tool for cost-effectiveness analysis of field scale sediment-bound phosphorus mitigation measures and application to analysis of spatial and temporal targeting in the Lunan Water catchment, Scotland. The Science of the total environment. 2017.
39.    Visser JJ, Oei EH, Hunink MG. Using Cost-Effectiveness Analysis to Measure Value in Musculoskeletal Imaging. Seminars in musculoskeletal radiology. 2017;21(1):37-42.
40.    Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2017;118(2):220-5.
41.    Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2017;28(2):643-52.


 January 2017

1.    Correction: Cost-Effectiveness Analysis of Test-Based versus Presumptive Treatment of Uncomplicated Malaria in Children under Five Years in an Area of High Transmission in Central Ghana. PloS one. 2017;12(1):e0170848.
2.    Albright CM, MacGregor C, Sutton D, Theva M, Hughes BL, Werner EF. Group B Streptococci Screening Before Repeat Cesarean Delivery: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2017;129(1):111-9.
3.    Baro E, Galperine T, Denies F, Lannoy D, Lenne X, Odou P, et al. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France. PloS one. 2017;12(1):e0170258.
4.    Breeze PR, Thomas C, Squires H, Brennan A, Greaves C, Diggle PJ, et al. The impact of Type 2 diabetes prevention programmes based on risk-identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis. Diabetic medicine : a journal of the British Diabetic Association. 2017.
5.    Canestaro W, Vodicka E, Downing D, Trussell J. Implications of employer coverage of contraception: Cost-effectiveness analysis of contraception coverage under an employer mandate. Contraception. 2017;95(1):77-89.
6.    Clement RC, Lang PJ, Pettett BJ, Overman RA, Ostrum RF, Tennant JN. Cost and Cost-effectiveness Analysis of Treatment Options for Sanders II and III Calcaneus Fractures In Laborers. Journal of orthopaedic trauma. 2017.
7.    de Jong LA, Dvortsin E, Janssen KJ, Postma MJ. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands. Clinical therapeutics. 2017.
8.    Dilokthornsakul P, Chaiyakunapruk N, Campbell JD. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter? The Journal of asthma : official journal of the Association for the Care of Asthma. 2017;54(1):17-23.
9.    Ekwunife OI, O'Mahony JF, Gerber Grote A, Mosch C, Paeck T, Lhachimi SK. Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations. PharmacoEconomics. 2017;35(1):65-82.
10.    Fernandes L, Roos EM, Overgaard S, Villadsen A, Sogaard R. Supervised neuromuscular exercise prior to hip and knee replacement: 12-month clinical effect and cost-utility analysis alongside a randomised controlled trial. BMC musculoskeletal disorders. 2017;18(1):5.
11.    Germar MJ, Purugganan C, Bernardino MS, Cuenca B, Chen YC, Li X, et al. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule. Human vaccines & immunotherapeutics. 2017:0.
12.    Gimeno-Ballester V, Mar J, O'Leary A, Adams R, San Miguel R. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert review of gastroenterology & hepatology. 2017;11(1):85-93.
13.    Goyert N, Eeson G, Kagedan DJ, Behman R, Lemke M, Hallet J, et al. Pasireotide for the Prevention of Pancreatic Fistula Following Pancreaticoduodenectomy: A Cost-effectiveness Analysis. Annals of surgery. 2017;265(1):2-10.
14.    Grau S, Azanza JR, Ruiz I, Vallejo C, Mensa J, Maertens J, et al. Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain. ClinicoEconomics and outcomes research : CEOR. 2017;9:39-47.
15.    Grover R, Rueda S, Gurunluoglu R. Letter to Editor: Is Single-Stage Prosthetic Reconstruction Cost effective? A Cost-Utility Analysis for the Use of Direct-to-Implant Breast Reconstruction Relative to Expander-Implant Reconstruction in Postmastectomy Patients. Plastic and reconstructive surgery. 2017.
16.    Hansen TB, Zwisler AD, Berg SK, Sibilitz KL, Thygesen LC, Kjellberg J, et al. Cost-utility analysis of cardiac rehabilitation after conventional heart valve surgery versus usual care. European journal of preventive cardiology. 2017:2047487317689908.
17.    Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, et al. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Advances in therapy. 2017;34(1):207-20.
18.    Huang QC, Ye D, Jiang XY, Li QL, Yao KY, Wang JB, et al. [Cost-effectiveness analysis on colorectal cancer screening program]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2017;38(1):65-8.
19.    Idrisov B, Murphy SM, Morrill T, Saadoun M, Lunze K, Shepard D. Implementation of methadone therapy for opioid use disorder in Russia - a modeled cost-effectiveness analysis. Substance abuse treatment, prevention, and policy. 2017;12(1):4.
20.    Igarashi A, Tang W, Cure S, Guerra I, Marie L, Lopresti M, et al. Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. Current medical research and opinion. 2017;33(1):1-10.
21.    Igarashi A, Tang W, Guerra I, Marie L, Cure S, Lopresti M. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Current medical research and opinion. 2017;33(1):11-21.
22.    Isaranuwatchai W, Alam F, Hoch J, Boet S. A cost-effectiveness analysis of self-debriefing versus instructor debriefing for simulated crises in perioperative medicine in Canada. Journal of educational evaluation for health professions. 2017;13:44.
23.    Kimura T, Igarashi A, Ikeda S, Nakajima K, Kashimura S, Kunitomi A, et al. A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan. Journal of cardiology. 2017;69(1):89-97.
24.    Krishnan NM, Fischer JP, Basta MN, Nahabedian MY. Is Single-Stage Prosthetic Reconstruction Cost Effective? A Cost Utility Analysis for the use of Direct-to-Implant Breast Reconstruction Relative to Expander-Implant Reconstruction in Post-Mastectomy Patients. Plastic and reconstructive surgery. 2017.
25.    Kulchaitanaroaj P, Brooks JM, Chaiyakunapruk N, Goedken AM, Chrischilles EA, Carter BL. Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. Journal of hypertension. 2017;35(1):178-87.
26.    Lam SW, Wai M, Lau JE, McNamara M, Earl M, Udeh B. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer. Pharmacotherapy. 2017;37(1):94-103.
27.    Lapointe-Shaw L, Voruganti T, Kohler P, Thein HH, Sander B, McGeer A. Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2017.
28.    McFarland A. A cost utility analysis of the clinical algorithm for nasogastric tube placement confirmation in adult hospital patients. Journal of advanced nursing. 2017;73(1):201-16.
29.    Nerich V, Fleck C, Chaigneau L, Isambert N, Borg C, Kalbacher E, et al. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors. Clinical drug investigation. 2017;37(1):85-94.
30.    Neumann PJ, Sanders GD. Cost-Effectiveness Analysis 2.0. The New England journal of medicine. 2017;376(3):203-5.
31.    Parker C, Woods B, Eaton J, Ma E, Selby R, Benson E, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. Journal of medical economics. 2017;20(1):8-18.
32.    Rivera F, Valladares M, Gea S, Lopez-Martinez N. Cost-effectiveness analysis in the Spanish setting of the peak trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Journal of medical economics. 2017:1-27.
33.    Scangas GA, Remenschneider AK, Su BM, Shrime MG, Metson R. Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyposis. The Laryngoscope. 2017;127(1):29-37.
34.    Sheng G, Chen S, Dong C, Zhang R, Miao M, Wu D, et al. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis. Journal of medical economics. 2017:1-11.
35.    Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, et al. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. Clinical lung cancer. 2017;18(1):e41-e7.
36.    Yang MC, Tan EC, Su JJ. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model. Human vaccines & immunotherapeutics. 2017;13(1):81-9.
37.    Zanocco KA, Wu JX, Yeh MW. Parathyroidectomy for asymptomatic primary hyperparathyroidism: A revised cost-effectiveness analysis incorporating fracture risk reduction. Surgery. 2017;161(1):16-24.
38.    Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA. A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK. The European journal of health economics : HEPAC : health economics in prevention and care. 2017.


December 2016

1.    Berm EJ, Gout-Zwart JJ, Luttjeboer J, Wilffert B, Postma MJ. A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy. PloS one. 2016;11(12):e0169065.
2.    Bohensky MA, Pasupathi K, Gorelik A, Kim H, Harrison JP, Liew D. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2016;19(8):1009-15.
3.    Castro Jaramillo HE, Moreno Viscaya M, Mejia AE. COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA. International journal of technology assessment in health care. 2016;32(5):337-47.
4.    Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, et al. Directly acting antivirals combination for elderly patients with Chronic Hepatitis C: a Cost-Effectiveness Analysis. Liver international : official journal of the International Association for the Study of the Liver. 2016.
5.    Connell NT, Abel GA, Connors JM. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. Thrombosis research. 2016;150:53-8.
6.    Cotton CC, Erim D, Eluri S, Palmer SH, Green DJ, Wolf WA, et al. Cost Utility Analysis of Topical Steroids Compared to Dietary Elimination for Treatment of Eosinophilic Esophagitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2016.
7.    Coyle D. Increasing the methodological quality and relevance of cost effectiveness analysis. Thrombosis research. 2016.
8.    Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, et al. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. PharmacoEconomics. 2016.
9.    Garrison LP, Jr., Zimmermann MR, Young CH, Crittendon J, Genereux P. Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-up. Cardiovascular revascularization medicine : including molecular interventions. 2016.
10.    Glassman A, Canon O, Silverman R. How to Get Cost-Effectiveness Analysis Right? The Case of Vaccine Economics in Latin America. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2016;19(8):913-20.
11.    Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, et al. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Advances in therapy. 2017;34(1):207-20.
12.    Isaranuwatchai W, Alam F, Hoch J, Boet S. A cost-effectiveness analysis of self-debriefing versus instructor debriefing for simulated crises in perioperative medicine in Canada. Journal of educational evaluation for health professions. 2017;13:44.
13.    Jenks M, Taylor M, Shore J. Cost-utility analysis of the insufflation of warmed humidified carbon dioxide during open and laparoscopic colorectal surgery. Expert review of pharmacoeconomics & outcomes research. 2016:1-9.
14.    Jiang M, You JH. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Cardiovascular drugs and therapy. 2016.
15.    Liu CY, Chen HC. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan. Clinical drug investigation. 2016.
16.    McGuffin M, Merino T, Keller B, Pignol JP. Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 2016.
17.    Mohiuddin S, Reeves B, Pufulete M, Maishman R, Dayer M, Macleod J, et al. Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. BMJ open. 2016;6(12):e014010.
18.    Mohr NM, Stoltze A, Ahmed A, Kiscaden E, Shane D. Using continuous quantitative capnography for emergency department procedural sedation: a systematic review and cost-effectiveness analysis. Internal and emergency medicine. 2016.
19.    Pinsky MR, Valentin A, Rubenfeld G. Intensive Care Medicine in 2050: cost-effectiveness analysis. Intensive care medicine. 2016.
20.    Restelli U, Alberti A, Lazzarin A, Bonfanti M, Nappi C, Croce D. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. The European journal of health economics : HEPAC : health economics in prevention and care. 2016.
21.    Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, et al. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. PharmacoEconomics. 2016.
22.    Shiffman D, Arellano AR, Caulfield MP, Louie JZ, Bare LA, Devlin JJ, et al. Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis. BMC cardiovascular disorders. 2016;16(1):251.
23.    Tan J, Liu L, Xie J, Hu L, Yang Q, Wang H. Cost-effectiveness analysis of ultrasound-guided Seldinger peripherally inserted central catheters (PICC). SpringerPlus. 2016;5(1):2051.
24.    Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2016.


November 2016

1.    Bugiantella W, Rondelli F, Mariani L, Polistena A, Sanguinetti A, Avenia N, et al. Cost-effectiveness analysis of the temporary percutaneous ileostomy for faecal diversion after colorectal resection in elderly. Aging clinical and experimental research. 2016.
2.    Bustillo-Lecompte CF, Mehrvar M. Treatment of an actual slaughterhouse wastewater by integration of biological and advanced oxidation processes: Modeling, optimization, and cost-effectiveness analysis. Journal of environmental management. 2016;182:651-66.
3.    Ceballos M, Orozco LE, Valderrama CO, Londono DI, Lugo LH. Cost-effectiveness analysis of the use of a prophylactic antibiotic for patients undergoing lower limb amputation due to diabetes or vascular illness in Colombia. Annals of vascular surgery. 2016.
4.    Cui S, Tobe RG, Mo X, Liu X, Xu L, Li S. Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option. BMC infectious diseases. 2016;16(1):677.
5.    Davidson C. Uncertainty in evidence synthesis limits clinical applicability of a clinical and cost-effectiveness analysis of induction of labour methods. Evidence-based medicine. 2016;21(6):226.
6.    Delgleize E, Leeuwenkamp O, Theodorou E, Van de Velde N. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model. BMJ open. 2016;6(11):e010776.
7.    Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, et al. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast cancer research and treatment. 2016;160(1):187-96.
8.    Gama E, Were V, Ouma P, Desai M, Niessen L, Buff AM, et al. Large-scale implementation of disease control programmes: a cost-effectiveness analysis of long-lasting insecticide-treated bed net distribution channels in a malaria-endemic area of western Kenya-a study protocol. BMJ open. 2016;6(11):e012776.
9.    Greenberg D, Neumann PJ. Cost-Effectiveness Analysis Expands its Reach Worldwide. Value in health regional issues. 2016;10:101-2.
10.    Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq SF. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. Journal of medical economics. 2016:1-11.
11.    Iannazzo S, Cortesi PA, Crea R, Steinitz K, Mantovani LG, Gringeri A. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2016.
12.    Ke W, Zhang C, Liu L, Gao Y, Yao Z, Ye X, et al. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Hepatology international. 2016;10(6):924-36.
13.    Kelly RJ, Smith TJ. Checkpoint Inhibitors in Lung Cancer Are Not Immune from Cost-Effectiveness Analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(11):1814-6.
14.    Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric Surgery for Nonalcoholic Steatohepatitis: A Clinical and Cost-Effectiveness Analysis. Hepatology (Baltimore, Md). 2016.
15.    Lam SW, Wai M, Lau JE, McNamara M, Earl M, Udeh B. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer. Pharmacotherapy. 2016.
16.    Lee D, Park SM. Cost-Effectiveness Analysis of Hepatitis B Vaccination Strategies to Prevent Perinatal Transmission in North Korea: Selective Vaccination vs. Universal Vaccination. PloS one. 2016;11(11):e0165879.
17.    Lee HD, Jeon CH, Chung NS, Seo YW. Cost-Utility Analysis of Pedicle Screw Removal after Successful Posterior Instrumented Fusion in Thoracolumbar Burst Fractures. Spine. 2016.
18.    Luttjeboer J, Setiawan D, Cao Q, Cahh Daemen T, Postma MJ. Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands. Vaccine. 2016;34(50):6381-7.
19.    Mantopoulos T, Mitchell PM, Welton NJ, McManus R, Andronis L. Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results. The European journal of health economics : HEPAC : health economics in prevention and care. 2016;17(8):927-38.
20.    Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, et al. A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(11):1846-55.
21.    Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Alimentary pharmacology & therapeutics. 2016;44(10):1090-101.
22.    Nogueira TE, Esfandiari S, Leles CR. Cost-effectiveness analysis of the single-implant mandibular overdenture versus conventional complete denture: study protocol for a randomized controlled trial. Trials. 2016;17(1):533.
23.    Padula WV, Millis MA, Worku AD, Pronovost PJ, Bridges JF, Meltzer DO. Individualized cost-effectiveness analysis of patient-centered care: a case series of hospitalized patient preferences departing from practice-based guidelines. Journal of medical economics. 2016:1-9.
24.    Park KW, Boyer MI, Gelberman RH, Calfee RP, Stepan JG, Osei DA. Simultaneous Bilateral Versus Staged Bilateral Carpal Tunnel Release: A Cost-effectiveness Analysis. The Journal of the American Academy of Orthopaedic Surgeons. 2016;24(11):796-804.
25.    Park SK, Park SH, Lee MY, Park JH, Jeong JH, Lee EK. Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. Clinical therapeutics. 2016;38(11):2430-46.e3.
26.    Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, et al. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Current medical research and opinion. 2016:1-11.
27.    Shim E. Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines. The American journal of tropical medicine and hygiene. 2016;95(5):1137-47.
28.    Silverstein A, Costas-Chavarri A, Gakwaya MR, Lule J, Mukhopadhyay S, Meara JG, et al. Laparoscopic Versus Open Cholecystectomy: A Cost-Effectiveness Analysis at Rwanda Military Hospital. World journal of surgery. 2016.
29.    Stawowczyk E, Kawalec P, Pilc A. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland. European journal of clinical pharmacology. 2016;72(11):1319-25.
30.    Tonmukayakul U, Arrow P. Cost-effectiveness analysis of the atraumatic restorative treatment-based approach to managing early childhood caries. Community dentistry and oral epidemiology. 2016.
31.    Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, et al. Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy. European journal of cancer (Oxford, England : 1990). 2016;67:38-45.
32.    Wen F, Zheng H, Wu Y, Wheeler J, Zeng X, Fu P, et al. Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma. Scientific reports. 2016;6:36060.
33.    Wilkinson A, Anderson S, Wheeler SB. Screening for and Treating Postpartum Depression and Psychosis: A Cost-Effectiveness Analysis. Maternal and child health journal. 2016.
34.    Zanocco KA, Wu JX, Yeh MW. Parathyroidectomy for asymptomatic primary hyperparathyroidism: A revised cost-effectiveness analysis incorporating fracture risk reduction. Surgery. 2016.


October 2016

1.    Landfeldt E, Alfredsson L, Straub V, Lochmuller H, Bushby K, Lindgren P. Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis. PharmacoEconomics. 2016.
2.    Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, et al. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. Journal of cancer research and clinical oncology. 2016.
3.    El Alaoui S, Lindefors N. Combining Time-Driven Activity-Based Costing with Clinical Outcome in Cost-Effectiveness Analysis to Measure Value in Treatment of Depression. PloS one. 2016;11(10):e0165389.
4.    Twiner MJ, Marinica AL, Kuper K, Goodman A, Mahn JJ, Burla MJ, et al. Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost Effectiveness Analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2016.
5.    Padula WV, Millis MA, Worku AD, Pronovost PJ, Bridges JF, Meltzer DO. Individualized cost-effectiveness analysis of patient-centered care: a case series of hospitalized patient preferences departing from practice-based guidelines. Journal of medical economics. 2016:1-19.
6.    Tsukiyama I, Ejiri M, Yamamoto Y, Nakao H, Yoneda M, Matsuura K, et al. A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan. Journal of gastrointestinal cancer. 2016.
7.    Smajerova M, Petrasova H, Little J, Ovesna P, Andrasina T, Valek V, et al. Contrast-enhanced ultrasonography in the evaluation of incidental focal liver lesions: A cost-effectiveness analysis. World journal of gastroenterology. 2016;22(38):8605-14.
8.    Stevanovic J, de Jong LA, Kappelhoff BS, Dvortsin EP, Voorhaar M, Postma MJ. Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands. PloS one. 2016;11(10):e0163550.
9.    Cradock AL, Barrett JL, Kenney EL, Giles CM, Ward ZJ, Long MW, et al. Using cost-effectiveness analysis to prioritize policy and programmatic approaches to physical activity promotion and obesity prevention in childhood. Preventive medicine. 2016.
10.    Park SK, Park SH, Lee MY, Park JH, Jeong JH, Lee EK. Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. Clinical therapeutics. 2016.
11.    Soini E, Hallinen T, Brignone M, Campbell R, Diamand F, Cure S, et al. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert review of pharmacoeconomics & outcomes research. 2016:1-10.
12.    Liu CC, Rudmik L. A Cost-effectiveness Analysis of Early vs Late Tracheostomy. JAMA otolaryngology-- head & neck surgery. 2016;142(10):981-7.
13.    Keller A, Gericke C, Whitty JA, Yaxley J, Kua B, Coughlin G, et al. A Cost-Utility Analysis of Prostate Cancer Screening in Australia. Applied health economics and health policy. 2016.
14.    Karnon J, Shafie AS, Orji N, Usman SK. What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia. Cost effectiveness and resource allocation : C/E. 2016;14:11.
15.    Le P, Rothberg MB. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis. Journal of general internal medicine. 2016.
16.    Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2016.
17.    Rocke DJ, Goldstein DP, de Almeida JR. A Cost-Utility Analysis of Recurrent Laryngeal Nerve Monitoring in the Setting of Total Thyroidectomy. JAMA otolaryngology-- head & neck surgery. 2016.
18.    Mason SE, Kinross JM, Hendricks J, Arulampalam TH. Postoperative hypothermia and surgical site infection following peritoneal insufflation with warm, humidified carbon dioxide during laparoscopic colorectal surgery: a cohort study with cost-effectiveness analysis. Surgical endoscopy. 2016.
19.    Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq SF. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. Journal of medical economics. 2016:1-29.
20.    Odnoletkova I, Ramaekers D, Nobels F, Goderis G, Aertgeerts B, Annemans L. Delivering Diabetes Education through Nurse-Led Telecoaching. Cost-Effectiveness Analysis. PloS one. 2016;11(10):e0163997.
21.    Gordon LG, James R, Tuffaha HW, Lowe A, Yaxley J. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia. Journal of magnetic resonance imaging : JMRI. 2016.
22.    Walusimbi S, Kwesiga B, Rodrigues R, Haile M, de Costa A, Bogg L, et al. Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda. BMC health services research. 2016;16(1):563.
23.    Pollock RF, Tikkanen CK. A short-term cost-utility analysis of insulin degludec versus insulin glargine in patients with type 1 or type 2 diabetes in Denmark. Journal of medical economics. 2016:1-19.
24.    Kotirum S, Chongmelaxme B, Chaiyakunapruk N. A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand. Journal of thrombosis and thrombolysis. 2016.
25.    Tawiah T, Hansen KS, Baiden F, Bruce J, Tivura M, Delimini R, et al. Cost-Effectiveness Analysis of Test-Based versus Presumptive Treatment of Uncomplicated Malaria in Children under Five Years in an Area of High Transmission in Central Ghana. PloS one. 2016;11(10):e0164055.
26.    Smith AF, Sutton A, Shinkins B. EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS: RESPONSE. International journal of technology assessment in health care. 2016:1-2.
27.    Korolija Marinic D, Varga S. Cost Utility Analysis Of Selected Medical Equipment And Procedures In Croatia. Clinical therapeutics. 2016;38(10s):e15.
28.    Dottino JA, Hasselblad V, Secord AA, Myers ER, Chino J, Havrilesky LJ. Levonorgestrel Intrauterine Device as an Endometrial Cancer Prevention Strategy in Obese Women: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2016;128(4):747-53.
29.    Picot MC, Jaussent A, Neveu D, Kahane P, Crespel A, Gelisse P, et al. Cost-effectiveness analysis of epilepsy surgery in a controlled cohort of adult patients with intractable partial epilepsy: A 5-year follow-up study. Epilepsia. 2016;57(10):1669-79.
30.    Fallah A, Weil AG, Wang S, Lewis E, Baca CB, Mathern GW. Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with Tuberous Sclerosis Complex. Epilepsy & behavior : E&B. 2016;63:79-88.
31.    Le QA, Bae YH, Kang JH. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast cancer research and treatment. 2016;159(3):565-73.
32.    Zimovetz EA, Beard SM, Hodgkins P, Bischof M, Mauskopf JA, Setyawan J. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate. CNS drugs. 2016;30(10):985-96.
33.    Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, Ternouth A, Miravitlles M, Rutten-van Molken M, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat(R) fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Therapeutic advances in respiratory disease. 2016;10(5):391-401.
34.    Taylor C, Thompson K, Finfer S, Higgins A, Jan S, Li Q, et al. Hydroxyethyl starch versus saline for resuscitation of patients in intensive care: long-term outcomes and cost-effectiveness analysis of a cohort from CHEST. The Lancet Respiratory medicine. 2016;4(10):818-25.
35.    Yun BJ, Myriam Hunink MG, Prabhakar AM, Heng M, Liu SW, Qudsi R, et al. Diagnostic Imaging Strategies for Occult Hip Fractures: A Decision and Cost-Effectiveness Analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2016;23(10):1161-9.
36.    Penaloza-Ramos MC, Jowett S, Barton P, Roalfe A, Fletcher K, Taylor CJ, et al. Cost-effectiveness analysis of different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack: Economic analysis of the PAST-BP study. European journal of preventive cardiology. 2016;23(15):1590-8.
37.    Qureshi N, Weng S, Hex N. The role of cost-effectiveness analysis in the development of indicators to support incentive-based behaviour in primary care in England. Journal of health services research & policy. 2016;21(4):263-71.
38.    Muduma G, Odeyemi I, Pollock RF. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. Journal of medical economics. 2016;19(10):995-1002.
39.    Angulo JC, Sanchez-Ballester F, Peral C, Rejas J, Ramos J, Snedecor SJ, et al. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective. Actas urologicas espanolas. 2016;40(8):513-22.
40.    Gibbons JP, Nugent E, O'Donohoe N, Maher B, Egan B, Feeley M, et al. Experience with botulinum toxin therapy for axillary hyperhidrosis and comparison to modelled data for endoscopic thoracic sympathectomy - A quality of life and cost effectiveness analysis. The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland. 2016;14(5):260-4.


September 2016

1.    Cost-Effectiveness Analysis of the Use of Probiotics for the Prevention of Clostridium difficile-Associated Diarrhea in a Provincial Healthcare System - ERRATUM. Infection control and hospital epidemiology. 2016;37(9):1133.
2.    Ahmadiani S, Nikfar S, Karimi S, Jamshidi AR, Akbari-Sari A, Kebriaeezadeh A. Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis. Rheumatology international. 2016;36(9):1291-300.
3.    Arrieta O, Anaya P, Morales-Oyarvide V, Ramirez-Tirado LA, Polanco AC. Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel. The European journal of health economics : HEPAC : health economics in prevention and care. 2016;17(7):855-63.
4.    Babu MA. Commentary: Surgical Management of the Elderly With Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. Neurosurgery. 2016;79(3):426-7.
5.    Burgers LT, Redekop WK, Al MJ, Lhachimi SK, Armstrong N, Walker S, et al. Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients. The European journal of health economics : HEPAC : health economics in prevention and care. 2016.
6.    Canestaro WJ. Capsule Commentary on Phibbs et. al., At-Home versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). Journal of general internal medicine. 2016;31(9):1082.
7.    Chalayer E, Bourmaud A, Tinquaut F, Chauvin F, Tardy B. Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma. Thrombosis research. 2016;145:119-25.
8.    Chang HW, Shin SH, Suh SH, Kim BS, Rho MH. Cost-Effectiveness Analysis of Endovascular Coiling versus Neurosurgical Clipping for Intracranial Aneurysms in Republic of Korea. Neurointervention. 2016;11(2):86-91.
9.    Coretti S, Codella P, Romano F, Ruggeri M, Cicchetti A. COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS. International journal of technology assessment in health care. 2016:1-8.
10.    Cromwell I, Regier DA, Peacock SJ, Poh CF. Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada. The oncologist. 2016;21(9):1099-106.
11.    Cui M, Tu CC, Chen EZ, Wang XL, Tan SC, Chen C. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China. Advances in therapy. 2016;33(9):1600-11.
12.    Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, et al. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast cancer research and treatment. 2016;160(1):187-96.
13.    Donovan P, McLeod D, Little R, Gordon L. Cost-Utility Analysis Comparing Radioactive Iodine, Antithyroid Drugs and Total Thyroidectomy for Primary Treatment of Graves' Disease. European journal of endocrinology. 2016.
14.    Ekwunife OI, O'Mahony JF, Gerber Grote A, Mosch C, Paeck T, Lhachimi SK. Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations. PharmacoEconomics. 2016.
15.    Freemantle N, Khalaf K, Loveman C, Stanisic S, Gultyaev D, Lister J, et al. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales. The European journal of health economics : HEPAC : health economics in prevention and care. 2016;17(7):911-21.
16.    Fukuda H, Moriwaki K. Cost-Effectiveness Analysis of Safety-Engineered Devices. Infection control and hospital epidemiology. 2016;37(9):1012-21.
17.    Furlan JC, Craven BC, Fehlings MG. Surgical Management of the Elderly With Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. Neurosurgery. 2016;79(3):418-25.
18.    Garcia A, Ortiz de Lejarazu R, Reina J, Callejo D, Cuervo J, Morano Larragueta R. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain. Human vaccines & immunotherapeutics. 2016;12(9):2269-77.
19.    Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, et al. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA cardiology. 2016;1(6):666-72.
20.    Georgalis L, de Sanjose S, Esnaola M, Bosch FX, Diaz M. Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). 2016;25(5):430-9.
21.    Green W, Taylor M. Cost-Effectiveness Analysis of d-Nav for People with Diabetes at High Risk of Neuropathic Foot Ulcers. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2016;7(3):511-25.
22.    Hahn-Pedersen J, Worm M, Green W, Andreasen JN, Taylor M. Cost utility analysis of the SQ((R)) HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting. Clinical and translational allergy. 2016;6(1):35.
23.    Hojjat H, Svider PF, Davoodian P, Hong RS, Folbe AJ, Eloy JA, et al. To image or not to image? A cost-effectiveness analysis of MRI for patients with asymmetric sensorineural hearing loss. The Laryngoscope. 2016.
24.    Igarashi A, Tang W, Cure S, Guerra I, Marie L, Lopresti M, et al. Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. Current medical research and opinion. 2016:1-10.
25.    Igarashi A, Tang W, Guerra I, Marie L, Cure S, Lopresti M. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Current medical research and opinion. 2016:1-11.
26.    Kang JR, Sin AT, Cheung EV. Treatment of Massive Irreparable Rotator Cuff Tears: A Cost-effectiveness Analysis. Orthopedics. 2016:1-12.
27.    Kempfle JS, BuSaba NY, Dobrowski JM, Westover MB, Bianchi MT. A cost-effectiveness analysis of nasal surgery to increase continuous positive airway pressure adherence in sleep apnea patients with nasal obstruction. The Laryngoscope. 2016.
28.    Krishnan NM, Fischer JP, Basta MN, Nahabedian MY. Is Single-Stage Prosthetic Reconstruction Cost Effective? A Cost-Utility Analysis for the Use of Direct-to-Implant Breast Reconstruction Relative to Expander-Implant Reconstruction in Postmastectomy Patients. Plastic and reconstructive surgery. 2016;138(3):537-47.
29.    Kulchaitanaroaj P, Brooks JM, Chaiyakunapruk N, Goedken AM, Chrischilles EA, Carter BL. Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. Journal of hypertension. 2016.
30.    Kuznik A, Iliyasu G, Habib AG, Musa BM, Kambugu A, Lamorde M. Initiation of antiretroviral therapy based on the 2015 WHO guidelines: A cost-effectiveness analysis in Nigeria, South Africa, Uganda and India. AIDS (London, England). 2016.
31.    Lanzeta I, Mar J, Arrospide A. Cost-utility analysis of an integrated care model for multimorbid patients based on a clinical trial. Gaceta sanitaria / SESPAS. 2016;30(5):352-8.
32.    Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M. Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. The Journal of infectious diseases. 2016;214(5):685-8.
33.    Launio CC, Asis CA, Manalili RG, Javier EF. Cost-effectiveness analysis of farmers' rice straw management practices considering CH4 and N2O emissions. Journal of environmental management. 2016;183:245-52.
34.    Leal JR, Heitman SJ, Conly JM, Henderson EA, Manns BJ. Cost-Effectiveness Analysis of the Use of Probiotics for the Prevention of Clostridium difficile-Associated Diarrhea in a Provincial Healthcare System. Infection control and hospital epidemiology. 2016;37(9):1079-86.
35.    Lindkvist M, Feldman I. Assessing outcomes for cost-utility analysis in mental health interventions: mapping mental health specific outcome measure GHQ-12 onto EQ-5D-3L. Health and quality of life outcomes. 2016;14(1):134.
36.    Machado de Assis TS, Azeredo-da-Silva AL, Werneck GL, Rabello A. Cost-effectiveness analysis of diagnostic tests for human visceral leishmaniasis in Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2016;110(8):464-71.
37.    Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis. Journal of medical genetics. 2016;53(9):591-9.
38.    Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, et al. Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis. Drug safety. 2016;39(9):859-72.
39.    Neary KC, Mormino MA, Wang H. Suture Button Fixation Versus Syndesmotic Screws in Supination-External Rotation Type 4 Injuries: A Cost-Effectiveness Analysis. The American journal of sports medicine. 2016.
40.    Nerich V, Fleck C, Chaigneau L, Isambert N, Borg C, Kalbacher E, et al. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors. Clinical drug investigation. 2016.
41.    Nichols BE, Boucher CA, van der Valk M, Rijnders BJ, van de Vijver DA. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. The Lancet Infectious diseases. 2016.
42.    Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Alimentary pharmacology & therapeutics. 2016.
43.    Park KW, Boyer MI, Gelberman RH, Calfee RP, Stepan JG, Osei DA. Simultaneous Bilateral Versus Staged Bilateral Carpal Tunnel Release: A Cost-effectiveness Analysis. The Journal of the American Academy of Orthopaedic Surgeons. 2016.
44.    Pearson-Stuttard J, Hooton W, Critchley J, Capewell S, Collins M, Mason H, et al. Cost-effectiveness analysis of eliminating industrial and all trans fats in England and Wales: modelling study. Journal of public health (Oxford, England). 2016.
45.    Phibbs CS, Love SR, Jacobson AK, Edson R, Su P, Uyeda L, et al. At-Home Versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). Journal of general internal medicine. 2016;31(9):1061-7.
46.    Picot MC, Jaussent A, Neveu D, Kahane P, Crespel A, Gelisse P, et al. Cost-effectiveness analysis of epilepsy surgery in a controlled cohort of adult patients with intractable partial epilepsy: A 5-year follow-up study. Epilepsia. 2016.
47.    Ramponi F, Ronco C, Mason G, Rettore E, Marcelli D, Martino F, et al. Cost-effectiveness analysis of online hemodiafiltration versus high-flux hemodialysis. ClinicoEconomics and outcomes research : CEOR. 2016;8:531-40.
48.    Roberts MS. The Next Chapter in Cost-effectiveness Analysis. Jama. 2016;316(10):1049-50.
49.    Ruiz-Sanchez D, Peinado, II, Alaguero-Calero M, Sastre-Heres AJ, Diez BG, Pena-Diaz J. Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences. Oncology letters. 2016;12(3):1935-40.
50.    Serra-Arbeloa P, Rabines-Juarez AO, Alvarez-Ruiz MS, Guillen-Grima F. Sentinel node biopsy in patients with primary cutaneous melanoma of any thickness: A cost-effectiveness analysis. Surgical oncology. 2016;25(3):205-11.
51.    Shim E. Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines. The American journal of tropical medicine and hygiene. 2016.
52.    Siribumrungwong B, Noorit P, Wilasrusmee C, Leelahavarong P, Thakkinstian A, Teerawattananon Y. Cost-utility analysis of great saphenous vein ablation with radiofrequency, foam and surgery in the emerging health-care setting of Thailand. Phlebology / Venous Forum of the Royal Society of Medicine. 2016;31(8):573-81.
53.    Sohn M, Talbert J, Moga DC, Blumenschein K. A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy. Attention deficit and hyperactivity disorders. 2016;8(3):149-58.
54.    Soini E, Hallinen T, Brignone M, Campbell R, Diamand F, Cure S, et al. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert review of pharmacoeconomics & outcomes research. 2016.
55.    Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, et al. Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy. European journal of cancer (Oxford, England : 1990). 2016;67:38-45.
56.    Verguet S, Kim JJ, Jamison DT. Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. PharmacoEconomics. 2016;34(9):913-23.
57.    Visco AG, Zyczynski H, Brubaker L, Nygaard I, Xu X, Lukacz ES, et al. Cost-Effectiveness Analysis of Anticholinergics Versus Botox for Urgency Urinary Incontinence: Results From the Anticholinergic Versus Botox Comparison Randomized Trial. Female pelvic medicine & reconstructive surgery. 2016;22(5):311-6.
58.    Yang MC, Tan EC, Su JJ. Cost-Effectiveness Analysis of Quadrivalent versus Trivalent Influenza Vaccine in Taiwan: A Lifetime Multi-Cohort Model. Human vaccines & immunotherapeutics. 2016:0.


August 2016

1.    Fallah A, Weil AG, Wang S, Lewis E, Baca CB, Mathern GW. Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with Tuberous Sclerosis Complex. Epilepsy & behavior : E&B. 2016;63:79-88.
2.    Alfirevic Z, Keeney E, Dowswell T, Welton NJ, Medley N, Dias S, et al. Which method is best for the induction of labour? A systematic review, network meta-analysis and cost-effectiveness analysis. Health technology assessment (Winchester, England). 2016;20(65):1-584.
3.    Lee VW, Tsai RB, Chow IH, Yan BP, Kaya MG, Park JW, et al. Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation. BMC cardiovascular disorders. 2016;16(1):167.
4.    de Jong PH, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, et al. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial. Rheumatology (Oxford, England). 2016.
5.    Vaidya V, Gangan N, Comerota A, Lurie F. Cost-effectiveness analysis of initial treatment strategies for nonembolic acute limb ischemia using real word data. Annals of vascular surgery. 2016.
6.    Zhang H, Huo M, Chao J, Liu P. Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B. PloS one. 2016;11(8):e0161936.
7.    Le QA, Bae YH, Kang JH. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast cancer research and treatment. 2016.
8.    Bustillo-Lecompte CF, Mehrvar M. Treatment of an actual slaughterhouse wastewater by integration of biological and advanced oxidation processes: Modeling, optimization, and cost-effectiveness analysis. Journal of environmental management. 2016;182:651-66.
9.    Drabo EF, Hay JW, Vardavas R, Wagner ZR, Sood N. A Cost-Effectiveness Analysis Of Pre-Exposure Prophylaxis For The Prevention Of HIV Among Los Angeles County Men Who Have Sex With Men. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016.
10.    Acevedo JR, Fero KE, Wilson B, Sacco AG, Mell LK, Coffey CS, et al. Cost-Effectiveness Analysis of Elective Neck Dissection in Patients With Clinically Node-Negative Oral Cavity Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016.
11.    Canestaro W, Vodicka E, Downing D, Trussell J. Implications of Employer Coverage of Contraception: Cost-Effectiveness Analysis of Contraception Coverage Under an Employer Mandate. Contraception. 2016.
12.    Goyert N, Eeson G, Kagedan DJ, Behman R, Lemke M, Hallet J, et al. Pasireotide for the Prevention of Pancreatic Fistula Following Pancreaticoduodenectomy: A Cost-effectiveness Analysis. Annals of surgery. 2016.
13.    Chalayer E, Bourmaud A, Tinquaut F, Chauvin F, Tardy B. Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma. Thrombosis research. 2016;145:119-25.
14.    Shemilt I, Khan N, Park S, Thomas J. Use of cost-effectiveness analysis to compare the efficiency of study identification methods in systematic reviews. Systematic reviews. 2016;5(1):140.
15.    Miller HJ, Neupane R, Fayezizadeh M, Majumder A, Marks JM. POEM is a cost-effective procedure: cost-utility analysis of endoscopic and surgical treatment options in the management of achalasia. Surgical endoscopy. 2016.
16.    Zimovetz EA, Beard SM, Hodgkins P, Bischof M, Mauskopf JA, Setyawan J. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate. CNS drugs. 2016.
17.    Tolla MT, Norheim OF, Memirie ST, Abdisa SG, Ababulgu A, Jerene D, et al. Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis. Cost effectiveness and resource allocation : C/E. 2016;14:10.
18.    McFarland A. A cost utility analysis of the clinical algorithm for nasogastric tube placement confirmation in adult hospital patients. Journal of advanced nursing. 2016.
19.    Leung W, Kvizhinadze G, Nair N, Blakely T. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis. PLoS medicine. 2016;13(8):e1002067.
20.    Gimeno-Ballester V, Mar J, O'Leary A, Adams R, San Miguel R. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert review of gastroenterology & hepatology. 2016:1-9.
21.    Stawowczyk E, Kawalec P, Pilc A. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland. European journal of clinical pharmacology. 2016.
22.    Tapper EB, Hughes MS, Buti M, Dufour JF, Flamm S, Firdoos S, et al. The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Transplantation. 2016.
23.    Stawowczyk E, Kawalec P, Pilc A. Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland. PloS one. 2016;11(8):e0160444.
24.    Cheng Q, Lazzarini PA, Gibb M, Derhy PH, Kinnear EM, Burn E, et al. A cost-effectiveness analysis of optimal care for diabetic foot ulcers in Australia. International wound journal. 2016.
25.    van Keep M, Gairy K, Seshagiri D, Thilakarathne P, Lee D. Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma. BMC cancer. 2016;16:598.
26.    Khunti K, Gillies CL, Dallosso H, Brady EM, Gray LJ, Kilgallen G, et al. Assessment of response rates and yields for Two opportunistic Tools for Early detection of Non-diabetic hyperglycaemia and Diabetes (ATTEND). A randomised controlled trial and cost-effectiveness analysis. Diabetes research and clinical practice. 2016;118:12-20.
27.    Chen YE, Kao SS, Chung RH. Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan. PloS one. 2016;11(8):e0160599.
28.    Sabater E, Lopez-Guillermo A, Rueda A, Salar A, Oyaguez I, Collar JM. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain. Applied health economics and health policy. 2016;14(4):465-77.
29.    Buti M, Dominguez-Hernandez R, Oyaguez I, Casado MA. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis]. Gastroenterologia y hepatologia. 2016;39(7):449-57.
30.    Alfirevic Z, Keeney E, Dowswell T, Welton NJ, Medley N, Dias S, et al. Methods to induce labour: a systematic review, network meta-analysis and cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2016;123(9):1462-70.
31.    McIntosh E, Gray A, Daniels J, Gill S, Ives N, Jenkinson C, et al. Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trial. Movement disorders : official journal of the Movement Disorder Society. 2016;31(8):1173-82.
32.    Cheung MC, Prica A, Graczyk J, Buckstein R, Chan KK. Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis. Leukemia & lymphoma. 2016;57(8):1865-75.
33.    Wilkins E, Fisher M, Brogan AJ, Talbird SE, La EM. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial. HIV medicine. 2016;17(7):505-15.
34.    Bagcioglu M, Demir A, Sulhan H, Karadag MA, Uslu M, Tekdogan UY. Comparison of flexible ureteroscopy and micropercutaneous nephrolithotomy in terms of cost-effectiveness: analysis of 111 procedures. Urolithiasis. 2016;44(4):339-44.


July 2016

1.    Ament JD, Yang Z, Nunley P, Stone MB, Lee D, Kim KD. Cost Utility Analysis of the Cervical Artificial Disc vs Fusion for the Treatment of 2-Level Symptomatic Degenerative Disc Disease: 5-Year Follow-up. Neurosurgery. 2016;79(1):135-45.
2.    Babu MA. Commentary: Surgical Management of the Elderly With Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. Neurosurgery. 2016.
3.    Brenner MJ. What Cost-Utility Analysis Can Teach Us About Facial Deformity: Gambles, Trade-offs, and Willingness to Pay. JAMA facial plastic surgery. 2016;18(4):249-50.
4.    Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Digestive diseases and sciences. 2016;61(7):2108-17.
5.    Cromwell I, Regier DA, Peacock SJ, Poh CF. Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada. The oncologist. 2016.
6.    Cui M, Tu CC, Chen EZ, Wang XL, Tan SC, Chen C. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China. Advances in therapy. 2016.
7.    Elias I, Ortega-Joaquin N, de la Cueva P, Del Pozo LJ, Moreno-Ramirez D, Boada A, et al. Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain. Actas dermo-sifiliograficas. 2016;107(6):498-508.
8.    Fundament T, Eldridge PR, Green AL, Whone AL, Taylor RS, Williams AC, et al. Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis. PloS one. 2016;11(7):e0159340.
9.    Gancarczyk SM, Jang ES, Swart EP, Makhni EC, Kadiyala RK. Percutaneous Trigger Finger Release: A Cost-effectiveness Analysis. The Journal of the American Academy of Orthopaedic Surgeons. 2016;24(7):475-82.
10.    Green W, Taylor M. Cost-Effectiveness Analysis of d-Nav for People with Diabetes at High Risk of Neuropathic Foot Ulcers. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2016.
11.    Greuter MJ, Berkhof J, Fijneman RJ, Demirel E, Lew JB, Meijer GA, et al. The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis. The British journal of radiology. 2016;89(1063):20150910.
12.    Hankin-Wei A, Rein DB, Hernandez-Romieu A, Kennedy MJ, Bulkow L, Rosenberg E, et al. Cost-effectiveness analysis of catch-up hepatitis A vaccination among unvaccinated/partially-vaccinated children. Vaccine. 2016;34(35):4243-9.
13.    Hernandez L, Guo S, Kinter E, Fay M. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Journal of medical economics. 2016;19(7):684-95.
14.    Hofer F, Achelrod D, Stargardt T. Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany. Applied health economics and health policy. 2016.
15.    Kabeshova A, Ben Hariz S, Tsakeu E, Benamouzig R, Launois R. Cost-effectiveness analysis of rifaximin-alpha administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France. Therapeutic advances in gastroenterology. 2016;9(4):473-82.
16.    Kidholm K, Rasmussen MK, Andreasen JJ, Hansen J, Nielsen G, Spindler H, et al. Cost-Utility Analysis of a Cardiac Telerehabilitation Program: The Teledialog Project. Telemedicine journal and e-health : the official journal of the American Telemedicine Association. 2016;22(7):553-63.
17.    Kim H, Gill B, Beriwal S, Huq MS, Roberts MS, Smith KJ. Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases. International journal of radiation oncology, biology, physics. 2016;95(4):1175-83.
18.    Kuznik A, Habib AG, Munube D, Lamorde M. Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis. BMC health services research. 2016;16(1):304.
19.    Leal JR, Heitman SJ, Conly JM, Henderson EA, Manns BJ. Cost-Effectiveness Analysis of the Use of Probiotics for the Prevention of Clostridium difficile-Associated Diarrhea in a Provincial Healthcare System. Infection control and hospital epidemiology. 2016:1-8.
20.    Lee JK, Jo YH, Kang CN. Cost-effectiveness Analysis of Existing Pedicle Screws Reusing Technique in Extension Revision Operation for Adjacent Segmental Stenosis After Lumbar Posterolateral Fusion. Spine. 2016;41(13):E785-90.
21.    Liu CC, Rudmik L. A Cost-effectiveness Analysis of Early vs Late Tracheostomy. JAMA otolaryngology-- head & neck surgery. 2016.
22.    Lodhia P, Gui C, Chandrasekaran S, Suarez-Ahedo C, Dirschl DR, Domb BG. The Economic Impact of Acetabular Labral Tears: A Cost-effectiveness Analysis Comparing Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Patients Without Osteoarthritis. The American journal of sports medicine. 2016;44(7):1771-80.
23.    Matteucci F, Solinas L, Turri V, Donati C, D'Errico V, Moretti A, et al. IntegoTM Infusion System: cost effectiveness analysis focusing on dosimetry, sterility and management. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the So. 2016.
24.    Parker C, Woods B, Eaton J, Ma E, Selby R, Benson E, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. Journal of medical economics. 2016:1-33.
25.    Rajagopalan K, Trueman D, Crowe L, Squirrell D, Loebel A. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. PharmacoEconomics. 2016;34(7):709-21.
26.    Raykar N, Nigam A, Chisholm D. An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance. Cost effectiveness and resource allocation : C/E. 2016;14:9.
27.    Richard P, Phillips M, Smith W, Davidson D, Kim E, Kane G. Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy for Preoperative Treatment of Extremity Soft Tissue Sarcomas. International journal of radiation oncology, biology, physics. 2016;95(3):999-1008.
28.    Scangas GA, Remenschneider AK, Su BM, Shrime MG, Metson R. Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyposis. The Laryngoscope. 2016.
29.    Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, Ternouth A, Miravitlles M, Rutten-van Molken M, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat(R) fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Therapeutic advances in respiratory disease. 2016.
30.    Shrime MG, Verguet S, Johansson KA, Desalegn D, Jamison DT, Kruk ME. Task-sharing or public finance for the expansion of surgical access in rural Ethiopia: an extended cost-effectiveness analysis. Health policy and planning. 2016;31(6):706-16.
31.    Varghese L, Mungall B, Zhang XH, Hoet B. Response to Wu et al. - Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong. Human vaccines & immunotherapeutics. 2016:1-6.
32.    Vennera Mdel C, Valero A, Uria E, Forne C, Picado C. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain. Clinical drug investigation. 2016;36(7):567-78.
33.    Verguet S, Kim JJ, Jamison DT. Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. PharmacoEconomics. 2016.
34.    Verhoef TI, Trend V, Kelly B, Robinson N, Fox P, Morris S. Cost-effectiveness analysis of offering free leisure centre memberships to physically inactive members of the public receiving state benefits: a case study. BMC public health. 2016;16:616.
35.    Wallbillich JJ, Forde B, Havrilesky LJ, Cohn DE. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. Gynecologic oncology. 2016;142(1):144-9.
36.    Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, et al. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. Clinical lung cancer. 2016.
37.    Xu X, Ma YY, Zou HD. Cost-Utility Analysis of Cataract Surgery in Advanced Glaucoma Patients. Journal of glaucoma. 2016;25(7):e657-62.
38.    Zhang P, Wen F, Li Q. FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2016.
39.    Zhou J, Zhao R, Wen F, Zhang P, Tang R, Chen H, et al. Economic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial. Medicine. 2016;95(27):e3762.


June 2016

1.    Lanzeta I, Mar J, Arrospide A. Cost-utility analysis of an integrated care model for multimorbid patients based on a clinical trial. Gaceta sanitaria / SESPAS. 2016.
2.    Sjostrom S, Kopp Kallner H, Simeonova E, Madestam A, Gemzell-Danielsson K. Medical Abortion Provided by Nurse-Midwives or Physicians in a High Resource Setting: A Cost-Effectiveness Analysis. PloS one. 2016;11(6):e0158645.
3.    Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence. Patient preference and adherence. 2016;10:1025-35.
4.    Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis. Journal of medical genetics. 2016.
5.    Cromwell I, Gaudet M, Peacock SJ, Aquino-Parsons C. Cost-effectiveness analysis of anal cancer screening in women with cervical neoplasia in British Columbia, Canada. BMC health services research. 2016;16(1):206.
6.    Mercer SW, Fitzpatrick B, Guthrie B, Fenwick E, Grieve E, Lawson K, et al. The CARE Plus study - a whole-system intervention to improve quality of life of primary care patients with multimorbidity in areas of high socioeconomic deprivation: exploratory cluster randomised controlled trial and cost-utility analysis. BMC medicine. 2016;14(1):88.
7.    Taylor C, Thompson K, Finfer S, Higgins A, Jan S, Li Q, et al. Hydroxyethyl starch versus saline for resuscitation of patients in intensive care: long-term outcomes and cost-effectiveness analysis of a cohort from CHEST. The Lancet Respiratory medicine. 2016.
8.    Heard C, Chaboyer W, Anderson V, Gillespie BM, Whitty JA. Cost-effectiveness analysis alongside a pilot study of prophylactic negative pressure wound therapy. Journal of tissue viability. 2016.
9.    Hankin-Wei A, Rein DB, Hernandez-Romieu A, Kennedy MJ, Bulkow L, Rosenberg E, et al. Cost-effectiveness analysis of catch-up hepatitis A vaccination among unvaccinated/partially-vaccinated children. Vaccine. 2016.
10.    Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, et al. Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis. Drug safety. 2016.
11.    Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016.
12.    Chuang LH, Verheggen BG, Charokopou M, Gibson D, Grandy S, Kartman B. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. Journal of medical economics. 2016:1-8.
13.    Furlan JC, Craven BC, Fehlings MG. Surgical Management of the Elderly With Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. Neurosurgery. 2016.
14.    Uruena A, Vizzotti C, San Juan JA. Response to Orellano et al. regarding cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission. Vaccine. 2016;34(28):3222.
15.    Orellano PW, Salomon OD. Will dengue vaccination be cost-effective for Argentina? Reply to letter by Uruena et al. regarding "Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission". Vaccine. 2016;34(28):3221.
16.    Yun BJ, Myriam Hunink MG, Prabhakar AM, Heng M, Liu SW, Qudsi R, et al. Diagnostic Imaging Strategies for Occult Hip Fractures - A Decision and Cost-effectiveness Analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2016.
17.    Dilokthornsakul P, Chaiyakunapruk N, Campbell JD. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter? The Journal of asthma : official journal of the Association for the Care of Asthma. 2016:0.
18.    Williams C, Lewsey JD, Briggs AH, Mackay DF. Cost-Effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial. Medical decision making : an international journal of the Society for Medical Decision Making. 2016.
19.    Ke W, Zhang C, Liu L, Gao Y, Yao Z, Ye X, et al. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Hepatology international. 2016.
20.    Berrigan P, Bardouille T, MacLellan M, Mohamed IS, Murthy M. Cost-utility analysis of magnetoencephalography used to inform intracranial electrode placement in patients with drug resistant epilepsy: a model based analysis. Journal of evaluation in clinical practice. 2016.
21.    Pedersen K, Sorbye SW, Kristiansen IS, Burger EA. Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2016.
22.    Muduma G, Odeyemi I, Pollock RF. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. Journal of medical economics. 2016:1-8.
23.    Tuffaha HW, Roberts S, Chaboyer W, Gordon LG, Scuffham PA. Cost-effectiveness Analysis of Nutritional Support for the Prevention of Pressure Ulcers in High-Risk Hospitalized Patients. Advances in skin & wound care. 2016;29(6):261-7.
24.    Riesco-Martinez MC, Berry SR, Ko YJ, Mittmann N, Giotis A, Lien K, et al. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. Journal of oncology practice / American Society of Clinical Oncology. 2016;12(6):e710-23.
25.    Zhou J, Zhao R, Wen F, Zhang P, Wu Y, Tang R, et al. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials. Tumori. 2016;2016(3):294-300.
26.    Merry M, Boulware DR. Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;62(12):1564-8.
27.    Scangas GA, Su BM, Remenschneider AK, Shrime MG, Metson R. Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis. International forum of allergy & rhinology. 2016;6(6):582-9.
28.    O'Day K, Levy WC, Johnson M, Jacobson AF. Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA. Applied health economics and health policy. 2016;14(3):361-73.
29.    Ono Y, Osuga K, Takura T, Nakamura M, Shibamoto K, Yamamoto A, et al. Cost-Effectiveness Analysis of Percutaneous Sclerotherapy for Venous Malformations. Journal of vascular and interventional radiology : JVIR. 2016;27(6):831-7.
30.    Foteff C, Kennedy S, Milton AH, Deger M, Payk F, Sanderson G. Cost-Utility Analysis of Cochlear Implantation in Australian Adults. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2016;37(5):454-61.
31.    Morris S, Patel NV, Dobson J, Featherstone RL, Richards T, Luengo-Fernandez R, et al. Cost-utility analysis of stenting versus endarterectomy in the International Carotid Stenting Study. International journal of stroke : official journal of the International Stroke Society. 2016;11(4):446-53.
32.    Perez-Ruiz F, Diaz-Torne C, Carcedo D. Cost-effectiveness analysis of febuxostat in patients with gout in Spain. Journal of medical economics. 2016;19(6):604-10.
33.    Escolar-Albaladejo G, Baron-Esquivias G, Zamorano JL, Betegon-Nicolas L, Canal-Fontcuberta C, de Salas-Cansado M, et al. [Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain]. Atencion primaria / Sociedad Espanola de Medicina de Familia y Comunitaria. 2016;48(6):394-405.
34.    Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA. Cost-utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients. The Journal of asthma : official journal of the Association for the Care of Asthma. 2016;53(5):538-45.
35.    Larsen MH, Wahl AK, Krogstad AL, Aas E. Cost-utility Analysis of Supported Self-management with Motiva-tional Interviewing for Patients with Psoriasis. Acta dermato-venereologica. 2016;96(5):664-8.
36.    Berenguer J, Rivero A, Blasco AJ, Arribas JR, Boix V, Clotet B, et al. Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades infecciosas y microbiologia clinica. 2016;34(6):361-71.
37.    Hansson E, Ekman I, Swedberg K, Wolf A, Dudas K, Ehlers L, et al. Person-centred care for patients with chronic heart failure - a cost-utility analysis. European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology. 2016;15(4):276-84.
38.    van den Akker-van Marle ME, Moojen WA, Arts MP, Vleggeert-Lankamp CL, Peul WC. Interspinous process devices versus standard conventional surgical decompression for lumbar spinal stenosis: cost-utility analysis. The spine journal : official journal of the North American Spine Society. 2016;16(6):702-10.


May 2016
1.    Stomberg C, Albaugh M, Shiffman S, Sood N. A cost-effectiveness analysis of over-the-counter statins. The American journal of managed care. 2016;22(5):e294-303.
2.    de Sonneville-Koedoot C, Stolk E, Rietveld T, Franken MC. Response to "Putting the cart before the horse: A cost effectiveness analysis of treatments for stuttering in young children requires evidence that the treatments analyzed were effective". Journal of communication disorders. 2016.
3.    Gulliford MC, Charlton J, Booth HP, Fildes A, Khan O, Reddy M, et al. Health Services and Delivery Research.  Costs and outcomes of increasing access to bariatric surgery for obesity: cohort study and cost-effectiveness analysis using electronic health records. Southampton (UK): NIHR Journals Library
4.    Castelnuovo G, Pietrabissa G, Cattivelli R, Manzoni GM, Molinari E. Not Only Clinical Efficacy in Psychological Treatments: Clinical Psychology Must Promote Cost-Benefit, Cost-Effectiveness, and Cost-Utility Analysis. Frontiers in psychology. 2016;7:563.
5.    Phibbs CS, Love SR, Jacobson AK, Edson R, Su P, Uyeda L, et al. At-Home Versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). Journal of general internal medicine. 2016.
6.    Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M. COMPARING 2- AND 3-DOSE 9-VALENT HPV VACCINE SCHEDULES IN THE U.S.: A COST-EFFECTIVENESS ANALYSIS. The Journal of infectious diseases. 2016.
7.    Takura T, Tachibana K, Isshiki T, Sumitsuji S, Kuroda T, Mizote I, et al. Preliminary report on a cost-utility analysis of revascularization by percutaneous coronary intervention for ischemic heart disease. Cardiovascular intervention and therapeutics. 2016.
8.    Penaloza-Ramos MC, Jowett S, Barton P, Roalfe A, Fletcher K, Taylor CJ, et al. Cost-effectiveness analysis of different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack: Economic analysis of the PAST-BP study. European journal of preventive cardiology. 2016.
9.    Fukuda H, Moriwaki K. Cost-Effectiveness Analysis of Safety-Engineered Devices. Infection control and hospital epidemiology. 2016:1-10.
10.    Romanelli M, Gilligan AM, Waycaster CR, Dini V. Difficult-to-heal wounds of mixed arterial/venous and venous etiology: a cost-effectiveness analysis of extracellular matrix. ClinicoEconomics and outcomes research : CEOR. 2016;8:153-61.
11.    Canestaro WJ. Capsule Commentary on Phibbs et. al., At-Home versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). Journal of general internal medicine. 2016.
12.    Qureshi N, Weng S, Hex N. The role of cost-effectiveness analysis in the development of indicators to support incentive-based behaviour in primary care in England. Journal of health services research & policy. 2016.
13.    Gounder PP, Bulkow LR, Meltzer MI, Bruce MG, Hennessy TW, Snowball M, et al. Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983-2012. International journal of circumpolar health. 2016;75:31115.
14.    Nguyen TP, Wright EP, Nguyen TT, Schuiling-Veninga CC, Bijlsma MJ, Nguyen TB, et al. Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam. PloS one. 2016;11(5):e0155699.
15.    Lodhia P, Gui C, Chandrasekaran S, Suarez-Ahedo C, Dirschl DR, Domb BG. The Economic Impact of Acetabular Labral Tears: A Cost-effectiveness Analysis Comparing Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Patients Without Osteoarthritis. The American journal of sports medicine. 2016.
16.    Fusco F, Turchetti G. Telerehabilitation after total knee replacement in Italy: cost-effectiveness and cost-utility analysis of a mixed telerehabilitation-standard rehabilitation programme compared with usual care. BMJ open. 2016;6(5):e009964.
17.    Garcia A, Ortiz de Lejarazu R, Reina J, Callejo D, Cuervo J, Morano R. Cost-Effectiveness Analysis Of Quadrivalent Influenza Vaccine In Spain. Human vaccines & immunotherapeutics. 2016:0.
18.    Jiang M, You JH. Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome. Pharmacogenomics. 2016;17(7):701-13.
19.    Kjerstad E, Tuntland HK. Reablement in community-dwelling older adults: a cost-effectiveness analysis alongside a randomized controlled trial. Health economics review. 2015;6(1):15.
20.    Gasparini R, Landa P, Amicizia D, Icardi G, Ricciardi W, de Waure C, et al. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero(R)) against meningococcal B disease: A cost-effectiveness analysis. Human vaccines & immunotherapeutics. 2016:1-14.
21.    Granados-Garcia V, Contreras AM, Garcia-Pena C, Salinas-Escudero G, Thein HH, Flores YN. Cost-Effectiveness Analysis of Different Testing Strategies that Use Antibody Levels to Detect Chronic Hepatitis C in Blood Donors. PloS one. 2016;11(5):e0154625.
22.    Zheng HR, Wen F, Wu YF, Wheeler JR, Li Q. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective. European journal of cancer care. 2016.
23.    Elias I, Oyaguez I, Alvarez-Sala LA, Garcia-Bragado F, Navarro A, Gonzalez P, et al. Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2016;40(n03):187-208.
24.    Riesco-Martinez MC, Berry SR, Ko YJ, Mittmann N, Giotis A, Lien K, et al. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. Journal of oncology practice / American Society of Clinical Oncology. 2016;12(6):e710-23.
25.    Sohn M, Talbert J, Moga DC, Blumenschein K. A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy. Attention deficit and hyperactivity disorders. 2016.
26.    Vennera MD, Valero A, Uria E, Forne C, Picado C. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain. Clinical drug investigation. 2016.
27.    Haacker M, Fraser-Hurt N, Gorgens M. Effectiveness of and Financial Returns to Voluntary Medical Male Circumcision for HIV Prevention in South Africa: An Incremental Cost-Effectiveness Analysis. PLoS medicine. 2016;13(5):e1002012.
28.    Wallbillich JJ, Forde B, Havrilesky LJ, Cohn DE. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. Gynecologic oncology. 2016.
29.    Russell LB, Sinha A. Strengthening Cost-Effectiveness Analysis for Public Health Policy. American journal of preventive medicine. 2016;50(5 Suppl 1):S6-s12.
30.    Fragoulakis V, Mitropoulou C, van Schaik RH, Maniadakis N, Patrinos GP. An Alternative Methodological Approach for Cost-Effectiveness Analysis and Decision Making in Genomic Medicine. Omics : a journal of integrative biology. 2016;20(5):274-82.
31.    Okumura LM, Riveros BS, Gomes-da-Silva MM, Veroneze I. A cost-effectiveness analysis of two different antimicrobial stewardship programs. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2016;20(3):255-61.
32.    Luyten J, Naci H, Knapp M. Economic evaluation of mental health interventions: an introduction to cost-utility analysis. Evidence-based mental health. 2016;19(2):49-53.
33.    Stawowczyk E, Kawalec P, Pilc A. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland. Pharmacotherapy. 2016;36(5):472-81.
34.    Nwachukwu BU, Schairer WW, McCormick F, Dines DM, Craig EV, Gulotta LV. Arthroplasty for the surgical management of complex proximal humerus fractures in the elderly: a cost-utility analysis. Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons  [et al]. 2016;25(5):704-13.
35.    Marcellusi A, Viti R, Russo S, Andreoni M, Antinori A, Mennini FS. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective. Clinical drug investigation. 2016;36(5):377-87.
36.    Kapoor A, Shaffer N, Hanchate A, Roberts M, Smith K. Massachusetts Health Reform Cost Less and Was More Effective for Uninsured Individuals With Venous Thromboembolism: A Cost-Effectiveness Analysis. Medical care. 2016;54(5):474-82.
37.    Kawamoto Y, Mouri M, Taira T, Iseki H, Masamune K. Cost-Effectiveness Analysis of Deep Brain Stimulation in Patients with Parkinson's Disease in Japan. World neurosurgery. 2016;89:628-35.e1.
38.    Whalen J, Stillman I, Ambavane A, Felber E, Makenbaeva D, Bolinder B. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia. Journal of medical economics. 2016;19(5):445-61.
39.    Jain KM, Zulliger R, Maulsby C, Kim JJ, Charles V, Riordan M, et al. Cost-Utility Analysis of Three U.S. HIV Linkage and Re-engagement in Care Programs from Positive Charge. AIDS and behavior. 2016;20(5):973-6.
40.    Strand KB, Chisholm D, Fekadu A, Johansson KA. Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis. Health policy and planning. 2016;31(4):504-13.
41.    Zur RM, Zaric GS. A microsimulation cost-utility analysis of alcohol screening and brief intervention to reduce heavy alcohol consumption in Canada. Addiction (Abingdon, England). 2016;111(5):817-31.
42.    Frederix I, Hansen D, Coninx K, Vandervoort P, Vandijck D, Hens N, et al. Effect of comprehensive cardiac telerehabilitation on one-year cardiovascular rehospitalization rate, medical costs and quality of life: A cost-effectiveness analysis. European journal of preventive cardiology. 2016;23(7):674-82.
43.    Garcia-Ruiz AJ, Quintano Jimenez JA, Garcia-Agua Soler N, Ginel Mendoza L, Hidalgo Requena A, Del Moral F. [Quality of life of patients with asthma on beclomethasone/formoterol. Cost-utility analysis]. Semergen / Sociedad Espanola de Medicina Rural y Generalista. 2016;42(4):225-34.
44.    De Lossada A, Oteo-Alvaro A, Gimenez S, Oyaguez I, Rejas J. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective]. Semergen / Sociedad Espanola de Medicina Rural y Generalista. 2016;42(4):235-43.
45.    Pinol C. Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain. Neurologia (Barcelona, Spain). 2016;31(4):247-54.
46.    Takura T, Yoshimatsu M, Sugimori H, Takizawa K, Furumatsu Y, Ikeda H, et al. Cost-Effectiveness Analysis of Percutaneous Vertebroplasty for Osteoporotic Compression Fractures. Clinical spine surgery. 2016.


Subscribe to: Posts (Atom)